


**CUMULATIVE  
SUPPLEMENT 11  
NOVEMBER 2016**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**36th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2016**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**36<sup>th</sup> EDITION**

**Cumulative Supplement 11  
November 2016**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition .....	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS**  
**with**  
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**36<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 11**  
**November 2016**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to:                   FDA/CDER Orange Book Staff  
                                   Office of Generic Drugs  
                                   7620 Standish Place  
                                   Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BD RX INC (BD RX)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
CITRON PHARMA LLC (CITRON PHARMA LLC)	CASPER PHARMA LLC (CASPER PHARMA LLC)
PROSAM LABS LLC (PROSAM LABS)	OXFORD PHARMACEUTICALS LLC (OXFORD PHARMS)
HIKMA MAPLE LTD (HIKMA MAPLE)	EUROHEALTH INTERNATIONAL SARL (EUROHLTH INTL SARL)

## 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.



## DEFINITIONS

### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

## REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)	17528 2664 (15.2%)	17765 2665 (15%)	
MULTISOURCE	14487 (84.5%)	14558 (84.4%)	14864 (84.8%)	15100 (85%)	
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)	14731 (84%)	14968 (84.3%)	
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)	133 (0.8%)	132 (0.7%)	
EXCEPTIONS <sup>1</sup>	73 (0.4%)	73 (0.4%)	73 (0.4%)	73 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	28	9	20	8	
NUMBER OF APPLICANTS	1011	1007	1023	1027	

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE

SOLUTION;ORAL		ABACAVIR SULFATE							
AA	HETERO LABS LTD III	EQ 20MG BASE/ML		A201107	001	Sep 26, 2016	Sep	NEWA	
ZIAGEN									
AA	+ VIIV HLTHCARE	EQ 20MG BASE/ML		N020978	001	Dec 17, 1998	Sep	CFTG	
TABLET;ORAL		ABACAVIR SULFATE							
>D>	AB STRIDES ARCOLAB LTD	EQ 300MG BASE		A091050	001	Oct 28, 2016	Nov	CAHN	
AB		EQ 300MG BASE		A091050	001	Oct 28, 2016	Oct	NEWA	
>A>	AB STRIDES PHARMA	EQ 300MG BASE		A091050	001	Oct 28, 2016	Nov	CAHN	

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
AB	TEVA PHARMS USA	EQ 600MG BASE;300MG		A079246	001	Sep 29, 2016	Sep	NEWA	
EPZICOM									
AB	+ VIIV HLTHCARE	EQ 600MG BASE;300MG		N021652	001	Aug 02, 2004	Sep	CFTG	

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL		ACAMPROSATE CALCIUM							
AB	+ GLENMARK GENERICS	333MG		A202229	001	Jul 16, 2013	May	CRLD	

ACARBOSE

TABLET;ORAL		ACARBOSE							
>D>	AB ROXANE	25MG		A078470	001	May 07, 2008	Nov	CAHN	
>D>	AB	50MG		A078470	002	May 07, 2008	Nov	CAHN	
>D>	AB	100MG		A078470	003	May 07, 2008	Nov	CAHN	
>A>	AB WEST-WARD PHARMS INT	25MG		A078470	001	May 07, 2008	Nov	CAHN	
>A>	AB	50MG		A078470	002	May 07, 2008	Nov	CAHN	
>A>	AB	100MG		A078470	003	May 07, 2008	Nov	CAHN	

ACETAMINOPHEN

SOLUTION;IV (INFUSION)		ACETAMINOPHEN							
AP	PADDOCK LLC	1GM/100ML (10MG/ML)		A202605	001	Jun 13, 2016	May	NEWA	
AP	SANDOZ INC	1GM/100ML (10MG/ML)		A204052	001	Mar 22, 2016	Mar	NEWA	
OFIRMEV									
AP	+ MALLINCKRODT IP	1GM/100ML (10MG/ML)		N022450	001	Nov 02, 2010	Mar	CFTG	

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN							
AA	CNTY LINE PHARMS	325MG;50MG		A205120	001	Oct 30, 2015	Aug	CAHN	
AA	MIKART INC	300MG;50MG		A207386	001	Nov 15, 2016	Oct	NEWA	
AA	+ NEXGEN PHARMA	300MG;50MG		A090956	001	Aug 23, 2011	Oct	CTEC	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
	+ MAYNE PHARMA INC	325MG;50MG;40MG		A089007	001	Mar 17, 1986	Aug	CAHN	
	+ METRIC	325MG;50MG;40MG		A089007	001	Mar 17, 1986	Jun	CAHN	
AB	+ NEXGEN PHARMA	300MG;50MG;40MG		A040885	001	Nov 16, 2009	Oct	CFTG	
AB	NUVO PHARM INC	300MG;50MG;40MG		A207118	001	Oct 28, 2016	Oct	NEWA	
TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
	@ INGENUS PHARMS NJ	325MG;50MG;40MG		A040864	001	Dec 01, 2008	Jan	CAHN	
	@ SUN PHARM INDS	325MG;50MG;40MG		A040601	001	Jul 29, 2005	Jan	CAHN	
FIORICET									
AA	ACTAVIS LABS UT INC	325MG;50MG;40MG		A088616	001	Nov 09, 1984	May	CMFD	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL		FIORICET W/ CODEINE							
AB	+ ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG		N020232	001	Jul 30, 1992	Jul	CAHN	
AB	+ ALLERGAN SALES LLC	325MG;50MG;40MG;30MG		N020232	001	Jul 30, 1992	Apr	CAHN	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

LARKEN LABS INC 325MG;30MG;16MG A204209 001 Sep 30, 2016 Sep NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ FRONTIDA BIOPHARM 300MG;15MG A089671 001 Feb 10, 1988 Sep CAHN

@ 300MG;30MG A089672 001 Feb 10, 1988 Sep CAHN

@ 300MG;60MG A089673 001 Feb 10, 1988 Jul CAHN

@ SUN PHARM INDS 300MG;60MG A089673 001 Feb 10, 1988 Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

ZYFREL

AA CYPRESS PHARM INC 325MG/15ML;7.5MG/15ML A090468 001 Apr 14, 2016 Apr NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ACTAVIS LABS FL INC 300MG;5MG A206470 001 Jun 02, 2016 May NEWA

AA 300MG;7.5MG A206470 002 Jun 02, 2016 May NEWA

AA 300MG;10MG A206470 003 Jun 02, 2016 May NEWA

&gt;D&gt; @ ALLERGAN SALES LLC 500MG;10MG A040148 002 Feb 14, 1997 Nov CAHN

@ 500MG;10MG A040148 002 Feb 14, 1997 Jun CAHN

&gt;A&gt; AA AMNEAL PHARMS 300MG;10MG A207137 001 Nov 29, 2016 Nov NEWA

AA AMNEAL PHARMS NY 325MG;7.5MG A040746 002 May 10, 2016 Apr NEWA

&gt;A&gt; @ APIL 500MG;10MG A040148 002 Feb 14, 1997 Nov CAHN

AA LARKEN LABS INC 325MG;5MG A202935 002 Jun 15, 2016 Jun NEWA

AA 325MG;7.5MG A202935 003 Jun 15, 2016 Jun NEWA

AA 325MG;10MG A202935 004 Jun 15, 2016 Jun NEWA

&gt;A&gt; AA NOVEL LABS INC 300MG;5MG A206142 001 Nov 14, 2016 Nov NEWA

&gt;A&gt; AA 300MG;7.5MG A206142 002 Nov 14, 2016 Nov NEWA

&gt;A&gt; AA 300MG;10MG A206142 003 Nov 14, 2016 Nov NEWA

&gt;A&gt; AA 325MG;5MG A206245 001 Dec 01, 2016 Nov NEWA

&gt;A&gt; AA 325MG;7.5MG A206245 002 Dec 01, 2016 Nov NEWA

&gt;A&gt; AA 325MG;10MG A206245 003 Dec 01, 2016 Nov NEWA

AA PAR PHARM 300MG;5MG A205001 001 Jul 05, 2016 Jun NEWA

AA 300MG;7.5MG A205001 002 Jul 05, 2016 Jun NEWA

AA 300MG;10MG A205001 003 Jul 05, 2016 Jun NEWA

AA RHODES PHARMS 325MG;5MG A202991 001 Apr 12, 2016 Mar NEWA

AA 325MG;7.5MG A202991 002 Apr 12, 2016 Mar NEWA

AA 325MG;10MG A202991 003 Apr 12, 2016 Mar NEWA

AA TRIS PHARMA INC 300MG;5MG A202214 004 Mar 15, 2016 Jun NEWA

AA 300MG;7.5MG A202214 005 Mar 15, 2016 Jun NEWA

AA 300MG;10MG A202214 006 Mar 15, 2016 Jun NEWA

NORCO

&gt;D&gt; AA ALLERGAN SALES LLC 325MG;2.5MG A040148 004 Jul 07, 2014 Nov CAHN

AA 325MG;2.5MG A040148 004 Jul 07, 2014 Jun CAHN

&gt;D&gt; AA + 325MG;5MG A040099 001 Jun 25, 1997 Nov CAHN

AA + 325MG;5MG A040099 001 Jun 25, 1997 Jun CAHN

&gt;D&gt; AA 325MG;5MG A040148 005 Jul 07, 2014 Nov CAHN

AA 325MG;5MG A040148 005 Jul 07, 2014 Jun CAHN

&gt;D&gt; AA + 325MG;7.5MG A040148 003 Sep 12, 2000 Nov CAHN

AA + 325MG;7.5MG A040148 003 Sep 12, 2000 Jun CAHN

&gt;D&gt; AA + 325MG;10MG A040148 001 Feb 14, 1997 Nov CAHN

AA + 325MG;10MG A040148 001 Feb 14, 1997 Jun CAHN

&gt;A&gt; AA APIL 325MG;2.5MG A040148 004 Jul 07, 2014 Nov CAHN

&gt;A&gt; AA + 325MG;5MG A040099 001 Jun 25, 1997 Nov CAHN

&gt;A&gt; AA 325MG;5MG A040148 005 Jul 07, 2014 Nov CAHN

&gt;A&gt; AA + 325MG;7.5MG A040148 003 Sep 12, 2000 Nov CAHN

&gt;A&gt; AA + 325MG;10MG A040148 001 Feb 14, 1997 Nov CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

AA + MALLINCKRODT INC 325MG/5ML;5MG/5ML A040680 001 Sep 29, 2006 Aug CRLD

AA 325MG/5ML;5MG/5ML A040680 001 Sep 29, 2006 May CMFD

ROXICET

&gt;D&gt; @ ROXANE 325MG/5ML;5MG/5ML A089351 001 Dec 03, 1986 Nov CAHN

@ 325MG/5ML;5MG/5ML A089351 001 Dec 03, 1986 Aug DISC

&gt;A&gt; @ WEST-WARD PHARMS INT 325MG/5ML;5MG/5ML A089351 001 Dec 03, 1986 Nov CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ALVOGEN MALTA	325MG;5MG	A202677	003	Mar 08, 2016	Feb	NEWA
AA		325MG;7.5MG	A202677	001	Jul 26, 2012	Jan	CAHN
AA		325MG;10MG	A202677	002	Jul 26, 2012	Jan	CAHN
AA	AMNEAL PHARMS NY	325MG;7.5MG	A040778	002	Jun 27, 2014	Apr	NEWA
>A>	AA CEROVENE INC	325MG;5MG	A207574	001	Dec 13, 2016	Nov	NEWA
AA	MAYNE PHARMA INC	325MG;2.5MG	A090177	001	Oct 20, 2008	Feb	CAHN
AA		325MG;5MG	A090177	002	Oct 20, 2008	Feb	CAHN
AA		325MG;7.5MG	A090177	003	Oct 20, 2008	Feb	CAHN
AA		325MG;10MG	A090177	004	Oct 20, 2008	Feb	CAHN
	@	500MG;7.5MG	A090177	005	Oct 20, 2008	Feb	CAHN
	@	650MG;10MG	A090177	006	Oct 20, 2008	Feb	CAHN
	ROXICET						
>D>	AA ROXANE	325MG;5MG	A087003	001		Nov	CAHN
>A>	AA WEST-WARD PHARMS INT	325MG;5MG	A087003	001		Nov	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ATLAS PHARMS LLC	325MG;37.5MG	A202076	001	Mar 30, 2012	May	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016	Mar	NEWA
AB	NOVAST LABS LTD	500MG	A203434	001	Sep 30, 2016	Sep	NEWA

TABLET;ORAL

ACETAZOLAMIDE

AB	HERITAGE PHARMA	125MG	A205530	001	Oct 27, 2016	Oct	NEWA
AB		250MG	A205530	002	Oct 27, 2016	Oct	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Sep	CAHN
----	----------------------	--------------------	---------	-----	--------------	-----	------

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016	Feb	NEWA
AP	FRESENIUS KABI USA	6GM/30ML (200MG/ML)	A200644	001	Nov 07, 2012	Sep	CAHN

TABLET, EFFERVESCENT;ORAL

CETYLEV

	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Jan	NEWA
+		2.5GM	N207916	002	Jan 29, 2016	Jan	NEWA

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB	IMPAX LABS INC	10MG	A202552	001	Dec 23, 2015	Aug	CAHN
AB		17.5MG	A202552	002	Dec 23, 2015	Aug	CAHN
AB		22.5MG	A202552	003	Dec 23, 2015	Aug	CAHN
AB		25MG	A202552	004	Dec 23, 2015	Aug	CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+	AUXILIUM PHARMS INC	8MG;60MG	N019806	001	Mar 25, 1994	Mar	CAHN
---	---------------------	----------	---------	-----	--------------	-----	------

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

	@ RANBAXY	200MG	A074975	001	Sep 30, 1998	Feb	DISC
AB	ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016	Mar	NEWA

OINTMENT;TOPICAL

ACYCLOVIR

AB	FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016	Apr	NEWA
----	--------------------	----	---------	-----	--------------	-----	------

TABLET;BUCCAL

SITAVIG

+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013	Jan	CAHN
---	------------------	------	---------	-----	--------------	-----	------

TABLET;ORAL

ACYCLOVIR

@ SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Feb	DISC
@	800MG	A074980	002	Sep 30, 1998	Feb	DISC

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

@ AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Jun	CAHN	
@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Jun	CAHN	
@ BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Feb	DISC	
@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	DISC	
AP +	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CTEC	
@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Apr	CAHN	
@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr	CAHN	
AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb	NEWA
AP +	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	CRLD	
AP	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb	NEWA	

ADAPALENE

GEL;TOPICAL

ADAPALENE

AB	TARO	0.3%	A208322	001	Jun 23, 2016	Jun	NEWA
AB	CALL INC	0.1%	A203981	001	Sep 23, 2016	Sep	NEWA
AB +		0.1%	A204593	001	Jan 05, 2016	Sep	CTEC

ADENOSINE

SOLUTION;IV (INFUSION)

ADENOSINE

AP +	TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr	CRLD
AP +		90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr	CRLD

ALBUTEROL SULFATE

SOLUTION;INHALATION

ALBUTEROL SULFATE

@ HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar	DISC	
@ LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar	DISC	
AN +	NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar	CRLD
@ TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar	DISC	
@ WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar	DISC	

TABLET;ORAL

ALBUTEROL SULFATE

@ DAVA PHARMS INC	EQ 2MG BASE	A072860	002	Dec 20, 1989	Oct	CMS1	
AB	SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar	CAHN
AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar	CAHN

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

>D>	+	ROXANE	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Nov	CAHN
	+		EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Aug	CRLD
>A>	+	WEST-WARD PHARMS INT	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013	Nov	CAHN
		FOSAMAX						
		@ MERCK	EQ 70MG BASE/75ML	N021575	001	Sep 17, 2003	Aug	DISC

TABLET;ORAL

ALENDRONATE SODIUM

AB	IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008	Aug	CAHN
AB		EQ 10MG BASE	A075710	002	Feb 06, 2008	Aug	CAHN
AB		EQ 35MG BASE	A075710	003	Feb 06, 2008	Aug	CAHN
AB		EQ 40MG BASE	A075710	004	Feb 06, 2008	Aug	CAHN
AB		EQ 70MG BASE	A075710	005	Feb 06, 2008	Aug	CAHN
AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	CAHN
AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	CAHN
AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	CAHN
AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	CAHN
	@ UPSHER-SMITH LABS	EQ 5MG BASE	A075871	001	Apr 22, 2009	Oct	CAHN
	@	EQ 10MG BASE	A075871	002	Apr 22, 2009	Oct	CAHN
	@	EQ 35MG BASE	A075871	004	Apr 22, 2009	Oct	CAHN
	@	EQ 40MG BASE	A075871	003	Apr 22, 2009	Oct	CAHN
	@	EQ 70MG BASE	A075871	005	Apr 22, 2009	Oct	CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

EQ 70MG BASE; 2,800 IU

N021762 001 Apr 07, 2005 Aug CMFD

+

EQ 70MG BASE; 5,600 IU

N021762 002 Apr 26, 2007 Aug CMFD

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB

UNICHEM LABS LTD

10MG

A203192 001 Jan 28, 2016 Jan NEWA

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

NODEN PHARMA

EQ 150MG BASE

N021985 001 Mar 05, 2007 Oct CAHN

+

EQ 300MG BASE

N021985 002 Mar 05, 2007 Oct CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

NODEN PHARMA

EQ 150MG BASE; 12.5MG

N022107 001 Jan 18, 2008 Oct CAHN

EQ 150MG BASE; 25MG

N022107 002 Jan 18, 2008 Oct CAHN

+

EQ 300MG BASE; 12.5MG

N022107 003 Jan 18, 2008 Oct CAHN

+

EQ 300MG BASE; 25MG

N022107 004 Jan 18, 2008 Oct CAHN

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB

INDOCO REMEDIES

100MG

A204467 001 Jul 28, 2016 Jul NEWA

AB

INDOCO REMEDIES

300MG

A204467 002 Jul 28, 2016 Jul NEWA

AB

SUN PHARM INDS

300MG

A071450 001 Jan 09, 1987 Mar CAHN

ZYLOPRIM

AB

SEBELA IRELAND LTD

100MG

N016084 001 Jan CAHN

AB

+

300MG

N016084 002 Jan CAHN

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP

WEST-WARD PHARMS INT

EQ 500MG BASE/VIAL

A076870 001 Aug 26, 2004 Oct CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB

AJANTA PHARMA LTD

EQ 6.25MG BASE

A205523 001 Mar 03, 2016 Feb NEWA

AB

AJANTA PHARMA LTD

EQ 12.5MG BASE

A205523 002 Mar 03, 2016 Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

>D> AB

ROXANE

EQ 0.5MG BASE

A200652 001 May 04, 2015 Nov CAHN

>D> AB

ROXANE

EQ 1MG BASE

A200652 002 May 04, 2015 Nov CAHN

>A> AB

WEST-WARD PHARMS INT

EQ 0.5MG BASE

A200652 001 May 04, 2015 Nov CAHN

>A> AB

ROXANE

EQ 1MG BASE

A200652 002 May 04, 2015 Nov CAHN

LOTRONEX

AB

SEBELA IRELAND LTD

EQ 0.5MG BASE

N021107 002 Dec 23, 2003 Feb CAHN

AB

+

EQ 1MG BASE

N021107 001 Feb 09, 2000 Feb CAHN

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

>D>

+

ROXANE

1MG/ML

A074312 001 Oct 31, 1993 Nov CAHN

>A>

+

WEST-WARD PHARMS INT

1MG/ML

A074312 001 Oct 31, 1993 Nov CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ ACTAVIS LABS FL INC

0.5MG

A077198 001 May 13, 2010 Jan DISC

@

1MG

A077198 002 May 13, 2010 Jan DISC

@

2MG

A077198 003 May 13, 2010 Jan DISC

@

3MG

A077198 004 May 13, 2010 Jan DISC

@ COREPHARMA

0.5MG

A077996 001 Jan 31, 2007 Mar DISC

@

1MG

A077996 002 Jan 31, 2007 Mar DISC

@

2MG

A077996 003 Jan 31, 2007 Mar DISC

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@	3MG	A077996	004	Jan 31, 2007	Mar	DISC
@ IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan	DISC
@	1MG	A077968	003	May 24, 2007	Jan	DISC
@	2MG	A077968	002	May 24, 2007	Jan	DISC
@	3MG	A077968	001	May 24, 2007	Jan	DISC

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP	WEST-WARD PHARMS INT	0.5MG/ML	A074815	001	Jan 20, 1998	Sep	CAHN
	EDEX						
	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar	CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar	CAHN
+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar	CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar	CAHN
+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar	CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar	CAHN
+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar	CAHN
	SUPPOSITORY; URETHRAL						
	MUSE						
+	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan	CRLD
+		0.25MG	N020700	002	Nov 19, 1996	Jan	CRLD
+		0.5MG	N020700	003	Nov 19, 1996	Jan	CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan	CAHN
AB	NEWGEN PHARMS LLC	100MG	A207570	001	Sep 30, 2016	Sep	NEWA
>A> AB	WATSON LABS INC	100MG	A208107	001	Dec 06, 2016	Nov	NEWA
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May	NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May	CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May	CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr	NEWA
	@	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A063274	001	May 18, 1992	Oct	CAHN
AP	+		EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Sep	CAHN
	@		EQ 250MG BASE/ML	A063275	001	May 18, 1992	Oct	CAHN
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Sep	CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	009	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	011	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678	012	Mar 26, 1997	Mar	CMS1
		CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	4.25%; 33MG/100ML; 5GM/100ML;	N020678	008	Mar 26, 1997	Mar	CMS1



INJECTABLE; INJECTION

	CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER							
		51MG/100ML; 261MG/100ML; 297MG/100ML						
		; 77MG/100ML						
	CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	016	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	017	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	018	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	019	Mar 26, 1997			Mar CMS1
	CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678	021	Mar 26, 1997			Mar CMS1

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%		N208081	001	May 10, 2016		May NEWA
---	-------------	-----	--	---------	-----	--------------	--	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

	@ IDT AUSTRALIA LTD	100MG		A085261	003			May CAHN
	@	100MG		A085262	002			May CAHN
	@	200MG		A085261	002			May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

>D>	AB	APOTEX CORP	200MG		A078578	001	Nov 06, 2008	Nov CAHN
>A>	AB	APOTEX INC	200MG		A078578	001	Nov 06, 2008	Nov CAHN
	AB	AUROBINDO PHARMA LTD	200MG		A204742	001	Jun 03, 2016	May NEWA
	AB	MURTY PHARMS	100MG		A077069	003	Oct 04, 2016	Sep NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@ ANI PHARMS INC	10MG		A085031	002			Sep CMS1
	@	50MG		A085031	003			Sep CMS1
	@	75MG		A085031	004			Sep CMS1
	@ SUN PHARM INDS INC	10MG		A040816	002	Jun 27, 2008		Mar DISC
	@	10MG		A089399	002	Jul 14, 1987		Mar DISC
AB	@	10MG		A089399	002	Jul 14, 1987		Mar CAHN
	@	25MG		A040816	001	Jun 27, 2008		Mar DISC
	@	25MG		A089399	001	Jul 14, 1987		Mar DISC
AB	@	25MG		A089399	001	Jul 14, 1987		Mar CAHN
	@	50MG		A040816	003	Jun 27, 2008		Mar DISC
	@	50MG		A089399	003	Jul 14, 1987		Mar DISC
AB	@	50MG		A089399	003	Jul 14, 1987		Mar CAHN
	@	75MG		A040816	004	Jun 27, 2008		Mar DISC
	@	75MG		A089399	004	Jul 14, 1987		Mar DISC
AB	@	75MG		A089399	004	Jul 14, 1987		Mar CAHN
	@	100MG		A040816	005	Jun 27, 2008		Mar DISC
	@	100MG		A089399	005	Jul 14, 1987		Mar DISC
AB	@	100MG		A089399	005	Jul 14, 1987		Mar CAHN
	@	150MG		A040816	006	Jun 27, 2008		Mar DISC
	@	150MG		A089399	006	Jul 14, 1987		Mar DISC
AB	@	150MG		A089399	006	Jul 14, 1987		Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Jul CAHN
@		EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Jul CAHN
@	SUN PHARM INDS	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Mar CAHN
@		EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG;2MG	A 071077	001	Nov 12, 1986	Mar CAHN
@		10MG;4MG	A 071078	001	Nov 12, 1986	Mar CAHN
@		25MG;2MG	A 070297	001	Nov 12, 1986	Mar CAHN
@		25MG;4MG	A 071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE	A 090752	003	May 16, 2016	May NEWA	
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A 206367	001	Dec 10, 2015	Feb CAHN	
AB		EQ 5MG BASE	A 206367	002	Dec 10, 2015	Feb CAHN	
AB		EQ 10MG BASE	A 206367	003	Dec 10, 2015	Feb CAHN	
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A 207821	001	Jul 11, 2016	Jun NEWA	
AB		EQ 5MG BASE	A 207821	002	Jul 11, 2016	Jun NEWA	
AB		EQ 10MG BASE	A 207821	003	Jul 11, 2016	Jun NEWA	
>D>	AB	ROXANE	EQ 2.5MG BASE	A 077262	001	Jul 09, 2007	Nov CAHN
>D>	AB		EQ 5MG BASE	A 077262	002	Jul 09, 2007	Nov CAHN
>D>	AB		EQ 10MG BASE	A 077262	003	Jul 09, 2007	Nov CAHN
	@	SUN PHARM INDS	EQ 2.5MG BASE	A 078081	001	Jan 31, 2008	Mar CAHN
	@		EQ 5MG BASE	A 078081	002	Jan 31, 2008	Mar CAHN
	@		EQ 10MG BASE	A 078081	003	Jan 31, 2008	Mar CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 2.5MG BASE	A 077262	001	Jul 09, 2007	Nov CAHN
>A>	AB		EQ 5MG BASE	A 077262	002	Jul 09, 2007	Nov CAHN
>A>	AB		EQ 10MG BASE	A 077262	003	Jul 09, 2007	Nov CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A 206137	001	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A 206137	002	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;25MG;40MG	A 206137	003	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A 206137	004	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;25MG;40MG	A 206137	005	Oct 26, 2016	Oct NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A 202491	001	Nov 03, 2016	Oct NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A 202491	002	Nov 03, 2016	Oct NEWA
AB		EQ 5MG BASE;25MG;40MG	A 202491	003	Nov 03, 2016	Oct NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A 202491	004	Nov 03, 2016	Oct NEWA
AB		EQ 10MG BASE;25MG;40MG	A 202491	005	Nov 03, 2016	Oct NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A 203580	001	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A 203580	002	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;25MG;40MG	A 203580	003	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A 203580	004	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;25MG;40MG	A 203580	005	Oct 26, 2016	Oct NEWA
	TRIBENZOR					
AB	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N 200175	001	Jul 23, 2010	Oct CFTG
AB		EQ 5MG BASE;12.5MG;40MG	N 200175	002	Jul 23, 2010	Oct CFTG
AB		EQ 5MG BASE;25MG;40MG	N 200175	003	Jul 23, 2010	Oct CFTG
AB		EQ 10MG BASE;12.5MG;40MG	N 200175	004	Jul 23, 2010	Oct CFTG
AB	+	EQ 10MG BASE;25MG;40MG	N 200175	005	Jul 23, 2010	Oct CFTG

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	AJANTA PHARMA LTD	EQ 5MG BASE;20MG	A 207216	001	Oct 28, 2016	Oct NEWA
AB		EQ 5MG BASE;40MG	A 207216	002	Oct 28, 2016	Oct NEWA
AB		EQ 10MG BASE;20MG	A 207216	003	Oct 28, 2016	Oct NEWA
AB		EQ 10MG BASE;40MG	A 207216	004	Oct 28, 2016	Oct NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE;20MG	A 206884	001	Oct 26, 2016	Oct NEWA
AB		EQ 5MG BASE;40MG	A 206884	003	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;20MG	A 206884	002	Oct 26, 2016	Oct NEWA
AB		EQ 10MG BASE;40MG	A 206884	004	Oct 26, 2016	Oct NEWA

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Oct	NEWA
AB		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Oct	NEWA
AB		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Oct	NEWA
>A>	TORRENT PHARMS LLC	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Nov	NEWA
>A>		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Nov	NEWA
>A>		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Nov	NEWA
>A>		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Nov	NEWA

AZOR

AB	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007	Oct	CFTG
AB		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007	Oct	CFTG
AB		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007	Oct	CFTG
AB	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007	Oct	CFTG

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

>A>	ALEMBIC PHARMS LTD	EQ 5MG BASE;40MG	A205234	001	Nov 17, 2016	Nov	NEWA
>A>		EQ 5MG BASE;80MG	A205234	003	Nov 17, 2016	Nov	NEWA
>A>		EQ 10MG BASE;40MG	A205234	002	Nov 17, 2016	Nov	NEWA
>A>		EQ 10MG BASE;80MG	A205234	004	Nov 17, 2016	Nov	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG	A206512	001	Apr 22, 2016	Apr	NEWA
AB		EQ 5MG BASE;320MG	A206512	002	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;160MG	A206512	003	Apr 22, 2016	Apr	NEWA
AB		EQ 10MG BASE;320MG	A206512	004	Apr 22, 2016	Apr	NEWA
AB	INVAGEN PHARMS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Sep	NEWA
AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Sep	NEWA
AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Sep	NEWA
AB	PAR PHARM INC	EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Oct	CMS1

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A207025	001	Feb 03, 2016	Jan	NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204457	001	Nov 18, 2015	Jan	NEWA

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr	CRLD
----	---	------------------	-------------	---------	-----	--------------	-----	------

LOTION;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr	CRLD
----	---	------------------	-------------	---------	-----	--------------	-----	------

AMOXAPINE

TABLET;ORAL

AMOXAPINE

>D>	@	SANDOZ	25MG	A072943	001	Jun 28, 1991	Nov	CAHN
>D>	@		50MG	A072944	001	Jun 28, 1991	Nov	CAHN
>D>	@		100MG	A072878	001	Jun 28, 1991	Nov	CAHN
>D>	@		150MG	A072879	001	Jun 28, 1991	Nov	CAHN
>A>	@	UPSHER-SMITH LABS	25MG	A072943	001	Jun 28, 1991	Nov	CAHN
>A>	@		50MG	A072944	001	Jun 28, 1991	Nov	CAHN
>A>	@		100MG	A072878	001	Jun 28, 1991	Nov	CAHN
>A>	@		150MG	A072879	001	Jun 28, 1991	Nov	CAHN

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Feb	DISC
@		500MG	A065016	002	Apr 08, 1999	Feb	DISC

TABLET;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Feb	DISC
@		875MG	A065059	002	Nov 24, 2000	Feb	DISC

TABLET, CHEWABLE;ORAL  
AMOXICILLIN

@ SUN PHARM INDS LTD 125MG A065021 001 Dec 23, 1999 Feb DISC  
@ 250MG A065021 002 Dec 23, 1999 Feb DISC

TABLET, EXTENDED RELEASE;ORAL  
MOXATAG

+ VERNALIS R AND D LTD 775MG N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL  
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB CITRON PHARMA LLC 500MG,N/A,N/A,N/A,500MG,N/A,N/A,N/A,30MG A206006 001 Oct 07, 2016 Sep NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB AUROBINDO PHARMA LTD 200MG/5ML;EQ 28.5MG BASE/5ML A201090 001 Dec 20, 2011 Feb CDFR  
AB 400MG/5ML;EQ 57MG BASE/5ML A201090 002 Dec 20, 2011 Feb CDFR  
AB 600MG/5ML;EQ 42.9MG BASE/5ML A201091 001 Dec 20, 2011 Feb CDFR  
@ SUN PHARM INDS LTD 200MG/5ML;EQ 28.5MG BASE/5ML A065132 001 Mar 19, 2003 Feb DISC  
@ 400MG/5ML;EQ 57MG BASE/5ML A065132 002 Mar 19, 2003 Feb DISC  
@ 600MG/5ML;EQ 42.9MG BASE/5ML A065207 002 Jan 30, 2007 Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB HIKMA PHARMS 875MG;EQ 125MG BASE A203824 001 Aug 23, 2016 Aug NEWA  
@ SUN PHARM INDS LTD 875MG;EQ 125MG BASE A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SANDOZ 200MG;EQ 28.5MG BASE A065065 001 Apr 18, 2002 Jul DISC  
@ 400MG;EQ 57MG BASE A065065 002 Apr 18, 2002 Jul DISC  
@ SUN PHARM INDS LTD 200MG;EQ 28.5MG BASE A065161 001 Dec 03, 2003 Feb DISC  
@ 400MG;EQ 57MG BASE A065161 002 Dec 03, 2003 Feb DISC  
AUGMENTIN '125'  
@ DR REDDYS LABS INC 125MG;EQ 31.25MG BASE N050597 001 Jul 22, 1985 Jul DISC  
125MG;EQ 31.25MG BASE N050597 001 Jul 22, 1985 Mar CTEC  
AUGMENTIN '250'  
@ DR REDDYS LABS INC 250MG;EQ 62.5MG BASE N050597 002 Jul 22, 1985 Jul DISC  
+ 250MG;EQ 62.5MG BASE N050597 002 Jul 22, 1985 Mar CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL  
ADZENYS XR-ODT

NEOS THERAPS EQ 3.1MG BASE N204326 001 Jan 27, 2016 Jan NEWA  
EQ 6.3MG BASE N204326 002 Jan 27, 2016 Jan NEWA  
EQ 9.4MG BASE N204326 003 Jan 27, 2016 Jan NEWA  
EQ 12.5MG BASE N204326 004 Jan 27, 2016 Jan NEWA  
EQ 15.7MG BASE N204326 005 Jan 27, 2016 Jan NEWA  
+ EQ 18.8MG BASE N204326 006 Jan 27, 2016 May CRLD  
EQ 18.8MG BASE N204326 006 Jan 27, 2016 Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB IMPAX LABS 1.25MG;1.25MG;1.25MG;1.25MG A076852 001 Feb 16, 2016 Feb NEWA  
AB 2.5MG;2.5MG;2.5MG;2.5MG A076852 002 Feb 16, 2016 Feb NEWA  
AB 3.75MG;3.75MG;3.75MG;3.75MG A076852 003 Feb 16, 2016 Feb NEWA  
AB 5MG;5MG;5MG;5MG A076852 004 Feb 16, 2016 Feb NEWA  
AB 6.25MG;6.25MG;6.25MG;6.25MG A076852 005 Feb 16, 2016 Feb NEWA  
AB 7.5MG;7.5MG;7.5MG;7.5MG A076852 006 Feb 16, 2016 Feb NEWA  
AB TEVA 1.25MG;1.25MG;1.25MG;1.25MG A077488 001 Apr 29, 2013 Feb CTNA  
AB 2.5MG;2.5MG;2.5MG;2.5MG A077488 002 Apr 29, 2013 Feb CTNA  
AB 3.75MG;3.75MG;3.75MG;3.75MG A077488 003 Apr 29, 2013 Feb CTNA  
AB 5MG;5MG;5MG;5MG A077488 004 Apr 29, 2013 Feb CTNA  
AB 6.25MG;6.25MG;6.25MG;6.25MG A077488 005 Apr 29, 2013 Feb CTNA  
AB 7.5MG;7.5MG;7.5MG;7.5MG A077488 006 Apr 29, 2013 Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB ACTAVIS ELIZABETH 1.25MG;1.25MG;1.25MG;1.25MG A206340 001 Feb 05, 2016 Jan NEWA  
AB 1.875MG;1.875MG;1.875MG;1.875MG A206340 002 Feb 05, 2016 Jan NEWA  
AB 2.5MG;2.5MG;2.5MG;2.5MG A206340 003 Feb 05, 2016 Jan NEWA  
AB 3.125MG;3.125MG;3.125MG;3.125MG A206340 004 Feb 05, 2016 Jan NEWA

TABLET;ORAL

		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE				
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG; 5MG; 5MG; 5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION  
AMPHOTEC

@	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@		100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

AMPICILLIN SODIUM

INJECTABLE; INJECTION  
AMPICILLIN SODIUM

AP	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug CAHN
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug CAHN
AP		EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Aug CAHN
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Aug CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL  
ANAGRELIDE HYDROCHLORIDE

@	UPSHER-SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Oct CAHN
@		EQ 1MG BASE	A076683	002	Apr 18, 2005	Oct CAHN

ANASTROZOLE

TABLET; ORAL  
ANASTROZOLE

>D>	AB	ROXANE	1MG	A078485	001	Jun 28, 2010	Nov CAHN
		@ SANDOZ	1MG	A079007	001	Jun 28, 2010	Aug DISC
>A>	AB	WEST-WARD PHARMS INT	1MG	A078485	001	Jun 28, 2010	Nov CAHN

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
IOPIDINE

>D>	AT	+ ALCON	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Nov CAHN
>D>			EQ 1% BASE	N019779	001	Dec 31, 1987	Nov CAHN
>A>	AT	+ NOVARTIS PHARMS CORP	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Nov CAHN
>A>			EQ 1% BASE	N019779	001	Dec 31, 1987	Nov CAHN

ARGATROBAN

INJECTABLE; INJECTION  
ARGATROBAN

AP	HOSPIRA INC	250MG/2.5ML (100MG/ML)	A204120	001	Sep 21, 2016	Sep NEWA
----	-------------	------------------------	---------	-----	--------------	----------

ARIPIPIRAZOLE

INJECTABLE; INTRAMUSCULAR  
ABILIFY

@	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
---	--------	-------------------------	---------	-----	--------------	----------

SOLUTION; ORAL  
ARIPIPIRAZOLE

AA	+ AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	-----------------	--------	---------	-----	--------------	----------

TABLET; ORAL

ARIPIPIRAZOLE

>A>	AB	ACCORD HLTHCARE	2MG	A206251	001	Dec 07, 2016	Nov NEWA
>A>	AB		5MG	A206251	002	Dec 07, 2016	Nov NEWA
>A>	AB		10MG	A206251	003	Dec 07, 2016	Nov NEWA
>A>	AB		15MG	A206251	004	Dec 07, 2016	Nov NEWA
>A>	AB		20MG	A206251	005	Dec 07, 2016	Nov NEWA
>A>	AB		30MG	A206251	006	Dec 07, 2016	Nov NEWA
	AB	AJANTA PHARMA LTD	2MG	A206174	001	Sep 12, 2016	Aug NEWA
	AB		5MG	A206174	002	Sep 12, 2016	Aug NEWA
	AB		10MG	A206174	003	Sep 12, 2016	Aug NEWA
	AB		15MG	A206174	004	Sep 12, 2016	Aug NEWA
	AB		20MG	A206174	005	Sep 12, 2016	Aug NEWA
	AB		30MG	A206174	006	Sep 12, 2016	Aug NEWA
	AB	AMNEAL PHARMS	2MG	A204838	001	Jun 17, 2016	Jun NEWA
	AB		5MG	A204838	002	Jun 17, 2016	Jun NEWA
	AB		10MG	A204838	003	Jun 17, 2016	Jun NEWA
	AB		15MG	A204838	004	Jun 17, 2016	Jun NEWA
	AB		20MG	A204838	005	Jun 17, 2016	Jun NEWA

TABLET;ORAL  
ARIPIPIRAZOLE

AB		30MG	A204838	006	Jun 17, 2016	Jun	NEWA
AB	MACLEODS PHARMS LTD	2MG	A204111	001	Oct 07, 2016	Sep	NEWA
AB		5MG	A204111	002	Oct 07, 2016	Sep	NEWA
AB		10MG	A204111	003	Oct 07, 2016	Sep	NEWA
AB		15MG	A204111	004	Oct 07, 2016	Sep	NEWA
AB		20MG	A204111	005	Oct 07, 2016	Sep	NEWA
AB		30MG	A204111	006	Oct 07, 2016	Sep	NEWA
AB	SCIEGEN PHARMS INC	2MG	A206383	001	Sep 29, 2016	Sep	NEWA
AB		5MG	A206383	002	Sep 29, 2016	Sep	NEWA
AB		10MG	A206383	003	Sep 29, 2016	Sep	NEWA
AB		15MG	A206383	004	Sep 29, 2016	Sep	NEWA
AB		20MG	A206383	005	Sep 29, 2016	Sep	NEWA
AB		30MG	A206383	006	Sep 29, 2016	Sep	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

	ABILIFY						
	@ OTSUKA	10MG	N021729	002	Jun 07, 2006	May	DISC
	@	15MG	N021729	003	Jun 07, 2006	May	DISC
	ARIPIPIRAZOLE						
+	ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	May	CRLD
		15MG	A202102	002	Apr 28, 2015	May	CTEC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

>A>	AB	LUPIN LTD	50MG	A200751	001	Nov 28, 2016	Nov	NEWA
>A>	AB		150MG	A200751	003	Nov 28, 2016	Nov	NEWA
>A>	AB		200MG	A200751	004	Nov 28, 2016	Nov	NEWA
>A>	AB		250MG	A200751	005	Nov 28, 2016	Nov	NEWA
	AB	MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Apr	CMFD
	AB		150MG	A200043	002	Jun 01, 2012	Apr	CMFD
	AB		250MG	A200043	003	Jun 01, 2012	Apr	CMFD
>A>	AB	NATCO PHARMA LTD	50MG	A202768	001	Nov 28, 2016	Nov	NEWA
>A>	AB		150MG	A202768	002	Nov 28, 2016	Nov	NEWA
>A>	AB		250MG	A202768	003	Nov 28, 2016	Nov	NEWA
	AB	NUVIGIL						
	AB	CEPHALON	50MG	N021875	001	Jun 15, 2007	Apr	CTEC
	AB		150MG	N021875	003	Jun 15, 2007	Apr	CTEC
>D>			200MG	N021875	005	Mar 26, 2009	Nov	CTEC
>A>	AB		200MG	N021875	005	Mar 26, 2009	Nov	CTEC
AB	+		250MG	N021875	004	Jun 15, 2007	Apr	CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

	@ TELIGENT PHARMA INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jan	CAHN
--	-----------------------	--	---------	-----	--------------	-----	------

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

	FOREST LABS LLC	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Mar	NEWA
--	-----------------	-------------	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

	@ NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	Jan	CAHN	
	FIORINAL							
AA	+	ALLERGAN SALES LLC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Apr	CAHN
	TABLET;ORAL							
	BUTALBITAL, ASPIRIN AND CAFFEINE							
AA	PHARMACEUTICS INTL	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Sep	NEWA	

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL		BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE						
AB	MAYNE PHARMA INC	325MG;50MG;40MG;30MG		A203335	001	Oct 30, 2015	Aug	CAHN
		FIORINAL W/CODEINE						
AB	+ ALLERGAN SALES LLC	325MG;50MG;40MG;30MG		N019429	003	Oct 26, 1990	Apr	CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL		CARISOPRODOL AND ASPIRIN						
AB	+ HERITAGE PHARMS INC	325MG;200MG		A089594	001	Mar 31, 1989	Jun	CRLD
AB	INGENUS PHARMS NJ	325MG;200MG		A040832	001	Jan 07, 2010	Jan	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL		CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE							
AB	INGENUS PHARMS NJ	325MG;200MG;16MG		A040860	001	Jan 07, 2010	Mar	CMFD	
		@	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan	CAHN	
AB	+ SANDOZ	325MG;200MG;16MG		A040118	001	Apr 16, 1996	Mar	CTEC	
		+	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan	CRLD	
		SOMA COMPOUND W/ CODEINE							
		@	MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan	DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL		ASPIRIN AND DIPYRIDAMOLE						
AB	AMNEAL PHARMS	25MG;200MG		A206392	001	Mar 08, 2016	Oct	CMFD
		@	25MG;200MG	A206392	001	Mar 08, 2016	Apr	DISC
AB		25MG;200MG		A206392	001	Mar 08, 2016	Feb	NEWA

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL		YOSPRALA						
		ARALEZ PHARMS	81MG;40MG	N205103	001	Sep 14, 2016	Sep	NEWA
		+	325MG;40MG	N205103	002	Sep 14, 2016	Sep	NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL		OXYCODONE AND ASPIRIN						
AA	MAYNE PHARMA INC	325MG;4.8355MG		A091670	001	Mar 16, 2011	Aug	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL		OXYCODONE AND ASPIRIN							
		@	SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998	Mar	CAHN
		@		325MG;4.5MG;0.38MG	A087794	001	May 26, 1982	Mar	CAHN

ATENOLOL

TABLET;ORAL		ATENOLOL							
AB	ALVOGEN MALTA	25MG		A073646	001	Jul 31, 1992	Jan	CAHN	
AB		50MG		A072303	001	Jul 15, 1988	Jan	CAHN	
AB		100MG		A072304	001	Jul 15, 1988	Jan	CAHN	
		@	NORTHSTAR HLTHCARE	25MG	A078254	001	Sep 25, 2009	Aug	DISC
		@		50MG	A078254	002	Sep 25, 2009	Aug	DISC
		@		100MG	A078254	003	Sep 25, 2009	Aug	DISC
		TENORMIN							
AB	ALVOGEN MALTA	25MG		N018240	004	Apr 09, 1990	Jan	CAHN	
AB		50MG		N018240	001		Jan	CAHN	
AB	+	100MG		N018240	002		Jan	CAHN	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL		ATENOLOL AND CHLORTHALIDONE						
AB	ALVOGEN MALTA	50MG;25MG		A072301	001	May 31, 1990	Jan	CAHN
AB		100MG;25MG		A072302	001	May 31, 1990	Jan	CAHN
AB	SUN PHARM INDS	100MG;25MG		A073582	001	Apr 29, 1993	Mar	CAHN
		TENORETIC 100						
AB	+	ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan	CAHN

TABLET;ORAL  
TENORETIC 50

AB ALVOGEN MALTA 50MG;25MG N018760 002 Jun 08, 1984 Jan CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL  
ATORVASTATIN CALCIUM

AB SCIEGEN PHARMS INC EQ 10MG BASE A205519 001 May 19, 2016 May NEWA  
 AB EQ 20MG BASE A205519 002 May 19, 2016 May NEWA  
 AB EQ 40MG BASE A205519 003 May 19, 2016 May NEWA  
 AB EQ 80MG BASE A205519 004 May 19, 2016 May NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION  
ATRACURIUM BESYLATE

AP NANJING KING-FRIEND 10MG/ML A091489 001 Feb 17, 2012 Sep CAHN  
 AP + WEST-WARD PHARMS INT 10MG/ML A074901 001 Jul 18, 1997 Oct CAHN  
 ATRACURIUM BESYLATE PRESERVATIVE FREE  
 AP NANJING KING-FRIEND 10MG/ML A091488 001 Feb 17, 2012 Sep CAHN  
 AP + WEST-WARD PHARMS INT 10MG/ML A074900 001 Jul 18, 1997 Sep CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D> AA + ROXANE 0.025MG/5ML;2.5MG/5ML A087708 001 May 03, 1982 Nov CAHN  
 >A> AA + WEST-WARD PHARMS INT 0.025MG/5ML;2.5MG/5ML A087708 001 May 03, 1982 Nov CAHN

TABLET;ORAL  
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE  
 @ SUN PHARM INDS 0.025MG;2.5MG  
 LONOX  
 @ SANDOZ 0.025MG;2.5MG

A085506 001 Mar CAHN  
 A085311 002 Aug DISC

AURANOFIN

CAPSULE;ORAL  
RIDAURA

+ SEBELA IRELAND LTD 3MG N018689 001 May 24, 1985 Jan CAHN

AVANAFIL

TABLET;ORAL  
STENDRA  
METUCHEN PHARMS 50MG

100MG N202276 001 Apr 27, 2012 Oct CAHN  
 200MG N202276 002 Apr 27, 2012 Oct CAHN

+ N202276 003 Apr 27, 2012 Oct CAHN

AXITINIB

TABLET;ORAL  
INLYTA

PF PRISM CV 1MG N202324 001 Jan 27, 2012 Apr CAHN  
 + 5MG N202324 002 Jan 27, 2012 Apr CAHN

AZACITIDINE

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS  
AZACITIDINE

AP MYLAN INSTITUTIONAL 100MG/VIAL A204949 001 Apr 28, 2016 Apr NEWA  
 AP SHILPA MEDICARE 100MG/VIAL A207518 001 Sep 29, 2016 Sep NEWA

POWDER;IV (INFUSION), SUBCUTANEOUS  
AZACITIDINE

ACTAVIS LLC 100MG/VIAL N208216 001 Apr 29, 2016 Apr NEWA

AZATHIOPRINE

TABLET;ORAL  
IMURAN

@ SEBELA IRELAND LTD 25MG N016324 002 Jan CAHN  
 AB + 50MG N016324 001 Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION  
AZATHIOPRINE SODIUM

+ WEST-WARD PHARMS INT EQ 100MG BASE/VIAL A074419 001 Mar 31, 1995 Sep CAHN  
 IMURAN  
 @ SEBELA IRELAND LTD EQ 100MG BASE/VIAL N017391 001 Jan CAHN



AZELASTINE HYDROCHLORIDE

		SOLUTION/DROPS;OPHTHALMIC							
		AZELASTINE HYDROCHLORIDE							
AT		AKORN	0.05%	A203660	001	Nov 08, 2016	Oct	NEWA	
		SPRAY, METERED;NASAL							
		AZELASTINE HYDROCHLORIDE							
>D>	AB	ROXANE	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Nov	CAHN	
>A>	AB	WEST-WARD PHARMS INT	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Nov	CAHN	

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

ARBOR PHARMS LLC

+

EQ 40MG MEDOXOMIL  
EQ 80MG MEDOXOMIL

N200796 001 Feb 25, 2011 Jan CAHN  
N200796 002 Feb 25, 2011 Jan CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

ARBOR PHARMS LLC

+

EQ 40MG MEDOXOMIL;12.5MG  
EQ 40MG MEDOXOMIL;25MG

N202331 001 Dec 20, 2011 Jan CAHN  
N202331 002 Dec 20, 2011 Jan CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

BX LUPIN LTD

BX

EQ 100MG BASE/5ML  
EQ 200MG BASE/5ML

A065488 001 May 15, 2015 Apr CTEC  
A065488 002 May 15, 2015 Apr CTEC

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

@ EUROHLTH INTL SARL

@

@ WEST-WARD PHARMS INT

@

1GM/VIAL  
2GM/VIAL  
1GM/VIAL  
2GM/VIAL

A065286 001 Mar 23, 2011 Mar DISC  
A065286 002 Mar 23, 2011 Mar DISC  
A065286 001 Mar 23, 2011 Sep CAHN  
A065286 002 Mar 23, 2011 Sep CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP SINTEtica SA

AP

AP

LIORESAL

AP + SAOL THERAPS RES LTD

AP

AP

0.05MG/ML  
0.5MG/ML  
2MG/ML  
0.05MG/ML  
0.5MG/ML  
2MG/ML

A091193 001 May 03, 2016 Apr NEWA  
A091193 002 May 03, 2016 Apr NEWA  
A091193 003 May 03, 2016 Apr NEWA  
N020075 003 Nov 07, 1996 May CAHN  
N020075 001 Jun 17, 1992 May CAHN  
N020075 002 Jun 17, 1992 May CAHN

TABLET;ORAL

BACLOFEN

>A> AB IMPAX LABS

AB

AB

NORTHSTAR HLTHCARE

>D> AB WATSON LABS

>A> @

>D> AB

>A> @

10MG  
10MG  
10MG  
10MG  
10MG  
20MG  
20MG

A077971 001 Oct 26, 2007 Nov CMS1  
A077241 002 Jul 06, 2007 Oct CMS1  
A078401 002 Sep 18, 2009 Jan CMS1  
A072824 001 Sep 18, 1991 Nov DISC  
A072824 001 Sep 18, 1991 Nov DISC  
A072825 001 Sep 18, 1991 Nov DISC  
A072825 001 Sep 18, 1991 Nov DISC

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>D> AB ROXANE

>A> AB

WEST-WARD PHARMS INT

750MG  
750MG

A077806 001 Dec 28, 2007 Nov CAHN  
A077806 001 Dec 28, 2007 Nov CAHN

BARIIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-HD

+ BRACCO

PASTE;ORAL

VARIBAR

+ BRACCO

334GM/BOTTLE  
40% (92GM/230ML)

N208036 001 Jan 11, 2016 Jan NEWA  
N208844 001 Oct 14, 2016 Oct NEWA

SUSPENSION; ORAL

READI-CAT 2

+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA
	READI-CAT 2 SMOOTHIES					
	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan DISC
@		10MG	A076267	002	Feb 11, 2004	Jan DISC
@		20MG	A076267	003	Feb 11, 2004	Jan DISC
@		40MG	A076267	004	Feb 11, 2004	Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	Jan DISC
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	Jan DISC
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	Jan DISC
@		20MG; 25MG	A076342	004	Feb 11, 2004	Jan DISC
@	IVAX SUB TEVA PHARMS	5MG; 6.25MG	A076348	001	Feb 11, 2004	Mar DISC
@		10MG; 12.5MG	A076348	002	Feb 11, 2004	Mar DISC
@		20MG; 12.5MG	A076348	003	Feb 11, 2004	Mar DISC
@		20MG; 25MG	A076348	004	Feb 11, 2004	Mar DISC
@	SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar DISC
@		10MG; 12.5MG	A077483	002	Sep 08, 2005	Mar DISC
@		20MG; 12.5MG	A077483	003	Sep 08, 2005	Mar DISC
@		20MG; 25MG	A077483	004	Sep 08, 2005	Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May NEWA
AP		100MG/VIAL	A205574	002	May 19, 2016	May NEWA
AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar NEWA
AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May NEWA
AP		100MG/VIAL	A204086	002	May 20, 2016	May NEWA
AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar NEWA

TREANDA

AP	+ CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar CFTG
AP	+	100MG/VIAL	N022249	001	Mar 20, 2008	Mar CFTG

SOLUTION; IV (INFUSION)

BENDEKA

+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Sep CRLD
---	--------------	---------------------	---------	-----	--------------	----------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	TOLMAR	5%; 1.2%	A203688	001	Aug 25, 2016	Aug NEWA
----	--------	----------	---------	-----	--------------	----------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+	CUTANEA	5%; 3%	N050769	001	Nov 27, 2000	Sep CTNA
+		5%; 3%	N050769	001	Nov 27, 2000	Feb CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar DISC
---	------------	------	---------	-----	--------------	----------

BENZTROPINE MESYLATE

TABLET; ORAL		BENZTROPINE MESYLATE					
AA	ASPEN GLOBAL INC	0.5MG		A204713	001	Apr 14, 2015	Jul CAHN
AA		1MG		A204713	002	Apr 14, 2015	Jul CAHN
AA		2MG		A204713	003	Apr 14, 2015	Jul CAHN
	@ FRONTIDA BIOPHARM	1MG		A081264	001	Jan 23, 1992	Sep CAHN
	@	2MG		A081265	001	Jan 23, 1992	Jul CAHN
AA	VINTAGE	0.5MG		A040715	001	Aug 27, 2007	Oct CMS1
AA		1MG		A040715	002	Aug 27, 2007	Oct CMS1

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL  
SERNIVO

+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY		N208079	001	Feb 05, 2016	Feb NEWA
---	--------------------	---------------------	--	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%		A202894	001	Oct 30, 2015	Mar CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE		A075630	001	Apr 12, 2001	Jan CAHN
----	---------------------	--------------	--	---------	-----	--------------	----------

SUSPENSION/DROPS; OPHTHALMIC  
BETOPTIC S

>D>	+	ALCON	EQ 0.25% BASE	N019845	001	Dec 29, 1989	Nov CAHN
>A>	+	NOVARTIS PHARMS CORP	EQ 0.25% BASE	N019845	001	Dec 29, 1989	Nov CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE							
	@ IMPAX LABS	5MG		A040739	001	Nov 01, 2006	Mar DISC
	@	10MG		A040741	001	Nov 01, 2006	Mar DISC
	@	25MG		A040740	001	Nov 01, 2006	Mar DISC
	@	50MG		A040721	004	Nov 01, 2006	Mar DISC
	@ SUN PHARM INDS INC	5MG		A040897	001	Apr 22, 2009	Oct DISC
	@	10MG		A040897	002	Apr 22, 2009	Oct DISC
	@	25MG		A040897	003	Apr 22, 2009	Oct DISC
	@	50MG		A040897	004	Apr 22, 2009	Oct DISC
DUVOID							
AA	BI-COASTAL PHARMA	10MG		A086262	001		Jul CAHN
AA		25MG		A086263	001		Jul CAHN
AA		50MG		A085882	003		Jul CAHN

BIMATOPROST

SOLUTION/DROPS; TOPICAL  
BIMATOPROST

AT	SANDOZ INC	0.03%		A202719	001	Apr 19, 2016	Apr NEWA
----	------------	-------	--	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL  
HELIDAC

@	SEBELA IRELAND LTD	262.4MG, N/A, N/A; N/A, 250MG, N/A, N/A, N/A, 500MG		N050719	001	Aug 15, 1996	Jan CAHN
---	--------------------	---	--	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE							
	@ FRONTIDA BIOPHARM	5MG		A075474	001	Oct 25, 2002	Jul CAHN
	@	10MG		A075474	002	Oct 25, 2002	Jul CAHN
AB	+	MYLAN	10MG	A075831	002	Dec 14, 2005	Aug CRLD
	@ SUN PHARM INDS	5MG		A075474	001	Oct 25, 2002	Mar CAHN
	@	10MG		A075474	002	Oct 25, 2002	Mar CAHN
ZEBETA							
	@ TEVA WOMENS	5MG		N019982	002	Jul 31, 1992	Aug DISC
	@	10MG		N019982	001	Jul 31, 1992	Aug DISC

BIVALIRUDIN

INJECTABLE; INTRAVENOUS  
 BIVALIRUDIN  
 AP FRESenius KABI USA 250MG/VIAL A090189 001 Oct 28, 2016 Oct NEWA

BLEOMYCIN SULFATE

INJECTABLE; INJECTION  
 BLEOMYCIN SULFATE  
 AP WEST-WARD PHARMS INT EQ 15 UNITS BASE/VIAL A065042 002 Oct 17, 2001 Sep CAHN  
 AP EQ 30 UNITS BASE/VIAL A065042 001 Oct 17, 2001 Sep CAHN

BOCEPREVIR

CAPSULE; ORAL  
 VICTRELIS  
 @ MERCK SHARP DOHME 200MG N202258 001 May 13, 2011 Jun DISC

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION  
 BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER  
 @ B BRAUN 100MG/100ML N019121 001 Apr 29, 1986 Sep DISC  
 @ 200MG/100ML N019121 002 Apr 29, 1986 Sep DISC  
 @ 400MG/100ML N019121 003 Apr 29, 1986 Sep DISC

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC  
 SIMBRINZA  
 >D> + ALCON RES LTD 0.2%;1% N204251 001 Apr 19, 2013 Nov CAHN  
 >A> + NOVARTIS PHARMS CORP 0.2%;1% N204251 001 Apr 19, 2013 Nov CAHN

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC  
 AZOPT  
 >D> + ALCON PHARMS LTD 1% N020816 001 Apr 01, 1998 Nov CAHN  
 >A> + NOVARTIS PHARMS CORP 1% N020816 001 Apr 01, 1998 Nov CAHN

BRIVARACETAM

SOLUTION; INTRAVENOUS  
 BRIVIACT  
 + UBC INC 50MG/5ML (10MG/ML) N205837 001 Feb 18, 2016 Feb NEWA  
 + UCB INC 50MG/5ML (10MG/ML) N205837 001 May 12, 2016 May CMS1  
 SOLUTION; ORAL  
 BRIVIACT  
 + UCB INC 10MG/ML N205838 001 May 12, 2016 May CMS1  
 + 10MG/ML N205838 001 Feb 18, 2016 Feb NEWA  
 TABLET; ORAL  
 BRIVIACT  
 UCB INC 10MG N205836 001 May 12, 2016 May CMS1  
 10MG N205836 001 Feb 18, 2016 Feb NEWA  
 25MG N205836 002 May 12, 2016 May CMS1  
 25MG N205836 002 Feb 18, 2016 Feb NEWA  
 50MG N205836 003 May 12, 2016 May CMS1  
 50MG N205836 003 Feb 18, 2016 Feb NEWA  
 75MG N205836 004 May 12, 2016 May CMS1  
 75MG N205836 004 Feb 18, 2016 Feb NEWA  
 + 100MG N205836 005 May 12, 2016 May CMS1  
 + 100MG N205836 005 Feb 18, 2016 Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC  
 BROMSITE  
 + INSITE VISION INC EQ 0.075% ACID N206911 001 Apr 08, 2016 Apr NEWA  
 + SUN PHARMA GLOBAL EQ 0.075% ACID N206911 001 Apr 08, 2016 Jul CAHN

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL  
 BROMOCRIPTINE MESYLATE  
 AB + MYLAN EQ 5MG BASE A077226 001 Apr 04, 2005 Jan CRLD  
 PARLODEL  
 >D> @ US PHARMS HOLDINGS I EQ 5MG BASE N017962 002 Mar 01, 1982 Nov CMFD  
 >A> AB EQ 5MG BASE N017962 002 Mar 01, 1982 Nov CMFD  
 @ EQ 5MG BASE N017962 002 Mar 01, 1982 Jan DISC

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan	CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb	CAHN
PARLODEL								
AB		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr	CMFD
		@	EQ 2.5MG BASE	N017962	001		Jan	DISC

BROMPHENIRAMINE MALEATE

TABLET;ORAL

BROMPHENIRAMINE MALEATE

@	UPSHER-SMITH LABS	4MG		A083215	001		Oct	CAHN
---	-------------------	-----	--	---------	-----	--	-----	------

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA PHARMS LLC	2MG/5ML;10MG/5ML;30MG/5ML	A203375	001	Sep 20, 2016	Sep	NEWA
----	--	-------------------	---------------------------	---------	-----	--------------	-----	------

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB		ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar	NEWA
>A>	AB	ALVOGEN MALTA	3MG	A206724	001	Nov 23, 2016	Nov	NEWA
AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Aug	CAHN
ENTOCORT EC								
AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan	CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May	CAHN

SUSPENSION;INHALATION

BUDESONIDE

AN		APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun	CMFD
AN			0.5MG/2ML	A078202	002	Mar 30, 2009	Jun	CMFD
AN		IMPAX LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Aug	CAHN
AN			0.5MG/2ML	A078404	002	Jul 31, 2012	Aug	CAHN
AN		TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb	NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun	CAHN
AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Apr	CAHN

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

+	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)		N022496	001	Oct 28, 2011	Sep	CMFD
---	-------------------	------------------------	--	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May	NEWA
AP			0.5%	A207183	002	May 13, 2016	May	NEWA

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		CLARIS	0.75%	A207266	001	Jul 25, 2016	Jul	NEWA
----	--	--------	-------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION

PROBUPHINE

+	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT		N204442	001	May 26, 2016	Jun	CAHN
+	TITAN PHARMS	EQ 80MG BASE/IMPLANT		N204442	001	May 26, 2016	May	NEWA

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Oct	CAHN
----	--	----------------------	------------------	---------	-----	--------------	-----	------

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>D>	AB	ROXANE	EQ 2MG BASE	A078633	001	Oct 08, 2009	Nov	CAHN
>D>	AB	+	EQ 8MG BASE	A078633	002	Oct 08, 2009	Nov	CAHN
	AB	SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan	NEWA
	AB		EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan	NEWA
>A>	AB	WEST-WARD PHARMS INT	EQ 2MG BASE	A078633	001	Oct 08, 2009	Nov	CAHN
>A>	AB	+	EQ 8MG BASE	A078633	002	Oct 08, 2009	Nov	CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	KREMERS URBAN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205022	001	Sep 19, 2016	Sep	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205022	002	Sep 19, 2016	Sep	NEWA
>D>	AB	ROXANE	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Nov CAHN
>D>	AB		EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Nov CAHN
AB	SUN PHARM INDS LTD	EQ 8MG BASE;EQ 2MG BASE	A201633	002	Aug 05, 2016	Jul	NEWA
>A>	AB	WEST-WARD PHARMS INT	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Nov CAHN
>A>	AB		EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Nov CAHN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A201633	001	Aug 05, 2016	Jul	NEWA
ZUBSOLV							
	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016	Oct	NEWA
		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Jul	CAHN
		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jul	CAHN
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Jul	CAHN
		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Jul	CAHN
		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Jul	CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	+	APOTEX INC	100MG	A076143	002	Jan 17, 2006	Sep CRLD
AB		HERITAGE PHARMA	75MG	A206975	001	Aug 19, 2016	Aug NEWA
AB			100MG	A206975	002	Aug 19, 2016	Aug NEWA
WELLBUTRIN							
	@	GLAXOSMITHKLINE	75MG	N018644	002	Dec 30, 1985	Sep DISC
	@		100MG	N018644	003	Dec 30, 1985	Sep DISC

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1		INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB3			150MG	A206556	001	Aug 26, 2016	Aug NEWA
AB1			150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1			200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB3			300MG	A206556	002	Aug 26, 2016	Aug NEWA
AB1		SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1			150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB2			150MG	A206122	001	Aug 17, 2016	Aug NEWA
AB1			200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	OREXIGEN	90MG;8MG	N200063	001	Sep 10, 2014	Apr	CAHN
---	----------	----------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
AB			10MG	A204582	002	Sep 18, 2015	Jun CAHN
AB			15MG	A204582	003	Sep 18, 2015	Jun CAHN
AB			30MG	A204582	004	Sep 18, 2015	Jun CAHN
AB		IMPAX LABS INC	5MG	A074253	001	Mar 28, 2001	Aug CAHN
AB			10MG	A074253	002	Mar 28, 2001	Aug CAHN
AB			15MG	A074253	003	Mar 13, 2002	Aug CAHN
>A>	AB	MYLAN	5MG	A076008	003	Mar 01, 2002	Nov CMS1
AB			7.5MG	A076008	002	Jul 08, 2013	Oct NEWA
>A>	AB		10MG	A076008	004	Mar 01, 2002	Nov CMS1
>A>	AB		15MG	A076008	005	Mar 28, 2001	Nov CMS1

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP		LUITPOLD PHARMS INC	6MG/ML	A202259	001	Dec 22, 2015	Mar CAHN
----	--	---------------------	--------	---------	-----	--------------	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL  
 BUTOCONAZOLE NITRATE  
 @ PERRIGO PHARMA INTL 2% N019881 001 Feb 07, 1997 Jun CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION  
 BUTORPHANOL TARTRATE  
 @ CLARIS 2MG/ML A075697 001 Oct 23, 2001 Jan CAHN  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE  
 @ CLARIS 1MG/ML A075695 001 Oct 23, 2001 Mar CAHN  
 @ 2MG/ML A075695 002 Oct 23, 2001 Mar CAHN  
 SPRAY, METERED;NASAL  
 BUTORPHANOL TARTRATE  
 AB APOTEX INC 1MG/SPRAY A075499 001 Dec 04, 2002 Sep CAHN  
 >D> AB ROXANE 1MG/SPRAY A075824 001 Mar 12, 2002 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT 1MG/SPRAY A075824 001 Mar 12, 2002 Nov CAHN

CABERGOLINE

TABLET;ORAL  
 CABERGOLINE  
 @ IMPAX LABS INC 0.5MG A077843 001 Jul 03, 2007 Mar DISC

CABOZANTINIB S-MALATE

TABLET;ORAL  
 CABOMETYX  
 EXELIXIS INC EQ 20MG BASE N208692 001 Apr 25, 2016 Apr NEWA  
 EQ 40MG BASE N208692 002 Apr 25, 2016 Apr NEWA  
 + EQ 60MG BASE N208692 003 Apr 25, 2016 Apr NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS  
 CAFKIT  
 AP + WEST-WARD PHARMS INT EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 001 Sep 21, 1999 Sep CAHN  
 SOLUTION;ORAL  
 CAFKIT  
 AA + WEST-WARD PHARMS INT EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 002 Apr 12, 2000 Sep CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL  
 MIGERGOT  
 + HORIZON PHARMA 100MG;2MG A086557 001 Oct 04, 1983 Jan CAHN

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL  
 RAYALDEE  
 + OPKO IRELAND GLOBAL 0.03MG N208010 001 Jun 17, 2016 Jun NEWA

CALCIPOTRIENE

CREAM;TOPICAL  
 CALCIPOTRIENE  
 AB GLENMARK PHARMS 0.005% A205772 001 Jun 09, 2015 Mar CAHN

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL  
 FORTICAL  
 @ UPSHER SMITH 200 IU/SPRAY N021406 001 Aug 12, 2005 Sep DISC

CALCITRIOL

CAPSULE;ORAL  
 CALCITRIOL  
 AB BIONPHARMA INC 0.25MCG A091174 001 May 24, 2013 Jan CAHN  
 AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN  
 >D> AB ROXANE 0.25MCG A076917 001 Mar 27, 2006 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT 0.25MCG A076917 001 Mar 27, 2006 Nov CAHN  
 INJECTABLE; INJECTION  
 CALCITRIOL  
 AKORN 0.001MG/ML A078066 001 Jan 29, 2008 Feb CTEC  
 @ ROCKWELL MEDCL 0.001MG/ML A076206 001 Sep 17, 2003 Feb DISC

SOLUTION;ORAL  
CALCITRIOL

>D>	AA	ROXANE	1MCG/ML	A 076242	001	Jul 18, 2003	Nov CAHN
>A>	AA	WEST-WARD PHARMS INT	1MCG/ML	A 076242	001	Jul 18, 2003	Nov CAHN

CALCIUM ACETATE

CAPSULE;ORAL  
CALCIUM ACETATE

>D>	AB	AMNEAL PHARMS	EQ 169MG CALCIUM 667MG	A 201658	001	Oct 06, 2014	Nov CPOT
>A>	AB			A 201658	001	Oct 06, 2014	Nov CPOT
>D>	AB	ECI PHARMS LLC	EQ 169MG CALCIUM 667MG	A 203298	001	Jul 26, 2016	Nov CPOT
>A>	AB			A 203298	001	Jul 26, 2016	Oct CAHN
>D>	AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM 667MG	A 202315	001	Jun 29, 2015	Nov CPOT
>A>	AB			A 202315	001	Jun 29, 2015	Nov CPOT
>D>	AB	INVAGEN PHARMS	EQ 169MG CALCIUM 667MG	A 203135	001	Feb 07, 2013	Nov CPOT
>A>	AB			A 203135	001	Feb 07, 2013	Nov CPOT
>D>	AB	LOTUS PHARM CO LTD	EQ 169MG CALCIUM 667MG	A 203298	001	Jul 26, 2016	Jul NEWA
>A>	AB	LUPIN LTD	EQ 169MG CALCIUM 667MG	A 202127	001	Jul 09, 2015	Nov CPOT
>D>	AB			A 202127	001	Jul 09, 2015	Nov CPOT
>D>	AB	NOSTRUM LABS INC	EQ 169MG CALCIUM 667MG	A 203179	001	Oct 26, 2015	Nov CPOT
>A>	AB			A 203179	001	Oct 26, 2015	Nov CPOT
>D>	AB	PADDOCK LLC	EQ 169MG CALCIUM 667MG	A 091312	001	Jun 01, 2012	Nov CPOT
>A>	AB			A 091312	001	Jun 01, 2012	Nov CPOT
>D>	AB	ROXANE	EQ 169MG CALCIUM 667MG	A 077728	001	Feb 26, 2008	Nov CPOT
>A>	AB			A 077728	001	Feb 26, 2008	Nov CPOT
>A>	AB	WEST-WARD PHARMS INT	667MG	A 077728	001	Feb 26, 2008	Nov CAHN

PHOSLO

>D>	@	FRESENIUS MEDCL	EQ 84.5MG CALCIUM	N 021160	001	Apr 02, 2001	Nov CPOT
>D>	@		EQ 169MG CALCIUM	N 021160	002	Apr 02, 2001	Nov CPOT
>A>	@		333.5MG	N 021160	001	Apr 02, 2001	Nov CPOT
>A>	@		667MG	N 021160	002	Apr 02, 2001	Nov CPOT

PHOSLO GELCAPS

>D>	AB	+ FRESENIUS MEDCL	EQ 169MG CALCIUM	N 021160	003	Apr 02, 2001	Nov CPOT
>A>	AB	+ 667MG		N 021160	003	Apr 02, 2001	Nov CPOT

SOLUTION;ORAL

PHOSLYRA

>D>	+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N 022581	001	Apr 18, 2011	Nov CPOT
>A>	+		667MG/5ML	N 022581	001	Apr 18, 2011	Nov CPOT

TABLET;ORAL

CALCIUM ACETATE

>D>	AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM 667MG	A 202885	001	Jan 22, 2015	Nov CPOT
>A>	AB			A 202885	001	Jan 22, 2015	Nov CPOT
>D>	AB	INVAGEN PHARMS	EQ 169MG CALCIUM 667MG	A 202420	001	Feb 05, 2013	Nov CPOT
>A>	AB			A 202420	001	Feb 05, 2013	Nov CPOT
>D>	AB	PADDOCK LLC	EQ 169MG CALCIUM 667MG	A 091561	001	Apr 13, 2011	Nov CPOT
>A>	AB			A 091561	001	Apr 13, 2011	Nov CPOT
>D>	@	ROXANE	EQ 169MG CALCIUM 667MG	A 077693	001	Jan 30, 2008	Nov CPOT
>A>	@			A 077693	001	Jan 30, 2008	Nov CPOT
>A>	@	WEST-WARD PHARMS INT	667MG	A 077693	001	Jan 30, 2008	Nov CAHN

ELIPHOS

>D>	AB	+ CYPRESS PHARM	EQ 169MG CALCIUM	A 078502	001	Nov 25, 2008	Nov CPOT
>A>	AB	+ 667MG		A 078502	001	Nov 25, 2008	Nov CPOT

PHOSLO

>D>	@	FRESENIUS MEDCL	EQ 169MG CALCIUM	N 019976	001	Dec 10, 1990	Nov CPOT
>A>	@		667MG	N 019976	001	Dec 10, 1990	Nov CPOT

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

@	B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML ;9.2GM/100ML;9.6GM/100ML	N 018807	001	Aug 26, 1983	Oct DISC
---	---------	--	----------	-----	--------------	----------

@		510MG/100ML;30GM/100ML;200MG/100ML ;9.4GM/100ML;11GM/100ML	N 018807	003	Aug 26, 1983	Oct DISC
---	--	---	----------	-----	--------------	----------

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

@	B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML ;9.2GM/100ML;9.6GM/100ML	N 018807	002	Aug 26, 1983	Oct DISC
---	---------	--	----------	-----	--------------	----------

@		510MG/100ML;50GM/100ML;200MG/100ML ;9.4GM/100ML;11GM/100ML	N 018807	004	Aug 26, 1983	Oct DISC
---	--	---	----------	-----	--------------	----------



CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML N018379 002 Feb DISC

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML N018379 003 Feb DISC

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML N018379 007 Jun 24, 1988 Feb DISC

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML N018379 001 Feb DISC

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N018379 004 Jul 07, 1982 Feb DISC

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N018379 005 Jul 07, 1982 Feb DISC

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N018379 008 Jun 24, 1988 Feb DISC

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N018379 006 Jul 07, 1982 Feb DISC

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ B BRAUN 26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML N018460 007 Jan 29, 1986 Oct DISC

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ B BRAUN 26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML N018460 005 Nov 02, 1983 Oct DISC

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ B BRAUN 26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML N018460 009 Jan 29, 1986 Oct DISC

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML N017512 010 Nov 18, 1985 Feb CTEC

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML N017512 011 Nov 18, 1985 Feb CTEC

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML N016682 001 Aug CRLD

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

JANSSEN PHARMS 50MG;500MG N205879 001 Sep 20, 2016 Sep NEWA

50MG;1GM N205879 002 Sep 20, 2016 Sep NEWA

150MG;500MG N205879 003 Sep 20, 2016 Sep NEWA

+ 150MG;1GM N205879 004 Sep 20, 2016 Oct CRLD

150MG;1GM N205879 004 Sep 20, 2016 Sep NEWA

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL

>A> AB MACLEODS PHARMS LTD 4MG A203813 001 Dec 05, 2016 Nov NEWA

>A> AB 8MG A203813 002 Dec 05, 2016 Nov NEWA

>A> AB 16MG A203813 003 Dec 05, 2016 Nov NEWA

>A> AB 32MG A203813 004 Dec 05, 2016 Nov NEWA

CANGRELOR

POWDER;IV (INFUSION)

KENGREAL

+ CHIESI USA INC 50MG/VIAL N204958 001 Jun 22, 2015 Jul CAHN

CAPECITABINE

TABLET; ORAL

CAPECITABINE

>D>	AB	ROXANE	150MG	A200483	001	Jul 14, 2016	Nov	CAHN
	AB		150MG	A200483	001	Jul 14, 2016	Jul	NEWA
>D>	AB		500MG	A200483	002	Jul 14, 2016	Nov	CAHN
	AB		500MG	A200483	002	Jul 14, 2016	Jul	NEWA
>A>	AB	SHILPA MEDICARE LTD	150MG	A207456	001	Dec 12, 2016	Nov	NEWA
>A>	AB		500MG	A207456	002	Dec 12, 2016	Nov	NEWA
>A>	AB	WEST-WARD PHARMS INT	150MG	A200483	001	Jul 14, 2016	Nov	CAHN
>A>	AB		500MG	A200483	002	Jul 14, 2016	Nov	CAHN

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	@	APOTEX	12.5MG	A074737	001	Oct 28, 1998	Mar	DISC
	@		25MG	A074737	002	Oct 28, 1998	Mar	DISC
	@		50MG	A074737	003	Oct 28, 1998	Mar	DISC
	@		100MG	A074737	004	Oct 28, 1998	Mar	DISC
AB		HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun	CAHN
AB			25MG	A074505	002	Feb 13, 1996	Jun	CAHN
AB			50MG	A074505	003	Feb 13, 1996	Jun	CAHN
AB			100MG	A074505	004	Feb 13, 1996	Jun	CAHN
AB		PRINSTON INC	12.5MG	A074477	001	Feb 13, 1996	Jul	CMFD
AB			25MG	A074477	002	Feb 13, 1996	Jul	CMFD
AB			50MG	A074477	003	Feb 13, 1996	Jul	CMFD
AB			100MG	A074477	004	Feb 13, 1996	Jul	CMFD
	@	SANDOZ	12.5MG	A074363	001	Nov 09, 1995	Jan	DISC
	@		25MG	A074363	002	Nov 09, 1995	Jan	DISC
	@		50MG	A074363	003	Nov 09, 1995	Jan	DISC
	@		100MG	A074363	004	Nov 09, 1995	Jan	DISC
	@	STASON	12.5MG	A074677	004	May 30, 1997	Mar	DISC
	@		25MG	A074677	002	May 30, 1997	Mar	DISC
	@		50MG	A074677	001	May 30, 1997	Mar	DISC
	@		100MG	A074677	003	May 30, 1997	Mar	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan	CAHN
AB			200MG	A076697	002	May 20, 2011	Jan	CAHN
AB			300MG	A076697	003	May 20, 2011	Jan	CAHN
		SOLUTION; IV (INFUSION)						
		CARNEXIV						
	+	LUNDBECK LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016	Oct	NEWA

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB		EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	--	-------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

	@	IDT AUSTRALIA LTD	10MG; 100MG	A073586	001	Jun 29, 1995	May	CAHN
	@		25MG; 100MG	A073587	001	Jun 29, 1995	May	CAHN
	@		25MG; 250MG	A073620	001	Jun 29, 1995	May	CAHN
AB		MAYNE PHARMA	10MG; 100MG	A073618	001	Aug 28, 1992	Aug	CAHN
AB			25MG; 100MG	A073589	001	Aug 28, 1992	Aug	CAHN
AB			25MG; 250MG	A073607	001	Aug 28, 1992	Aug	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

		MIKART INC	6MG	A207484	001	May 31, 2016	May	NEWA
--	--	------------	-----	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION		CARBOPLATIN							
	@ WEST-WARD PHARMS INT	50MG/VIAL		A 076099	001	Oct 14, 2004	Oct	CAHN	
	@	150MG/VIAL		A 076099	002	Oct 14, 2004	Oct	CAHN	
	@	450MG/VIAL		A 076099	003	Oct 14, 2004	Oct	CAHN	
INJECTABLE; IV (INFUSION)		CARBOPLATIN							
	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)		A 078732	001	Feb 06, 2012	Apr	DISC	
	@	150MG/15ML (10MG/ML)		A 078732	002	Feb 06, 2012	Apr	DISC	
	@	450MG/45ML (10MG/ML)		A 078732	003	Feb 06, 2012	Apr	DISC	
	@	600MG/60ML (10MG/ML)		A 078732	004	Feb 06, 2012	Apr	DISC	
AP	NANJING KING-FRIEND	50MG/5ML (10MG/ML)		A 077096	001	Jun 14, 2005	Oct	CAHN	
AP		150MG/15ML (10MG/ML)		A 077096	002	Jun 14, 2005	Oct	CAHN	
AP		450MG/45ML (10MG/ML)		A 077096	003	Jun 14, 2005	Oct	CAHN	
AP		600MG/60ML (10MG/ML)		A 077096	004	Jun 03, 2013	Oct	CAHN	
AP	SANDOZ INC	50MG/5ML (10MG/ML)		A 078280	001	May 08, 2008	Feb	CAHN	
AP		150MG/15ML (10MG/ML)		A 078280	002	May 08, 2008	Feb	CAHN	
AP		450MG/45ML (10MG/ML)		A 078280	003	May 08, 2008	Feb	CAHN	
AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)		A 205487	001	Mar 28, 2016	Mar	NEWA	
AP		150MG/15ML (10MG/ML)		A 205487	002	Mar 28, 2016	Mar	NEWA	
AP		450MG/45ML (10MG/ML)		A 205487	003	Mar 28, 2016	Mar	NEWA	
AP	WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)		A 077244	001	Oct 15, 2004	Oct	CAHN	
AP		150MG/15ML (10MG/ML)		A 077244	002	Oct 15, 2004	Oct	CAHN	
AP		450MG/45ML (10MG/ML)		A 077244	003	Oct 15, 2004	Oct	CAHN	
AP		600MG/60ML (10MG/ML)		A 077244	004	Jan 20, 2006	Oct	CAHN	

CARFILZOMIB

POWDER; INTRAVENOUS  
KYPROLIS

	ONYX THERAP	30MG/VIAL		N 202714	002	Jun 03, 2016	Jun	NEWA	
+		60MG/VIAL		N 202714	001	Jul 20, 2012	Feb	CAHN	

CARISOPRODOL

TABLET; ORAL  
CARISOPRODOL

AB	AUROBINDO PHARMA	250MG		A 040792	002	Nov 08, 2016	Oct	NEWA	
AA	INGENUS PHARMS NJ	350MG		A 040823	001	Oct 22, 2008	Jan	CAHN	
AB	STRIDES PHARMA	250MG		A 205513	001	Nov 12, 2015	May	CAHN	
AA		350MG		A 205513	002	Nov 12, 2015	May	CAHN	

CARVEDILOL

TABLET; ORAL  
COREG

AB	SMITHKLINE BEECHAM	3.125MG		N 020297	004	May 29, 1997	May	CAHN	
AB		6.25MG		N 020297	003	Sep 14, 1995	May	CAHN	
AB	+	12.5MG		N 020297	002	Sep 14, 1995	May	CAHN	
AB		25MG		N 020297	001	Sep 14, 1995	May	CAHN	

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL  
COREG CR

	SMITHKLINE BEECHAM	10MG		N 022012	001	Oct 20, 2006	May	CAHN	
		20MG		N 022012	002	Oct 20, 2006	May	CAHN	
+		40MG		N 022012	003	Oct 20, 2006	May	CAHN	
		80MG		N 022012	004	Oct 20, 2006	May	CAHN	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL  
CEFADROXIL

@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML		A 065115	001	Mar 26, 2003	Feb	DISC	
@		EQ 250MG BASE/5ML		A 065115	002	Mar 26, 2003	Feb	DISC	
@		EQ 500MG BASE/5ML		A 065115	003	Mar 26, 2003	Feb	DISC	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION  
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL		A 201654	001	Feb 03, 2016	Jan	NEWA	
@	WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL		A 062807	001	Jan 12, 1988	Oct	CAHN	
@		EQ 500MG BASE/VIAL		A 062807	002	Jan 12, 1988	Oct	CAHN	
@		EQ 1GM BASE/VIAL		A 062807	003	Jan 12, 1988	Oct	CAHN	

INJECTABLE; INJECTION							
CEFAZOLIN SODIUM							
	@	EQ 5GM BASE/VIAL	A062807	004	Jan 12, 1988	Oct CAHN	
	@	EQ 10GM BASE/VIAL	A062807	005	Jan 12, 1988	Oct CAHN	
	@	EQ 20GM BASE/VIAL	A062807	006	Jan 12, 1988	Oct CAHN	
<u>CEFDITOREN PIVOXIL</u>							
TABLET; ORAL							
SPECTRACEF							
	@	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr DISC
	@		400MG	N021222	002	Jul 21, 2008	Apr DISC
<u>CEFEPIME HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CEFEPIME HYDROCHLORIDE							
AP		QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan NEWA
AP			EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan NEWA
AP			EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan NEWA
<u>CEFOTAXIME SODIUM</u>							
INJECTABLE; INJECTION							
CEFOTAXIME SODIUM							
AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
AP			EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA
CLAFORAN							
AP	+	US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
AP	+		EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
AP	+		EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
AP	+		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun DISC
	@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun DISC
	+		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@	US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
	@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN
<u>CEFOTETAN DISODIUM</u>							
INJECTABLE; INJECTION							
CEFOTAN							
	@	TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan CAHN
AP			EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
	@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
	@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
AP			EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
	@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER							
	+	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun CMS2
	+		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun CMS2
<u>CEFOXITIN SODIUM</u>							
INJECTABLE; INJECTION							
CEFOXITIN							
AP		ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
AP			EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
AP			EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER							
AP	+	B BRAUN	EQ 1GM BASE/VIAL	N065214	001	Mar 10, 2006	Aug CRLD
AP	+		EQ 2GM BASE/VIAL	N065214	002	Mar 10, 2006	Aug CRLD
<u>CEFPODOXIME PROXETIL</u>							
FOR SUSPENSION; ORAL							
CEFPODOXIME PROXETIL							
	@	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
	@		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC
TABLET; ORAL							
CEFPODOXIME PROXETIL							
	@	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
	@		EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC

<u>CEFTIBUTEN DIHYDRATE</u>									
CAPSULE; ORAL									
CEDAX									
	@	PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun	DISC	
FOR SUSPENSION; ORAL									
CEDAX									
	@	PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun	DISC	
	@		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun	DISC	
<u>CEFTRIAZONE SODIUM</u>									
INJECTABLE; INJECTION									
CEFTRIAZONE									
	@	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr	DISC	
	@		EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr	DISC	
	@		EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr	DISC	
	@		EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr	DISC	
ROCEPHIN									
	@	HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr	DISC	
	@		EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr	DISC	
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS									
CEFTRIAZONE									
	@	BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun	DISC	
	@		EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun	DISC	
	@		EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun	DISC	
	@		EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun	DISC	
AP		QILU PHARM CO LTD	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jun	NEWA	
AP			EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jun	NEWA	
AP			EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jun	NEWA	
AP			EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jun	NEWA	
<u>CEFUROXIME AXETIL</u>									
FOR SUSPENSION; ORAL									
CEFTIN									
		GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb	CTEC	
	+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb	CTEC	
CEFUROXIME AXETIL									
	@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb	DISC	
	@		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb	DISC	
TABLET; ORAL									
CEFUROXIME AXETIL									
	@	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb	DISC	
	@		EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb	DISC	
	@		EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb	DISC	
<u>CEFUROXIME SODIUM</u>									
INJECTABLE; INJECTION									
ZINACEF									
AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan	CAHN	
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan	CAHN	
ZINACEF IN PLASTIC CONTAINER									
	@	IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan	CAHN	
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan	CAHN	
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS									
ZINACEF									
AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan	CAHN	
<u>CELECOXIB</u>									
CAPSULE; ORAL									
CELECOXIB									
AB		AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan	NEWA	
AB			100MG	A206827	002	Feb 01, 2016	Jan	NEWA	
AB			200MG	A206827	003	Feb 01, 2016	Jan	NEWA	
AB			400MG	A206827	004	Feb 01, 2016	Jan	NEWA	
AB		MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb	NEWA	
AB			100MG	A204590	002	Mar 16, 2016	Feb	NEWA	
AB			200MG	A204590	003	Mar 16, 2016	Feb	NEWA	
AB			400MG	A204590	004	Mar 16, 2016	Feb	NEWA	

CEPHALEXIN

CAPSULE;ORAL		CEPHALEXIN						
	@ SUN PHARM INDS LTD	EQ 250MG BASE		A 065007	001	Sep 16, 1999	Feb	DISC
	@	EQ 500MG BASE		A 065007	002	Sep 16, 1999	Feb	DISC
KEFLEX								
AB	PRAGMA PHARMS LLC	EQ 250MG BASE		N 050405	002		Jul	CAHN
	@	EQ 333MG BASE		N 050405	004	May 12, 2006	Jul	CAHN
AB		EQ 500MG BASE		N 050405	003		Jul	CAHN
AB	+	EQ 750MG BASE		N 050405	005	May 12, 2006	Jul	CAHN
FOR SUSPENSION;ORAL		KEFLEX						
	@ PRAGMA PHARMS LLC	EQ 100MG BASE/ML		N 050406	003		Mar	CAHN
	@	EQ 125MG BASE/5ML		N 050406	001		Mar	CAHN
	@	EQ 250MG BASE/5ML		N 050406	002		Mar	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL		CETIRIZINE HYDROCHLORIDE						
AA	NOSTRUM LABS INC	5MG/5ML		A 090191	001	Nov 12, 2009	Mar	CAHN
AA	+ PERRIGO R AND D	5MG/5ML		A 078398	001	Jun 17, 2008	Aug	CRLD
	@ WOCKHARDT	5MG/5ML		A 078757	001	Aug 28, 2009	Apr	DISC

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL		CEVIMELINE HYDROCHLORIDE						
>D>	AB ROXANE	30MG		A 091591	001	Jul 08, 2013	Nov	CAHN
>A>	AB WEST-WARD PHARMS INT	30MG		A 091591	001	Jul 08, 2013	Nov	CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL		CHLORDIAZEPOXIDE HYDROCHLORIDE						
>D>	@ SANDOZ	25MG		A 084679	002		Nov	CAHN
	@ UPSHER-SMITH LABS	5MG		A 084678	001		Oct	CAHN
	@	10MG		A 084041	001		Oct	CAHN
>A>	@	25MG		A 084679	002		Nov	CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL		LIBRAX						
	+ VALEANT PHARMS	5MG;2.5MG		N 012750	001		Jul	NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL		PERIOGARD						
AT	COLGATE-PALMOLIVE CO	0.12%		A 203212	001	Jan 28, 2016	Jan	NEWA

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION		CHLOROPROCAINE HYDROCHLORIDE						
AP	WEST-WARD PHARMS INT	2%		A 040273	001	Sep 09, 1998	Sep	CAHN
AP		3%		A 040273	002	Sep 09, 1998	Sep	CAHN

CHLOROQUINE PHOSPHATE

TABLET;ORAL		CHLOROQUINE PHOSPHATE						
	@ IMPAX LABS	EQ 150MG BASE		A 080880	001		Mar	DISC
	@	EQ 300MG BASE		A 040516	001	Aug 29, 2003	Mar	DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL		CHLORPHENIRAMINE MALEATE						
	@ AUROLIFE PHARMA LLC	4MG		A 080961	001		Mar	CAHN
	@ SUN PHARM INDS	4MG		A 080700	001		Jun	CAHN

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL  
 CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE  
 @ SPRIASO LLC 8MG;54.3MG

N206323 001 Jun 22, 2015 Jun DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL  
 HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA MAYNE PHARMA INC 4MG/5ML;5MG/5ML;60MG/5ML

A205657 001 Aug 03, 2015 Feb CAHN

CHLORPROPAMIDE

TABLET;ORAL  
 CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC 100MG  
 @ 250MG

A088725 001 Aug 31, 1984 Mar CAHN  
 A088726 001 Aug 31, 1984 Mar CAHN

CHLORTHALIDONE

TABLET;ORAL  
 CHLORTHALIDONE

AB MYLAN 25MG  
 AB SUN PHARM INDS 25MG

A086831 002 Jan CTEC  
 A089286 002 Jul 21, 1986 Jan CMS1

CHLORZOXAZONE

TABLET;ORAL  
 CHLORZOXAZONE

@ AUROLIFE PHARMA LLC 250MG  
 @ 500MG  
 + MIKART 750MG  
 + MIKART INC 250MG  
 @ SUN PHARM INDS 500MG  
 AA + WATSON LABS 500MG

A089852 001 May 04, 1988 Feb CAHN  
 A089853 001 May 04, 1988 Feb CAHN  
 A040861 002 Jun 01, 2010 Apr CRLD  
 A207483 001 Jun 24, 2016 Jun NEWA  
 A089970 001 Sep 27, 1990 Mar CAHN  
 A089859 001 May 04, 1988 Jul CRLD

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL  
 FENOFIBRIC ACID

AB IMPAX LABS INC EQ 45MG FENOFIBRIC ACID  
 AB EQ 135MG FENOFIBRIC ACID

A200264 001 Sep 07, 2016 Aug NEWA  
 A200264 002 Sep 07, 2016 Aug NEWA

CICLESONIDE

AEROSOL, METERED;INHALATION  
 ALVESCO

+ TAKEDA GMBH 0.08MG/INH

N021658 002 Jan 10, 2008 Jan CRLD

CILOSTAZOL

TABLET;ORAL  
 CILOSTAZOL

@ FRONTIDA BIOPHARM 50MG  
 @ 100MG  
 >D> AB ROXANE 50MG  
 >D> AB 100MG  
 @ SUN PHARM INDS 50MG  
 @ 100MG  
 AB + TEVA 50MG  
 AB + 100MG  
 >A> AB WEST-WARD PHARMS INT 50MG  
 >A> AB 100MG

A077208 002 Mar 29, 2006 Jul CAHN  
 A077208 001 Mar 29, 2006 Jul CAHN  
 A077024 001 May 17, 2005 Nov CAHN  
 A077024 002 May 17, 2005 Nov CAHN  
 A077208 002 Mar 29, 2006 Jun CAHN  
 A077208 001 Mar 29, 2006 Jun CAHN  
 A077027 001 Nov 24, 2004 Jun CRLD  
 A077027 002 Nov 24, 2004 Jun CRLD  
 A077024 001 May 17, 2005 Nov CAHN  
 A077024 002 May 17, 2005 Nov CAHN

CIMETIDINE

TABLET;ORAL  
 CIMETIDINE

@ UPSHER-SMITH LABS 200MG  
 @ 300MG  
 @ 400MG  
 @ 800MG

A074506 001 Jan 24, 1996 Oct CAHN  
 A074506 002 Jan 24, 1996 Oct CAHN  
 A074506 003 Jan 24, 1996 Oct CAHN  
 A074506 004 Jan 24, 1996 Oct CAHN

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC  
 CILOXAN

>D> + ALCON PHARMS LTD EQ 0.3% BASE  
 >A> + NOVARTIS PHARMS CORP EQ 0.3% BASE

N020369 001 Mar 30, 1998 Nov CAHN  
 N020369 001 Mar 30, 1998 Nov CAHN

SOLUTION/DROPS;OPHTHALMIC  
CILOXAN

>D> AT + ALCON PHARMS LTD EQ 0.3% BASE N019992 001 Dec 31, 1990 Nov CAHN  
>A> AT + NOVARTIS PHARMS CORP EQ 0.3% BASE N019992 001 Dec 31, 1990 Nov CAHN

CIPROFLOXACIN HYDROCHLORIDE

AT TELIGENT PHARMA INC EQ 0.3% BASE A076754 001 Jun 09, 2004 Jul CAHN

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ IDT AUSTRALIA LTD EQ 100MG BASE A075939 001 Mar 03, 2005 May CAHN  
@ EQ 250MG BASE A075939 002 Jun 09, 2004 May CAHN  
@ EQ 500MG BASE A075939 003 Jun 09, 2004 May CAHN  
@ EQ 750MG BASE A075939 004 Jun 09, 2004 May CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE;0.025% N208251 001 Apr 29, 2016 Apr NEWA

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

>D> + ALCON PHARMS LTD EQ 0.2% BASE;1% N020805 001 Feb 10, 1998 Nov CAHN  
>A> + NOVARTIS PHARMS CORP EQ 0.2% BASE;1% N020805 001 Feb 10, 1998 Nov CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC 212.6MG;EQ 287.5MG BASE A077417 001 Nov 30, 2010 Jan DISC  
@ 425.2MG;EQ 574.9MG BASE A077809 001 Nov 30, 2010 Jan DISC

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

>D> + ALCON PHARMS LTD 0.3%;0.1% N021537 001 Jul 18, 2003 Nov CAHN  
>A> + NOVARTIS PHARMS CORP 0.3%;0.1% N021537 001 Jul 18, 2003 Nov CAHN

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP WEST-WARD PHARMS INT 1MG/ML A075036 001 Nov 07, 2000 Oct CAHN

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

>D> AA + ROXANE EQ 10MG BASE/5ML A077043 001 Dec 13, 2004 Nov CAHN  
>A> AA + WEST-WARD PHARMS INT EQ 10MG BASE/5ML A077043 001 Dec 13, 2004 Nov CAHN

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

@ SUN PHARM INDS EQ 10MG BASE A077052 001 Jul 03, 2006 Mar CAHN  
@ EQ 20MG BASE A077052 002 Jul 03, 2006 Mar CAHN  
@ EQ 40MG BASE A077052 003 Jul 03, 2006 Mar CAHN

CLADRIBINE

INJECTABLE;INJECTION

CLADRIBINE

AP WEST-WARD PHARMS INT 1MG/ML A075405 001 Feb 28, 2000 Oct CAHN

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

>D> AB ROXANE 250MG A065178 002 May 25, 2004 Nov CAHN  
>D> AB 500MG A065178 001 May 25, 2004 Nov CAHN  
>A> AB WEST-WARD PHARMS INT 250MG A065178 002 May 25, 2004 Nov CAHN  
>A> AB 500MG A065178 001 May 25, 2004 Nov CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB ALLIED PHARMA INC 500MG A203243 001 Feb 29, 2016 Feb NEWA  
@ IDT AUSTRALIA LTD 500MG A065250 001 Aug 25, 2005 May CAHN  
AB + MAYNE PHARMA 500MG A065154 001 May 18, 2005 Aug CAHN



CLEVIDIPINEEMULSION; INTRAVENOUS  
CLEVIPREX

	+	CHIESI USA INC	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008	Aug	CAHN
	+		50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008	Aug	CAHN
	+		125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013	Aug	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL  
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		MYLAN PHARMS INC	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	May	NEWA
----	--	------------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATECREAM; VAGINAL  
CLINDESSE

	+	PERRIGO PHARMA INTL	EQ 2% BASE	N050793	001	Nov 30, 2004	Jun	CAHN
--	---	---------------------	------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

		CLINDAMYCIN PHOSPHATE						
		@ WEST-WARD PHARMS INT	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987	Oct	CAHN
AP			EQ 150MG BASE/ML	A062889	001	Apr 25, 1988	Oct	CAHN
		@	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988	Oct	CAHN
		@	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989	Oct	CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

		@ INGENUS PHARMS LLC	EQ 1% BASE	A064108	001	Sep 27, 1996	Oct	CAHN
--	--	----------------------	------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	AQUA PHARMS LLC	1.2%; 0.025%	N050803	001	Jul 16, 2010	Jan	CAHN
----	---	-----------------	--------------	---------	-----	--------------	-----	------

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

		@ INGENUS PHARMS LLC	0.05%	A075733	001	Aug 22, 2001	Oct	CAHN
--	--	----------------------	-------	---------	-----	--------------	-----	------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

>A>	AB	TELIGENT PHARMA INC	0.05%	A208667	001	Nov 29, 2016	Nov	NEWA
-----	----	---------------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar	CRLD
----	---	----------------	-------	---------	-----	--------------	-----	------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan	CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan	CRLD

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CLONIDINE

AB		MAYNE PHARMA	0.1MG/24HR	A079090	001	Aug 20, 2010	Aug	CAHN
AB			0.2MG/24HR	A079090	002	Aug 20, 2010	Aug	CAHN
AB			0.3MG/24HR	A079090	003	Aug 20, 2010	Aug	CAHN

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

		@ AUROLIFE PHARMA LLC	0.1MG	A070887	001	Aug 31, 1988	Feb	CAHN
		@	0.2MG	A070886	001	Aug 31, 1988	Feb	CAHN
		@	0.3MG	A071294	001	Aug 31, 1988	Feb	CAHN
AB		FRONTIDA BIOPHARM	0.1MG	A070925	001	Sep 04, 1987	Jul	CAHN
AB			0.2MG	A070924	001	Sep 04, 1987	Jul	CAHN
AB			0.3MG	A070923	001	Sep 04, 1987	Jul	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL		CLOPIDOGREL BISULFATE					
	@ ACTAVIS TOTOWA	EQ 75MG BASE		A 090307	001	May 28, 2013	Jun DISC
AB	SUN PHARM INDS	EQ 75MG BASE		A 078133	001	Jun 10, 2013	Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL		CLORAZEPATE DIPOTASSIUM					
	@ AUROLIFE PHARMA LLC	3.75MG		A 072219	001	Aug 26, 1988	Apr CAHN
	@	7.5MG		A 072220	001	Aug 26, 1988	Feb CAHN
	@	15MG		A 072112	001	Aug 26, 1988	Feb CAHN
TABLET; ORAL		CLORAZEPATE DIPOTASSIUM					
	@ AUROLIFE PHARMA LLC	3.75MG		A 072512	001	May 11, 1990	Mar CAHN
	@	7.5MG		A 072513	001	May 11, 1990	Mar CAHN
	@	15MG		A 072514	001	May 11, 1990	Feb CAHN
TRANXENE		@ RECORDATI RARE		3.75MG			
				N 017105	006		Jun DISC

CLOTTRIMAZOLE

TROCHE/LOZENGE; ORAL		CLOTTRIMAZOLE					
>D>	AB +	ROXANE	10MG	A 076387	001	Jul 29, 2004	Nov CAHN
>A>	AB +	WEST-WARD PHARMS INT	10MG	A 076387	001	Jul 29, 2004	Nov CAHN

CLOZAPINE

TABLET; ORAL		CLOZAPINE					
>A>	AB	AUROBINDO PHARMA LTD	25MG	A 206433	001	Nov 29, 2016	Nov NEWA
>A>	AB		50MG	A 206433	002	Nov 29, 2016	Nov NEWA
>A>	AB		100MG	A 206433	003	Nov 29, 2016	Nov NEWA
>A>	AB		200MG	A 206433	004	Nov 29, 2016	Nov NEWA
	AB	MAYNE PHARMA	25MG	A 203807	001	Sep 17, 2015	Aug CAHN
	AB		100MG	A 203807	002	Sep 17, 2015	Aug CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE					
AA		NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML	A 090180	001	Mar 17, 2010	Feb CAHN

COLCHICINE

CAPSULE; ORAL		MITIGARE					
	+	HIKMA INTL PHARMS	0.6MG	N 204820	001	Sep 26, 2014	Mar CRLD
TABLET; ORAL		COLCRYS					
	+	TAKEDA PHARMS USA	0.6MG	N 022352	001	Jul 29, 2009	Oct CTEC
AB	+		0.6MG	N 022352	001	Jul 29, 2009	Sep CFTG

COLCHICINE; PROBENECID

TABLET; ORAL		PROBENECID AND COLCHICINE					
AB		INGENUS PHARMS NJ	0.5MG; 500MG	A 040618	001	May 13, 2008	Jan CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC		COLY-MYCIN S					
	+	ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N 050356	001		Feb CAHN

CORTICOTROPIN

INJECTABLE; INJECTION		PURIFIED CORTROPHIN GEL					
	@	ANI PHARMS	40 UNITS/ML	N 008975	001		Feb CAHN
	@		80 UNITS/ML	N 008975	002		Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION  
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML N009854 001 Feb CAHN

CROFELEMER

TABLET, DELAYED RELEASE; ORAL  
FULYZAQ

+ NAPO PHARMS INC 125MG N202292 001 Dec 31, 2012 Jun CAHN

CROTAMITON

LOTION; TOPICAL  
CROTAN

AT MARNEL PHARMS 10% A087204 001 Aug CAHN

CYANOCOBALAMIN

INJECTABLE; INJECTION  
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML A206503 001 Dec 11, 2015 Mar CAHN

AP WEST-WARD PHARMS INT 1MG/ML A080515 002 Oct CMFD

SPRAY, METERED; NASAL  
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005 Feb CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
AMRIX

>D> AB TEVA PHARMS INTL 15MG N021777 001 Feb 01, 2007 Nov CTEC

>A> 15MG N021777 001 Feb 01, 2007 Nov CTEC

AB 15MG N021777 001 Feb 01, 2007 Oct CAHN

>D> AB + 30MG N021777 002 Feb 01, 2007 Nov CTEC

>A> + 30MG N021777 002 Feb 01, 2007 Nov CTEC

AB + 30MG N021777 002 Feb 01, 2007 Oct CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

@ TWI PHARMS INC 15MG A091281 001 Jan 31, 2013 Oct DISC

@ 30MG A091281 002 Jan 31, 2013 Oct DISC

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB FRONTIDA BIOPHARM 5MG A073541 002 Apr 06, 2006 Jul CAHN

AB 10MG A073541 001 May 23, 1995 Jul CAHN

@ UPSHER-SMITH LABS 5MG A072854 002 Feb 03, 2006 Oct CAHN

@ 10MG A072854 001 Nov 19, 1991 Oct CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION  
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL N012142 003 Mar DISC

@ 1GM/VIAL N012142 004 Aug 30, 1982 Mar DISC

@ 2GM/VIAL N012142 005 Aug 30, 1982 Mar DISC

TABLET; ORAL

CYCLOPHOSPHAMIDE

@ ROXANE 25MG A040032 001 Aug 17, 1999 Oct DISC

@ 50MG A040032 002 Aug 17, 1999 Oct DISC

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1 MAYNE PHARMA 25MG A065044 002 Dec 20, 2000 Aug CAHN

AB1 100MG A065044 001 Dec 20, 2000 Aug CAHN

EMULSION; OPHTHALMIC

>A> RESTASIS MULTIDOSE

>A> + ALLERGAN 0.05% N050790 002 Oct 27, 2016 Nov NEWA

INJECTABLE; INJECTION

CYCLOSPORINE

AP WEST-WARD PHARMS INT 50MG/ML A065004 001 Oct 29, 1999 Sep CAHN

SOLUTION; ORAL

CYCLOSPORINE

AB1 MAYNE PHARMA 100MG/ML A065054 001 Dec 18, 2001 Aug CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	APPCO PHARMA LLC	4MG	A206553	001	Nov 29, 2016	Nov	NEWA
	AA	INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan	CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
AP		20MG/ML	A200916	001	Dec 13, 2011	Mar	CAHN
AP	WEST-WARD PHARMS INT	100MG/VIAL	A071471	001	Aug 02, 1989	Sep	CAHN
AP		500MG/VIAL	A071472	001	Aug 02, 1989	Sep	CAHN
AP		1GM/VIAL	A074245	001	Aug 31, 1994	Sep	CAHN
AP		2GM/VIAL	A074245	002	Aug 31, 1994	Sep	CAHN

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP	WEST-WARD PHARMS INT	200MG/VIAL	A075812	001	Jun 15, 2001	Oct	CAHN
AP		500MG/VIAL	A075812	002	Oct 31, 2002	Oct	CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

BRISTOL-MYERS SQUIBB EQ 90MG BASE

N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL

A090304 001 Mar 16, 2010 Feb DISC

@ WEST-WARD PHARMS INT 0.5MG/VIAL

A090304 001 Mar 16, 2010 Oct CAHN

DALBAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jan CDFR

DANAZOL

CAPSULE; ORAL

DANAZOL

AB LANNETT 50MG

A077246 002 Apr 19, 2007 Sep NEWA

AB 100MG

A077246 003 Apr 19, 2007 Sep NEWA

DANTROLENE SODIUM

FOR SUSPENSION; INTRAVENOUS

RYANODEX

+ EAGLE PHARMS 250MG/VIAL

N205579 001 Jul 22, 2014 Jun CRLD

INJECTABLE; INJECTION

DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Feb NEWA

DAPSONE

GEL; TOPICAL

ACZONE

+ ALLERGAN INC 7.5%

N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL

DAPSONE

AB ALVOGEN 25MG

A205429 001 Jan 07, 2016 Mar CAHN

AB 100MG

A205429 002 Jan 07, 2016 Mar CAHN

AB NORTH CREEK PHARMS 25MG

A204074 001 May 10, 2016 Apr NEWA

AB 100MG

A204074 002 May 10, 2016 Apr NEWA

AB NOSTRUM LABS INC 25MG

A203887 001 May 06, 2016 Apr NEWA

AB 100MG

A203887 002 May 06, 2016 Apr NEWA

&gt;A&gt; AB PAR PHARM INC 25MG

A206505 001 Dec 01, 2016 Nov NEWA

&gt;A&gt; AB 100MG

A206505 002 Dec 01, 2016 Nov NEWA

DAPTOMYCINPOWDER; INTRAVENOUS  
CUBICIN

AP	+	CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan CDFR
AP	+	CUBIST PHARMS LLC	500MG/VIAL	N021572	002	Sep 12, 2003	Aug CAHN
		CUBICIN RF					
	+	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016	Aug NEWA
		DAPTOMYCIN					
AP		CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016	Jun NEWA
AP		HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR
AP		TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Mar NEWA
		POWDER; IV (INFUSION)					
		CUBICIN					
		@ CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR
		@ CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003	Aug CAHN

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	EQ 7.5MG BASE	A206743	001	Sep 19, 2016	Sep NEWA
AB			EQ 15MG BASE	A206743	002	Sep 19, 2016	Sep NEWA
AB		CIPLA LTD	EQ 7.5MG BASE	A207664	001	Sep 01, 2016	Aug NEWA
AB			EQ 15MG BASE	A207664	002	Sep 01, 2016	Aug NEWA
AB		JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Oct NEWA
AB			EQ 15MG BASE	A205550	002	Oct 12, 2016	Oct NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 7.5MG BASE	A205209	001	Nov 17, 2016	Nov NEWA
>A>	AB		EQ 15MG BASE	A205209	002	Nov 17, 2016	Nov NEWA
		ENABLEX					
AB		APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL  
VIEKIRA XR

	+	ABBVIE INC	EQ 200MG BASE; 8.33MG; 50MG; 33.33MG	N208624	001	Jul 22, 2016	Jul NEWA
--	---	------------	--------------------------------------	---------	-----	--------------	----------

DASATINIBTABLET; ORAL  
DASATINIB

AB		APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
AB			50MG	A202103	002	Jun 10, 2016	May NEWA
AB			70MG	A202103	003	Jun 10, 2016	May NEWA
AB			100MG	A202103	004	Jun 10, 2016	May NEWA
		SPRYCEL					
AB		BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
AB			50MG	N021986	002	Jun 28, 2006	May CFTG
AB			70MG	N021986	003	Jun 28, 2006	May CFTG
AB	+		100MG	N021986	004	May 30, 2008	May CFTG

DAUNORUBICIN CITRATEINJECTABLE, LIPOSOMAL; INJECTION  
DAUNOXOME

		@ GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	May DISC
--	--	--------------	----------------	---------	-----	--------------	----------

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION  
CERUBIDINE

AP	+	WEST-WARD PHARMS INT	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Sep CAHN
		DAUNORUBICIN HYDROCHLORIDE					
AP	+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Sep CAHN

DEFERASIROXTABLET, FOR SUSPENSION; ORAL  
DEFERASIROX

AB		ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB			250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB			500MG	A203560	003	Jan 26, 2016	Jan NEWA
		EXJADE					
AB		NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB			250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+		500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION  
DEFEROXAMINE MESYLATE

AP	WEST-WARD PHARMS INT	500MG/VIAL	A078086	001	May 30, 2007	Oct	CAHN
AP		2GM/VIAL	A078086	002	May 30, 2007	Oct	CAHN

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)  
DEFITELIO

+	GENTIUM SPA	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Mar	NEWA
+	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016	Aug	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL  
DEMECLOCYCLINE HYDROCHLORIDE

@	IMPAX LABS	150MG	A065094	001	Mar 22, 2004	Mar	DISC
@		300MG	A065094	002	Mar 22, 2004	Mar	DISC

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL  
DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar	NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar	NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar	NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar	NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar	NEWA
AB		150MG	A208105	006	Mar 17, 2016	Mar	NEWA
AB	COREPHARMA	10MG	A205153	001	Oct 28, 2016	Oct	NEWA
AB		25MG	A205153	002	Oct 28, 2016	Oct	NEWA
AB		50MG	A205153	003	Oct 28, 2016	Oct	NEWA
AB		75MG	A205153	004	Oct 28, 2016	Oct	NEWA
AB		100MG	A205153	005	Oct 28, 2016	Oct	NEWA
AB		150MG	A205153	006	Oct 28, 2016	Oct	NEWA
AB	HERITAGE PHARMS INC	10MG	A207433	001	May 05, 2016	Jun	CAHN
AB		25MG	A207433	002	May 05, 2016	Jun	CAHN
AB		50MG	A207433	003	May 05, 2016	Jun	CAHN
AB		75MG	A207433	004	May 05, 2016	Jun	CAHN
AB		100MG	A207433	005	May 05, 2016	Jun	CAHN
AB		150MG	A207433	006	May 05, 2016	Jun	CAHN
AB	INDICUS PHARMA	10MG	A207433	001	May 05, 2016	Apr	NEWA
AB		25MG	A207433	002	May 05, 2016	Apr	NEWA
AB		50MG	A207433	003	May 05, 2016	Apr	NEWA
AB		75MG	A207433	004	May 05, 2016	Apr	NEWA
AB		100MG	A207433	005	May 05, 2016	Apr	NEWA
AB		150MG	A207433	006	May 05, 2016	Apr	NEWA
	NORPRAMIN						
AB	US PHARM HOLDINGS	10MG	N014399	007	Feb 11, 1982	Jan	CAHN
AB		25MG	N014399	001		Jan	CAHN
AB		50MG	N014399	003		Jan	CAHN
AB		75MG	N014399	004		Jan	CAHN
AB	+	100MG	N014399	005		Jan	CAHN
AB		150MG	N014399	006		Jan	CAHN

DESLORATADINE

SOLUTION; ORAL  
DESLORATADINE

AA	TARO	0.5MG/ML	A202936	001	May 26, 2016	May	NEWA
----	------	----------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL  
STIMATE (NEEDS NO REFRIGERATION)

+	CSL BEHRING	0.15MG/SPRAY	N020355	002	Oct 24, 2007	Aug	CPOT
---	-------------	--------------	---------	-----	--------------	-----	------

TABLET; ORAL  
DESMOPRESSIN ACETATE

@	FERRING	0.1MG	N021795	001	May 08, 2008	Jun	DISC
@		0.2MG	N021795	002	May 08, 2008	Jun	DISC
AB	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006	Aug	CAHN
AB		0.2MG	A077122	002	Jan 25, 2006	Aug	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB	+	DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	002	Aug 12, 1999	Sep	CRLD
AB		MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Aug	CAHN
AB			0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Aug	CAHN

ORTHO-CEPT

@ JANSSEN PHARMS  
VOLNEA

			0.15MG;0.03MG	N020301	002	Dec 14, 1992	Sep	DISC
AB		SANDOZ INC	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug	NEWA

DESONIDE

CREAM; TOPICAL

DESONIDE

AB		G AND W LABS INC	0.05%	A074027	001	Sep 28, 1992	Jan	CAHN
----	--	------------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB		GROUPE PARIMA INC	0.05%	A204675	001	Aug 12, 2016	Aug	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	0.25%	A204965	001	Nov 07, 2016	Oct	NEWA
>A>	AB	GROUPE PARIMA INC	0.25%	A204272	001	Nov 30, 2016	Nov	NEWA
>A>	AB	LUPIN ATLANTIS	0.05%	A208044	001	Dec 12, 2016	Nov	NEWA
>A>	AB		0.25%	A208104	001	Dec 01, 2016	Nov	NEWA
	AB	NOVEL LABS INC	0.25%	A206792	001	May 10, 2016	Apr	NEWA
	AB	PERRIGO ISRAEL	0.25%	A077770	001	Apr 20, 2015	May	CAHN
	AB	TELLIGENT PHARMA INC	0.25%	A208101	001	Feb 25, 2016	Feb	NEWA

TOPICORT

>D>	+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	Nov	CFTG
>A>	AB	+	0.05%	N018594	001	Jan 17, 1985	Nov	CFTG

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL INC	EQ 25MG BASE	A204065	001	Jul 29, 2016	Jul	NEWA
AB			EQ 50MG BASE	A204065	002	Jul 29, 2016	Jul	NEWA
AB			EQ 100MG BASE	A204065	003	Jul 29, 2016	Jul	NEWA
>D>	AB	ROXANE	EQ 50MG BASE	A204082	001	Feb 16, 2016	Nov	CAHN
	AB		EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb	NEWA
>D>	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Nov	CAHN
	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb	NEWA
>A>	AB	WEST-WARD PHARMS INT	EQ 50MG BASE	A204082	001	Feb 16, 2016	Nov	CAHN
>A>	AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Nov	CAHN
		PRISTIQ						
AB		WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014	Jul	CFTG

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

>D>	+	ROXANE	1MG/ML	A088252	001	Sep 01, 1983	Nov	CAHN
>A>	+	WEST-WARD PHARMS INT	1MG/ML	A088252	001	Sep 01, 1983	Nov	CAHN

SOLUTION; ORAL

DEXAMETHASONE

>D>	+	ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983	Nov	CAHN
>A>	+	WEST-WARD PHARMS INT	0.5MG/5ML	A088248	001	Sep 01, 1983	Nov	CAHN

SUSPENSION/DROPS; OPHTHALMIC

MAXIDEX

>D>	+	ALCON	0.1%	N013422	001		Nov	CAHN
>A>	+	NOVARTIS PHARMS CORP	0.1%	N013422	001		Nov	CAHN

TABLET; ORAL

DEXAMETHASONE

		@ IDT AUSTRALIA LTD	0.75MG	A080399	001		May	CAHN
>D>	BP	ROXANE	0.5MG	A084611	001		Nov	CAHN
>D>	BP		0.75MG	A084613	001		Nov	CAHN
>D>	BP		1MG	A088306	001	Sep 15, 1983	Nov	CAHN
>D>	AB		1.5MG	A084610	001		Nov	CAHN
>D>	BP		2MG	A087916	001	Aug 26, 1982	Nov	CAHN
>D>	BP		4MG	A084612	001		Nov	CAHN

TABLET; ORAL

DEXAMETHASONE

>D>	BP	+	6MG	A088316	001	Sep 15, 1983	Nov	CAHN	
		@	SUN PHARM INDS	0.25MG	A084013	001	Mar	CAHN	
		@		0.25MG	A084764	001	Mar	CAHN	
		@		0.5MG	A084084	001	Mar	CAHN	
		@		0.5MG	A084766	001	Mar	CAHN	
		@		0.75MG	A084081	001	Mar	CAHN	
		@		0.75MG	A084765	001	Mar	CAHN	
		@		1.5MG	A084086	001	Mar	CAHN	
		@		1.5MG	A084763	001	Mar	CAHN	
>A>	BP		WEST-WARD PHARMS INT	0.5MG	A084611	001	Nov	CAHN	
>A>	BP			0.75MG	A084613	001	Nov	CAHN	
>A>	BP			1MG	A088306	001	Sep 15, 1983	Nov	CAHN
>A>	AB			1.5MG	A084610	001	Nov	CAHN	
>A>	BP			2MG	A087916	001	Aug 26, 1982	Nov	CAHN
>A>	BP			4MG	A084612	001	Nov	CAHN	
>A>	BP	+		6MG	A088316	001	Sep 15, 1983	Nov	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar	CTNA
----	---	--------------------	----------------------	---------	-----	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

MAXITROL

>D>	AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Nov	CAHN
>A>	AT	+	NOVARTIS PHARMS CORP	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Nov	CAHN

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL

DEXILANT SOLUTAB

+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan	NEWA
AP		ACTAVIS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204686	001	Oct 17, 2016	Oct	NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar	NEWA
AP		SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May	NEWA
		PRECEDEX						
+		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb	CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015	Aug	CAHN
AB			10MG	A079108	002	Aug 05, 2015	Aug	CAHN
AB			15MG	A079108	003	May 19, 2014	Aug	CAHN
AB			20MG	A079108	004	Dec 21, 2015	Aug	CAHN
AB			30MG	A079108	005	Nov 21, 2013	Aug	CAHN
>A>	AB	PAR PHARM INC	5MG	A202842	001	Nov 30, 2016	Nov	NEWA
>A>	AB		10MG	A202842	002	Nov 30, 2016	Nov	NEWA
>A>	AB		15MG	A202842	003	Nov 30, 2016	Nov	NEWA
>A>	AB		20MG	A202842	004	Nov 30, 2016	Nov	NEWA
>A>	AB		25MG	A202842	005	Nov 30, 2016	Nov	NEWA
>A>	AB		30MG	A202842	006	Nov 30, 2016	Nov	NEWA
>A>	AB		35MG	A202842	007	Nov 30, 2016	Nov	NEWA
>A>	AB		40MG	A202842	008	Nov 30, 2016	Nov	NEWA
		FOCALIN XR						
>D>		NOVARTIS	25MG	N021802	008	Apr 21, 2011	Nov	CFTG
>A>	AB		25MG	N021802	008	Apr 21, 2011	Nov	CFTG
>D>			35MG	N021802	007	Apr 21, 2011	Nov	CFTG
>A>	AB		35MG	N021802	007	Apr 21, 2011	Nov	CFTG



TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
AB		5MG	A201231	002	Sep 24, 2015	Feb CAHN
AB		10MG	A201231	003	Sep 24, 2015	Feb CAHN
AB	TRIS PHARMA INC	2.5MG	A207901	001	Aug 26, 2016	Aug NEWA
AB		5MG	A207901	002	Aug 26, 2016	Aug NEWA
AB		10MG	A207901	003	Aug 26, 2016	Aug NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

>A>	AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A207321	001	Nov 28, 2016	Nov NEWA
	AP	WEST-WARD PHARMS INT	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Oct CAHN
	AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Oct CAHN
		TOTECT					
	+	CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

AB	MAYNE PHARMA	5MG	A076137	001	Jan 18, 2002	Aug CAHN
AB		10MG	A076137	002	Jan 18, 2002	Aug CAHN
AB		15MG	A076137	003	Jan 18, 2002	Aug CAHN
AB	MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB		10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB		15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

	@	COREPHARMA	5MG	A090652	001	Mar 07, 2014	Sep DISC
	@		10MG	A090652	002	Mar 07, 2014	Sep DISC
	@	IDT AUSTRALIA LTD	5MG	A085370	001		Aug CAHN
AA		NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA			10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA		NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA			10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	@	ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984	Feb CMS1
--	---	------------	----------------------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	50MG/ML	A207449	001	Oct 21, 2016	Oct NEWA
----	--	--------------------	---------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986	Sep DISC
--	---	---------	---	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001		Feb CMS1
--	--	-----------------	--	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983	Feb CMS1
--	---	-----------------	---	---------	-----	--------------	----------

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

Code	Product Name	Strength	NDC	Unit	Start Date	End Date	Status
AP	+ BAXTER HLTHCARE	2.5GM/100ML; 450MG/100ML	N016697	001			Oct CRLD
	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
	+ HOSPIRA	5GM/100ML; 225MG/100ML	N017606	001			Oct CRLD
	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
	+ HOSPIRA	5GM/100ML; 300MG/100ML	N017799	001			Oct CRLD
	DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM INTENSOL

>D>	AA	+ ROXANE	5MG/ML	A071415	001	Apr 03, 1987	Nov CAHN
>A>	AA	+ WEST-WARD PHARMS INT	5MG/ML	A071415	001	Apr 03, 1987	Nov CAHN

INJECTABLE; INJECTION

DIAZEPAM

>D>	AP	+ @ EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan CAHN
>D>	AP	+ HOSPIRA	5MG/ML	A071583	001	Oct 13, 1987	Nov CPOT
>A>			5MG/ML	A072079	001	Dec 20, 1988	Nov CPOT
>A>		+ @	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Nov CPOT
>A>		+ @	50MG/10ML (5MG/ML)	A071583	001	Oct 13, 1987	Nov CPOT
		+ @ WEST-WARD PHARMS INT	5MG/ML	A070311	001	Dec 16, 1985	Oct CAHN
		+ @	5MG/ML	A070312	001	Dec 16, 1985	Oct CAHN
		+ @	5MG/ML	A070313	001	Dec 16, 1985	Oct CAHN
		+ @	5MG/ML	A071308	001	Jul 17, 1987	Oct CAHN
		+ @	5MG/ML	A071309	001	Jul 17, 1987	Oct CAHN
		+ @	5MG/ML	A071310	001	Jul 17, 1987	Oct CAHN

SOLUTION; ORAL

DIAZEPAM

AA		LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun NEWA
>D>	AA	+ ROXANE	5MG/5ML	A070928	001	Apr 03, 1987	Nov CAHN
AA		+ @	5MG/5ML	A070928	001	Apr 03, 1987	Jun CFTG
>A>	AA	+ WEST-WARD PHARMS INT	5MG/5ML	A070928	001	Apr 03, 1987	Nov CAHN

TABLET; ORAL

DIAZEPAM

		DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan CMS1
			5MG	A070228	003	Sep 26, 1985	Jan CMS1
AB		MAYNE PHARMA	2MG	A071134	001	Feb 03, 1987	Aug CAHN
AB			5MG	A071135	001	Feb 03, 1987	Aug CAHN
AB			10MG	A071136	001	Feb 03, 1987	Aug CAHN
		+ @ UPSHER-SMITH LABS	2MG	A070302	001	Dec 20, 1985	Oct CAHN
		+ @	5MG	A070303	001	Dec 20, 1985	Oct CAHN
		+ @	10MG	A070304	001	Dec 20, 1985	Oct CAHN

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

>D>		+ @ TARO	50MG	N011366	001		Nov CAHN
>A>		+ @ TARO PHARMS NORTH	50MG	N011366	001		Nov CAHN
		KEVEYIS					
>D>		TARO	50MG	N011366	002	Aug 07, 2015	Nov CAHN
>A>		TARO PHARMS NORTH	50MG	N011366	002	Aug 07, 2015	Nov CAHN

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB		BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb NEWA
		ZIPSOR					
AB		+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb CFTG
		FOR SOLUTION; ORAL					
		CAMBIA					
AB		+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr CFTG
		DICLOFENAC POTASSIUM					
AB		PAR FORM	50MG	A202964	001	May 02, 2016	Apr NEWA

TABLET; ORAL

CATAFLAM

		+ @ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Mar DISC
		DICLOFENAC POTASSIUM					
AB		+ MYLAN	50MG	A075463	001	Jul 26, 1999	Mar CRLD
		+ @ SUN PHARM INDS	50MG	A075470	001	Feb 21, 2002	Jun CAHN

DICLOFENAC SODIUM

GEL;TOPICAL

AB	DICLOFENAC SODIUM						
	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar	NEWA
	GLENMARK PHARMS LTD	3%	A208301	001	Sep 13, 2016	Aug	NEWA
	TARO	3%	A206298	001	Apr 28, 2016	Apr	NEWA
	VOLTAREN						
AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar	CFTG
	SOLUTION;TOPICAL						
	DICLOFENAC SODIUM						
AT	AMNEAL PHARMS	1.5%	A206116	001	Sep 02, 2016	Aug	NEWA
AT	TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May	CAHN
	SOLUTION/DROPS;OPHTHALMIC						
	DICLOFENAC SODIUM						
AT	RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	DICLOFENAC SODIUM						
AB	+ ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb	CRLD
	VOLTAREN-XR						
	@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb	DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

>A>	AB	DICLOFENAC SODIUM AND MISOPROSTOL					
		AMNEAL PHARMS	50MG;0.2MG	A203995	001	Nov 25, 2016	Nov NEWA
			75MG;0.2MG	A203995	002	Nov 25, 2016	Nov NEWA
	AB	EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar CAHN
	AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

	DICYCLOMINE HYDROCHLORIDE						
	@ SUN PHARM INDS	10MG	A084505	001	Oct 21, 1986	Mar	CAHN
	INJECTABLE;INJECTION						
	DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)						
AP	EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar	CMS1
AP	WEST-WARD PHARMS INT	10MG/ML	A040465	001	Jun 30, 2003	Sep	CAHN
	SYRUP;ORAL						
	DICYCLOMINE HYDROCHLORIDE						
	+ MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan	CRLD
	TABLET;ORAL						
	DICYCLOMINE HYDROCHLORIDE						
	@ SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985	Mar	CAHN

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

	ESTRADIOL VALERATE AND DIENOGEST						
AB	WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	A202349	001	May 06, 2016	Apr	NEWA
	NATAZIA						
AB	+ BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N022252	001	May 06, 2010	Apr	CFTG
	G, N/A						

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

	DIETHYLPROPION HYDROCHLORIDE						
	@ COREPHARMA	25MG	A040828	001	Nov 05, 2008	Mar	DISC
	TENUATE						
AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Apr	CAHN
AA	+ ALLERGAN SALES LLC	25MG	N011722	002		Mar	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	TENUATE DOSPAN						
AB	+ ACTAVIS LABS UT INC	75MG	N012546	001		Apr	CAHN
AB	+ ALLERGAN SALES LLC	75MG	N012546	001		Mar	CAHN

DIFLUNISAL

TABLET; ORAL  
DIFLUNISAL

@ IDT AUSTRALIA LTD 500MG A074604 001 Jun 10, 1996 May CAHN

DIFLUPREDNATE

EMULSION; OPHTHALMIC  
DUREZOL

>D> + ALCON PHARMS LTD 0.05% N022212 001 Jun 23, 2008 Nov CAHN  
>A> + NOVARTIS PHARMS CORP 0.05% N022212 001 Jun 23, 2008 Nov CAHN

DIGOXIN

INJECTABLE; INJECTION  
LANOXIN

AP + COVIS PHARMA SARL 0.25MG/ML N009330 002 Jun CAHN  
LANOXIN PEDIATRIC  
+ COVIS PHARMA SARL 0.1MG/ML N009330 004 Jun CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
DILACOR XR

@ ALLERGAN SALES LLC 120MG N020092 001 May 29, 1992 Jul CAHN  
@ 180MG N020092 002 May 29, 1992 Jul CAHN  
@ 240MG N020092 003 May 29, 1992 Jul CAHN

DILTIAZEM HYDROCHLORIDE

@ ACTAVIS LABS FL INC 120MG A074852 001 Oct 10, 1997 Jan DISC  
@ 180MG A074852 002 Oct 10, 1997 Jan DISC  
@ 240MG A074852 003 Oct 10, 1997 Jan DISC  
AB3 VALEANT PHARMS NORTH 120MG A075116 001 Dec 23, 1999 Jan CAHN  
AB3 180MG A075116 002 Dec 23, 1999 Jan CAHN  
AB3 240MG A075116 003 Dec 23, 1999 Jan CAHN  
AB3 300MG A075116 004 Dec 23, 1999 Jan CAHN

INJECTABLE; INJECTION  
DILTIAZEM HYDROCHLORIDE

AP + AMPHASTAR PHARMS INC 5MG/ML A074617 001 Feb 28, 1996 Jun CAHN  
AP + EUROHLTH INTL SARL 5MG/ML A074617 001 Feb 28, 1996 Apr CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL  
CERVIDIL

+ FERRING PHARMS INC 10MG N020411 001 Mar 30, 1995 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL  
DIPHENHYDRAMINE HYDROCHLORIDE

@ HIKMA INTL PHARMS 50MG A083567 001 Jul CAHN  
@ HIKMA PHARMS 50MG A083567 001 Feb CAHN  
@ SUN PHARM INDS 25MG A089488 001 Jan 02, 1987 Mar CAHN  
@ 50MG A089489 001 Jan 02, 1987 Jun CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION  
DIPYRIDAMOLE

AP + AMPHASTAR PHARMS INC 5MG/ML A074939 001 Apr 13, 1998 Jun CAHN  
AP + EUROHLTH INTL SARL 5MG/ML A074939 001 Apr 13, 1998 Apr CAHN  
AP WEST-WARD PHARMS INT 5MG/ML A074521 001 Oct 18, 1996 Oct CAHN

TABLET; ORAL

DIPYRIDAMOLE

@ IDT AUSTRALIA LTD 25MG A086944 002 Apr 16, 1991 May CAHN  
@ 50MG A087562 001 Feb 25, 1992 May CAHN  
@ 75MG A087561 001 Feb 25, 1992 May CAHN  
@ LANNETT 25MG A040898 001 Apr 23, 2008 Aug DISC  
@ 50MG A040898 002 Apr 23, 2008 Aug DISC  
@ 75MG A040898 003 Apr 23, 2008 Aug DISC  
@ PUREPAC PHARM 25MG A089425 001 Jul 12, 1990 Jul DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL		DISOPYRAMIDE PHOSPHATE					
	@ AUROLIFE PHARMA LLC	EQ 100MG BASE		A 070470	001	Dec 10, 1985	Feb CAHN
	@	EQ 150MG BASE		A 070471	001	Dec 10, 1985	Feb CAHN
AB	MAYNE PHARMA	EQ 100MG BASE		A 070173	001	May 31, 1985	Aug CAHN
AB		EQ 150MG BASE		A 070174	001	May 31, 1985	Aug CAHN
	@ SUN PHARM INDS	EQ 100MG BASE		A 070351	001	Dec 17, 1985	Mar CAHN
	@	EQ 150MG BASE		A 070352	001	Dec 17, 1985	Mar CAHN

DISULFIRAM

TABLET; ORAL		DISULFIRAM					
>D>	AB	ROXANE	250MG	A 202652	001	Feb 05, 2014	Nov CAHN
>D>	AB		500MG	A 202652	002	Feb 05, 2014	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	250MG	A 202652	001	Feb 05, 2014	Nov CAHN
>A>	AB		500MG	A 202652	002	Feb 05, 2014	Nov CAHN
		DISULFIRAM					
AB		ALVOGEN MALTA	250MG	A 091681	001	Aug 08, 2013	Jan CAHN

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL		DIVALPROEX SODIUM					
>D>	@ IMPAX LABS	EQ 250MG VALPROIC ACID		A 078791	001	May 06, 2009	Nov CMFD
>A>	AB	EQ 250MG VALPROIC ACID		A 078791	001	May 06, 2009	Nov CMFD
	@	EQ 250MG VALPROIC ACID		A 078791	001	May 06, 2009	Feb DISC
>D>	@	EQ 500MG VALPROIC ACID		A 078791	002	Aug 04, 2009	Nov CMFD
>A>	AB	EQ 500MG VALPROIC ACID		A 078791	002	Aug 04, 2009	Nov CMFD
	@	EQ 500MG VALPROIC ACID		A 078791	002	Aug 04, 2009	Feb DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION		DOBUTAMINE HYDROCHLORIDE					
	@ TELIGENT PHARMA INC	EQ 12.5MG BASE/ML		A 074098	001	Feb 21, 1995	Jan CAHN
AP	WEST-WARD PHARMS INT	EQ 12.5MG BASE/ML		A 074277	001	Oct 31, 1994	Sep CAHN

DOCETAXEL

INJECTABLE; INJECTION		DOCETAXEL					
		HOSPIRA INC	20MG/ML (20MG/ML)	N 022234	004	Jun 23, 2016	Jun NEWA
			80MG/4ML (20MG/ML)	N 022234	005	Jun 23, 2016	Jun NEWA
			120MG/6ML (20MG/ML)	N 022234	006	Jun 23, 2016	Jun NEWA
		SOLUTION; IV (INFUSION)					
		DOCETAXEL					
		EAGLE PHARMS	20MG/ML (20MG/ML)	N 205934	001	Dec 22, 2015	Jan CAHN
			80MG/4ML (20MG/ML)	N 205934	002	Dec 22, 2015	Jan CAHN
			160MG/8ML (20MG/ML)	N 205934	003	Dec 22, 2015	Jan CAHN

DOFETILIDE

CAPSULE; ORAL		DOFETILIDE					
AB	TIGER PHARMS LLC	0.125MG		A 207058	001	Jun 06, 2016	May NEWA
AB		0.25MG		A 207058	002	Jun 06, 2016	May NEWA
AB		0.5MG		A 207058	003	Jun 06, 2016	May NEWA
		TIKOSYN					
AB	PFIZER	0.125MG		N 020931	001	Oct 01, 1999	May CFTG
AB		0.25MG		N 020931	002	Oct 01, 1999	May CFTG
AB	+	0.5MG		N 020931	003	Oct 01, 1999	May CFTG

DOLASETRON MESYLATE

INJECTABLE; INJECTION		ANZEMET					
+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)		N 020624	002	Sep 11, 1997	Jan CAHN
+		12.5MG/0.625ML (20MG/ML)		N 020624	002	Sep 11, 1997	Jan CAHN
+		100MG/5ML (20MG/ML)		N 020624	001	Sep 11, 1997	Jan CAHN
	@	500MG/25ML (20MG/ML)		N 020624	003	Dec 11, 2001	Jun DISC
+		500MG/25ML (20MG/ML)		N 020624	003	Dec 11, 2001	Jan CAHN
		TABLET; ORAL					
		ANZEMET					
	US PHARM HOLDINGS	50MG		N 020623	001	Sep 11, 1997	Jan CAHN
+		100MG		N 020623	002	Sep 11, 1997	Jan CAHN

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jun	NEWA
	EQ 25MG BASE	N204790	003	Jun 09, 2016	Jun	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb	NEWA
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar	NEWA
AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jan	NEWA
AB	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Jun	CAHN
AB	UNICHEM LABS LTD	5MG	A203656	001	Jun 23, 2016	Jun	NEWA
AB		10MG	A203656	002	Jun 23, 2016	Jun	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

@	SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar	CAHN
@		10MG	A077975	001	Dec 11, 2009	Mar	CAHN
AB	UNICHEM LABS LTD	5MG	A204831	001	Nov 10, 2016	Oct	NEWA
AB		10MG	A204831	002	Nov 10, 2016	Oct	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

FOREST LABS LLC	10MG;7MG	N206439	003	Jul 18, 2016	Aug	NEWA
	10MG;21MG	N206439	004	Jul 18, 2016	Aug	NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@	LANNETT HOLDINGS INC	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014	Aug	DISC
---	----------------------	-------------------------	---------	-----	--------------	-----	------

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	+ WEST-WARD PHARMS INT	20MG/ML	N014879	001		Oct	CAHN
	DOXAPRAM HYDROCHLORIDE						
AP	AMPHASTAR PHARMS INC	20MG/ML	A076266	001	Jan 10, 2003	Jun	CAHN
AP	EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Apr	CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar	CAHN
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar	CAHN
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar	CAHN
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar	CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

@	SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar	CAHN
@		EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar	CAHN
@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar	CAHN
@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar	CAHN

TABLET;ORAL

DOXEPIIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	NEWA

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB	RISING PHARMS INC	0.5MCG	A201518	001	Sep 09, 2016	Aug	NEWA	
AB		1MCG	A201518	002	Sep 09, 2016	Aug	NEWA	
AB		2.5MCG	A201518	003	Sep 09, 2016	Aug	NEWA	
>D>	AB	ROXANE	0.5MCG	A091433	001	Sep 23, 2011	Nov	CAHN
>D>	AB		1MCG	A091433	002	Jan 14, 2014	Nov	CAHN
>D>	AB		2.5MCG	A091433	003	Jan 14, 2014	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	0.5MCG	A091433	001	Sep 23, 2011	Nov	CAHN

CAPSULE;ORAL  
DOXERCALCIFEROL

>A> AB 1MCG A091433 002 Jan 14, 2014 Nov CAHN  
>A> AB 2.5MCG A091433 003 Jan 14, 2014 Nov CAHN

INJECTABLE;INJECTION  
DOXERCALCIFEROL

AP AKORN INC 2MCG/ML (2MCG/ML) A203929 002 Mar 28, 2016 Mar NEWA  
HECTOROL  
AP GENZYME CORP 2MCG/ML (2MCG/ML) N021027 002 Apr 06, 2000 Mar CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION  
DOXORUBICIN HYDROCHLORIDE

AP ACTAVIS INC 2MG/ML A203622 001 Jun 27, 2014 May CRLD  
AP 200MG/100ML A203622 002 Jun 27, 2014 May CRLD  
AP + PHARMACIA AND UPJOHN 2MG/ML N050629 001 Dec 23, 1987 May CRLD  
AP + 200MG/100ML N050629 002 May 03, 1988 May CRLD  
>D> AP SANDOZ INC 2MG/ML A200146 001 Jul 18, 2012 Nov DISC  
>A> @ 2MG/ML A200146 001 Jul 18, 2012 Nov DISC  
AP WEST-WARD PHARMS INT 2MG/ML A062975 001 Mar 17, 1989 Sep CAHN  
AP + 10MG/VIAL A062921 001 Mar 17, 1989 Sep CAHN  
AP + 20MG/VIAL A062921 002 Mar 17, 1989 Sep CAHN  
AP + 50MG/VIAL A062921 003 Mar 17, 1989 Sep CAHN  
AP 200MG/100ML A064097 001 Sep 13, 1994 Sep CAHN

DOXYCYCLINE

CAPSULE;ORAL  
DOXYCYCLINE

AB G AND W LABS INC EQ 50MG BASE A204446 001 May 28, 2015 Mar CAHN  
AB EQ 75MG BASE A204446 002 May 28, 2015 Mar CAHN  
AB EQ 100MG BASE A204446 003 May 28, 2015 Mar CAHN  
AB ZYDUS PHARMS USA INC EQ 50MG BASE A205115 001 Feb 18, 2016 Feb NEWA  
AB EQ 75MG BASE A205115 002 Feb 18, 2016 Feb NEWA  
AB EQ 100MG BASE A205115 003 Feb 18, 2016 Feb NEWA

TABLET;ORAL  
DOXYCYCLINE

@ SUN PHARM INDS EQ 50MG BASE A065471 001 Apr 17, 2009 Jun CAHN  
@ EQ 75MG BASE A065471 002 Apr 17, 2009 Jun CAHN  
@ EQ 100MG BASE A065471 003 Apr 17, 2009 Jun CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL  
ACTICLATE CAP

+ AQUA PHARMS EQ 75MG BASE N208253 001 Apr 26, 2016 Apr NEWA  
DOXYCYCLINE HYCLATE  
AB AMNEAL PHARMS EQ 100MG BASE A207289 001 Jun 27, 2016 Jun NEWA  
AB SUN PHARM INDS EQ 100MG BASE A062676 001 Jul 10, 1986 Mar CAHN

INJECTABLE;INJECTION  
DOXYCYCLINE

@ WEST-WARD PHARMS INT EQ 100MG BASE/VIAL A062450 001 Oct 27, 1983 Oct CAHN  
AP + EQ 100MG BASE/VIAL A062569 001 Mar 09, 1988 Sep CAHN  
@ EQ 200MG BASE/VIAL A062450 002 Oct 27, 1983 Oct CAHN  
@ EQ 200MG BASE/VIAL A062569 002 Mar 09, 1988 Sep CAHN  
DOXYCYCLINE HYCLATE  
@ WEST-WARD PHARMS INT EQ 100MG BASE/VIAL A062992 001 Feb 16, 1989 Oct CAHN  
@ EQ 200MG BASE/VIAL A062992 002 Feb 16, 1989 Oct CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ COREPHARMA EQ 20MG BASE A065182 001 May 13, 2005 Mar DISC  
AB SUN PHARM INDS EQ 20MG BASE A065134 001 May 13, 2005 Mar CAHN  
AB EQ 100MG BASE A062677 001 Jul 10, 1986 Mar CAHN  
@ VINTAGE PHARMS EQ 100MG BASE A062538 001 Apr 07, 1986 Mar DISC

TABLET, DELAYED RELEASE;ORAL

DORYX

AB MAYNE PHARMA EQ 50MG BASE N050795 006 Dec 19, 2014 Jul CTNA  
AB EQ 50MG BASE N050795 006 Dec 19, 2014 May CFTG  
AB EQ 80MG BASE N050795 004 Apr 11, 2013 Apr CFTG  
AB + EQ 200MG BASE N050795 005 Apr 11, 2013 May CFTG  
DORYX MPC  
MAYNE PHARMA EQ 60MG BASE N050795 007 May 20, 2016 Jul CTNA  
EQ 60MG BASE N050795 007 May 20, 2016 May NEWA  
>D> EQ 120MG BASE N050795 008 May 20, 2016 Nov CRLD

TABLET, DELAYED RELEASE;ORAL  
DORYX MPC

>A>	+	EQ 120MG BASE	N050795	008	May 20, 2016	Nov	CRLD	
		EQ 120MG BASE	N050795	008	May 20, 2016	Jul	CTNA	
		EQ 120MG BASE	N050795	008	May 20, 2016	May	NEWA	
		DOXYCYCLINE HYCLATE						
	@	IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar	DISC
	@		EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar	DISC
AB		MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May	NEWA
AB			EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	NEWA
AB			EQ 200MG BASE	A090431	005	May 19, 2016	May	NEWA
AB		PRINSTON INC	EQ 150MG BASE	A207494	001	Nov 15, 2016	Oct	NEWA
AB			EQ 200MG BASE	A207494	002	Nov 15, 2016	Oct	NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL  
DICLEGIS

AB	+	DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013	Aug	CFTG
		DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE						
AB		ACTAVIS LABS FL INC	10MG;10MG	A205811	001	Aug 19, 2016	Aug	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
>A>		BONJESTA						
>A>	+	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016	Nov	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL  
MELAMISA

AB		NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan	NEWA
		TABLET;ORAL-28						
		DROSPIRENONE AND ETHINYL ESTRADIOL						
>A>	AB	ACCORD HLTHCARE	3MG;0.03MG	A207245	001	Nov 22, 2016	Nov	NEWA
AB		APOTEX INC	3MG;0.03MG	A205876	001	Sep 21, 2016	Sep	NEWA
AB		GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar	NEWA
AB		MAYNE PHARMA	3MG;0.03MG	A090081	001	Sep 07, 2010	Aug	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL  
BEYAZ

AB		BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep	CFTG
		DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM						
AB		WATSON LABS INC	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	A203593	001	Oct 11, 2016	Sep	NEWA
AB			3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	A203594	001	Oct 11, 2016	Sep	NEWA
		SAFYRAL						
AB	+	BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Sep	CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

AB		HETERO LABS LTD III	EQ 20MG BASE	A204343	001	Aug 03, 2016	Jul	NEWA
AB			EQ 30MG BASE	A204343	002	Aug 03, 2016	Jul	NEWA
AB			EQ 60MG BASE	A204343	003	Aug 03, 2016	Jul	NEWA

DUTASTERIDE

CAPSULE;ORAL  
DUTASTERIDE

AB		ASCENT PHARMS INC	0.5MG	A206574	001	Oct 21, 2016	Oct	NEWA
AB		AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr	CAHN
AB		BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan	CAHN
AB		INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb	NEWA
AB		MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May	NEWA
>D>	AB	ROXANE	0.5MG	A202204	001	Nov 23, 2015	Nov	CAHN
AB		STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar	CAHN
>A>	AB	WEST-WARD PHARMS INT	0.5MG	A202204	001	Nov 23, 2015	Nov	CAHN

DYPHYLLINE

TABLET;ORAL  
LUFYLLIN

	@	MEDA PHARMS	200MG	A084566	001		Jun	DISC
	@		400MG	A084566	002		Jun	DISC



ECONAZOLE NITRATE

	AEROSOL, FOAM;TOPICAL								
	ECOZA								
	+ EXELTIS SUISSE	1%		N205175	001	Oct 24, 2013	Jul	CAHN	
	CREAM;TOPICAL								
	ECONAZOLE NITRATE								
AB	TELIGENT PHARMA INC	1%		A076574	001	Dec 17, 2004	May	CAHN	
	SPECTAZOLE								
	@ ALVOGEN MALTA	1%		N018751	001	Dec 23, 1982	Jul	CAHN	

EDROPHONIUM CHLORIDE

	INJECTABLE;INJECTION								
	TENSILON PRESERVATIVE FREE								
	@ TELIGENT PHARMA INC	10MG/ML		N007959	002		Jan	CAHN	

EFAVIRENZ

	TABLET;ORAL								
	EFAVIRENZ								
AB	MYLAN LABS LTD	600MG		A091471	001	Feb 17, 2016	Feb	NEWA	
AB	MYLAN PHARMS INC	600MG		A091471	001	Feb 17, 2016	Jun	CAHN	
	SUSTIVA								
AB	+ BRISTOL MYERS SQUIBB	600MG		N021360	002	Feb 01, 2002	Feb	CFTG	

ELBASVIR; GRAZOPREVR

	TABLET;ORAL								
	ZEPATIER								
	+ MERCK SHARP DOHME	50MG;100MG		N208261	001	Jan 28, 2016	Jan	NEWA	

ELUXADOLINE

	TABLET;ORAL								
	VIBERZI								
	ALLERGAN HOLDINGS	75MG		N206940	001	May 27, 2015	May	CAHN	
	+ ALLERGAN HOLDINGS	100MG		N206940	002	May 27, 2015	May	CAHN	

EMEDASTINE DIFUMARATE

	SOLUTION/DROPS;OPHTHALMIC								
	EMADINE								
>D>	+ ALCON	0.05%		N020706	001	Dec 29, 1997	Nov	CAHN	
>A>	+ NOVARTIS PHARMS CORP	0.05%		N020706	001	Dec 29, 1997	Nov	CAHN	

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

	TABLET;ORAL								
	ODEFSEY								
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE		N208351	001	Mar 01, 2016	Apr	CAIN	

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL								
	ODEFSEY								
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE		N208351	001	Mar 01, 2016	Mar	NEWA	

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

	TABLET;ORAL								
	DESCOVY								
	+ GILEAD SCIENCES INC	200MG;EQ 25MG BASE		N208215	001	Apr 04, 2016	Apr	NEWA	

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL								
	TRUVADA								
	GILEAD	100MG;150MG		N021752	002	Mar 10, 2016	Mar	NEWA	
		133MG;200MG		N021752	003	Mar 10, 2016	Mar	NEWA	
		167MG;250MG		N021752	004	Mar 10, 2016	Mar	NEWA	

ENALAPRIL MALEATE

	SOLUTION;ORAL								
	EPANED								
	SILVERGATE PHARMS	1MG/ML		N208686	001	Sep 20, 2016	Sep	NEWA	

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ UPSHER-SMITH LABS 5MG;12.5MG  
 @ 10MG;25MG

A076116 001 Sep 19, 2001 Oct CAHN  
 A076116 002 Sep 19, 2001 Oct CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP + AMPHASTAR PHARMS INC 1.25MG/ML  
 AP + EUROHLTH INTL SARL 1.25MG/ML

A075634 001 Aug 22, 2000 Jun CAHN  
 A075634 001 Aug 22, 2000 Apr CAHN

ENFLURANE

LIQUID; INHALATION

ENFLURANE

@ PIRAMAL CRITICAL 99.9%

A074396 001 Jul 29, 1994 Aug DISC

ENTECAVIR

TABLET; ORAL

ENTECAVIR

>A> AB CIPLA LTD 0.5MG  
 >A> AB 1MG  
 >A> AB PAR PHARM INC 0.5MG  
 >A> AB 1MG

A206872 001 Dec 06, 2016 Nov NEWA  
 A206872 002 Dec 06, 2016 Nov NEWA  
 A206294 001 Nov 23, 2016 Nov NEWA  
 A206294 002 Nov 23, 2016 Nov NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

+ FLAMEL IRELAND LTD 50MG/ML

N208289 001 Apr 29, 2016 Apr NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

>A> AT ALCON RES LTD 0.05%  
 AT SOMERSET THERAPS LLC 0.05%

A203384 001 Dec 07, 2016 Nov NEWA  
 A090951 001 Oct 31, 2011 Mar CAHN

EPINEPHRINE

INJECTABLE; INJECTION

SUS-PHRINE SULFITE FREE

@ FOREST LABS 1.5MG/AMP  
 @ 5MG/ML

N007942 003 Feb 05, 1999 Mar CMS1  
 N007942 001 Mar CMS1

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q

BX + KALEO INC EQ 0.15MG/DELIVERY  
 BX EQ 0.3MG/DELIVERY

N201739 002 Aug 10, 2012 Mar CAHN  
 N201739 001 Aug 10, 2012 Mar CAHN

TWINJECT 0.15

@ AMEDRA PHARMS EQ 0.15MG/DELIVERY  
 TWINJECT 0.3

N020800 002 May 28, 2004 May DISC  
 N020800 001 May 30, 2003 May DISC

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014 Jul CAIN

EPINEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014 Feb CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP IMPAX LABS INC 50MG/25ML (2MG/ML)  
 AP 200MG/100ML (2MG/ML)  
 AP WEST-WARD PHARMS INT 50MG/25ML (2MG/ML)  
 AP 200MG/100ML (2MG/ML)

A065331 001 Aug 09, 2007 Aug CAHN  
 A065331 002 Aug 09, 2007 Aug CAHN  
 A065289 001 Jun 27, 2007 Sep CAHN  
 A065289 002 Jun 27, 2007 Sep CAHN

EPTIFIBATIDE

INJECTABLE; INJECTION  
EPTIFIBATIDE

>A>	AP	AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016	Nov	NEWA
>A>	AP		75MG/100ML	A205581	002	Dec 08, 2016	Nov	NEWA
		@ TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015	Aug	DISC

ERGOCALCIFEROL

CAPSULE; ORAL  
DRISDOL

AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Jan	CAHN
		VITAMIN D						
AA		BIONPHARMA INC	50,000 IU	A080704	001		Jan	CAHN

ERGOLOID MESYLATES

TABLET; ORAL  
ERGOLOID MESYLATES

AB		SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar	CAHN
		TABLET; SUBLINGUAL						
		ERGOLOID MESYLATES						
		@ SUN PHARM INDS	0.5MG	A087407	001		Jun	CAHN
		@	1MG	A087552	001		Jun	CAHN

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL  
ERGOMAR

+		TERSERA THERAP	2MG	A087693	001	Feb 24, 1983	Aug	CAHN
---	--	----------------	-----	---------	-----	--------------	-----	------

ERYTHROMYCIN

SOLUTION; TOPICAL  
C-SOLVE-2

		@ FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb	DISC
		ERYTHRO-STATIN						
		@ HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb	DISC
		ERYTHROMYCIN						
AT	+	FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan	CRLD
AT		PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan	CRLD

ESCITALOPRAM OXALATE

SOLUTION; ORAL  
ESCITALOPRAM OXALATE

AA		MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar	NEWA
----	--	---------------------	-----------------	---------	-----	--------------	-----	------

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION  
ESMOLOL HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	10MG/ML	A076323	001	Aug 10, 2004	Oct	CAHN
		SOLUTION; INTRAVENOUS						
		ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER						
+		HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr	NEWA
		ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER						
+		HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun	CRLD
			2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL  
ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr	NEWA
AB			EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr	NEWA
BX		HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr	CTEC
BX			EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr	CTEC

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS  
ESOMEPRAZOLE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 20MG BASE/VIAL	A204657	001	Aug 10, 2016	Jul	NEWA
AP			EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul	NEWA

ESTAZOLAM

	TABLET; ORAL							
	ESTAZOLAM							
AB	MAYNE PHARMA	1MG	A074921	001	Jul 10, 1997	Aug	CAHN	
AB	+	2MG	A074921	002	Jul 10, 1997	Aug	CAHN	

ESTRADIOL

	CREAM; VAGINAL							
	ESTRACE							
	+ ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr	CAHN	
	FILM, EXTENDED RELEASE; TRANSDERMAL							
	ALORA							
BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN	
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN	
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN	
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN	
	TABLET; ORAL							
	ESTRADIOL							
AB	EPIC PHARMA INC	0.5MG	A040275	001	Dec 29, 1998	Oct	CMFD	
AB		1MG	A040275	002	Dec 29, 1998	Oct	CMFD	
AB		2MG	A040275	003	Dec 29, 1998	Oct	CMFD	
AB	MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Aug	CAHN	
AB		1MG	A040114	001	Mar 14, 1996	Aug	CAHN	
AB		2MG	A040114	002	Mar 14, 1996	Aug	CAHN	
	TABLET; VAGINAL							
	ESTRADIOL							
AB	AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	Aug	CMFD	
	VAGIFEM							
AB	+ NOVO NORDISK INC	10MCG	N020908	002	Nov 25, 2009	Aug	CTEC	

ESTRADIOL ACETATE

	INSERT, EXTENDED RELEASE; VAGINAL							
	FEMRING							
	APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN	
	+	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN	
	TABLET; ORAL							
	FEMTRACE							
	APIL	0.45MG	N021633	001	Aug 20, 2004	Jan	CAHN	
		0.9MG	N021633	002	Aug 20, 2004	Jan	CAHN	
	+	1.8MG	N021633	003	Aug 20, 2004	Jan	CAHN	

ESTRADIOL HEMIHYDRATE

	EMULSION; TOPICAL							
	ESTRASORB							
	+ EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun	CAHN	

ESTRADIOL; NORETHINDRONE ACETATE

	TABLET; ORAL							
	AMABELZ							
AB	LUPIN LTD	0.5MG; 0.1MG	A203339	001	Jun 20, 2016	Jun	NEWA	
AB		1MG; 0.5MG	A203339	002	Jun 20, 2016	Jun	NEWA	

ESTROGENS, CONJUGATED SYNTHETIC A

	TABLET; ORAL							
	CENESTIN							
	@ TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	DISC	
	@	0.45MG	N020992	005	Feb 05, 2004	Jun	DISC	
	@	0.625MG	N020992	002	Mar 24, 1999	Jun	DISC	
	@	0.9MG	N020992	003	Mar 24, 1999	Jun	DISC	
	@	1.25MG	N020992	004	Mar 13, 2000	Jun	DISC	

ESTROGENS, CONJUGATED SYNTHETIC B

	TABLET; ORAL							
	ENJUWIA							
	@ TEVA WOMENS	0.625MG	N021443	003	May 10, 2004	Jun	DISC	
	@	1.25MG	N021443	004	May 10, 2004	Sep	DISC	

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB	AUROBINDO PHARMA LTD	1MG	A208451	001	Sep 15, 2016	Sep	NEWA
AB		2MG	A208451	002	Sep 15, 2016	Sep	NEWA
AB		3MG	A208451	003	Sep 15, 2016	Sep	NEWA
>D>	AB	ROXANE	1MG	A091153	001	Apr 15, 2014	Nov CAHN
>D>	AB		2MG	A091153	002	Apr 15, 2014	Nov CAHN
>D>	AB		3MG	A091153	003	Apr 15, 2014	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	1MG	A091153	001	Apr 15, 2014	Nov CAHN
>A>	AB		2MG	A091153	002	Apr 15, 2014	Nov CAHN
>A>	AB		3MG	A091153	003	Apr 15, 2014	Nov CAHN

ETEPLIRSEN

SOLUTION; IV (INFUSION)

EXONDYS 51

+	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016	Sep	NEWA
+		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016	Sep	NEWA

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

ETHACRYNATE SODIUM

AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016	Aug	NEWA
----	---------------------	-------------------	---------	-----	--------------	-----	------

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

AB	+	ATON	25MG	N016092	001		Jun CFTG
AB		ETHACRYNIC ACID		A205609	001	Jun 30, 2016	Jun NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	0.05MG; 1MG	A204704	001	Feb 09, 2016	Jan	NEWA
AB		ZOVIA 1/35E-28					
AB	MAYNE PHARMA	0.035MG; 1MG	A072721	001	Dec 30, 1991	Aug	CAHN
AB		ZOVIA 1/50E-28					
AB	+	WATSON LABS	0.05MG; 1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

FAYOSIM

AB	LUPIN LTD	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	A205943	001	Mar 29, 2016	Mar	NEWA
AB		LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB	AMNEAL PHARMS	0.03MG; 0.15MG	A203871	001	Nov 13, 2015	Jul	CAHN
>A>	AB	0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Nov	CAHN
>D>	AB	HAUPT PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Nov CAHN
AB		0.03MG, 0.01MG; 0.15MG, N/A	A203872	001	Dec 22, 2015	Jul	CMS1
AB	MAYNE PHARMA	0.02MG, 0.01MG; 0.1MG, N/A	A200407	001	Oct 25, 2011	Aug	CAHN
AB		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL					
AB	MAYNE PHARMA	0.03MG, 0.01MG; 0.15MG, N/A	A078834	001	May 31, 2011	Aug	CAHN
AB	+	TEVA BRANDED PHARM	0.02MG, 0.15MG; 0.025MG, 0.15MG; 0.03MG, 0.15MG; 0.01MG, N/A	N204061	001	Mar 28, 2013	Mar CFTG

TABLET; ORAL-21

TRIVORA-21

@	MAYNE PHARMA	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A074538	001	Dec 18, 1997	Aug	CAHN
---	--------------	--	---------	-----	--------------	-----	------

TABLET; ORAL-28

AFIRMELLE

AB1	AUROBINDO PHARMA LTD	0.02MG; 0.1MG	A206886	001	Nov 14, 2016	Oct	NEWA
AB		AYUNA					
AB	AUROBINDO PHARMA LTD	0.03MG; 0.15MG	A206866	001	Sep 23, 2016	Sep	NEWA
AB1		LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1	AMNEAL PHARMS	0.02MG; 0.1MG	A201108	001	Feb 05, 2014	May	CAHN
AB		0.03MG; 0.15MG	A201095	001	Dec 08, 2014	Jul	CAHN
AB1	+	MAYNE PHARMA	0.02MG; 0.1MG	A076625	001	Nov 18, 2004	Aug CAHN
AB2	+	0.02MG; 0.1MG	A077681	001	May 31, 2006	Aug	CAHN

TABLET;ORAL-28  
LEVORA 0.15/30-28

AB	+	MAYNE PHARMA	0.03MG;0.15MG	A 073594	001	Dec 13, 1993	Aug CAHN
----	---	--------------	---------------	----------	-----	--------------	----------

TRIVORA-28

AB	+	MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A 074538	002	Dec 18, 1997	Aug CAHN
----	---	--------------	---	----------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21  
BREVICON 21-DAY

		@ ALLERGAN SALES LLC	0.035MG;0.5MG	N 017566	001		Apr CAHN
--	--	----------------------	---------------	----------	-----	--	----------

NORINYL 1+35 21-DAY

AB		ALLERGAN SALES LLC	0.035MG;1MG	N 017565	001		Mar CAHN
----	--	--------------------	-------------	----------	-----	--	----------

TRI-NORINYL 21-DAY

		@ MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N 018977	001	Apr 13, 1984	Aug CAHN
--	--	----------------	---	----------	-----	--------------	----------

TABLET;ORAL-28  
BREVICON 28-DAY

AB		ALLERGAN SALES LLC	0.035MG;0.5MG	N 017743	001		Mar CAHN
----	--	--------------------	---------------	----------	-----	--	----------

CYONANZ

AB		AUROBINDO PHARMA LTD	0.035MG;0.5MG	A 207055	001	Oct 21, 2016	Oct NEWA
----	--	----------------------	---------------	----------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL

AB		MAYNE PHARMA	0.035MG;0.5MG	A 070686	001	Jan 29, 1987	Aug CAHN
----	--	--------------	---------------	----------	-----	--------------	----------

NORINYL 1+35 28-DAY

AB		ALLERGAN SALES LLC	0.035MG;1MG	N 017565	002		Mar CAHN
----	--	--------------------	-------------	----------	-----	--	----------

NYLIA 1/35

AB		AUROBINDO PHARMA LTD	0.035MG;1MG	A 207056	001	Oct 21, 2016	Oct NEWA
----	--	----------------------	-------------	----------	-----	--------------	----------

NYLIA 7/7/7

AB		AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A 207054	001	Oct 21, 2016	Oct NEWA
----	--	----------------------	--	----------	-----	--------------	----------

TRI-NORINYL 28-DAY

AB	+	MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N 018977	002	Apr 13, 1984	Aug CAHN
----	---	--------------	---	----------	-----	--------------	----------

TABLET, CHEWABLE;ORAL  
FEMCON FE

AB	+	APIL	0.035MG;0.4MG	N 021490	001	Nov 14, 2003	Jan CAHN
----	---	------	---------------	----------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	APIL	0.025MG;0.8MG	N 022573	001	Dec 22, 2010	Jan CAHN
----	---	------	---------------	----------	-----	--------------	----------

AB		LUPIN LTD	0.035MG;0.4MG	A 091332	001	Mar 23, 2016	Mar NEWA
----	--	-----------	---------------	----------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL  
TAYTULLA

	+	APIL	0.02MG;1MG	N 204426	001	Apr 19, 2013	Aug CTNA
--	---	------	------------	----------	-----	--------------	----------

@

			0.02MG;1MG	N 204426	001	Apr 19, 2013	Apr CAHN
--	--	--	------------	----------	-----	--------------	----------

TABLET;ORAL  
FEMHRT

AB		APIL	0.0025MG;0.5MG	N 021065	001	Jan 14, 2005	Jan CAHN
----	--	------	----------------	----------	-----	--------------	----------

@

			0.005MG;1MG	N 021065	002	Oct 15, 1999	Jan CAHN
--	--	--	-------------	----------	-----	--------------	----------

LERIBANE

AB		NOVAST LABS LTD	0.0025MG;0.5MG	A 203435	002	Jun 03, 2016	May NEWA
----	--	-----------------	----------------	----------	-----	--------------	----------

AB			0.005MG;1MG	A 203435	001	Jun 03, 2016	May NEWA
----	--	--	-------------	----------	-----	--------------	----------

LO LOESTRIN FE

AB	+	APIL	0.01MG,0.01MG;1MG,N/A	N 022501	001	Oct 21, 2010	May CFTG
----	---	------	-----------------------	----------	-----	--------------	----------

	+		0.01MG,0.01MG;1MG,N/A	N 022501	001	Oct 21, 2010	Jan CAHN
--	---	--	-----------------------	----------	-----	--------------	----------

LOESTRIN 24 FE

AB		APIL	0.02MG;1MG	N 021871	001	Feb 17, 2006	Aug CAHN
----	--	------	------------	----------	-----	--------------	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A 205049	001	May 31, 2016	May NEWA
----	--	----------------	-----------------------	----------	-----	--------------	----------

TABLET;ORAL-21  
ESTROSTEP 21

		@ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N 020130	001	Oct 09, 1996	Jan CAHN
--	--	--------	-----------------------------------	----------	-----	--------------	----------

LOESTRIN 21 1.5/30

AB		APIL	0.03MG;1.5MG	N 017875	001		Apr CAHN
----	--	------	--------------	----------	-----	--	----------

LOESTRIN 21 1/20

AB		APIL	0.02MG;1MG	N 017876	001		Apr CAHN
----	--	------	------------	----------	-----	--	----------

MICROGESTIN 1.5/30

AB		MAYNE PHARMA	0.03MG;1.5MG	A 075548	002	Jul 30, 2003	Aug CAHN
----	--	--------------	--------------	----------	-----	--------------	----------

MICROGESTIN 1/20

AB		MAYNE PHARMA	0.02MG;1MG	A 075647	002	Jul 30, 2003	Aug CAHN
----	--	--------------	------------	----------	-----	--------------	----------

TABLET;ORAL-21							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan	NEWA
TABLET;ORAL-28							
ESTROSTEP FE							
AB	+ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan	CAHN
LOESTRIN FE 1.5/30							
AB	+ APIL	0.03MG;1.5MG	N017355	001		Apr	CAHN
LOESTRIN FE 1/20							
AB	APIL	0.02MG;1MG	N017354	001		Apr	CAHN
MICROGESTIN FE 1.5/30							
AB	MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Aug	CAHN
MICROGESTIN FE 1/20							
AB	MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Aug	CAHN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
AB	MAYNE PHARMA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Aug	CAHN
TABLET, CHEWABLE;ORAL							
MIBELAS 24 FE							
AB	LUPIN ATLANTIS	0.02MG;1MG	A206287	001	May 24, 2016	May	NEWA
MINASTRIN 24 FE							
AB	+ APIL	0.02MG;1MG	N203667	001	May 08, 2013	May	CFTG
AB	+ APIL	0.02MG;1MG	N203667	001	May 08, 2013	Jan	CAHN
TABLET, CHEWABLE, TABLET;ORAL							
LO MINASTRIN FE							
AB	+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28							
MILI							
AB	AUROBINDO PHARMA LTD	0.035MG;0.25MG	A205449	001	Jul 07, 2016	Jun	NEWA
NORGESTIMATE AND ETHINYL ESTRADIOL							
AB	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.25MG,0.25MG	A203870	001	Nov 12, 2015	Sep	CAHN
AB		0.035MG;0.25MG	A203865	001	Oct 27, 2015	May	CAHN
AB	GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.25MG,0.25MG	A204057	001	Feb 23, 2016	Jun	CAHN
AB	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.25MG,0.25MG	A204057	001	Feb 23, 2016	Feb	NEWA
AB	HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.25MG,0.25MG	A203873	001	May 12, 2016	May	NEWA
AB	JAI PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A201897	001	Jan 27, 2016	Jan	NEWA
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan	NEWA
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.25MG,0.25MG	A205588	001	Apr 26, 2016	Apr	NEWA
AB		0.035MG;0.25MG	A205630	001	Oct 27, 2016	Oct	NEWA
TRI-LO-MILI							
AB	AUROBINDO PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.25MG,0.25MG	A205762	001	Nov 04, 2016	Oct	NEWA
TRI-MILI							
AB	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.25MG,0.25MG	A205441	001	Jul 06, 2016	Jun	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21							
LO/OVRAL							
	@ PELAGIUS	0.03MG;0.3MG	N017612	001		Jun	CAHN
LOW-OGESTREL-21							
	@ MAYNE PHARMA	0.03MG;0.3MG	A075288	001	Jul 28, 1999	Aug	CAHN
TABLET;ORAL-28							
LO/OVRAL-28							
	@ WYETH PHARMS	0.03MG;0.3MG	N017802	001		Jun	DISC
LOW-OGESTREL-28							
AB	MAYNE PHARMA	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Aug	CAHN
NORGESTREL AND ETHINYL ESTRADIOL							
AB	JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun	NEWA

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE							
LIPIODOL							
AB	+ GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001		Aug	CPOT

ETHOSUXIMIDE

CAPSULE; ORAL  
 ETHOSUXIMIDE  
 AB BIONPHARMA INC 250MG A040430 001 Oct 28, 2002 Jan CAHN

ETIDRONATE DISODIUM

TABLET; ORAL  
 DIDRONEL  
 AB APIL 200MG N017831 001 Apr CAHN  
 AB + 400MG N017831 002 Apr CAHN

ETODOLAC

CAPSULE; ORAL  
 ETODOLAC  
 @ IDT AUSTRALIA LTD 200MG A074840 001 Aug 29, 1997 May CAHN  
 @ 300MG A074840 002 Aug 29, 1997 May CAHN  
 @ LEHIGH VALLEY 300MG A074929 001 Jan 30, 1998 Feb CAHN  
 TABLET, EXTENDED RELEASE; ORAL  
 ETODOLAC  
 @ IDT AUSTRALIA LTD 400MG A075943 001 Jul 26, 2002 Aug CAHN  
 @ 500MG A075943 002 Jul 26, 2002 Aug CAHN  
 @ 600MG A075943 003 Jul 26, 2002 Aug CAHN

ETOMIDATE

INJECTABLE; INJECTION  
 ETOMIDATE  
 AP HIKMA FARMACEUTICA 2MG/ML A202354 001 Feb 25, 2016 Feb NEWA

ETOPOSIDE

INJECTABLE; INJECTION  
 ETOPOSIDE  
 AP WEST-WARD PHARMS INT 20MG/ML A074290 001 Jul 17, 1995 Sep CAHN

EXEMESTANE

TABLET; ORAL  
 EXEMESTANE  
 AB ALVOGEN MALTA 25MG A200898 001 Jul 28, 2014 Jan CAHN  
 >D> AB ROXANE 25MG A077431 001 Apr 01, 2011 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT 25MG A077431 001 Apr 01, 2011 Nov CAHN

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS  
 BYDUREON PEN  
 + ASTRAZENECA AB 2MG N022200 002 Feb 28, 2014 Feb NEWA

EZETIMIBE

TABLET; ORAL  
 EZETIMIBE  
 AB GLENMARK PHARMS LTD 10MG A078560 001 Jun 26, 2015 Oct CMFD  
 ZETIA  
 AB + MSD INTL GMBH 10MG N021445 001 Oct 25, 2002 Oct CTEC

FAMCICLOVIR

TABLET; ORAL  
 FAMCICLOVIR  
 >D> AB ROXANE 125MG A090128 001 Mar 21, 2011 Nov CAHN  
 >D> AB 250MG A090128 002 Mar 21, 2011 Nov CAHN  
 >D> AB 500MG A090128 003 Mar 21, 2011 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT 125MG A090128 001 Mar 21, 2011 Nov CAHN  
 >A> AB 250MG A090128 002 Mar 21, 2011 Nov CAHN  
 >A> AB 500MG A090128 003 Mar 21, 2011 Nov CAHN

FAMOTIDINE

INJECTABLE; INJECTION  
 FAMOTIDINE  
 AP AMPHASTAR PHARMS INC 10MG/ML A075651 001 Apr 16, 2001 Jun CAHN  
 AP 10MG/ML A075684 001 Apr 16, 2001 Jun CAHN  
 AP EUROHLTH INTL SARL 10MG/ML A075651 001 Apr 16, 2001 Apr CAHN  
 AP 10MG/ML A075684 001 Apr 16, 2001 Apr CAHN



INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE						
AP	AMPHASTAR PHARMS INC	10MG/ML	A 075622	001	Apr 16, 2001	Jun CAHN
AP		10MG/ML	A 075825	001	Apr 17, 2001	Jun CAHN
AP	EUROHLTH INTL SARL	10MG/ML	A 075622	001	Apr 16, 2001	Apr CAHN
AP		10MG/ML	A 075825	001	Apr 17, 2001	Apr CAHN

TABLET; ORAL

FAMOTIDINE						
	@ SUN PHARM INDS	20MG	A 075639	002	Dec 12, 2001	Mar CAHN
	@	40MG	A 075639	001	Dec 12, 2001	Mar CAHN

FELBAMATE

FELBAMATE						
AB	ALVOGEN MALTA	400MG	A 204595	001	Jan 11, 2016	Aug CAHN
AB		600MG	A 204595	002	Jan 11, 2016	Aug CAHN

FELODIPINE

FELODIPINE						
AB	JUBILANT GENERICS	2.5MG	A 203983	001	Aug 19, 2016	Aug NEWA
AB		5MG	A 203983	002	Aug 19, 2016	Aug NEWA
AB		10MG	A 203983	003	Aug 19, 2016	Aug NEWA
AB	SUN PHARM INDS	2.5MG	A 075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A 075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A 075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

FENOFIBRATE (MICRONIZED)						
>A>	AB RHODES PHARMS	67MG	A 075753	001	Sep 03, 2002	Nov CAHN
>A>	AB	134MG	A 075753	002	Apr 09, 2002	Nov CAHN
>A>	AB +	200MG	A 075753	003	Apr 09, 2002	Nov CAHN
>D>	AB TEVA	67MG	A 075753	001	Sep 03, 2002	Nov CAHN
>D>	AB	134MG	A 075753	002	Apr 09, 2002	Nov CAHN
>D>	AB +	200MG	A 075753	003	Apr 09, 2002	Nov CAHN

FENOGLIDE						
AB	AUROBINDO PHARMA LTD	48MG	A 205118	001	May 05, 2016	Apr NEWA
AB		145MG	A 205118	002	May 05, 2016	Apr NEWA
AB	HETERO LABS LTD III	48MG	A 204598	001	Jul 12, 2016	Jun NEWA
AB		145MG	A 204598	002	Jul 12, 2016	Jun NEWA
AB	MYLAN	40MG	A 204475	001	Jun 23, 2016	Jun NEWA
AB		120MG	A 204475	002	Jun 23, 2016	Jun NEWA
>A>	AB RHODES PHARMS	54MG	A 076433	001	May 13, 2005	Nov CAHN
>A>	AB +	160MG	A 076433	002	May 13, 2005	Nov CAHN
>D>	AB TEVA	54MG	A 076433	001	May 13, 2005	Nov CAHN
>D>	AB +	160MG	A 076433	002	May 13, 2005	Nov CAHN

FENOFIBRATE						
AB	SANTARUS INC	40MG	N 022118	001	Aug 10, 2007	Jun CFTG
AB	+	120MG	N 022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACID

FIBRICOR						
	ARALENZ PHARMS	35MG	N 022418	001	Aug 14, 2009	Apr CAHN
	+	105MG	N 022418	002	Aug 14, 2009	Apr CAHN
	ARALEZ PHARMS INC	35MG	N 022418	001	Aug 14, 2009	Jun CAHN
	+	105MG	N 022418	002	Aug 14, 2009	Jun CAHN

FENOLDOPAM MESYLATE

FENOLDOPAM MESYLATE						
AP	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A 076582	001	Oct 12, 2004	Oct CAHN

FENOPROFEN CALCIUM

FENOPROFEN CALCIUM						
	@ AUROLIFE PHARMA LLC	EQ 200MG BASE	A 072394	001	Oct 17, 1988	Mar CAHN
	@	EQ 300MG BASE	A 072395	001	Oct 17, 1988	Feb CAHN

## TABLET;ORAL

## FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC EQ 600MG BASE  
 @ SUN PHARM INDS EQ 600MG BASE

A072396 001 Oct 17, 1988 Feb CAHN  
 A072902 001 Dec 21, 1990 Mar CAHN

FENTANYL

## FILM, EXTENDED RELEASE;TRANSDERMAL

## FENTANYL-100

AB 3M DRUG DELIVERY 100MCG/HR

A202097 005 Nov 04, 2016 Oct NEWA

## FENTANYL-12

AB 3M DRUG DELIVERY 12.5MCG/HR

A202097 001 Nov 04, 2016 Oct NEWA

AB AVEVA 12.5MCG/HR

A077449 005 Sep 11, 2015 Jan NEWA

## FENTANYL-25

AB 3M DRUG DELIVERY 25MCG/HR

A202097 002 Nov 04, 2016 Oct NEWA

## FENTANYL-50

AB 3M DRUG DELIVERY 50MCG/HR

A202097 003 Nov 04, 2016 Oct NEWA

## FENTANYL-75

AB 3M DRUG DELIVERY 75MCG/HR

A202097 004 Nov 04, 2016 Oct NEWA

FENTANYL CITRATE

## INJECTABLE;INJECTION

## FENTANYL CITRATE PRESERVATIVE FREE

AP + WEST-WARD PHARMS INT EQ 0.05MG BASE/ML

N019101 001 Jul 11, 1984 Oct CAHN

FERRIC PYROPHOSPHATE CITRATE

## FOR SOLUTION;INTRAVENOUS

## TRIFERIC

+ ROCKWELL MEDICAL INC 272MG IRON/PACKET

N208551 001 Apr 25, 2016 Apr NEWA

FESOTERODINE FUMARATE

## TABLET, EXTENDED RELEASE;ORAL

## FESOTERODINE FUMARATE

@ ALKEM LABS LTD 4MG

A204827 001 Dec 10, 2015 Jan DISC

@ 8MG

A204827 002 Dec 10, 2015 Jan DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ BARR 60MG;120MG

A076236 001 Apr 14, 2005 Mar DISC

@ IMPAX PHARMS 60MG;120MG

A076298 001 Nov 12, 2010 Mar DISC

FINAFLOXACIN

## SUSPENSION/DROPS;OTIC

## XTORO

>D> + ALCON RES LTD 0.3%

N206307 001 Dec 17, 2014 Nov CAHN

>A> + NOVARTIS PHARMS CORP 0.3%

N206307 001 Dec 17, 2014 Nov CAHN

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

## EMULSION;INTRAVENOUS

## SMOFLIPID 20%

+ FRESENIUS KABI USA 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)

N207648 001 Jul 13, 2016 Jul NEWA

+ 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)

N207648 002 Jul 13, 2016 Jul NEWA

+ 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)

N207648 003 Jul 13, 2016 Jul NEWA

FLAVOXATE HYDROCHLORIDE

## TABLET;ORAL

## FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS 100MG

A076234 001 Aug 28, 2003 Mar DISC

FLECAINIDE ACETATE

## TABLET;ORAL

## FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD 50MG

A076030 001 Oct 28, 2002 May CAHN

@ 100MG

A076030 002 Oct 28, 2002 May CAHN

@ 150MG

A076030 003 Oct 28, 2002 May CAHN

>D> AB ROXANE 50MG

A076278 001 Jan 14, 2003 Nov CAHN

>D> AB 100MG

A076278 002 Jan 14, 2003 Nov CAHN

>D> AB + 150MG

A076278 003 Jan 14, 2003 Nov CAHN

>A> AB WEST-WARD PHARMS INT 50MG

A076278 001 Jan 14, 2003 Nov CAHN

		TABLET;ORAL							
		FLECAINIDE ACETATE							
>A>	AB		100MG	A076278	002	Jan 14, 2003	Nov	CAHN	
>A>	AB	+	150MG	A076278	003	Jan 14, 2003	Nov	CAHN	
		TAMBOCOR							
	AB		50MG	N018830	004	Aug 23, 1988	Oct	CMFD	
	AB		100MG	N018830	001	Oct 31, 1985	Oct	CMFD	
	AB		150MG	N018830	003	Jun 03, 1988	Oct	CMFD	
		<u>FLORBETAPIR F-18</u>							
		SOLUTION;INTRAVENOUS							
		AMYVID							
		@ AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012	Sep	DISC	
		<u>FLOXURIDINE</u>							
		INJECTABLE;INJECTION							
		FLOXURIDINE							
AP		+	WEST-WARD PHARMS INT	500MG/VIAL	A075387	001	Apr 16, 2000	Oct	CAHN
		<u>FLUCICLOVINE F-18</u>							
		SOLUTION;INTRAVENOUS							
		AXUMIN							
		+	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May	NEWA
		<u>FLUCONAZOLE</u>							
		FOR SUSPENSION;ORAL							
		FLUCONAZOLE							
>D>	AB		ROXANE	50MG/5ML	A076246	001	Jul 29, 2004	Nov	CAHN
>D>	AB			200MG/5ML	A076246	002	Jul 29, 2004	Nov	CAHN
			@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC
			@	200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC
>A>	AB		WEST-WARD PHARMS INT	50MG/5ML	A076246	001	Jul 29, 2004	Nov	CAHN
>A>	AB			200MG/5ML	A076246	002	Jul 29, 2004	Nov	CAHN
		INJECTABLE;INJECTION							
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9%							
		@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan	DISC	
		@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan	DISC	
		FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP			ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CMS1
AP				400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CMS1
		TABLET;ORAL							
		FLUCONAZOLE							
		@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May	CAHN	
		@	100MG	A076086	002	Jul 29, 2004	May	CAHN	
		@	150MG	A076086	003	Jul 29, 2004	May	CAHN	
		@	200MG	A076086	004	Jul 29, 2004	May	CAHN	
		<u>FLUDARABINE PHOSPHATE</u>							
		INJECTABLE;INJECTION							
		FLUDARABINE PHOSPHATE							
AP			SAGENT PHARMS	50MG/VIAL	A076349	001	Aug 28, 2003	Aug	CAHN
AP				50MG/2ML (25MG/ML)	A076661	001	Apr 28, 2004	Aug	CAHN
		<u>FLUDEOXYGLUCOSE F-18</u>							
		INJECTABLE;INTRAVENOUS							
		FLUDEOXYGLUCOSE F18							
AP			KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar	NEWA
>A>	AP		MEM SLOAN-KETTERING	20-300mCi/ML	A208679	001	Dec 08, 2016	Nov	NEWA
AP		+	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar	CTEC
AP			ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb	CAHN
		<u>FLUOCINOLONE ACETONIDE</u>							
		OIL;TOPICAL							
		FLUOCINOLONE ACETONIDE							
AT			LYNE	0.01%	A090982	001	Apr 25, 2016	Apr	NEWA
AT				0.01%	A203377	001	Apr 25, 2016	Apr	NEWA
AT			TARO	0.01%	A202368	001	May 19, 2016	May	NEWA
AT				0.01%	A209336	001	May 19, 2016	May	NEWA
		OIL/DROPS;OTIC							
		FLUOCINOLONE ACETONIDE							
AT			LYNE	0.01%	A203378	001	Apr 25, 2016	Apr	NEWA

## SOLUTION;TOPICAL

## FLUOCINOLONE ACETONIDE

AT		ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Oct	NEWA
AT		G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Sep	NEWA

FLUOCINONIDE

## OINTMENT;TOPICAL

## LIDEX

AB		CNTY LINE PHARMS	0.05%	N016909	002		Sep	CMFD
----	--	------------------	-------	---------	-----	--	-----	------

FLUORESCEIN SODIUM

## INJECTABLE;INTRAVENOUS

## FLUORESCITE

>D>	AP	+	ALCON PHARMS LTD	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Nov	CAHN
>A>	AP	+	NOVARTIS PHARMS CORP	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Nov	CAHN

FLUOROMETHOLONE ACETATE

## SUSPENSION/DROPS;OPHTHALMIC

## FLAREX

>D>		+	ALCON	0.1%	N019079	001	Feb 11, 1986	Nov	CAHN
>A>		+	NOVARTIS PHARMS CORP	0.1%	N019079	001	Feb 11, 1986	Nov	CAHN

FLUOROURACIL

## INJECTABLE;INJECTION

## FLUOROURACIL

AP			SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb	NEWA
AP				5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb	NEWA
>A>		+	SPECTRUM PHARMS	2.5GM/50ML (50MG/ML)	N012209	002	Jul 29, 2016	Nov	NEWA

FLUOXETINE HYDROCHLORIDE

## CAPSULE;ORAL

## FLUOXETINE

## @ SUN PHARM INDS

EQ 10MG BASE

A075787	001	Jan 29, 2002	Mar	CAHN
A075787	002	Jan 29, 2002	Mar	CAHN

## @

EQ 20MG BASE

## FLUOXETINE HYDROCHLORIDE

## MYLAN

EQ 10MG BASE

A078045	001	Nov 17, 2008	Sep	CTEC
---------	-----	--------------	-----	------

## SOLUTION;ORAL

## FLUOXETINE HYDROCHLORIDE

## @ LANNETT

EQ 20MG BASE/5ML

A076458	001	May 14, 2004	Aug	DISC
---------	-----	--------------	-----	------

## TABLET;ORAL

## FLUOXETINE HYDROCHLORIDE

		+	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar	CRLD
AB		+	MYLAN	EQ 20MG BASE	A075755	002	Aug 02, 2001	Aug	CTEC
AB			PAR FORM	EQ 10MG BASE	A203836	001	Aug 19, 2016	Aug	NEWA
AB				EQ 20MG BASE	A203836	002	Aug 19, 2016	Aug	NEWA
AB1			TORRENT PHARMS LTD	EQ 10MG BASE	A206937	001	Oct 21, 2016	Oct	NEWA
AB1				EQ 20MG BASE	A206937	002	Oct 21, 2016	Oct	NEWA
			SARAFEM						
AB1			APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CAHN
AB1				EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CAHN
AB1		+		EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CAHN

FLUPHENAZINE DECANOATE

## INJECTABLE;INJECTION

## FLUPHENAZINE DECANOATE

AO			WEST-WARD PHARMS INT	25MG/ML	A074531	001	Aug 30, 1996	Sep	CAHN
----	--	--	----------------------	---------	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

## TABLET;ORAL

## FLUPHENAZINE HYDROCHLORIDE

AB			LANNETT	1MG	A089743	002	Aug 25, 1988	Sep	NEWA
AB				2.5MG	A089743	003	Aug 25, 1988	Sep	NEWA
AB				5MG	A089743	004	Aug 25, 1988	Sep	NEWA
AB			SANDOZ	1MG	A089586	002	Oct 16, 1987	Oct	CMS1
AB				2.5MG	A089586	003	Oct 16, 1987	Oct	CMS1
AB				5MG	A089586	004	Oct 16, 1987	Oct	CMS1



FLUVOXAMINE MALEATE

TABLET; ORAL		FLUVOXAMINE MALEATE						
	@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb	CAHN
	@		50MG	A075900	002	Feb 23, 2006	Feb	CAHN
	@		100MG	A075900	003	Feb 23, 2006	Feb	CAHN
	@	SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar	CAHN
	@		50MG	A076125	002	Apr 29, 2002	Mar	CAHN
	@		100MG	A076125	003	Apr 29, 2002	Mar	CAHN
	@	UPSHER-SMITH LABS	25MG	A075887	001	Jan 05, 2001	Oct	CAHN
AB			25MG	A075888	001	Nov 29, 2000	Oct	CAHN
	@		50MG	A075887	002	Jan 05, 2001	Oct	CAHN
AB			50MG	A075888	002	Nov 29, 2000	Oct	CAHN
	@		100MG	A075887	003	Jan 05, 2001	Oct	CAHN
AB	+		100MG	A075888	003	Nov 29, 2000	Oct	CAHN

FOLIC ACID

INJECTABLE; INJECTION		FOLVITE						
	@	WYETH PHARMS INC	5MG/ML	N005897	008		May	CAHN
TABLET; ORAL		FOLIC ACID						
	@	SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar	CAHN
		FOLVITE						
	@	WYETH PHARMS INC	1MG	N005897	004		May	CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS		FOLLISTIM AQ						
	@	ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005	Jun	DISC
	@		150 IU/0.5ML	N021273	002	Aug 26, 2005	Jun	DISC

FOMEPIZOLE

INJECTABLE; INJECTION		ANTIZOL						
AP	+	PAR PHARM INC	1.5GM/1.5ML (1GM/ML)	N020696	001	Dec 04, 1997	Oct	CAHN

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION		BEVESPI AEROSPHERE						
	+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Apr	NEWA

FOSAMPRENAVIR CALCIUM

TABLET; ORAL		FOSAMPRENAVIR CALCIUM						
AB		MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr	NEWA
		LEXIVA						
AB	+	VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr	CFTG

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS		EMEND						
AP	+	MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May	CFTG
		FOSAPREPITANT DIMEGLUMINE						
AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May	NEWA

FOSINOPRIL SODIUM

TABLET; ORAL		FOSINOPRIL SODIUM						
	@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan	DISC
	@		20MG	A076620	002	Oct 15, 2004	Jan	DISC
	@		40MG	A076620	003	Oct 15, 2004	Jan	DISC
AB		PRINSTON INC	10MG	A205670	001	Aug 29, 2016	Aug	NEWA
AB			20MG	A205670	002	Aug 29, 2016	Aug	NEWA
AB			40MG	A205670	003	Aug 29, 2016	Aug	NEWA
>D>	@	SANDOZ	10MG	A076188	001	Oct 08, 2004	Nov	CAHN
>D>	@		20MG	A076188	002	Oct 08, 2004	Nov	CAHN
>D>	@		40MG	A076188	003	Oct 08, 2004	Nov	CAHN
>A>	@	UPSHER-SMITH LABS	10MG	A076188	001	Oct 08, 2004	Nov	CAHN
AB			10MG	A076483	001	Apr 23, 2004	Oct	CAHN
>A>	@		20MG	A076188	002	Oct 08, 2004	Nov	CAHN

TABLET;ORAL		FOSINOPRIL SODIUM							
AB		20MG		A076483	002	Apr 23, 2004	Oct	CAHN	
>A>	@	40MG		A076188	003	Oct 08, 2004	Nov	CAHN	
AB		40MG		A076483	003	Apr 23, 2004	Oct	CAHN	
<u>FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE</u>									
TABLET;ORAL		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE							
	@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan	DISC	
	@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan	DISC	
	@	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb	DISC	
	@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb	DISC	
<u>FOSPHENYTOIN SODIUM</u>									
INJECTABLE;INJECTION		CEREBYX							
AP	+	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Aug	CRLD	
		FOSPHENYTOIN SODIUM							
	@	FRESENIUS KABI USA	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Aug	DISC	
<u>FROVATRIPTAN SUCCINATE</u>									
TABLET;ORAL		FROVATRIPTAN SUCCINATE							
AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb	NEWA	
<u>FUROSEMIDE</u>									
INJECTABLE;INJECTION		FUROSEMIDE							
AP		AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016	Jul	NEWA	
AP		CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May	CAHN	
	@	EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan	CAHN	
	@	WEST-WARD PHARMS INT	10MG/ML	A071439	001	Sep 14, 1990	Oct	CAHN	
	@		10MG/ML	N018267	001		Oct	CAHN	
SOLUTION;ORAL		FUROSEMIDE							
>D>	AA	+	ROXANE	A070434	001	Apr 22, 1987	Nov	CAHN	
>D>			40MG/5ML	A070433	001	Apr 22, 1987	Nov	CAHN	
>A>	AA	+	WEST-WARD PHARMS INT	A070434	001	Apr 22, 1987	Nov	CAHN	
>A>			40MG/5ML	A070433	001	Apr 22, 1987	Nov	CAHN	
TABLET;ORAL		FUROSEMIDE							
>D>	AB		ROXANE	A070086	001	Jan 24, 1986	Nov	CAHN	
	@	SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar	CAHN	
	@		80MG	A070100	001	Jan 26, 1988	Mar	CAHN	
>A>	AB		WEST-WARD PHARMS INT	A070086	001	Jan 24, 1986	Nov	CAHN	
		LASIX							
AB		US PHARM HOLDINGS	20MG	N016273	002		Jan	CAHN	
AB			40MG	N016273	001		Jan	CAHN	
AB	+		80MG	N016273	003		Jan	CAHN	
<u>GABAPENTIN</u>									
CAPSULE;ORAL		GABAPENTIN							
AB		SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb	NEWA	
AB			300MG	A204989	002	Feb 18, 2016	Feb	NEWA	
AB			400MG	A204989	003	Feb 18, 2016	Feb	NEWA	
	@	SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar	CAHN	
	@		300MG	A076537	002	Jun 30, 2005	Mar	CAHN	
	@		400MG	A076537	003	Jun 30, 2005	Mar	CAHN	
	@	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Sep	DISC	
	@		300MG	A076606	002	Oct 07, 2005	Sep	DISC	
	@		400MG	A076606	003	Oct 07, 2005	Sep	DISC	
SOLUTION;ORAL		GABAPENTIN							
AA		TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb	NEWA	
TABLET;ORAL		GABAPENTIN							
AB		SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan	NEWA	
AB			800MG	A205101	002	Feb 04, 2016	Jan	NEWA	

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL  
HORIZANT

	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011	Jul	CAHN
+		600MG	N022399	001	Apr 06, 2011	Jul	CAHN

GADOFOSVESET TRISODIUM

SOLUTION;INTRAVENOUS  
ABLAVAR

@	LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711	001	Dec 22, 2008	Sep	DISC
@		3660MG/15ML (244MG/ML)	N021711	002	Dec 22, 2008	Sep	DISC

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL  
GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 8MG BASE	A204895	001	Aug 05, 2016	Jul	NEWA
AB		EQ 16MG BASE	A204895	002	Aug 05, 2016	Jul	NEWA
AB		EQ 24MG BASE	A204895	003	Aug 05, 2016	Jul	NEWA
	@ IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb	DISC
	@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb	DISC
	@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb	DISC

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

>D>	+	ROXANE	4MG/ML	A078185	001	Jan 30, 2009	Nov	CAHN
	+		4MG/ML	A078185	001	Jan 30, 2009	May	CRLD
>A>	+	WEST-WARD PHARMS INT	4MG/ML	A078185	001	Jan 30, 2009	Nov	CAHN
		RAZADYNE						
	@	JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May	DISC

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	ROXANE	EQ 4MG BASE	A077608	001	Feb 11, 2009	Nov	CAHN
>D>	AB		EQ 8MG BASE	A077608	002	Feb 11, 2009	Nov	CAHN
>D>	AB		EQ 12MG BASE	A077608	003	Feb 11, 2009	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 4MG BASE	A077608	001	Feb 11, 2009	Nov	CAHN
>A>	AB		EQ 8MG BASE	A077608	002	Feb 11, 2009	Nov	CAHN
>A>	AB		EQ 12MG BASE	A077608	003	Feb 11, 2009	Nov	CAHN

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS  
NETSPOT

+	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016	Aug	NEWA
---	-------------	---------------	---------	-----	--------------	-----	------

GANCICLOVIR SODIUM

INJECTABLE;INJECTION  
GANCICLOVIR

>A>	AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Nov	NEWA
		GANCICLOVIR SODIUM						
	@	WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Oct	CAHN

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC  
GATIFLOXACIN

AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun	NEWA
----	---------------	------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION  
GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar	NEWA	
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar	NEWA	
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar	NEWA	
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar	CFTG
AP	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar	CFTG
AP	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar	CFTG

GEMFIBROZIL

TABLET;ORAL  
GEMFIBROZIL

AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------



GENTAMICIN SULFATE

INJECTABLE; INJECTION  
GENTAMICIN SULFATE

@ WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A 062251	002		Oct	CAHN
@	EQ 40MG BASE/ML	A 062251	001		Oct	CAHN

GLIMEPIRIDE

TABLET; ORAL  
GLIMEPIRIDE

@ ACTAVIS LABS FL INC	1MG	A 076995	001	Apr 27, 2010	Jan	DISC
@	2MG	A 076995	002	Apr 27, 2010	Jan	DISC
@	4MG	A 076995	003	Apr 27, 2010	Jan	DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL  
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+ TEVA PHARMS USA	1MG; 4MG	A 078709	001	Apr 01, 2016	Mar	NEWA
	2MG; 4MG	A 078709	002	Apr 01, 2016	Mar	NEWA
	2MG; 8MG	A 078709	004	Apr 01, 2016	Mar	NEWA
	4MG; 4MG	A 078709	003	Apr 01, 2016	Mar	NEWA
	4MG; 8MG	A 078709	005	Apr 01, 2016	Mar	NEWA

GLUTETHIMIDE

TABLET; ORAL  
GLUTETHIMIDE

>D>	@ SANDOZ	500MG	A 083234	002		Nov	CAHN
>A>	@ UPSHER-SMITH LABS	500MG	A 083234	002		Nov	CAHN

GLYBURIDE

TABLET; ORAL  
GLYBURIDE

AB1	PHARMADAX INC	1.25MG	A 203581	001	Apr 14, 2016	Apr	NEWA
AB1		2.5MG	A 203581	002	Apr 14, 2016	Apr	NEWA
AB1		5MG	A 203581	003	Apr 14, 2016	Apr	NEWA
AB1	ZYDUS PHARMS USA INC	1.25mg	A 206749	001	May 10, 2016	Apr	NEWA
AB1		2.5mg	A 206749	002	May 10, 2016	Apr	NEWA
AB1		5MG	A 206749	003	May 10, 2016	Apr	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL  
GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ COREPHARMA	1.25MG; 250MG	A 076731	001	Nov 19, 2004	Jan	DISC	
@	2.5MG; 500MG	A 076731	002	Nov 19, 2004	Jan	DISC	
@	5MG; 500MG	A 076731	003	Nov 19, 2004	Jan	DISC	
AB	IMPAX LABS INC	1.25MG; 250MG	A 076345	001	Feb 18, 2004	Aug	CAHN
AB		2.5MG; 500MG	A 076345	002	Feb 18, 2004	Aug	CAHN
AB		5MG; 500MG	A 076345	003	Feb 18, 2004	Aug	CAHN
AB	ZYDUS PHARMS USA INC	1.25MG; 250MG	A 206748	001	Feb 29, 2016	Feb	NEWA
AB		2.5MG; 500MG	A 206748	002	Feb 29, 2016	Feb	NEWA
AB		5MG; 500MG	A 206748	003	Feb 29, 2016	Feb	NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION  
GLYCOPYRROLATE

AP	+ HIKMA FARMACEUTICA	0.2MG/ML	A 090963	001	Sep 21, 2011	Feb	CRLD
	ROBINUL						
	@ EUROHLTH INTL SARL	0.2MG/ML	N 017558	001		Feb	DISC
	@ WEST-WARD PHARMS INT	0.2MG/ML	N 017558	001		Oct	CAHN

TABLET; ORAL  
GLYCOPYRROLATE

@ HIKMA INTL PHARMS	1MG	A 040836	001	Mar 05, 2009	May	CAHN	
@	2MG	A 040836	002	Mar 05, 2009	May	CAHN	
AA	NATCO PHARMA LTD	1MG	A 091413	001	Jun 20, 2016	Jun	NEWA
AA		2MG	A 091413	002	Jun 20, 2016	Jun	NEWA
AA	RISING PHARMS INC	1MG	A 040821	001	Dec 29, 2008	Jan	CAHN
AA		2MG	A 040821	002	Dec 29, 2008	Jan	CAHN
	ROBINUL						
AA	+ CASPER PHARMA LLC	1MG	N 012827	001		Jan	CAHN
	ROBINUL FORTE						
AA	+ CASPER PHARMA LLC	2MG	N 012827	002		Jan	CAHN

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL  
SANCUSO

	+	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008	Aug CAHN
		INJECTION, EXTENDED RELEASE;SUBCUTANEOUS					
		SUSTOL					
	+	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016	Aug NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION  
GRANISETRON HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
AP		BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG	A078863	001	Jun 30, 2008	Jan CAHN
			BASE/ML)				
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@	CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG	A078197	001	Dec 31, 2007	May CAHN
			BASE/ML)				
AP		HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
		TABLET;ORAL					
		GRANISETRON HYDROCHLORIDE					
	@	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC
>D>	AB	ROXANE	EQ 1MG BASE	A077842	001	Dec 31, 2007	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Nov CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL  
GRISEOFULVIN

AB		CIPLA LTD	125MG/5ML	A065354	001	Sep 10, 2007	Sep CAHN
----	--	-----------	-----------	---------	-----	--------------	----------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL  
HYCOFENIX

	+	MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
--	---	----------------------	------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
GUANFACINE HYDROCHLORIDE

	@	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
	@		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
	@		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
	@		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL  
ULTRAVATE

	+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
--	---	----------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL  
HALOPERIDOL

	@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
	@	FRONTIDA BIOPHARM	0.5MG	A071156	001	Jan 02, 1987	Jul CAHN
	@		1MG	A071157	001	Jan 02, 1987	Jul CAHN
	@		2MG	A071172	001	Jan 02, 1987	Jul CAHN
	@		5MG	A071212	001	Jan 07, 1988	Jul CAHN
	@		10MG	A071173	001	Jan 07, 1988	Jul CAHN
	@	SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
	@		1MG	A071157	001	Jan 02, 1987	Jun CAHN
	@		2MG	A071172	001	Jan 02, 1987	Mar CAHN
	@		5MG	A071212	001	Jan 07, 1988	Mar CAHN
	@		10MG	A071173	001	Jan 07, 1988	Mar CAHN
	@		20MG	A071177	001	Jan 07, 1988	Mar CAHN
	@	VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
	@		1MG	A071235	003	Nov 03, 1986	Jan CMS1
	@		5MG	A071235	004	Nov 03, 1986	Jan CMS1
	@		10MG	A071235	005	Jul 20, 1987	Jan CMS1

HALOPERIDOL DECANOATE

	INJECTABLE; INJECTION						
	HALOPERIDOL DECANOATE						
AO	WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Sep	CAHN
AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Oct	CAHN

HALOPERIDOL LACTATE

	INJECTABLE; INJECTION						
	HALOPERIDOL						
AP	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Oct	CAHN

HEPARIN SODIUM

	INJECTABLE; INJECTION						
	HEPARIN SODIUM						
AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May	NEWA
AP	+ WEST-WARD PHARMS INT	1,000 UNITS/ML	N017037	001		Oct	CAHN
AP	+ @	5,000 UNITS/ML	N017037	002		Oct	CAHN
		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Oct	CAHN
AP	+ @	10,000 UNITS/ML	N017037	003		Oct	CAHN

HEXACHLOROPHENE

	EMULSION; TOPICAL						
	PHISOHEX						
	@ SANOFI AVENTIS US	3%	N006882	001		May	DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

	TABLET; ORAL						
	HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE						
	@ ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000	Jan	CMS1

HYDRALAZINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	HYDRALAZINE HYDROCHLORIDE						
AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr	NEWA
	TABLET; ORAL						
	HYDRALAZINE HYDROCHLORIDE						
	@ ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr	DISC
	@	25MG	A091679	002	Mar 04, 2013	Apr	DISC
	@	50MG	A091679	003	Mar 04, 2013	Apr	DISC
	@	100MG	A091679	004	Mar 04, 2013	Apr	DISC
	@ FRONTIDA BIOPHARM	10MG	A089359	001	Jul 25, 1986	Jul	CAHN
	@	25MG	A089258	001	May 05, 1986	Jul	CAHN
	@	50MG	A089259	001	May 05, 1986	Jul	CAHN
	@	100MG	A088729	001	Apr 11, 1985	Jul	CAHN
>D>	@ SANDOZ	10MG	A083241	001		Nov	CAHN
>D>	@	25MG	A083560	001		Nov	CAHN
>D>	@	50MG	A083561	001		Nov	CAHN
	@ SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar	CAHN
	@	25MG	A089258	001	May 05, 1986	Mar	CAHN
	@	50MG	A089259	001	May 05, 1986	Mar	CAHN
	@	100MG	A088729	001	Apr 11, 1985	Jun	CAHN
>A>	@ UPSHER-SMITH LABS	10MG	A083241	001		Nov	CAHN
>A>	@	25MG	A083560	001		Nov	CAHN
>A>	@	50MG	A083561	001		Nov	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

	TABLET; ORAL						
	HYDRALAZINE AND HYDROCHLOROTHIAZIDE						
	@ WATSON LABS	25MG; 15MG	A085827	001		Feb	CMS1

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

	TABLET; ORAL						
	RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE						
	@ SUN PHARM INDS	25MG; 15MG; 0.1MG	A088570	001	Apr 10, 1984	Mar	CAHN

HYDROCHLOROTHIAZIDE

	CAPSULE; ORAL						
	HYDROCHLOROTHIAZIDE						
	@ LANNETT HOLDINGS INC	12.5MG	A091662	001	Jan 27, 2012	Aug	DISC
AB	+ ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr	CAHN

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	@ AUROLIFE PHARMA LLC	25MG	A 083899	001		Feb	CAHN
	@	50MG	A 085219	001		Feb	CAHN
	@ HIKMA INTL PHARMS	25MG	A 084878	002	Jul 12, 2006	May	CAHN
AB		50MG	A 084878	001		May	CAHN
	@ LANNETT	25MG	A 084325	001		Aug	DISC
	@	50MG	A 084324	001		Aug	DISC
	@ SUN PHARM INDS	25MG	A 083972	001		Mar	CAHN
	@	50MG	A 083972	002		Mar	CAHN
	@	100MG	A 083972	003		Mar	CAHN
	ORETIC						
	@ ABBVIE	50MG	N 011971	002		Jan	DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;150MG	A 091370	001	Oct 15, 2012	Sep	CAHN
AB		12.5MG;300MG	A 091370	002	Oct 15, 2012	Sep	CAHN
AB		25MG;300MG	A 091370	003	Oct 12, 2016	Sep	NEWA
AB		25MG;300MG	A 091370	003	Oct 12, 2016	Sep	CAHN
AB	AUROBINDO PHARMA LTD	25MG;300MG	A 203630	003	Mar 31, 2016	Mar	NEWA
AB	HISUN PHARM HANGZHOU	12.5MG;150MG	A 207896	001	Oct 14, 2016	Oct	NEWA
AB		12.5MG;300MG	A 207896	002	Oct 14, 2016	Oct	NEWA
AB	INTL SPECLT CHEMS	12.5MG;150MG	A 203036	001	Jan 15, 2016	Jan	NEWA
AB		12.5MG;300MG	A 203036	002	Jan 15, 2016	Jan	NEWA
AB		25MG;300MG	A 203036	003	Jan 15, 2016	Mar	CTEC
AB		25MG;300MG	A 203036	003	Jan 15, 2016	Jan	NEWA
AB	MYLAN PHARMS INC	25MG;300MG	A 077969	003	Jul 20, 2016	Jul	NEWA
>D>	AB	ROXANE	A 090351	001	Oct 15, 2012	Nov	CAHN
>D>	AB		A 090351	002	Oct 15, 2012	Nov	CAHN
>D>	AB	WATSON LABS INC	A 091539	001	Oct 22, 2012	Nov	DISC
>A>	@		A 091539	001	Oct 22, 2012	Nov	DISC
>D>	AB		A 091539	002	Oct 22, 2012	Nov	DISC
>A>	@		A 091539	002	Oct 22, 2012	Nov	DISC
>A>	AB	WEST-WARD PHARMS INT	A 090351	001	Oct 15, 2012	Nov	CAHN
>A>	AB		A 090351	002	Oct 15, 2012	Nov	CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

ZESTORETIC

AB	ALVOGEN MALTA	12.5MG;10MG	N 019888	003	Nov 18, 1993	Jan	CAHN
AB	+	12.5MG;20MG	N 019888	001	Sep 20, 1990	Jan	CAHN
AB	+	25MG;20MG	N 019888	002	Jul 20, 1989	Jan	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	ROXANE	A 077732	002	Oct 06, 2010	Nov	CAHN
>D>	AB		A 077732	001	Apr 06, 2010	Nov	CAHN
>D>	AB		A 077732	003	Oct 06, 2010	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	A 077732	002	Oct 06, 2010	Nov	CAHN
>A>	AB		A 077732	001	Apr 06, 2010	Nov	CAHN
>A>	AB		A 077732	003	Oct 06, 2010	Nov	CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	+	TEVA	A 076980	002	Mar 07, 2007	Aug	CRLD
----	---	------	----------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR HCT

AB	DAIICHI SANKYO	12.5MG;20MG	N 021532	002	Jun 05, 2003	Oct	CFTG
AB		12.5MG;40MG	N 021532	003	Jun 05, 2003	Oct	CFTG
AB	+	25MG;40MG	N 021532	005	Jun 05, 2003	Oct	CFTG
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE						
AB	MYLAN PHARMS INC	12.5MG;20MG	A 078827	001	Oct 26, 2016	Oct	NEWA
AB		12.5MG;40MG	A 078827	002	Oct 26, 2016	Oct	NEWA
AB		25MG;40MG	A 078827	003	Oct 26, 2016	Oct	NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL  
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE  
 AB SUN PHARM INDS 25MG; 25MG A089534 001 Jul 02, 1987 Mar CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL  
 VALSARTAN AND HYDROCHLOROTHIAZIDE  
 AB PRINSTON INC 12.5MG; 80MG A206083 001 Feb 08, 2016 Jan NEWA  
 AB 12.5MG; 160MG A206083 002 Feb 08, 2016 Jan NEWA  
 AB 12.5MG; 320MG A206083 003 Feb 08, 2016 Jan NEWA  
 AB 25MG; 160MG A206083 004 Feb 08, 2016 Jan NEWA  
 AB 25MG; 320MG A206083 005 Feb 08, 2016 Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL  
 HYDROCODONE BITARTRATE AND IBUPROFEN  
 @ ACTAVIS LABS FL INC 5MG; 200MG A077454 001 Jun 23, 2010 Jan DISC  
 AB AUROLIFE PHARMA LLC 7.5MG; 200MG A204575 001 Jun 02, 2016 May NEWA

HYDROCORTISONE

LOTION; TOPICAL  
 NUTRACORT  
 >D> AT DOW PHARM 2.5% A087644 001 Aug 24, 1982 Nov DISC  
 >A> @ 2.5% A087644 001 Aug 24, 1982 Nov DISC  
 TABLET; ORAL  
 HYDROCORTISONE  
 >D> AB AMEDRA PHARMS 5MG A040646 001 Mar 30, 2007 Nov CAHN  
 >D> AB 10MG A040646 002 Mar 30, 2007 Nov CAHN  
 >D> AB 20MG A040646 003 Mar 30, 2007 Nov CAHN  
 >A> AB IMPAX LABS INC 5MG A040646 001 Mar 30, 2007 Nov CAHN  
 >A> AB 10MG A040646 002 Mar 30, 2007 Nov CAHN  
 >A> AB 20MG A040646 003 Mar 30, 2007 Nov CAHN  
 AB PHARMACEUTICS INTL 5MG A207029 001 Apr 26, 2016 Apr NEWA  
 AB 10MG A207029 002 Apr 26, 2016 Apr NEWA  
 AB 20MG A207029 003 Apr 26, 2016 Apr NEWA

HYDROCORTISONE VALERATE

CREAM; TOPICAL  
 WESTCORT  
 @ RANBAXY LABS LTD 0.2% N017950 001 Jul CAHN  
 @ SUN PHARM INDS LTD 0.2% N017950 001 Jun CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC  
 PEDIOTIC  
 @ MONARCH PHARMS 1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML A062822 001 Sep 29, 1987 Jan DISC

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL  
 HYDROMORPHONE HYDROCHLORIDE  
 >D> AA ROXANE 5MG/5ML A074653 001 Jul 29, 1998 Nov CAHN  
 >A> AA WEST-WARD PHARMS INT 5MG/5ML A074653 001 Jul 29, 1998 Nov CAHN  
 TABLET; ORAL  
 HYDROMORPHONE HYDROCHLORIDE  
 AB AUROLIFE PHARMA LLC 2MG A205814 001 May 13, 2016 May NEWA  
 AB 4MG A205814 002 May 13, 2016 May NEWA  
 AB 8MG A205814 003 May 13, 2016 May NEWA  
 AB MALLINCKRODT 2MG A076855 002 Sep 19, 2007 Aug CMS1  
 AB 4MG A076855 003 Sep 19, 2007 Aug CMS1  
 >D> AB ROXANE 4MG A074597 003 May 29, 2009 Nov CAHN  
 >D> AB 8MG A074597 001 Jul 29, 1998 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT 4MG A074597 003 May 29, 2009 Nov CAHN  
 >A> AB 8MG A074597 001 Jul 29, 1998 Nov CAHN  
 TABLET, EXTENDED RELEASE; ORAL  
 EXALGO  
 AB + MALLINCKRODT INC 32MG N021217 004 Aug 24, 2012 Jun CFTG  
 HYDROMORPHONE HYDROCHLORIDE  
 AB ACTAVIS LABS FL INC 32MG A202144 004 Jun 30, 2016 Jun NEWA  
 AB OSMOTICA 8MG A205629 001 Jul 07, 2016 Jun NEWA

TABLET, EXTENDED RELEASE;ORAL  
HYDROMORPHONE HYDROCHLORIDE

AB		12MG	A205629	002	Jul 07, 2016	Jun NEWA
AB		16MG	A205629	003	Jul 07, 2016	Jun NEWA
AB		32MG	A205629	004	Jul 07, 2016	Jun NEWA

HYDROXOCOBALAMIN

INJECTABLE; INJECTION  
CYANOKIT

	@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Jan CAHN
+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Jan CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL  
HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb CMFD
----	-------------	-------	---------	-----	--------------	----------

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION  
HYDROXYPROGESTERONE CAPROATE

	@ ALLERGAN SALES LLC	125MG/ML	N017439	001		Jul CAHN
	@	250MG/ML	N017439	002		Jul CAHN
+	ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015	Jan CAHN
SOLUTION; INTRAMUSCULAR MAKENA						
+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Jun CAHN
MAKENA PRESERVATIVE FREE						
+	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Oct CTNA
+		250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun CAHN
+	LUMARA HEALTH INC	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Feb NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL  
HYDROXYZINE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	10MG	A087869	001	Dec 20, 1982	Feb CAHN
	@	25MG	A087870	001	Dec 20, 1982	Feb CAHN
	@	50MG	A087871	001	Dec 20, 1982	Feb CAHN
AB	ECI PHARMS LLC	10MG	A040804	001	Jun 30, 2008	May CAHN
AB		25MG	A040804	002	Jun 30, 2008	May CAHN
AB		50MG	A040804	003	Jun 30, 2008	May CAHN
AB	ELITE LABS INC	10MG	A040604	002	Dec 28, 2004	Jun NEWA
AB		25MG	A040604	003	Dec 28, 2004	Jun NEWA
	@ SUN PHARM INDS	10MG	A089381	001	May 19, 1986	Mar CAHN
	@	25MG	A089382	001	May 19, 1986	Mar CAHN
	@	50MG	A089383	001	May 19, 1986	Mar CAHN
	@	100MG	A087862	001	Apr 18, 1983	Mar CAHN

HYDROXYZINE PAMOATE

CAPSULE; ORAL  
HYDROXYZINE PAMOATE

AB	IMPAX LABS INC	EQ 25MG HCL	A040156	001	Jul 15, 1996	Aug CAHN
AB		EQ 50MG HCL	A040156	002	Jul 15, 1996	Aug CAHN

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS  
IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan NEWA
----	-----------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL  
IBANDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar CAHN

IBUPROFEN

SUSPENSION; ORAL  
IBUPROFEN

AB	HI-TECH PHARMACAL	100MG/5ML	A205647	001	Nov 03, 2016	Oct NEWA
----	-------------------	-----------	---------	-----	--------------	----------

TABLET; ORAL  
IBUPROFEN

>A>	AB	AIPING PHARM INC	400MG	A202413	001	Nov 23, 2016	Nov NEWA
>A>	AB		600MG	A202413	002	Nov 23, 2016	Nov NEWA
>A>	AB		800MG	A202413	003	Nov 23, 2016	Nov NEWA
>A>		@ AUROLIFE PHARMA LLC	300MG	A070736	002	Jun 12, 1986	Nov CMS1

TABLET; ORAL

IBUPROFEN

>A>	@	400MG		A 070736	003	Jun 12, 1986	Nov CMS1
	@	600MG		A 070736	001	Jun 12, 1986	Feb CAHN
	@	800MG		A 071938	001	Jan 14, 1988	Mar CAHN
AB	CONTRACT PHARMACAL	400MG		A 071268	002	Oct 15, 1986	Sep CMS1
AB		800MG		A 071268	003	Jul 01, 1988	Sep CMS1
	@ J AND J CONSUMER INC	400MG		A 070081	001	Jun 16, 1986	Jul CAHN
AB	STRIDES PHARMA	400MG		A 078329	001	Feb 05, 2009	May CAHN
AB		600MG		A 078329	002	Feb 05, 2009	May CAHN
AB		800MG		A 078329	003	Feb 05, 2009	May CAHN
	@ SUN PHARM INDS	400MG		A 070079	001	Jul 24, 1985	Mar CAHN
	@	600MG		A 070080	001	Jul 24, 1985	Mar CAHN
	@	800MG		A 071448	001	Feb 18, 1987	Mar CAHN

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYSINE

AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A 202402	001	Mar 30, 2016	Mar NEWA
AP	+ RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N 021903	001	Apr 13, 2006	Mar CFTG

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	1MG/ML	A 065275	001	Dec 14, 2006	Sep CAHN
AP		1MG/ML	A 065288	001	May 15, 2007	Sep CAHN

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID

+ ALCON	0.1%	N 014169	001			Aug CTEC
HERPLEX						
@ ALLERGAN	0.1%	N 013935	002			Aug DISC

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP	WEST-WARD PHARMS INT	1GM/20ML (50MG/ML)	A 076619	001	Jun 29, 2011	Oct CAHN
AP		3GM/60ML (50MG/ML)	A 076619	002	Jun 29, 2011	Oct CAHN

ILOPERIDONE

TABLET; ORAL

FANAPT

>D>	+ VANDA PHARMS INC	1MG	N 022192	001	May 06, 2009	Nov CFTG
>A> AB	+	1MG	N 022192	001	May 06, 2009	Nov CFTG
>D>		2MG	N 022192	002	May 06, 2009	Nov CFTG
>A> AB		2MG	N 022192	002	May 06, 2009	Nov CFTG
>D>		4MG	N 022192	003	May 06, 2009	Nov CFTG
>A> AB		4MG	N 022192	003	May 06, 2009	Nov CFTG
>D>		6MG	N 022192	004	May 06, 2009	Nov CFTG
>A> AB		6MG	N 022192	004	May 06, 2009	Nov CFTG
>D>		8MG	N 022192	005	May 06, 2009	Nov CFTG
>A> AB		8MG	N 022192	005	May 06, 2009	Nov CFTG
>D>		10MG	N 022192	006	May 06, 2009	Nov CFTG
>A> AB		10MG	N 022192	006	May 06, 2009	Nov CFTG
>D>		12MG	N 022192	007	May 06, 2009	Nov CFTG
>A> AB		12MG	N 022192	007	May 06, 2009	Nov CFTG
>A>	ILOPERIDONE					
>A> AB	INVENTIA HLTHCARE	1MG	A 207231	001	Nov 28, 2016	Nov NEWA
>A> AB		2MG	A 207231	002	Nov 28, 2016	Nov NEWA
>A> AB		4MG	A 207231	003	Nov 28, 2016	Nov NEWA
>A> AB		6MG	A 207231	004	Nov 28, 2016	Nov NEWA
>A> AB		8MG	A 207231	005	Nov 28, 2016	Nov NEWA
>A> AB		10MG	A 207231	006	Nov 28, 2016	Nov NEWA
>A> AB		12MG	A 207231	007	Nov 28, 2016	Nov NEWA

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	APOTEX INC	EQ 100MG BASE	A 079179	001	Aug 05, 2016	Jul	NEWA
AB		EQ 400MG BASE	A 079179	002	Aug 05, 2016	Jul	NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A 204285	001	Aug 04, 2016	Jul	NEWA
AB		EQ 400MG BASE	A 204285	002	Aug 04, 2016	Jul	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB	LUPIN LTD	10MG	A 090441	002	Mar 11, 2010	Oct	CMS1
AB		25MG	A 090441	003	Mar 11, 2010	Oct	CMS1
AB	SUN PHARM INDS	10MG	A 081048	001	Jun 05, 1990	Mar	CAHN
AB		25MG	A 081049	001	Jun 05, 1990	Mar	CAHN
AB		50MG	A 081050	001	Jun 05, 1990	Mar	CAHN

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

>D>	AB	+ ROXANE	EQ 75MG HCL	A 091099	001	Apr 16, 2010	Nov	CAHN
	AB	+	EQ 75MG HCL	A 091099	001	Apr 16, 2010	Feb	CRLD
>D>	AB		EQ 100MG HCL	A 091099	002	Apr 16, 2010	Nov	CAHN
>D>	AB		EQ 125MG HCL	A 091099	003	Apr 16, 2010	Nov	CAHN
>D>	AB		EQ 150MG HCL	A 091099	004	Apr 16, 2010	Nov	CAHN
>A>	AB	+ WEST-WARD PHARMS INT	EQ 75MG HCL	A 091099	001	Apr 16, 2010	Nov	CAHN
>A>	AB		EQ 100MG HCL	A 091099	002	Apr 16, 2010	Nov	CAHN
>A>	AB		EQ 125MG HCL	A 091099	003	Apr 16, 2010	Nov	CAHN
>A>	AB		EQ 150MG HCL	A 091099	004	Apr 16, 2010	Nov	CAHN

INAMRINONE LACTATE

INJECTABLE;INJECTION

AMRINONE LACTATE

+	WEST-WARD PHARMS INT	EQ 5MG BASE/ML	A 075513	001	May 09, 2000	Oct	CAHN
---	----------------------	----------------	----------	-----	--------------	-----	------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB	AMERIGEN PHARMS LTD	1.25MG	A 075201	001	Dec 04, 1998	Sep	CMFD
AB		2.5MG	A 075201	002	Dec 04, 1998	Sep	CMFD

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N 019841	001	Sep 27, 1994	Jan	CAHN
---	---------------------	------------	----------	-----	--------------	-----	------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE;INJECTION

INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N 019044	001	Dec 24, 1985	Mar	CMS1
---	---------------	---------	----------	-----	--------------	-----	------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N 020314	001	Jun 02, 1994	Jan	CAHN
---	---------------------	---------	----------	-----	--------------	-----	------

INDOCYANINE GREEN

INJECTABLE;INJECTION

INDOCYANINE GREEN

AP	DIAGNOSTIC GREEN	25MG/VIAL	A 040811	001	Nov 21, 2007	Jan	CAHN
----	------------------	-----------	----------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE;ORAL

INDOMETHACIN

@	SUN PHARM INDS	25MG	A 070900	002	Feb 09, 1987	Sep	CMS1
@		50MG	A 070900	001	Feb 09, 1987	Sep	CAHN



INDOMETHACIN SODIUM

	INJECTABLE; INJECTION						
	INDOMETHACIN SODIUM						
AP	HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr	NEWA
AP	WEST-WARD PHARMS INT	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Oct	CAHN

>A> INSULIN DEGLUDEC; LIRAGLUTIDE

>A>	SOLUTION; SUBCUTANEOUS						
>A>	XULTOPHY 100/3.6						
>A>	+ NOVO NORDISK INC	300 UNITS/3ML; 10.8MG/3ML (100 UNITS/ML; 3.6MG/ML)	N208583	001	Nov 21, 2016	Nov	NEWA

INSULIN DETEMIR RECOMBINANT

	INJECTABLE; SUBCUTANEOUS						
	LEVEMIR FLEXPEN						
	@ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb	DISC

>A> INSULIN GLARGINE; LIXISENATIDE

>A>	SOLUTION; SUBCUTANEOUS						
>A>	SOLIQUA 100/33						
>A>	+ SANOFI-AVENTIS US	300 UNITS/3ML; 99MCG/3ML (100 UNITS/ML; 33MCG/ML)	N208673	001	Nov 21, 2016	Nov	NEWA

INSULIN HUMAN

	SOLUTION; SUBCUTANEOUS						
	HUMULIN R						
+ LILLY		10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan	CAIN
	HUMULIN R KWIKPEN						
+ LILLY		1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan	NEWA

INSULIN RECOMBINANT HUMAN

	POWDER; INHALATION						
	AFREZZA						
	MANKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar	CAHN
+		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar	CAHN
		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar	CAHN

IOXILAN

	INJECTABLE; INJECTION						
	OXILAN-300						
@ GUERBET		62%	N020316	001	Dec 21, 1995	Jun	DISC
	OXILAN-350						
@ GUERBET		73%	N020316	002	Dec 21, 1995	Jun	DISC

IPRATROPIUM BROMIDE

	SOLUTION; INHALATION						
	IPRATROPIUM BROMIDE						
AN	AUROBINDO PHARMA LTD	0.02%	A206543	001	Oct 27, 2016	Oct	NEWA
	@ MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Jul	DISC
AN	+ RITEDOSE CORP	0.02%	A075693	001	Jan 26, 2001	Jul	CRLD
	SPRAY, METERED; NASAL						
	IPRATROPIUM BROMIDE						
>D> AB	ROXANE	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Nov	CAHN
>D> AB		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Nov	CAHN
>A> AB	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Nov	CAHN
>A> AB		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Nov	CAHN

IRBESARTAN

	TABLET; ORAL						
	IRBESARTAN						
AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May	NEWA
AB		150MG	A206194	002	Jun 14, 2016	May	NEWA
AB		300MG	A206194	003	Jun 14, 2016	May	NEWA
>D> AB	ROXANE	75MG	A090201	001	Oct 15, 2012	Nov	CAHN
>D> AB		150MG	A090201	002	Oct 15, 2012	Nov	CAHN
>D> AB		300MG	A090201	003	Oct 15, 2012	Nov	CAHN
>D> AB	WATSON LABS INC	75MG	A090720	001	Oct 12, 2012	Nov	DISC
>A>	@	75MG	A090720	001	Oct 12, 2012	Nov	DISC
>D> AB		150MG	A090720	002	Oct 12, 2012	Nov	DISC
>A>	@	150MG	A090720	002	Oct 12, 2012	Nov	DISC
>D> AB		300MG	A090720	003	Oct 12, 2012	Nov	DISC

TABLET;ORAL  
IRBESARTAN

>A>	@		300MG	A090720	003	Oct 12, 2012	Nov	DISC
>A>	AB	WEST-WARD PHARMS INT	75MG	A090201	001	Oct 15, 2012	Nov	CAHN
>A>	AB		150MG	A090201	002	Oct 15, 2012	Nov	CAHN
>A>	AB		300MG	A090201	003	Oct 15, 2012	Nov	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
CAMPTOSAR

AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr	CTEC
		IRINOTECAN HYDROCHLORIDE						
AP		QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr	NEWA
AP			100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr	NEWA
AP			300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr	NEWA
AP		SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan	CAHN
AP			100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan	CAHN

IRON DEXTRAN

INJECTABLE; INJECTION  
INFED

BP	+	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr	CAHN
----	---	--------------------	-----------------	---------	-----	--	-----	------

ISONIAZID

TABLET;ORAL  
ISONIAZID

AA		MIKART	100MG	A040090	001	Jun 26, 1997	Jun	CMFD
AA			300MG	A040090	002	Jun 26, 1997	Jun	CMFD
		@ SUN PHARM INDS	100MG	A080136	001		Mar	CAHN
		@	300MG	A083633	001		Mar	CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE;ORAL  
DILATRATE-SR

+		AUXILIUM PHARMS INC	40MG	N019790	001	Sep 02, 1988	Mar	CAHN
+		AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Jul	CAHN

TABLET;ORAL

ISOSORBIDE DINITRATE

@		SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar	CAHN
@			10MG	A086169	001	Sep 19, 1986	Jun	CAHN
@			20MG	A086167	001	Sep 19, 1986	Jun	CAHN
@			30MG	A087564	001	Sep 18, 1986	Jun	CAHN

TABLET;SUBLINGUAL

ISOSORBIDE DINITRATE

@		SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun	CAHN
@			5MG	A086168	001	Sep 18, 1986	Jun	CAHN
@			10MG	A087545	001	Sep 18, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

@		COREPHARMA	40MG	A040723	001	Mar 17, 2008	Mar	DISC
+		SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Mar	CTEC

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL  
ISOSORBIDE MONONITRATE

AB		DEXCEL LTD	30MG	A075522	002	Sep 20, 2016	Sep	NEWA
----	--	------------	------	---------	-----	--------------	-----	------

ISOSULFAN BLUE

INJECTABLE; INJECTION  
ISOSULFAN BLUE

AP		AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan	NEWA
AP	+	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan	CTEC

ISOTRETINOIN

CAPSULE;ORAL  
ABSORICA

BX		RANBAXY	10MG	N021951	001	May 25, 2012	Aug	CAHN
BX			20MG	N021951	002	May 25, 2012	Aug	CAHN
			25MG	N021951	005	Aug 15, 2014	Aug	CAHN
BX			30MG	N021951	003	May 25, 2012	Aug	CAHN
			35MG	N021951	006	Aug 15, 2014	Aug	CAHN
BX	+		40MG	N021951	004	May 25, 2012	Aug	CAHN

CAPSULE;ORAL  
 ABSORICA

BX		RANBAXY LABS LTD	10MG	N021951	001	May 25, 2012	Jul	CAHN
BX			20MG	N021951	002	May 25, 2012	Jul	CAHN
			25MG	N021951	005	Aug 15, 2014	Aug	CAHN
			25MG	N021951	005	Aug 15, 2014	Jul	CAHN
BX			30MG	N021951	003	May 25, 2012	Jul	CAHN
			35MG	N021951	006	Aug 15, 2014	Aug	CAHN
			35MG	N021951	006	Aug 15, 2014	Jul	CAHN
BX	+		40MG	N021951	004	May 25, 2012	Jul	CAHN
		SOTRET						
		@ SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Sep	DISC
		@	20MG	A076041	002	Dec 24, 2002	Sep	DISC
		@	30MG	A076503	001	Jun 20, 2003	Sep	DISC
		@	40MG	A076041	003	Dec 24, 2002	Sep	DISC

ITRACONAZOLE

CAPSULE;ORAL  
 ITRACONAZOLE

AB		ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May	NEWA
>A>	AB	ALEMBIC PHARMS LTD	100MG	A206741	001	Dec 13, 2016	Nov	NEWA
AB		AMNEAL PHARMS	100MG	A205080	001	Sep 26, 2016	Sep	NEWA
>A>	AB	PAR PHARM INC	100MG	A205724	001	Dec 13, 2016	Nov	NEWA

SOLUTION;ORAL

ITRACONAZOLE

		@ AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Apr	DISC
		SPORANOX						
	+	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Apr	CTEC

IVACAFTOR; LUMACAF TOR

TABLET;ORAL

ORKAMBI

		VERTEX PHARMS INC	125MG;100MG	N206038	002	Sep 28, 2016	Sep	NEWA
--	--	-------------------	-------------	---------	-----	--------------	-----	------

IVERMECTIN

LOTION;TOPICAL

SKLICE

	+	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012	May	CAHN
--	---	------------------	------	---------	-----	--------------	-----	------

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

KETAMINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Sep	CAHN
AP			EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Sep	CAHN

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE

		@ SUN PHARM INDS	200MG	A075314	001	Jun 15, 1999	Jan	CAHN
--	--	------------------	-------	---------	-----	--------------	-----	------

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN

		@ AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995	Feb	CAHN
		@	75MG	A074024	002	Dec 29, 1995	Feb	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP		GLAND PHARMA LTD	15MG/ML	A204216	001	Nov 01, 2016	Oct	NEWA
AP			30MG/ML	A204216	002	Nov 01, 2016	Oct	NEWA

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

	+	OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Aug	CPOT
--	---	--------	-------------------------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan	CTNA
AP	WEST-WARD PHARMS INT	5MG/ML	A075303	001	May 28, 1999	Oct	CAHN
	TRANDATE						
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan	CAHN

LACOSAMIDE

SOLUTION; ORAL

LACOSAMIDE

AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr	NEWA
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr	CFTG

TABLET; ORAL

LACOSAMIDE

AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204855	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204855	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204855	004	Apr 28, 2016	Apr	NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204974	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204974	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204974	004	Apr 28, 2016	Apr	NEWA
AB	AMNEAL PHARMS	50MG	A204857	001	Sep 09, 2016	Aug	NEWA
AB		100MG	A204857	002	Sep 09, 2016	Aug	NEWA
AB		150MG	A204857	003	Sep 09, 2016	Aug	NEWA
AB		200MG	A204857	004	Sep 09, 2016	Aug	NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204994	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204994	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204994	004	Apr 28, 2016	Apr	NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204921	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204921	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr	NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A205026	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr	NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr	NEWA
	VIMPAT						
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr	CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr	CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr	CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr	CFTG

LACTULOSE

SOLUTION; ORAL

CONSTULOSE

@ ACTAVIS MID ATLANTIC

LACTULOSE

		10GM/15ML	A070288	001	Aug 15, 1988	Aug	DISC
AA	+ HI TECH PHARMA	10GM/15ML	A074076	001	Jul 03, 1995	Aug	CRLD
>D>	AA	ROXANE	A073591	001	May 29, 1992	Nov	CAHN
>A>	AA	WEST-WARD PHARMS INT	A073591	001	May 29, 1992	Nov	CAHN

LAMIVUDINE

SOLUTION; ORAL

LAMIVUDINE

>A>	AA	AUROBINDO PHARMA LTD	10MG/ML	A077695	001	Nov 21, 2016	Nov	NEWA
		TABLET; ORAL						
		LAMIVUDINE						
>A>	AB	APPCO PHARMA LLC	150MG	A206974	001	Nov 21, 2016	Nov	NEWA
>A>	AB		300MG	A206974	002	Nov 21, 2016	Nov	NEWA
>A>	AB	AUROBINDO PHARMA LTD	150MG	A077464	001	Nov 21, 2016	Nov	NEWA
>A>	AB		300MG	A077464	002	Nov 21, 2016	Nov	NEWA
>A>	AB	CENTAUR PHARMS PVT	150MG	A203586	001	Nov 21, 2016	Nov	NEWA
>A>	AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb	NEWA

TABLET;ORAL									
LAMIVUDINE									
AB		300MG		A204528	002	Mar 04, 2016	Feb	NEWA	
<u>LAMOTRIGINE</u>									
TABLET;ORAL									
LAMOTRIGINE									
AB	JUBILANT CADISTA	25MG		A079132	001	Jan 27, 2009	Jun	CAHN	
AB		100MG		A079132	002	Jan 27, 2009	Jun	CAHN	
AB		150MG		A079132	003	Jan 27, 2009	Jun	CAHN	
AB		200MG		A079132	004	Jan 27, 2009	Jun	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
LAMICTAL XR									
AB	+ GLAXOSMITHKLINE LLC	200MG		N022115	004	May 29, 2009	Jan	CRLD	
TABLET, ORALLY DISINTEGRATING;ORAL									
LAMOTRIGINE									
AB	SCIEGEN PHARMS INC	25MG		A206382	001	Jun 17, 2016	Jun	NEWA	
AB		50MG		A206382	002	Jun 17, 2016	Jun	NEWA	
AB		100MG		A206382	003	Jun 17, 2016	Jun	NEWA	
AB		200MG		A206382	004	Jun 17, 2016	Jun	NEWA	
<u>LANSOPRAZOLE</u>									
CAPSULE, DELAYED REL PELLETS;ORAL									
LANSOPRAZOLE									
AB	AJANTA PHARMA LTD	15MG		A203957	001	Oct 14, 2016	Oct	NEWA	
AB		30MG		A203957	002	Oct 14, 2016	Oct	NEWA	
AB	ANCHEN PHARMS	15MG		A203203	001	Jul 25, 2016	Jul	NEWA	
AB		30MG		A203203	002	Jul 25, 2016	Jul	NEWA	
>A>	AB	SUN PHARM INDS LTD	15MG	A202637	001	Sep 13, 2013	Nov	CAHN	
>A>	AB		30MG	A091509	001	Sep 13, 2013	Nov	CAHN	
>D>	AB	SUN PHARMA GLOBAL	15MG	A202637	001	Sep 13, 2013	Nov	CAHN	
>D>	AB		30MG	A091509	001	Sep 13, 2013	Nov	CAHN	
<u>LATANOPROST</u>									
SOLUTION/DROPS;OPHTHALMIC									
LATANOPROST									
AT	FDC LTD	0.005%		A202442	001	Apr 22, 2016	Apr	NEWA	
<u>LESINURAD</u>									
TABLET;ORAL									
ZURAMPIC									
	+ IRONWOOD PHARMS INC	200MG		N207988	001	Dec 22, 2015	Aug	CAHN	
<u>LETROZOLE</u>									
TABLET;ORAL									
LETROZOLE									
AB	HIKMA PHARMS	2.5MG		A203796	001	Jun 03, 2016	May	NEWA	
AB	KREMERS URBAN PHARMS	2.5MG		A091098	001	Jun 03, 2011	Jan	CAHN	
>D>	AB	ROXANE	2.5MG	A090838	001	Jun 03, 2011	Nov	CAHN	
>A>	AB	WEST-WARD PHARMS INT	2.5MG	A090838	001	Jun 03, 2011	Nov	CAHN	
<u>LEUCOVORIN CALCIUM</u>									
INJECTABLE;INJECTION									
LEUCOVORIN CALCIUM									
AP	+ WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL		A089384	001	Sep 14, 1987	Oct	CAHN	
AP	+	EQ 100MG BASE/VIAL		A089717	001	Mar 28, 1988	Oct	CAHN	
LEUCOVORIN CALCIUM PRESERVATIVE FREE									
	+ WEST-WARD PHARMS INT	EQ 10MG BASE/ML		A040347	001	Apr 25, 2000	Sep	CAHN	
AP	+	EQ 200MG BASE/VIAL		A040056	001	May 23, 1995	Sep	CAHN	
AP	+	EQ 350MG BASE/VIAL		A040335	001	Apr 20, 2000	Sep	CAHN	
TABLET;ORAL									
LEUCOVORIN CALCIUM									
	@ IDT AUSTRALIA LTD	EQ 15MG BASE		A075327	001	Mar 24, 1999	May	CAHN	
>D>	AB	ROXANE	EQ 5MG BASE	A072733	001	Feb 22, 1993	Nov	CAHN	
>D>			EQ 10MG BASE	A072734	001	Feb 22, 1993	Nov	CAHN	
>D>			EQ 15MG BASE	A072735	001	Feb 22, 1993	Nov	CAHN	
>D>			EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun	CTEC	
>D>	AB	+	EQ 25MG BASE	A072736	001	Feb 22, 1993	Nov	CAHN	
>A>	AB	WEST-WARD PHARMS INT	EQ 5MG BASE	A072733	001	Feb 22, 1993	Nov	CAHN	
>A>			EQ 10MG BASE	A072734	001	Feb 22, 1993	Nov	CAHN	
>A>			EQ 15MG BASE	A072735	001	Feb 22, 1993	Nov	CAHN	
>A>	AB	+	EQ 25MG BASE	A072736	001	Feb 22, 1993	Nov	CAHN	

LEVAlBUTEROL HYDROCHLORIDE

## SOLUTION; INHALATION

## LEVAlBUTEROL HYDROCHLORIDE

AN	IMPAX LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Aug	CAHN
AN		EQ 0.021% BASE	A077756	001	Apr 09, 2008	Aug	CAHN
AN		EQ 0.042% BASE	A077756	002	Apr 09, 2008	Aug	CAHN
AN	RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar	NEWA
AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar	NEWA
AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar	NEWA

LEVETIRACETAM

## INJECTABLE; IV (INFUSION)

## LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan	NEWA
AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May	NEWA
AP	MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Sep	NEWA

## TABLET; ORAL

## LEVETIRACETAM

AB	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Oct	NEWA
----	--------------	-------	---------	-----	--------------	-----	------

## TABLET, EXTENDED RELEASE; ORAL

## LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb	NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb	NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May	NEWA
AB		750MG	A202095	001	Jun 06, 2016	May	NEWA
AB	NOSTRUM LABS INC	500MG	A204754	001	Aug 26, 2016	Aug	NEWA
AB		750MG	A204754	002	Aug 26, 2016	Aug	NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar	CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar	CAHN

## TABLET, FOR SUSPENSION; ORAL

## SPRITAM

## APRECIA PHARMS CO

		250MG	N207958	001	Jul 31, 2015	Feb	CDFR
		500MG	N207958	002	Jul 31, 2015	Feb	CDFR
		750MG	N207958	003	Jul 31, 2015	Feb	CDFR
+		1GM	N207958	004	Jul 31, 2015	Mar	CRLD
		1GM	N207958	004	Jul 31, 2015	Feb	CDFR

LEVObUNOLOL HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## LEVObUNOLOL HYDROCHLORIDE

AT	ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996	Jul	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

LEVOCARNITINE

## INJECTABLE; INJECTION

## LEVOCARNITINE

AP	WEST-WARD PHARMS INT	200MG/ML	A075567	001	Mar 29, 2001	Oct	CAHN
----	----------------------	----------	---------	-----	--------------	-----	------

LEVOfLOXACIN

## INJECTABLE; INJECTION

## LEVOfLOXACIN

## @ HOSPIRA INC

## @

## LEVOfLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

		EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Oct	DISC
		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Oct	DISC
>D>	AP	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Nov	CRLD
>A>	AP	+	A090343	001	Jul 07, 2011	Nov	CRLD
>D>	AP	EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Nov	CRLD
>A>	AP	+	A090343	002	Jul 07, 2011	Nov	CRLD
>D>	AP	EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Nov	CRLD
>A>	AP	+	A090343	003	Jul 07, 2011	Nov	CRLD
AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan	NEWA

## SOLUTION/DROPS; OPHTHALMIC

## LEVOfLOXACIN

AT	+	RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan	CAHN
----	---	-------------------	------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

		POWDER; IV (INFUSION)							
		FUSILEV							
AP	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun	CFTG	
		LEVOLEUCOVORIN CALCIUM							
		ACTAVIS LLC		EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	Sep	NEWA
AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun	NEWA	
AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Oct	CAHN	

LEVONORGESTREL

		INTRAUTERINE DEVICE; INTRAUTERINE							
		KYLEENA							
	+	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016	Sep	NEWA	
		TABLET; ORAL							
		LEVONORGESTREL							
AB		JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug	NEWA	
AB		LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug	NEWA	
AB	+	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Aug	CTEC	
	+		0.75MG	A090740	001	Dec 30, 2010	Apr	CRLD	

LEVOTHYROXINE SODIUM

		POWDER; INTRAVENOUS							
		LEVOTHYROXINE SODIUM							
AP		FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun	NEWA	
AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jun	NEWA	
AP	+	FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun	CFTG	
AP	+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun	CFTG	

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

		TABLET; ORAL							
		LEVOLET							
	@	LEHIGH VALLEY	0.025MG	N021137	001	Jun 06, 2003	Jul	CAHN	
	@		0.05MG	N021137	002	Jun 06, 2003	Jul	CAHN	
	@		0.075MG	N021137	003	Jun 06, 2003	Jul	CAHN	
	@		0.088MG	N021137	004	Jun 06, 2003	Jul	CAHN	
	@		0.1MG	N021137	005	Jun 06, 2003	Jul	CAHN	
	@		0.112MG	N021137	006	Jun 06, 2003	Jul	CAHN	
	@		0.125MG	N021137	007	Jun 06, 2003	Jul	CAHN	
	@		0.137MG	N021137	008	Jun 06, 2003	Jul	CAHN	
	@		0.15MG	N021137	009	Jun 06, 2003	Jul	CAHN	
	@		0.175MG	N021137	010	Jun 06, 2003	Jul	CAHN	
	@		0.2MG	N021137	011	Jun 06, 2003	Jul	CAHN	
	@		0.3MG	N021137	012	Jun 06, 2003	Jul	CAHN	
		LEVOTHROID							
	@	LLOYD	0.025MG	N021116	001	Oct 24, 2002	May	DISC	
	@		0.05MG	N021116	002	Oct 24, 2002	May	DISC	
	@		0.075MG	N021116	003	Oct 24, 2002	May	DISC	
	@		0.088MG	N021116	010	Oct 24, 2002	May	DISC	
	@		0.1MG	N021116	004	Oct 24, 2002	May	DISC	
	@		0.112MG	N021116	011	Oct 24, 2002	May	DISC	
	@		0.125MG	N021116	005	Oct 24, 2002	May	DISC	
	@		0.137MG	N021116	012	Dec 07, 2004	May	DISC	
	@		0.15MG	N021116	006	Oct 24, 2002	May	DISC	
	@		0.175MG	N021116	007	Oct 24, 2002	May	DISC	
	@		0.2MG	N021116	008	Oct 24, 2002	May	DISC	
	@		0.3MG	N021116	009	Oct 24, 2002	May	DISC	
		LEVOTHYROXINE SODIUM							
AB1,		MYLAN	0.3MG	A076187	011	Jun 05, 2002	May	CRLD	
AB2,									
AB3,									
AB4,	+								

LIDOCAINE

		OINTMENT; TOPICAL							
		LIDOCAINE							
AT		GLENMARK PHARMS LTD	5%	A206498	001	Sep 09, 2016	Aug	NEWA	
AT		SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun	CAHN	
AT		TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan	NEWA	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 400MG/100ML N018388 002 Feb DISC

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 800MG/100ML N018388 003 Nov 05, 1982 Feb DISC

JELLY; TOPICAL

ANESTACON

@ BIONPHARMA INC 2% A080429 001 Jan CAHN

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT + VINTAGE 2% A040708 001 Feb 27, 2007 Aug CRLD

LIDOCAINE VISCOUS

&gt;D&gt; AT ROXANE 2% A088802 001 Apr 26, 1985 Nov CAHN

&gt;A&gt; AT WEST-WARD PHARMS INT 2% A088802 001 Apr 26, 1985 Nov CAHN

SOLUTION; TOPICAL

LIDOCAINE HYDROCHLORIDE

&gt;D&gt; AT ROXANE 4% A088803 001 Apr 03, 1985 Nov CAHN

AT TELIGENT PHARMA INC 4% A204494 001 Mar 12, 2014 May CAHN

&gt;A&gt; AT WEST-WARD PHARMS INT 4% A088803 001 Apr 03, 1985 Nov CAHN

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

XIIDRA

+ SHIRE DEV LLC 5% N208073 001 Jul 11, 2016 Jul NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

BOEHRINGER INGELHEIM 2.5MG;1GM N208026 001 May 27, 2016 May NEWA

+ 5MG;1GM N208026 002 May 27, 2016 May NEWA

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

&gt;D&gt; AB ROXANE 100MG/5ML A200068 001 Jun 03, 2015 Nov CAHN

&gt;A&gt; AB WEST-WARD PHARMS INT 100MG/5ML A200068 001 Jun 03, 2015 Nov CAHN

SOLUTION; IV (INFUSION)

LINEZOLID

AP AUROBINDO PHARMA LTD 600MG/300ML (2MG/ML) A206917 001 Aug 04, 2016 Jul NEWA

AP FRESENIUS KABI USA 600MG/300ML (2MG/ML) A204764 001 Mar 15, 2016 Feb NEWA

TABLET; ORAL

LINEZOLID

AB GATE PHARMS 600MG A091210 001 Feb 05, 2016 Jan NEWA

AB GLENMARK PHARMS 600MG A078987 001 Dec 21, 2015 Mar CAHN

AB NOVEL LABS INC 600MG A207526 001 Aug 22, 2016 Aug NEWA

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

AB MAYNE PHARMA INC EQ 0.005MG BASE A090097 001 Mar 20, 2009 Mar CAHN

AB EQ 0.025MG BASE A090097 002 Mar 20, 2009 Mar CAHN

AB EQ 0.05MG BASE A090097 003 Mar 20, 2009 Mar CAHN

AB SUN PHARM INDS LTD EQ 0.005MG BASE A091382 001 Apr 20, 2016 Apr NEWA

AB EQ 0.025MG BASE A091382 002 Apr 20, 2016 Apr NEWA

AB EQ 0.05MG BASE A091382 003 Apr 20, 2016 Apr NEWA

LISINOPRIL

SOLUTION; ORAL

QBRELIS

+ SILVERGATE PHARMS 1MG/ML N208401 001 Jul 29, 2016 Jul NEWA

TABLET; ORAL

ZESTRIL

AB ALVOGEN MALTA 2.5MG N019777 005 Apr 29, 1993 Jan CAHN

AB 5MG N019777 001 May 19, 1988 Jan CAHN

AB 10MG N019777 002 May 19, 1988 Jan CAHN

AB 20MG N019777 003 May 19, 1988 Jan CAHN

AB 30MG N019777 006 Jan 20, 1999 Jan CAHN

AB + 40MG N019777 004 May 19, 1988 Jan CAHN



LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		DELCOR ASSET CORP	150MG	A 076243	002	Feb 24, 2003	Feb	CAHN
AB			300MG	A 076243	001	Jun 27, 2002	Feb	CAHN
AB			600MG	A 078763	001	Apr 15, 2008	Feb	CAHN
AB		HIKMA PHARMS	600MG	A 078763	001	Apr 15, 2008	Jan	CMFD

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		HERITAGE PHARMA	300MG	A 205532	001	Sep 29, 2016	Sep	NEWA
>D>	AB	ROXANE	300MG	A 076832	001	Oct 28, 2004	Nov	CAHN
>D>	AB	+	450MG	A 076691	001	Jan 05, 2004	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	300MG	A 076832	001	Oct 28, 2004	Nov	CAHN
>A>	AB	+	450MG	A 076691	001	Jan 05, 2004	Nov	CAHN

LIXISENATIDE

SOLUTION;SUBCUTANEOUS

ADLYXIN

+		SANOFI-AVENTIS US	0.15MG/3ML (0.05MG/ML)	N 208471	001	Jul 27, 2016	Aug	CPOT
+			0.05MG/ML	N 208471	001	Jul 27, 2016	Jul	NEWA
+			0.1MG/ML	N 208471	002	Jul 27, 2016	Jul	NEWA
+			0.3MG/3ML (0.1MG/ML)	N 208471	002	Jul 27, 2016	Aug	CPOT

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

>D>	+	ALCON	EQ 0.1% BASE	N 020191	001	Sep 23, 1993	Nov	CAHN
>A>	+	NOVARTIS PHARMS CORP	EQ 0.1% BASE	N 020191	001	Sep 23, 1993	Nov	CAHN

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

		AEGERION	EQ 20MG BASE	N 203858	003	Dec 21, 2012	Jan	CRLD
	+		EQ 60MG BASE	N 203858	006	Apr 23, 2015	Jan	CRLD

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

@ J AND J CONSUMER INC 2MG

N 017694	001			Feb	DISC
----------	-----	--	--	-----	------

LOPERAMIDE HYDROCHLORIDE

AB	+	MYLAN	2MG	A 072741	001	Sep 18, 1991	Feb	CRLD
----	---	-------	-----	----------	-----	--------------	-----	------

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM INTENSOL

>D>	AA	+	ROXANE	2MG/ML	A 072755	001	Jun 28, 1991	Nov	CAHN
>A>	AA	+	WEST-WARD PHARMS INT	2MG/ML	A 072755	001	Jun 28, 1991	Nov	CAHN

INJECTABLE;INJECTION

ATIVAN

AP	+	WEST-WARD PHARMS INT	2MG/ML	N 018140	001		Oct	CAHN
AP	+		4MG/ML	N 018140	002		Oct	CAHN

TABLET;ORAL

LORAZEPAM

@ FRONTIDA BIOPHARM

@

@

0.5MG	A 072553	001	Mar 29, 1991	Sep	CAHN
1MG	A 072554	001	Mar 29, 1991	Sep	CAHN
2MG	A 072555	001	Mar 29, 1991	Jul	CAHN

LORCASERIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BELVIQ XR

+		EISAI INC	20MG	N 208524	001	Jul 15, 2016	Jul	NEWA
---	--	-----------	------	----------	-----	--------------	-----	------

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

BX		HETERO LABS LTD V	25MG	A 203835	001	Aug 12, 2015	Apr	CTEC
BX			50MG	A 203835	002	Aug 12, 2015	Apr	CTEC
BX			100MG	A 203835	003	Aug 12, 2015	Apr	CTEC
AB		LUPIN LTD	25MG	A 078232	001	Oct 06, 2010	Oct	CTEC
BX			25MG	A 078232	001	Oct 06, 2010	Apr	CTEC
AB			50MG	A 078232	002	Oct 06, 2010	Oct	CTEC

TABLET;ORAL

LOSARTAN POTASSIUM

BX		50MG	A078232	002	Oct 06, 2010	Apr	CTEC
AB		100MG	A078232	003	Oct 06, 2010	Oct	CTEC
BX		100MG	A078232	003	Oct 06, 2010	Apr	CTEC
>D>	AB	ROXANE	25MG	A077459	001	Oct 06, 2010	Nov CAHN
>D>	AB		50MG	A077459	002	Oct 06, 2010	Nov CAHN
>D>	AB		100MG	A077459	003	Oct 06, 2010	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	25MG	A077459	001	Oct 06, 2010	Nov CAHN
>A>	AB		50MG	A077459	002	Oct 06, 2010	Nov CAHN
>A>	AB		100MG	A077459	003	Oct 06, 2010	Nov CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar CAHN
AB			20MG	A077520	002	Apr 14, 2006	Mar CAHN
AB			40MG	A077520	003	Apr 14, 2006	Mar CAHN

LOXAPINE

POWDER; INHALATION

ADASUVE

+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb	CAHN
---	---------------	------	---------	-----	--------------	-----	------

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

@	WINDTREE THERAP	8.5ML	N021746	001	Mar 06, 2012	Aug	CAHN
---	-----------------	-------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb NEWA
AP	+	HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb CFTG
AP		HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb NEWA
MAGNESIUM SULFATE IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb NEWA
AP			4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb NEWA
AP			2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar NEWA
AP			20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar NEWA
AP			40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar NEWA
AP		HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar CFTG
AP	+		4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb CFTG
AP	+		4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb CFTG
AP			20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar CFTG
AP			40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar CFTG

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan	NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan	NEWA

MARAVIROC

>A>	SOLUTION;ORAL						
>A>	SELZENTRY						
>A>	+	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016	Nov NEWA
>A>	TABLET;ORAL						
>A>	SELZENTRY						
>A>		VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Nov NEWA
>A>			75MG	N022128	004	Nov 04, 2016	Nov NEWA

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

EMVERM

+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Aug	CTNA
+	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Oct	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@	RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan	CAHN
@		25MG	A040179	002	Jan 30, 1997	Jan	CAHN

TABLET, CHEWABLE; ORAL

ANTIVERT

@	CASPER PHARMA LLC	25MG	N010721	005		Jun	DISC
---	-------------------	------	---------	-----	--	-----	------

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

>D>	AB	@ HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May	CAHN
>A>	AB	ROXANE	250MG	A076523	001	Oct 01, 2004	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	250MG	A076523	001	Oct 01, 2004	Nov	CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB	+	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb	CAHN
>D>	AB	ROXANE	40MG/ML	A075997	001	Feb 15, 2002	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	40MG/ML	A075997	001	Feb 15, 2002	Nov	CAHN

TABLET; ORAL

MEGESTROL ACETATE

>D>	AB	ROXANE	20MG	A074458	001	Sep 29, 1995	Nov	CAHN
>D>	AB		40MG	A074458	002	Sep 29, 1995	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	20MG	A074458	001	Sep 29, 1995	Nov	CAHN
>A>	AB		40MG	A074458	002	Sep 29, 1995	Nov	CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

@	FRONTIDA BIOPHARM	7.5MG	A077935	001	Jul 19, 2006	Jul	CAHN
@		15MG	A077935	002	Jul 19, 2006	Jul	CAHN
@	SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jan	CAHN
@		15MG	A077935	002	Jul 19, 2006	Jan	CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

+	APOTEX INC	2MG	N014691	002		Jan	CAHN
---	------------	-----	---------	-----	--	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP	+	APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan	CAHN
AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	Aug	NEWA
AP		WEST-WARD PHARMS INT	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Oct	CAHN

POWDER; IV (INFUSION)

EVOMELA

		SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	NEWA
--	--	-----------------	-------------------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	7MG	A205825	001	Oct 12, 2016	Oct	NEWA
AB			14MG	A205825	002	Oct 12, 2016	Oct	NEWA
AB			21MG	A205825	003	Oct 12, 2016	Oct	NEWA
AB			28MG	A205825	004	Oct 12, 2016	Oct	NEWA
>A>	AB	APOTEX INC	7MG	A206135	001	Nov 22, 2016	Nov	NEWA
>A>	AB		14MG	A206135	002	Nov 22, 2016	Nov	NEWA
>A>	AB		21MG	A206135	003	Nov 22, 2016	Nov	NEWA
>A>	AB		28MG	A206135	004	Nov 22, 2016	Nov	NEWA
AB		LUPIN LTD	7MG	A206028	001	Sep 28, 2016	Sep	NEWA
AB			14MG	A206028	002	Sep 28, 2016	Sep	NEWA
AB			21MG	A206028	003	Sep 28, 2016	Sep	NEWA
AB			28MG	A206028	004	Sep 28, 2016	Sep	NEWA
AB		MYLAN PHARMS INC	7MG	A206032	001	Sep 28, 2016	Sep	NEWA
AB			14MG	A206032	002	Sep 28, 2016	Sep	NEWA

CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE

AB		21MG	A206032	003	Sep 28, 2016	Sep	NEWA
AB		28MG	A206032	004	Sep 28, 2016	Sep	NEWA
AB	SUN PHARMA GLOBAL	7MG	A205905	001	Sep 28, 2016	Sep	NEWA
AB		14MG	A205905	002	Sep 28, 2016	Sep	NEWA
AB		21MG	A205905	003	Sep 28, 2016	Sep	NEWA
AB		28MG	A205905	004	Sep 28, 2016	Sep	NEWA
	NAMENDA XR						
AB	FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Sep	CFTG
AB		14MG	N022525	002	Jun 21, 2010	Sep	CFTG
AB		21MG	N022525	003	Jun 21, 2010	Sep	CFTG
AB	+	28MG	N022525	004	Jun 21, 2010	Sep	CFTG

TABLET;ORAL  
MEMANTINE HYDROCHLORIDE

AB	SILARX PHARMS INC	5MG	A207236	001	Nov 10, 2016	Oct	NEWA
AB		10MG	A207236	002	Nov 10, 2016	Oct	NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION  
DEMEROL

	@ US PHARM HOLDINGS	25MG/ML	N005010	007		Jan	CAHN
	@	50MG/ML	N005010	002		Jan	CAHN
	@	75MG/ML	N005010	009		Jan	CAHN
	@	100MG/ML	N005010	003		Jan	CAHN

SYRUP;ORAL

	@ US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan	CAHN
--	---------------------	----------	---------	-----	--	-----	------

MEPERIDINE HYDROCHLORIDE

>D>	+	ROXANE	50MG/5ML	A088744	001	Jan 30, 1985	Nov	CAHN
>A>	+	WEST-WARD PHARMS INT	50MG/5ML	A088744	001	Jan 30, 1985	Nov	CAHN

TABLET;ORAL

AA	+	US PHARM HOLDINGS	50MG	N005010	001		Jan	CAHN
AA	+		100MG	N005010	004		Jan	CAHN

MEPERIDINE HYDROCHLORIDE

>D>	AA	ROXANE	50MG	A040110	001	Mar 12, 1997	Nov	CAHN
>D>	AA		100MG	A040110	002	Mar 12, 1997	Nov	CAHN
		@ SUN PHARM INDS	50MG	A080448	001		Mar	CAHN
		@	100MG	A080448	002		Mar	CAHN
>A>	AA	WEST-WARD PHARMS INT	50MG	A040110	001	Mar 12, 1997	Nov	CAHN
>A>	AA		100MG	A040110	002	Mar 12, 1997	Nov	CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION  
MEPERGAN

	@ WEST-WARD PHARMS INT	25MG/ML;25MG/ML	N011730	001		Oct	CAHN
--	------------------------	-----------------	---------	-----	--	-----	------

MEPROBAMATE

TABLET;ORAL  
MEPROBAMATE

	@ AUROLIFE PHARMA LLC	400MG	A080655	001		Feb	CAHN
	@ SUN PHARM INDS	200MG	A080699	001		Mar	CAHN
	@	400MG	A080699	002		Mar	CAHN

MERCAPTOPYRINE

TABLET;ORAL  
MERCAPTOPYRINE

AB		DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr	CAHN	
>D>	AB	+	ROXANE	50MG	A040528	001	Feb 13, 2004	Nov	CAHN
>A>	AB	+	WEST-WARD PHARMS INT	50MG	A040528	001	Feb 13, 2004	Nov	CAHN

PURINETHOL

AB	STASON PHARMS	50MG	N009053	002		Aug	CMFD
	@	50MG	N009053	002		Jan	CAHN

MEROPENEM

INJECTABLE;INJECTION  
MEROPENEM

AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar	NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May	NEWA
AP		1GM/VIAL	A206141	002	Jun 08, 2016	May	NEWA

INJECTABLE; INJECTION

MEROPENEM

AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016	May NEWA
AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+	APIL	400MG	N204412	001	Feb 01, 2013	Jan CAHN
---	------	-------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

ASACOL

@	APIL	400MG	N019651	001	Jan 31, 1992	Jan CAHN
---	------	-------	---------	-----	--------------	----------

ASACOL HD

+	APIL	800MG	N021830	001	May 29, 2008	Jan CAHN
---	------	-------	---------	-----	--------------	----------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	WEST-WARD PHARMS INT	100MG/ML	A075739	001	Jan 09, 2004	Oct CAHN
----	----------------------	----------	---------	-----	--------------	----------

METAXALONE

TABLET; ORAL

METAXALONE

>A>	AB	LANNETT HOLDINGS INC	800MG	A204770	001	Nov 22, 2016	Nov NEWA
-----	----	----------------------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016	Jun NEWA
AB			850MG	A205096	002	Jul 11, 2016	Jun NEWA
AB			1GM	A205096	003	Jul 11, 2016	Jun NEWA
AB		SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar CAHN
AB			850MG	A076038	002	Feb 21, 2002	Mar CAHN
AB			1GM	A076038	003	Feb 21, 2002	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

AB3		SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan CTEC
AB3	+		1GM	N021748	002	Jun 03, 2005	Jan CTEC
AB3		ACTAVIS LABS FL INC	500MG	A203755	001	Aug 01, 2016	Jul NEWA
AB3			1GM	A203755	002	Aug 01, 2016	Jul NEWA
>A>	AB1	BEXIMCO PHARMS USA	500MG	A207427	001	Dec 13, 2016	Nov NEWA
>A>	AB		750MG	A207427	002	Dec 13, 2016	Nov NEWA
		@ IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar DISC
		@	750MG	A076985	001	Sep 13, 2005	Mar DISC
>A>	AB1	MACLEODS PHARMS LTD	500MG	A206955	001	Dec 07, 2016	Nov NEWA
>A>	AB		750MG	A206955	002	Dec 07, 2016	Nov NEWA
AB1		MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr NEWA
AB			750MG	A090295	002	Apr 29, 2016	Apr NEWA
		@ SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar CAHN
AB3		SUN PHARMA GLOBAL	500MG	A202917	001	Aug 01, 2016	Jul NEWA
AB3			1GM	A202917	002	Aug 01, 2016	Jul NEWA

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

		METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016	Oct NEWA
--	--	------------	-------------	---------	-----	--------------	----------

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

>D>	AA	ROXANE	10MG/ML	A040180	001	Apr 30, 1998	Nov CAHN
>A>	AA	WEST-WARD PHARMS INT	10MG/ML	A040180	001	Apr 30, 1998	Nov CAHN
		METHADONE HYDROCHLORIDE	INTENSOL				
>D>	AA	ROXANE	10MG/ML	A089897	001	Sep 06, 1988	Nov CAHN
>A>	AA	WEST-WARD PHARMS INT	10MG/ML	A089897	001	Sep 06, 1988	Nov CAHN
		INJECTABLE; INJECTION					
>D>		DOLOPHINE HYDROCHLORIDE					
>D>		+ MYLAN INSTITUTIONAL	10MG/ML	N021624	001		Nov CTNA

	INJECTABLE; INJECTION						
>A>	METHADONE HYDROCHLORIDE						
>A>	+	MYLAN INSTITUTIONAL	10MG/ML	N021624	001		Nov CTNA
	SOLUTION; ORAL						
	METHADONE HYDROCHLORIDE						
>D>	AA	+	ROXANE	5MG/5ML	A087393	001	Nov CAHN
>D>	AA	+		10MG/5ML	A087997	001	Aug 30, 1982 Nov CAHN
>A>	AA	+	WEST-WARD PHARMS INT	5MG/5ML	A087393	001	Nov CAHN
>A>	AA	+		10MG/5ML	A087997	001	Aug 30, 1982 Nov CAHN
	TABLET, FOR SUSPENSION; ORAL						
	METHADOSE						
AA		MALLINCKRODT INC	40MG	A074184	001	Apr 29, 1993	Aug CAHN
	<u>METHAMPHETAMINE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	METHAMPHETAMINE HYDROCHLORIDE						
AA		MAYNE PHARMA INC	5MG	A091189	001	Apr 21, 2010	Aug CAHN
>D>	AA		ROXANE	5MG	A203846	001	Nov 17, 2015 Nov CAHN
>A>	AA		WEST-WARD PHARMS INT	5MG	A203846	001	Nov 17, 2015 Nov CAHN
	<u>METHENAMINE HIPPURATE</u>						
	TABLET; ORAL						
	HIPREX						
AB	+	US PHARM HOLDINGS	1GM	N017681	001		Jan CAHN
	METHENAMINE HIPPURATE						
AB		AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun NEWA
	<u>METHIMAZOLE</u>						
	TABLET; ORAL						
	METHIMAZOLE						
AB		ECI PHARMS LLC	5MG	A040547	001	Feb 18, 2005	Jul CAHN
AB			10MG	A040547	002	Feb 18, 2005	Jul CAHN
		@	20MG	A040547	004	Feb 18, 2005	Jul CAHN
AB		RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan CAHN
AB			10MG	A202068	002	Mar 07, 2012	Jan CAHN
	<u>METHOCARBAMOL</u>						
	SOLUTION; IM-IV						
	METHOCARBAMOL						
AP		AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
AP		MONTEREY PHARMS LLC	1GM/10ML (100MG/ML)	A205354	001	Oct 27, 2016	Oct NEWA
	ROBAXIN						
AP	+	WEST-WARD PHARMS INT	1GM/10ML (100MG/ML)	N011790	001		Oct CAHN
	TABLET; ORAL						
	METHOCARBAMOL						
		@ LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Aug DISC
		@	750MG	A084756	001		Aug DISC
		@ SANDOZ	500MG	A084616	001		Feb DISC
		@	750MG	A084615	001		Feb DISC
		@ SUN PHARM INDS	500MG	A084488	001		Mar CAHN
		@	750MG	A084486	001		Mar CAHN
	ROBAXIN						
AA	+	AUXILIUM PHARMS INC	500MG	N011011	004		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004		Jul CAHN
	ROBAXIN-750						
AA	+	AUXILIUM PHARMS INC	750MG	N011011	006		Mar CAHN
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Jul CAHN
	<u>METHOHEXITAL SODIUM</u>						
	INJECTABLE; INJECTION						
	BREVITAL SODIUM						
		@ PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC
	<u>METHOTREXATE</u>						
	SOLUTION; SUBCUTANEOUS						
	OTREXUP						
		@ ANTARES PHARMA INC	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Sep DISC
			12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May NEWA
			17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May NEWA
			22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May NEWA

METHOTREXATE SODIUM

		INJECTABLE; INJECTION		METHOTREXATE SODIUM					
AP	+	WEST-WARD PHARMS INT	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Oct	CAHN	
	+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Oct	CAHN	
		METHOTREXATE SODIUM PRESERVATIVE FREE							
AP		SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan	CAHN	
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan	CAHN	
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan	CAHN	
AP	+	WEST-WARD PHARMS INT	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Oct	CAHN	
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Oct	CAHN	
	+		EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Sep	CAHN	
		TABLET; ORAL		METHOTREXATE SODIUM					
>D>	AB	ROXANE	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Nov	CAHN	
>A>	AB	WEST-WARD PHARMS INT	EQ 2.5MG BASE	A040054	001	Aug 01, 1994	Nov	CAHN	

METHOXSALLEN

		CAPSULE; ORAL		METHOXSALLEN					
		@ IDT AUSTRALIA LTD	10MG	A087781	001	Jun 08, 1982	Aug	CAHN	
		INJECTABLE; INJECTION		UVADEX					
	+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr	CAHN	

METHYLDOPA

		TABLET; ORAL		METHYLDOPA					
		@ SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar	CAHN	
		@	250MG	A070060	001	Oct 09, 1986	Mar	CAHN	
		@	500MG	A070074	001	Oct 09, 1986	Mar	CAHN	

METHYLENE BLUE

		SOLUTION; INTRAVENOUS		PROVAYBLUE					
	+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr	NEWA	

METHYLERGONOVINE MALEATE

		TABLET; ORAL		METHERGINE					
		@ EDISON THERAPS LLC	0.2MG	N006035	003		Jan	DISC	
		METHYLERGONOVINE MALEATE							
	+	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan	CRLD	

METHYLNALTREXONE BROMIDE

		SOLUTION; SUBCUTANEOUS		RELISTOR					
	+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Jul	CRLD	
		TABLET; ORAL		RELISTOR					
	+	SALIX PHARMS INC	150MG	N208271	001	Jul 19, 2016	Jul	NEWA	

METHYLPHENIDATE HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE; ORAL		METHYLPHENIDATE HYDROCHLORIDE					
AB2		COREPHARMA	10MG	A205105	001	Jul 28, 2016	Jul	NEWA	
AB2			20MG	A205105	002	Jul 28, 2016	Jul	NEWA	
AB2			30MG	A205105	003	Jul 28, 2016	Jul	NEWA	
AB2			40MG	A205105	004	Jul 28, 2016	Jul	NEWA	
AB2			50MG	A205105	005	Jul 28, 2016	Jul	NEWA	
AB2			60MG	A205105	006	Jul 28, 2016	Jul	NEWA	
AB1		MAYNE PHARMA	20MG	A078458	001	Dec 01, 2011	Aug	CAHN	
AB1			30MG	A078458	002	Dec 01, 2011	Aug	CAHN	
AB1			40MG	A078458	003	Dec 01, 2011	Aug	CAHN	
AB1			60MG	A078458	004	Jun 23, 2016	Aug	CAHN	
AB1		WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun	NEWA	

	CAPSULE, EXTENDED RELEASE;ORAL							
	RITALIN LA							
AB1	+	NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun	CFTG
	SOLUTION;ORAL							
	METHYLPHENIDATE HYDROCHLORIDE							
>A>	AA	ABHAI	5MG/5ML	A207485	001	Nov 18, 2016	Nov	NEWA
>A>	AA		10MG/5ML	A207485	002	Nov 18, 2016	Nov	NEWA
	AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN
	AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN
	TABLET;ORAL							
	METHYLPHENIDATE HYDROCHLORIDE							
AB		CNTY LINE PHARMS	5MG	A206840	001	Sep 15, 2016	Sep	NEWA
AB			10MG	A206840	002	Sep 15, 2016	Sep	NEWA
AB			20MG	A206840	003	Sep 15, 2016	Sep	NEWA
	TABLET, CHEWABLE;ORAL							
	METHYLPHENIDATE HYDROCHLORIDE							
AB		NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Oct	CTEC
AB			5MG	A204115	002	Feb 25, 2015	Oct	CTEC
AB	+		10MG	A204115	003	Feb 25, 2015	Oct	CTEC
AB		TEDOR PHARMA INC	2.5MG	A205756	001	Nov 07, 2016	Oct	NEWA
AB			5MG	A205756	002	Nov 07, 2016	Oct	NEWA
AB			10MG	A205756	003	Nov 07, 2016	Oct	NEWA
	TABLET, EXTENDED RELEASE;ORAL							
	CONCERTA							
AB		JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000	Oct	CTEC
AB			27MG	N021121	004	Apr 01, 2002	Oct	CTEC
AB			36MG	N021121	002	Aug 01, 2000	Oct	CTEC
AB	+		54MG	N021121	003	Dec 08, 2000	Oct	CTEC
	METHYLPHENIDATE HYDROCHLORIDE							
AB		CNTY LINE PHARMS	10MG	A204772	001	Feb 29, 2016	Aug	CAHN
AB			20MG	A204772	002	Feb 29, 2016	Aug	CAHN
AB		MYLAN PHARMS INC	18MG	A206726	001	Oct 21, 2016	Oct	NEWA
AB			27MG	A206726	002	Oct 21, 2016	Oct	NEWA
AB			36MG	A206726	003	Oct 21, 2016	Oct	NEWA
AB			54MG	A206726	004	Oct 21, 2016	Oct	NEWA
AB		TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb	NEWA
AB			20MG	A204772	002	Feb 29, 2016	Feb	NEWA
	<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>							
	INJECTABLE;INJECTION							
	METHYLPREDNISOLONE SODIUM SUCCINATE							
AP		AMNEAL PHARMS CO	EQ 40MG BASE/VIAL	A207549	001	Nov 09, 2016	Oct	NEWA
AP			EQ 125MG BASE/VIAL	A207549	002	Nov 09, 2016	Oct	NEWA
AP		HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb	NEWA
AP			EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb	NEWA
AP		SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan	CAHN
AP			EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan	CAHN
AP			EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan	CAHN
	<u>METHYLTESTOSTERONE</u>							
	TABLET;ORAL							
	ANDROID 10							
		@ VALEANT PHARM INTL	10MG	A086450	001		Apr	DISC
	METHYLTESTOSTERONE							
		@ IMPAX LABS	25MG	A084310	001		Mar	DISC
	<u>METOCLOPRAMIDE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	REGLAN							
		@ WEST-WARD PHARMS INT	EQ 5MG BASE/ML	N017862	001		Oct	CAHN
		@	EQ 10MG BASE/ML	N017862	004	May 28, 1987	Oct	CAHN
	SOLUTION;ORAL							
	METOCLOPRAMIDE HYDROCHLORIDE							
		@ SILARX	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992	Aug	DISC
	TABLET;ORAL							
	METOCLOPRAMIDE HYDROCHLORIDE							
AB		IMPAX LABS INC	EQ 5MG BASE	A072750	001	Dec 28, 1995	Aug	CAHN
AB			EQ 10MG BASE	A071250	001	Feb 03, 1988	Aug	CAHN
AB		SUN PHARM INDS	EQ 5MG BASE	A071536	002	Jan 16, 1997	Mar	CAHN
		@	EQ 10MG BASE	A071536	001	Apr 28, 1993	Mar	CAHN



METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL  
METOPROLOL SUCCINATE

>A>	AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	Nov	NEWA
>A>	AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	Nov	NEWA
>A>	AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	Nov	NEWA
>A>	AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	Nov	NEWA

METOPROLOL TARTRATE

TABLET;ORAL  
METOPROLOL TARTRATE

		@ SANDOZ	50MG	A073288	001	Mar 25, 1994	May	DISC
		@	100MG	A073289	001	Mar 25, 1994	May	DISC
AB		SUN PHARM INDS	25MG	A073654	002	Jul 15, 2009	Mar	CAHN
AB			100MG	A073654	001	Dec 21, 1993	Mar	CAHN

METRONIDAZOLE

GEL;VAGINAL  
NUVESSA

+		ALLERGAN SALES LLC	1.3%	N205223	001	Mar 24, 2014	Apr	CAHN
---	--	--------------------	------	---------	-----	--------------	-----	------

TABLET;ORAL  
METRONIDAZOLE

AB		FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	May	NEWA
AB			500MG	A207309	002	May 16, 2016	May	NEWA
AB		STRIDES PHARMA	250MG	A208162	001	May 25, 2016	May	NEWA
AB			500MG	A208162	002	May 25, 2016	May	NEWA
AB		VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	May	CMFD
AB			500MG	A070039	001	Jan 29, 1985	May	CMFD
AB		ZYDUS PHARMS USA INC	250MG	A206560	001	Nov 16, 2016	Oct	NEWA
AB			500MG	A206560	002	Nov 16, 2016	Oct	NEWA

MICAFUNGIN SODIUM

INJECTABLE;IV (INFUSION)  
MYCAMINE

+		ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	Sep	CPOT
+			EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	Sep	CPOT

MICONAZOLE

TABLET;BUCCAL  
ORAVIG

+		MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Jan	CAHN
---	--	--------------------	------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

SYRUP;ORAL  
MIDAZOLAM HYDROCHLORIDE

>D>	AA	+	ROXANE	EQ 2MG BASE/ML	A075873	001	Apr 30, 2002	Nov	CAHN
>A>	AA	+	WEST-WARD PHARMS INT	EQ 2MG BASE/ML	A075873	001	Apr 30, 2002	Nov	CAHN

MIGLITOL

TABLET;ORAL  
GLYSET

AB	+	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb	CRLD
AB			100MG	N020682	003	Dec 18, 1996	Feb	CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL  
MILNACIPRAN HYDROCHLORIDE

AB		AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016	Apr	NEWA
AB			25MG	A205081	002	Apr 22, 2016	Apr	NEWA
AB			50MG	A205081	003	Apr 22, 2016	Apr	NEWA
AB			100MG	A205081	004	Apr 22, 2016	Apr	NEWA
		@ LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Jan	DISC
			12.5MG	A205071	001	Jan 27, 2016	Jan	NEWA
		@	25MG	A205071	002	Jan 27, 2016	Jan	DISC
			25MG	A205071	002	Jan 27, 2016	Jan	NEWA
		@	50MG	A205071	003	Jan 27, 2016	Jan	DISC
			50MG	A205071	003	Jan 27, 2016	Jan	NEWA
		@	100MG	A205071	004	Jan 27, 2016	Jan	DISC
			100MG	A205071	004	Jan 27, 2016	Jan	NEWA
		SAVELLA						
AB		CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr	CFTG

<u>TABLET;ORAL</u>							
SAVELLA							
AB		25MG		N022256	002	Jan 14, 2009	Apr CFTG
AB	+	50MG		N022256	003	Jan 14, 2009	Apr CFTG
AB		100MG		N022256	004	Jan 14, 2009	Apr CFTG
<u>MILRINONE LACTATE</u>							
INJECTABLE; INJECTION							
MILRINONE LACTATE IN DEXTROSE 5%							
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)		A077151	002	Jul 20, 2005	Mar CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
	@ B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A076414	001	Aug 18, 2004	Sep DISC
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A077151	001	Jul 20, 2005	Mar CAHN
<u>MINOCYCLINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
DYNACIN							
	@ CNTY LINE PHARMS	EQ 50MG BASE		A063067	003	Aug 14, 1990	Oct CMS1
MINOCYCLINE HYDROCHLORIDE							
AB	ZYDUS WORLDWIDE	EQ 50MG BASE		A063011	001	Mar 02, 1992	Aug CAHN
AB		EQ 75MG BASE		A063009	002	Aug 12, 2003	Aug CAHN
AB	+	EQ 100MG BASE		A063009	001	Mar 02, 1992	Aug CAHN
TABLET;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS	EQ 50MG BASE		A090217	001	Jan 29, 2016	Jan NEWA
AB		EQ 75MG BASE		A090217	002	Jan 29, 2016	Jan NEWA
AB		EQ 100MG BASE		A090217	003	Jan 29, 2016	Jan NEWA
TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	ALKEM LABS LTD	EQ 45MG BASE		A204453	001	Sep 28, 2016	Sep NEWA
AB		EQ 80MG BASE		A204453	002	Sep 28, 2016	Sep NEWA
AB		EQ 90MG BASE		A204453	003	Sep 28, 2016	Sep NEWA
AB		EQ 105MG BASE		A204453	004	Sep 28, 2016	Sep NEWA
AB		EQ 135MG BASE		A204453	005	Sep 28, 2016	Sep NEWA
AB	AUROBINDO PHARMA LTD	EQ 80MG BASE		A202261	006	Jun 13, 2016	May NEWA
AB		EQ 105MG BASE		A202261	007	Jun 13, 2016	May NEWA
	@ IMPAX LABS INC	EQ 45MG BASE		A090024	001	Feb 03, 2009	Mar DISC
	@	EQ 90MG BASE		A090024	002	Feb 03, 2009	Mar DISC
	@	EQ 135MG BASE		A090024	003	Feb 03, 2009	Mar DISC
<u>MINOXIDIL</u>							
TABLET;ORAL							
MINOXIDIL							
AB	SUN PHARM INDS	10MG		A072709	001	Dec 14, 1995	Mar CAHN
<u>MIPOMERSEN SODIUM</u>							
SOLUTION;SUBCUTANEOUS							
KYNAMRO							
	+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN
<u>MIRTAZAPINE</u>							
TABLET;ORAL							
MIRTAZAPINE							
	@ ACTAVIS LABS FL INC	15MG		A076336	001	Jun 20, 2003	Jan DISC
	@	30MG		A076336	002	Jun 20, 2003	Jan DISC
	@	45MG		A076336	003	Jun 20, 2003	Jan DISC
	@ UPSHER-SMITH LABS	15MG		A076189	001	Jun 19, 2003	Oct CAHN
AB		15MG		A076219	001	Jun 19, 2003	Oct CAHN
	@	30MG		A076189	002	Jun 19, 2003	Oct CAHN
AB		30MG		A076219	002	Jun 19, 2003	Oct CAHN
	@	45MG		A076189	003	Jun 19, 2003	Oct CAHN
AB		45MG		A076219	003	Jun 19, 2003	Oct CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
MIRTAZAPINE							
AB	IMPAX LABS INC	15MG		A076901	001	Jun 28, 2005	Aug CAHN
AB		30MG		A076901	002	Jun 28, 2005	Aug CAHN
AB		45MG		A076901	003	Jun 28, 2005	Aug CAHN

MITOMYCIN

INJECTABLE; INJECTION  
MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064180	001	Dec 23, 1999	Jan	CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan	CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION  
MITOXANTRONE HYDROCHLORIDE

AP	WEST-WARD PHARMS INT	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Oct	CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Oct	CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Oct	CAHN

MODAFINIL

TABLET; ORAL  
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan	CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan	CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL  
MOEXIPRIL HYDROCHLORIDE

AB	+ TEVA	15MG	A076204	002	May 08, 2003	Aug	CRLD
----	--------	------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

CREAM; TOPICAL  
ELOCON

AB	+ @ MERCK SHARP DOHME	0.1%	N019625	001	May 06, 1987	Aug	DISC
		0.1%	N019625	002	Apr 19, 2013	Aug	CRLD

SPRAY, METERED; NASAL  
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar	NEWA
AB	+ NASONEX						
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar	CFTG

MONTELUKAST SODIUM

TABLET; ORAL  
MONTELUKAST SODIUM

AB	CIPLA LTD	EQ 10MG BASE	A207463	001	Oct 28, 2016	Oct	NEWA
>D>	AB	ROXANE	A090655	001	Aug 03, 2012	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	A090655	001	Aug 03, 2012	Nov	CAHN

TABLET, CHEWABLE; ORAL  
MONTELUKAST SODIUM

>D>	AB	ROXANE	A091128	001	Aug 03, 2012	Nov	CAHN
>D>	AB		A091128	002	Aug 03, 2012	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	A091128	001	Aug 03, 2012	Nov	CAHN
>A>	AB		A091128	002	Aug 03, 2012	Nov	CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL  
KADIAN

AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb	CTEC
AB		20MG	N020616	001	Jul 03, 1996	Feb	CTEC
AB		30MG	N020616	004	Mar 09, 2001	Feb	CTEC
AB		40MG	N020616	009	Jul 09, 2012	Feb	CTEC
AB		50MG	N020616	002	Jul 03, 1996	Feb	CTEC
AB		60MG	N020616	005	Mar 09, 2001	Feb	CTEC
AB		70MG	N020616	010	Jul 09, 2012	Feb	CTEC
AB		80MG	N020616	006	Oct 27, 2006	Feb	CTEC
AB	+	100MG	N020616	003	Jul 03, 1996	Feb	CTEC
AB	+	200MG	N020616	007	Feb 27, 2007	Feb	CTEC
AB	+ ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr	CAHN
AB		20MG	N020616	001	Jul 03, 1996	Apr	CAHN
AB		30MG	N020616	004	Mar 09, 2001	Apr	CAHN
AB		40MG	N020616	009	Jul 09, 2012	Apr	CAHN
AB		50MG	N020616	002	Jul 03, 1996	Apr	CAHN
AB		60MG	N020616	005	Mar 09, 2001	Apr	CAHN
AB		70MG	N020616	010	Jul 09, 2012	Apr	CAHN
AB		80MG	N020616	006	Oct 27, 2006	Apr	CAHN
AB	+	100MG	N020616	003	Jul 03, 1996	Apr	CAHN

CAPSULE, EXTENDED RELEASE;ORAL  
KADIAN

		130MG	N020616	011	Jul 09, 2012	Apr CAHN
		150MG	N020616	012	Jul 09, 2012	Apr CAHN
+		200MG	N020616	007	Feb 27, 2007	Apr CAHN
	MORPHINE SULFATE					
AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB		30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb CTEC

INJECTABLE;INJECTION  
DURAMORPH PF

AP	+	WEST-WARD PHARMS INT	0.5MG/ML	N018565	001	Sep 18, 1984	Oct CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Oct CAHN
		INFUMORPH					
	+	WEST-WARD PHARMS INT	10MG/ML	N018565	003	Jul 19, 1991	Oct CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Oct CAHN

SOLUTION;ORAL

	MORPHINE SULFATE						
AA		NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA			20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
AA			100MG/5ML	A204053	001	Oct 06, 2016	Sep NEWA
AA		PHARM ASSOC	100MG/5ML	A206573	001	Nov 14, 2016	Oct NEWA
AA		RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun NEWA
AA		TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL

	MORPHINE SULFATE						
AB		COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun NEWA
AB			30MG	A091357	002	Jun 23, 2016	Jun NEWA
AB			60MG	A091357	003	Jun 23, 2016	Jun NEWA
AB			100MG	A091357	004	Jun 23, 2016	Jun NEWA
AB			200MG	A091357	005	Jun 23, 2016	Jun NEWA
AB		MAYNE PHARMA INC	15MG	A205386	001	Oct 28, 2016	Oct NEWA
AB			30MG	A205386	002	Oct 28, 2016	Oct NEWA
AB			60MG	A205386	003	Oct 28, 2016	Oct NEWA
AB			100MG	A205386	004	Oct 28, 2016	Oct NEWA
AB		SUN PHARM INDS LTD	15MG	A205634	001	Aug 25, 2016	Aug NEWA
AB			30MG	A205634	002	Aug 25, 2016	Aug NEWA
AB			60MG	A205634	003	Aug 25, 2016	Aug NEWA
AB			100MG	A205634	004	Aug 25, 2016	Aug NEWA
AB			200MG	A205634	005	Aug 25, 2016	Aug NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
MOXEZA

>D>	AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Nov CAHN
>A>	AT2	+	NOVARTIS PHARMS CORP	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Nov CAHN

TABLET; ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB CROSSMEDIKA SA EQ 400MG BASE A205348 001 Jan 14, 2016 Jan NEWA

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB JUBILANT CADISTA 250MG A090762 001 Dec 15, 2014 Jun CAHN  
 >D> AB ROXANE 250MG A065410 001 Jul 29, 2008 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT 250MG A065410 001 Jul 29, 2008 Nov CAHN

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB JUBILANT CADISTA 500MG A090661 001 Dec 15, 2014 Jun CAHN  
 >D> AB ROXANE 500MG A065413 001 Jul 29, 2008 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT 500MG A065413 001 Jul 29, 2008 Nov CAHN

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

AP + ROCHE PALO 500MG/VIAL N050758 001 Aug 12, 1998 Oct CFTG  
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE  
 AP PAR STERILE PRODUCTS 500MG/VIAL A203575 001 Oct 28, 2016 Oct NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

AB IMPAX LABS INC 500MG A075189 001 May 26, 2000 Aug CAHN  
 AB + 750MG A075189 002 Sep 24, 2001 Aug CAHN

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

AB TARO 1% A205975 001 Sep 08, 2016 Aug NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NUBAIN

@ PAR PHARM INC 10MG/ML  
 @ 20MG/ML

N018024 001 Aug CAHN  
 N018024 002 May 27, 1982 Aug CAHN

NALIDIXIC ACID

TABLET; ORAL

NALIDIXIC ACID

@ SUN PHARM INDS 250MG  
 @ 500MG  
 @ 1GM

A070270 001 Jun 29, 1988 Mar CAHN  
 A070271 001 Jun 29, 1988 Jun CAHN  
 A070272 001 Jun 29, 1988 Mar CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

AP WEST-WARD PHARMS INT 0.4MG/ML A070299 001 Sep 24, 1986 Oct CAHN  
 NALOXONE HYDROCHLORIDE  
 AP MYLAN INSTITUTIONAL 0.4MG/ML A205014 001 Jun 29, 2016 Jun NEWA  
 SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS  
 EVZIO  
 + KALEO INC 0.4MG/0.4ML (0.4MG/0.4ML) N205787 001 Apr 03, 2014 Oct CPOT  
 + 2MG/0.4ML (2MG/0.4ML) N209862 001 Oct 19, 2016 Oct NEWA

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB + MALLINCKRODT 50MG A076264 002 Mar 22, 2002 Oct CRLD  
 REVIA  
 @ TEVA WOMENS 50MG N018932 001 Nov 20, 1984 Oct DISC

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROXYCA ER

PFIZER INC 1.2MG; 10MG  
 2.4MG; 20MG  
 3.6MG; 30MG

N207621 001 Aug 19, 2016 Aug NEWA  
 N207621 002 Aug 19, 2016 Aug NEWA  
 N207621 003 Aug 19, 2016 Aug NEWA

CAPSULE, EXTENDED RELEASE;ORAL  
TROXYCA ER

		4.8MG;40MG	N207621	004	Aug 19, 2016	Aug NEWA
		7.2MG;60MG	N207621	005	Aug 19, 2016	Aug NEWA
		9.6MG;80MG	N207621	006	Aug 19, 2016	Aug NEWA

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB	+	ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun CAHN
		NAPROXEN					
>D>	AB	ROXANE	25MG/ML	A074190	001	Mar 30, 1994	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	25MG/ML	A074190	001	Mar 30, 1994	Nov CAHN

TABLET;ORAL

NAPROSYN

AB		ATNAHS PHARMA US	250MG	N017581	002		Feb CAHN
AB			375MG	N017581	003		Feb CAHN
AB	+		500MG	N017581	004	Apr 15, 1982	Feb CAHN
		NAPROXEN					
		@ SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb DISC
		@	375MG	A074140	002	Dec 21, 1993	Feb DISC
		@	500MG	A074140	003	Dec 21, 1993	Feb DISC

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb CAHN
AB	+		500MG	N020067	003	Oct 14, 1994	Feb CAHN
		NAPROXEN					
		@ SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb DISC
		@	500MG	A075061	002	Feb 18, 1998	Feb DISC

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb CAHN
		ANAPROX DS					
AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB	+	ALVOGEN MALTA	EQ 750MG BASE	N020353	003	Jan 05, 1996	Aug CFTG
		NAPROXEN SODIUM					
AB		ACTAVIS LABS FL INC	EQ 750MG BASE	A075416	003	Aug 11, 2016	Aug NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

>D>	AB	ROXANE	EQ 1MG BASE	A090381	001	Jul 07, 2010	Nov CAHN
>D>	AB		EQ 2.5MG BASE	A090381	002	Jul 07, 2010	Nov CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 1MG BASE	A090381	001	Jul 07, 2010	Nov CAHN
>A>	AB		EQ 2.5MG BASE	A090381	002	Jul 07, 2010	Nov CAHN

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB		ZYDUS PHARMS USA INC	60MG	A205248	001	Jul 06, 2016	Jun NEWA
AB			120MG	A205248	002	Jul 06, 2016	Jun NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

		FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jun NEWA
--	--	-----------------	------------------	---------	-----	--------------	----------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

		@ SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Feb DISC
		@	100MG	A076409	002	Sep 16, 2003	Feb DISC
		@	150MG	A076409	003	Sep 16, 2003	Feb DISC
		@	200MG	A076409	004	Sep 16, 2003	Feb DISC
		@	250MG	A076409	005	Sep 16, 2003	Feb DISC

NEOMYCIN SULFATE

TABLET;ORAL  
 NEOMYCIN SULFATE  
 AA LANNETT HOLDINGS INC 500MG A204435 001 Jun 10, 2016 May NEWA

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC  
 ILEVRO  
 >D> + ALCON RES LTD 0.3% N203491 001 Oct 16, 2012 Nov CAHN  
 >A> + NOVARTIS PHARMS CORP 0.3% N203491 001 Oct 16, 2012 Nov CAHN

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL  
 NEVIRAPINE  
 >A> AB AUROBINDO PHARMA LTD 100MG A208616 001 Nov 23, 2016 Nov NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
 CARDENE  
 @ CHIESI USA INC 20MG N019488 001 Dec 21, 1988 May DISC  
 @ 30MG N019488 002 Dec 21, 1988 May DISC  
 NICARDIPINE HYDROCHLORIDE  
 AB + MYLAN 30MG A074642 002 Jul 18, 1996 May CRLD

NIFEDIPINE

CAPSULE;ORAL  
 NIFEDIPINE  
 AB VALIDUS PHARMS 10MG A073250 001 Oct 08, 1991 Jul CMFD  
 @ 10MG A073250 001 Oct 08, 1991 Mar CAHN  
 AB 20MG A074045 001 Apr 30, 1992 Jul CMFD  
 @ 20MG A074045 001 Apr 30, 1992 Mar CAHN  
 TABLET, EXTENDED RELEASE;ORAL  
 ADALAT CC  
 AB1 ALVOGEN 30MG N020198 001 Apr 21, 1993 Feb CAHN  
 AB1 + 60MG N020198 002 Apr 21, 1993 Feb CAHN  
 AB1 + 90MG N020198 003 Apr 21, 1993 Feb CAHN  
 NIFEDIPINE  
 AB1 NOVAST LABS LTD 30MG A202987 001 Aug 25, 2016 Aug NEWA  
 AB1 60MG A202987 002 Aug 25, 2016 Aug NEWA  
 AB1 90MG A202987 003 Aug 25, 2016 Aug NEWA  
 AB2 OSMOTICA PHARM US 30MG A077127 001 Nov 21, 2005 Jun CAHN  
 AB2 60MG A077127 002 Nov 21, 2005 Jun CAHN  
 AB1 VALEANT PHARMS NORTH 30MG A075269 001 Dec 04, 2000 Jan CAHN  
 AB1 60MG A075269 002 Dec 04, 2000 Jan CAHN  
 AB1 90MG A076070 001 Aug 16, 2002 Jan CAHN

NILUTAMIDE

TABLET;ORAL  
 NILANDRON  
 AB + CONCORDIA PHARMS INC 150MG N020169 002 Apr 30, 1999 Jul CFTG  
 NILUTAMIDE  
 AB ANI PHARMS INC 150MG A207631 001 Jul 15, 2016 Jul NEWA

NIMODIPINE

CAPSULE;ORAL  
 NIMODIPINE  
 AB + BIONPHARMA INC 30MG A076740 001 Jan 17, 2008 Jan CAHN  
 AB HERITAGE PHARMS INC 30MG A077811 001 May 02, 2007 Aug CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL  
 SULAR  
 >A> AB + COVIS PHARMA SARL 8.5MG N020356 008 Jan 02, 2008 Nov CAHN  
 >A> @ 10MG N020356 001 Feb 02, 1995 Nov CAHN  
 >A> AB + 17MG N020356 007 Jan 02, 2008 Nov CAHN  
 >A> @ 20MG N020356 002 Feb 02, 1995 Nov CAHN  
 >A> @ 25.5MG N020356 006 Jan 02, 2008 Nov CAHN  
 >A> @ 30MG N020356 003 Feb 02, 1995 Nov CAHN  
 >A> AB + 34MG N020356 005 Jan 02, 2008 Nov CAHN  
 >A> @ 40MG N020356 004 Feb 02, 1995 Nov CAHN  
 >D> AB + SHIONOGI INC 8.5MG N020356 008 Jan 02, 2008 Nov CAHN

TABLET, EXTENDED RELEASE;ORAL  
SULAR

>D>	@	10MG	N020356	001	Feb 02, 1995	Nov	CAHN
>D>	AB +	17MG	N020356	007	Jan 02, 2008	Nov	CAHN
>D>	@	20MG	N020356	002	Feb 02, 1995	Nov	CAHN
>D>	@	25.5MG	N020356	006	Jan 02, 2008	Nov	CAHN
>D>	@	30MG	N020356	003	Feb 02, 1995	Nov	CAHN
>D>	AB +	34MG	N020356	005	Jan 02, 2008	Nov	CAHN
>D>	@	40MG	N020356	004	Feb 02, 1995	Nov	CAHN

NITISINONE

CAPSULE;ORAL

ORFADIN

+	SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016	Jun	NEWA
---	----------------	------	---------	-----	--------------	-----	------

SUSPENSION;ORAL

ORFADIN

+	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016	Apr	NEWA
---	----------------	--------	---------	-----	--------------	-----	------

NITRIC OXIDE

GAS;INHALATION

INOMAX

+	MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999	Jan	CAHN
---	-------------------	--------	---------	-----	--------------	-----	------

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN

AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun	CAHN
----	---	-------------------	----------	---------	-----	--	-----	------

NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr	NEWA
----	--	----------------------	----------	---------	-----	--------------	-----	------

AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb	CAHN
----	--	------------------	----------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB		IMPAX LABS INC	50MG	A073671	001	Jan 28, 1993	Aug	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

AB			100MG	A073652	001	Jan 28, 1993	Aug	CAHN
----	--	--	-------	---------	-----	--------------	-----	------

AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb	NEWA
----	--	----------------	------	---------	-----	--------------	-----	------

AB			50MG	A201722	002	Feb 16, 2016	Feb	NEWA
----	--	--	------	---------	-----	--------------	-----	------

AB			100MG	A201722	003	Feb 16, 2016	Feb	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan	CAHN
----	---	---------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	CAHN
-----	--	----------------------	----------	---------	-----	--------------	-----	------

POWDER;SUBLINGUAL

GONITRO

+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	NEWA
---	--------------	--------------	---------	-----	--------------	-----	------

TABLET;SUBLINGUAL

NITROGLYCERIN

AB		DR REDDYS LABS INC	0.3MG	A208191	001	Aug 26, 2016	Aug	NEWA
----	--	--------------------	-------	---------	-----	--------------	-----	------

AB			0.4MG	A208191	002	Aug 26, 2016	Aug	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

AB			0.6MG	A208191	003	Aug 26, 2016	Aug	NEWA
----	--	--	-------	---------	-----	--------------	-----	------

NITROSTAT

AB		PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000	Aug	CFTG
----	--	---------------	-------	---------	-----	--------------	-----	------

AB			0.4MG	N021134	002	May 01, 2000	Aug	CFTG
----	--	--	-------	---------	-----	--------------	-----	------

AB	+		0.6MG	N021134	003	May 01, 2000	Aug	CFTG
----	---	--	-------	---------	-----	--------------	-----	------

NIZATIDINE

SOLUTION;ORAL

NIZATIDINE

+	AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Feb	CRLD
---	---------------	---------	---------	-----	--------------	-----	------



NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION  
NOREPINEPHRINE BITARTRATE

AP CLARIS EQ 1MG BASE/ML A040859 001 Mar 27, 2012 Jan CAHN

NORETHINDRONE

TABLET; ORAL-28  
CAMILA

AB1 MAYNE PHARMA 0.35MG A076177 001 Oct 21, 2002 Aug CAHN

ERRIN

AB2 MAYNE PHARMA 0.35MG A076225 001 Oct 21, 2002 Aug CAHN

INCASSIA

AB1 AUROBINDO PHARMA LTD 0.35MG A207304 001 Sep 23, 2016 Sep NEWA

NOR-QD

AB1 + APIL 0.35MG N017060 001 Jan CAHN

NORETHINDRONE

>A> AB1 ACCORD HLTHCARE 0.35MG A206807 001 Dec 13, 2016 Nov NEWA

AB1 AMNEAL PHARMS 0.35MG A202260 001 Aug 01, 2013 Aug CAHN

AB2 GLENMARK GENERICS 0.35MG A091209 001 Jul 22, 2010 Oct CMS1

NORETHINDRONE ACETATE

TABLET; ORAL  
NORETHINDRONE ACETATE

AB JAI PHARMA LTD 5MG A205278 001 Nov 10, 2016 Oct NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL  
NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC EQ 10MG BASE A074835 001 Jun 30, 1997 Feb CAHN

@ EQ 25MG BASE A074835 002 Jun 30, 1997 Feb CAHN

@ EQ 50MG BASE A074835 003 Jun 30, 1997 Feb CAHN

@ EQ 75MG BASE A074835 004 Jun 30, 1997 Feb CAHN

@ IDT AUSTRALIA LTD EQ 10MG BASE A074054 001 Dec 31, 1992 May CAHN

@ EQ 25MG BASE A074054 002 Dec 31, 1992 May CAHN

@ EQ 50MG BASE A074054 003 Dec 31, 1992 May CAHN

@ EQ 75MG BASE A074054 004 Dec 31, 1992 May CAHN

AB MAYNE PHARMA EQ 10MG BASE A073553 001 Mar 30, 1992 Aug CAHN

AB EQ 25MG BASE A073554 001 Mar 30, 1992 Aug CAHN

AB EQ 50MG BASE A073555 001 Mar 30, 1992 Aug CAHN

AB EQ 75MG BASE A073556 001 Mar 30, 1992 Aug CAHN

NYSTATIN

POWDER; TOPICAL  
NYSTATIN

AT + MAYNE PHARMA INC 100,000 UNITS/GM A065203 001 Jul 15, 2004 Aug CAHN

TABLET; ORAL  
NYSTATIN

AA SUN PHARM INDS 500,000 UNITS A062838 001 Dec 22, 1988 Mar CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT DR REDDYS LABS LTD 100,000 UNITS/GM;0.1% A208326 001 Oct 26, 2016 Oct NEWA

AT GLENMARK PHARMS LTD 100,000 UNITS/GM;0.1% A208136 001 Oct 24, 2016 Oct NEWA

NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM 100,000 UNITS/GM;0.1% A062596 001 Oct 08, 1985 Mar CMS1

OINTMENT; TOPICAL  
MYKACET

AT G AND W LABS INC 100,000 UNITS/GM;0.1% A062733 001 Mar 06, 1987 May CMS1

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT GLENMARK PHARMS LTD 100,000 UNITS/GM;0.1% A208300 001 Jun 23, 2016 Jun NEWA

OBETICHOIC ACID

TABLET; ORAL  
OCALIVA

+ INTERCEPT PHARMS INC 5MG N207999 001 May 27, 2016 May NEWA

10MG N207999 002 May 27, 2016 May NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION  
OCTREOTIDE ACETATE

AP	+	WEST-WARD PHARMS INT	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005	Oct	CAHN
AP	+		EQ 1MG BASE/ML	A076330	002	Apr 08, 2005	Oct	CAHN
		@ WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan	DISC
		@	EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan	DISC
		OCTREOTIDE ACETATE (PRESERVATIVE FREE)						
AP	+	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005	Oct	CAHN
AP	+		EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005	Oct	CAHN
AP	+		EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005	Oct	CAHN
		@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan	DISC
		@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan	DISC
		@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan	DISC
		OCTREOTIDE ACETATE PRESERVATIVE FREE						
		@ WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb	CMS1
		@	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb	CMS1
		@	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb	CMS1

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC  
OFLOXACIN

AT		ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar	CAHN
		SOLUTION/DROPS; OTIC						
		OFLOXACIN						
AT		ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar	CAHN
AT	+	BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb	CRLD

OLANZAPINE

TABLET; ORAL  
OLANZAPINE

AB		AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016	Aug	NEWA
AB			5MG	A206711	002	Aug 30, 2016	Aug	NEWA
AB			7.5MG	A206711	003	Aug 30, 2016	Aug	NEWA
AB			10MG	A206711	004	Aug 30, 2016	Aug	NEWA
AB			15MG	A206711	005	Aug 30, 2016	Aug	NEWA
AB			20MG	A206711	006	Aug 30, 2016	Aug	NEWA
AB		INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb	NEWA
AB			5MG	A203333	002	Mar 15, 2016	Feb	NEWA
AB			7.5MG	A203333	003	Mar 15, 2016	Feb	NEWA
AB			10MG	A203333	004	Mar 15, 2016	Feb	NEWA
AB			15MG	A203333	005	Mar 15, 2016	Feb	NEWA
AB			20MG	A203333	006	Mar 15, 2016	Feb	NEWA
AB		QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan	NEWA
AB			5MG	A204319	002	Jan 27, 2016	Jan	NEWA
AB			7.5MG	A204319	003	Jan 27, 2016	Jan	NEWA
AB			10MG	A204319	004	Jan 27, 2016	Jan	NEWA
AB			15MG	A204319	005	Jan 27, 2016	Jan	NEWA
AB			20MG	A204319	006	Jan 27, 2016	Jan	NEWA
		TABLET, ORALLY DISINTEGRATING; ORAL						
		OLANZAPINE						
AB		INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb	NEWA
AB			10MG	A203456	002	Mar 16, 2016	Feb	NEWA
AB			15MG	A203456	003	Mar 16, 2016	Feb	NEWA
AB			20MG	A203456	004	Mar 16, 2016	Feb	NEWA

OLMESARTAN MEDOXOMIL

TABLET; ORAL  
BENICAR

AB		DAIICHI SANKYO	5MG	N021286	001	Apr 25, 2002	Oct	CFTG
AB			20MG	N021286	003	Apr 25, 2002	Oct	CFTG
AB	+		40MG	N021286	004	Apr 25, 2002	Oct	CFTG
		OLMESARTAN MEDOXOMIL						
AB		MYLAN PHARMS INC	5MG	A078276	001	Oct 26, 2016	Oct	NEWA
AB			20MG	A078276	002	Oct 26, 2016	Oct	NEWA
AB			40MG	A078276	003	Oct 26, 2016	Oct	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar	CAHN
		SPRAY, METERED;NASAL						
		PATANASE						
>D>	AB	+	ALCON PHARMS LTD	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Nov
>A>	AB	+	NOVARTIS PHARMS CORP	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Nov

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL  
OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan	CMS1
----	--	---------------	--	---------	-----	--------------	-----	------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL  
OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar	CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar	CRLD

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL  
OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	20MG;1.1GM	A204228	001	Jul 15, 2016	Jul	NEWA
AB			40MG;1.1GM	A204228	002	Jul 15, 2016	Jul	NEWA
AB		AUROLIFE PHARMA LLC	20MG;1.1GM	A204922	001	Aug 19, 2016	Aug	NEWA
AB			40MG;1.1GM	A204922	002	Aug 19, 2016	Aug	NEWA
AB		DR REDDYS LABS LTD	20MG;1.1GM	A204068	001	Jul 15, 2016	Jul	NEWA
AB			40MG;1.1GM	A204068	002	Jul 15, 2016	Jul	NEWA
>A>	AB		20MG;1.1GM	A207476	001	Dec 06, 2016	Nov	NEWA
>A>	AB		40MG;1.1GM	A207476	002	Dec 06, 2016	Nov	NEWA

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AA		AJANTA PHARMA LTD	20MG/PACKET;1.68GM/PACKET	A205545	001	Jul 27, 2016	Jul	NEWA
AA			40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Jul	NEWA
		ZEGERID						
AA		SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jul	CTEC
AA	+		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jul	CTEC

ONDANSETRON

FILM;ORAL  
ZUPLENZ

MIDATECH PHARMA US

4MG  
8MG

N022524	001	Jul 02, 2010	Jun	CAHN
N022524	002	Jul 02, 2010	Jun	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION  
ONDANSETRON HYDROCHLORIDE

AP	+	CLARIS	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Aug	CRLD
		@ LANNETT	EQ 2MG BASE/ML	A090883	001	Aug 05, 2010	Aug	DISC

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb	NEWA
AP	+	CLARIS	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Aug	CRLD
		ZOFRAN						
		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Aug	DISC
		ZOFRAN PRESERVATIVE FREE						
		@ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Aug	DISC

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

>D>	AA		ROXANE	EQ 4MG BASE/5ML	A076960	001	Dec 26, 2006	Nov
>A>	AA		WEST-WARD PHARMS INT	EQ 4MG BASE/5ML	A076960	001	Dec 26, 2006	Nov

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@ HIKMA INTL PHARMS  
EQ 4MG BASE  
EQ 8MG BASE  
EQ 24MG BASE

A077545	001	Sep 06, 2007	May	CAHN
A077545	002	Sep 06, 2007	May	CAHN
A077545	003	Sep 06, 2007	May	CAHN

ORPHENADRINE CITRATEINJECTABLE; INJECTION  
ORPHENADRINE CITRATE

AP	WEST-WARD PHARMS INT	30MG/ML	A040463	001	Mar 04, 2003	Sep	CAHN
----	----------------------	---------	---------	-----	--------------	-----	------

OSELTAMIVIR PHOSPHATECAPSULE; ORAL  
OSELTAMIVIR PHOSPHATE

AB	NATCO PHARMA LTD	EQ 30MG BASE	A202595	001	Aug 03, 2016	Jul	NEWA
AB		EQ 45MG BASE	A202595	002	Aug 03, 2016	Jul	NEWA
AB		EQ 75MG BASE	A202595	003	Aug 03, 2016	Jul	NEWA
	TAMIFLU						
AB	ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Jul	CFTG
AB		EQ 45MG BASE	N021087	002	Jul 02, 2007	Jul	CFTG
AB	+	EQ 75MG BASE	N021087	001	Oct 27, 1999	Jul	CFTG

OXALIPLATININJECTABLE; IV (INFUSION)  
OXALIPLATIN

AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May	NEWA
AP		50MG/VIAL	A204616	001	May 11, 2016	Apr	NEWA
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May	NEWA
AP		100MG/VIAL	A204616	002	May 11, 2016	Apr	NEWA
	+	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun	CRLD
AP		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May	NEWA
	@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Aug	DISC
	@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Aug	DISC

OXAZEPAMCAPSULE; ORAL  
OXAZEPAM

@	FRONTIDA BIOPHARM	10MG	A071026	002	Aug 10, 1987	Oct	CAHN
@		15MG	A071026	003	Aug 10, 1987	Oct	CAHN
@		30MG	A071026	001	Aug 10, 1987	Oct	CAHN
@	SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar	CAHN
@		15MG	A071026	003	Aug 10, 1987	Mar	CAHN
@		30MG	A071026	001	Aug 10, 1987	Mar	CAHN

TABLET; ORAL

@	FRONTIDA BIOPHARM	15MG	A070683	001	Jan 16, 1987	Jul	CAHN
@	SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jun	CAHN

OXCARBAZEPINESUSPENSION; ORAL  
OXCARBAZEPINE

>D>	AB	ROXANE	300MG/5ML	A201193	001	Oct 03, 2012	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	300MG/5ML	A201193	001	Oct 03, 2012	Nov	CAHN

TABLET; ORAL

		OXCARBAZEPINE						
AB	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jun	CMFD	
AB		300MG	A078005	002	Dec 11, 2007	Jun	CMFD	
AB		600MG	A078005	003	Dec 11, 2007	Jun	CMFD	
>D>	AB	ROXANE	150MG	A077795	001	Oct 09, 2007	Nov	CAHN
>D>	AB		300MG	A077795	002	Oct 09, 2007	Nov	CAHN
>D>	AB		600MG	A077795	003	Oct 09, 2007	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	150MG	A077795	001	Oct 09, 2007	Nov	CAHN
>A>	AB		300MG	A077795	002	Oct 09, 2007	Nov	CAHN
>A>	AB		600MG	A077795	003	Oct 09, 2007	Nov	CAHN

OXICONAZOLE NITRATECREAM; TOPICAL  
OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb	NEWA	
	OXISTAT							
AB	+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb	CFTG



OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL  
KOVANAZE

	+	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016	Jun	NEWA
--	---	------------	-----------------------	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL  
OXYMORPHONE HYDROCHLORIDE

AB		AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr	NEWA
AB			10MG	A204459	002	Apr 26, 2016	Apr	NEWA
>D>	AB	ROXANE	5MG	A090964	001	Sep 27, 2010	Nov	CAHN
>D>	AB		10MG	A090964	002	Sep 27, 2010	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	5MG	A090964	001	Sep 27, 2010	Nov	CAHN
>A>	AB		10MG	A090964	002	Sep 27, 2010	Nov	CAHN

TABLET, EXTENDED RELEASE;ORAL  
OXYMORPHONE HYDROCHLORIDE

>D>	AB	ROXANE	5MG	A200822	002	Jul 15, 2013	Nov	CAHN
>D>	AB		7.5MG	A200822	003	Jul 15, 2013	Nov	CAHN
>D>	AB		10MG	A200822	004	Jul 15, 2013	Nov	CAHN
>D>	AB		15MG	A200822	005	Jul 15, 2013	Nov	CAHN
>D>	AB		20MG	A200822	006	Jul 15, 2013	Nov	CAHN
>D>	AB		30MG	A200822	007	Jul 15, 2013	Nov	CAHN
>D>	AB		40MG	A200822	001	Jul 15, 2013	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	5MG	A200822	002	Jul 15, 2013	Nov	CAHN
>A>	AB		7.5MG	A200822	003	Jul 15, 2013	Nov	CAHN
>A>	AB		10MG	A200822	004	Jul 15, 2013	Nov	CAHN
>A>	AB		15MG	A200822	005	Jul 15, 2013	Nov	CAHN
>A>	AB		20MG	A200822	006	Jul 15, 2013	Nov	CAHN
>A>	AB		30MG	A200822	007	Jul 15, 2013	Nov	CAHN
>A>	AB		40MG	A200822	001	Jul 15, 2013	Nov	CAHN

OXYTOCIN

INJECTABLE;INJECTION  
OXYTOCIN

AP	+	WEST-WARD PHARMS INT	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Oct	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Oct	CAHN

PACLITAXEL

INJECTABLE;INJECTION  
PACLITAXEL

AP		GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Aug	NEWA
AP		SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan	CAHN
AP		WEST-WARD PHARMS INT	6MG/ML	A075190	001	Jan 28, 2002	Oct	CAHN

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
INVEGA SUSTENNA

		JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CRLD
	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar	CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS  
PALONOSETRON HYDROCHLORIDE

AP		DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr	NEWA
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	NEWA

SOLUTION;INTRAVENOUS  
PALONOSETRON HYDROCHLORIDE

		DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar	NEWA
			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar	NEWA
		EXELA PHARMA SCIENCE	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Aug	NEWA

PAMIDRONATE DISODIUMINJECTABLE; INJECTION  
PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan CAHN
AP	WEST-WARD PHARMS INT	30MG/VIAL	A075290	001	Apr 30, 2001	Oct CAHN
AP	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Sep CAHN
AP		90MG/VIAL	A075290	003	Apr 30, 2001	Oct CAHN
AP	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Sep CAHN

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)CAPSULE, DELAYED RELEASE; ORAL  
PERTZYE

	DIGESTIVE CARE INC	15,125USP UNITS; 4,000USP UNITS; 14,375USP UNITS	N022175	003	Oct 06, 2016	Oct NEWA
--	--------------------	--	---------	-----	--------------	----------

PANTOPRAZOLE SODIUMINJECTABLE; IV (INFUSION)  
PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar NEWA
----	----------------------	-------------------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL  
PANTOPRAZOLE SODIUM

AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan NEWA
AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan NEWA

PARICALCITOLCAPSULE; ORAL  
PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN
AB	ECI PHARMS LLC	1MCG	A206710	001	Feb 24, 2016	Oct CAHN
AB		2MCG	A206710	002	Feb 24, 2016	Oct CAHN
AB		4MCG	A206710	003	Feb 24, 2016	Oct CAHN
AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb NEWA
AB		2MCG	A206710	002	Feb 24, 2016	Feb NEWA
AB		4MCG	A206710	003	Feb 24, 2016	Feb NEWA
AB	MARKSANS PHARMA	1MCG	A204948	001	Oct 07, 2016	Sep NEWA
AB		2MCG	A204948	002	Oct 07, 2016	Sep NEWA
AB		4MCG	A204948	003	Oct 07, 2016	Sep NEWA
AB	+	TEVA PHARMS USA	A090829	003	Sep 27, 2013	Aug CRLD

ZEMPLAR  
@ ABBVIE

		4MCG	N021606	003	May 26, 2005	Aug DISC
--	--	------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS  
PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb NEWA
AP		0.005MG/ML (0.005MG/ML)	N207174	002	Feb 04, 2016	Feb NEWA
AP		0.01MG/2ML (0.005MG/ML)	N207174	003	Feb 04, 2016	Feb NEWA
AP	DR REDDYS LABS LTD	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Aug NEWA
AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Aug NEWA
AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Aug NEWA

PAROXETINE HYDROCHLORIDETABLET; ORAL  
PAROXETINE HYDROCHLORIDE

	@ UPSHER-SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004	Oct CAHN
	@	EQ 20MG BASE	A075566	002	Mar 08, 2004	Oct CAHN
	@	EQ 30MG BASE	A075566	003	Mar 08, 2004	Oct CAHN
	@	EQ 40MG BASE	A075566	004	Mar 08, 2004	Oct CAHN

TABLET, EXTENDED RELEASE; ORAL  
PAROXETINE HYDROCHLORIDE

AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE	A204744	001	Jun 10, 2016	May NEWA
AB		EQ 25MG BASE	A204744	002	Jun 10, 2016	May NEWA
AB		EQ 37.5MG BASE	A204744	003	Jun 10, 2016	May NEWA

PAROXETINE MESYLATECAPSULE; ORAL  
BRISDELLE

+	SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Aug CAHN
---	--------------------	---------------	---------	-----	--------------	----------

TABLET;ORAL

PEXEVA								
	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003	Aug	CAHN	
		EQ 20MG BASE	N021299	002	Jul 03, 2003	Aug	CAHN	
		EQ 30MG BASE	N021299	003	Jul 03, 2003	Aug	CAHN	
+		EQ 40MG BASE	N021299	004	Jul 03, 2003	Aug	CAHN	

PENBUTOLOL SULFATE

TABLET;ORAL								
LEVATOL								
@	AUXILIUM PHARMS INC	10MG	N018976	001	Dec 30, 1987	Mar	CAHN	
@		20MG	N018976	004	Jan 05, 1989	Mar	CAHN	
@	AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Aug	CAHN	
@		20MG	N018976	004	Jan 05, 1989	Aug	CAHN	

PENCICLOVIR

CREAM;TOPICAL								
DENA VIR								
+	DENCO ASSET	1%	N020629	001	Sep 24, 1996	Apr	CAIN	

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS								
PENTETATE CALCIUM TRISODIUM								
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Apr	CMFD	
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749	001	Aug 11, 2004	Feb	CAHN	

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS								
PENTETATE ZINC TRISODIUM								
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Apr	CMFD	
@		EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751	001	Aug 11, 2004	Feb	CAHN	

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION								
NEMBUTAL SODIUM								
AP	+	OAK PHARMS	50MG/ML	A083246	001		May	CTEC
PENTOBARBITAL SODIUM								
AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May	NEWA

PENTOSTATIN

INJECTABLE;INJECTION								
PENTOSTATIN								
AP		WEST-WARD PHARMS INT	10MG/VIAL	A077841	001	Aug 07, 2007	Oct	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL								
PENTOXIFYLLINE								
AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar	CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar	DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar	DISC

PERAMPANEL

SUSPENSION;ORAL								
FYCOMPA								
+	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016	Apr	NEWA	

PERINDOPRIL ERBUMINE

TABLET;ORAL								
PERINDOPRIL ERBUMINE								
>D>	AB	ROXANE	2MG	A090072	001	Nov 10, 2009	Nov	CAHN
>D>	AB		4MG	A090072	002	Nov 10, 2009	Nov	CAHN
>D>	AB		8MG	A090072	003	Nov 10, 2009	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	2MG	A090072	001	Nov 10, 2009	Nov	CAHN
>A>	AB		4MG	A090072	002	Nov 10, 2009	Nov	CAHN
>A>	AB		8MG	A090072	003	Nov 10, 2009	Nov	CAHN



PERPHENAZINE

TABLET; ORAL		PERPHENAZINE							
AB	SANDOZ	2MG		A 089685	002	Dec 08, 1988	Sep	CMS1	
AB		4MG		A 089685	003	Dec 08, 1988	Sep	CMS1	
AB	+	16MG		A 089685	004	Dec 08, 1988	Sep	CMS1	
AB	WATSON LABS INC	2MG		A 207582	001	Oct 17, 2016	Oct	NEWA	
AB		4MG		A 207582	002	Oct 17, 2016	Oct	NEWA	
AB		8MG		A 207582	003	Oct 17, 2016	Oct	NEWA	
AB		16MG		A 207582	004	Oct 17, 2016	Oct	NEWA	
AB	WILSHIRE PHARMS INC	2MG		A 205973	001	Dec 17, 2015	Jan	CAHN	
AB		4MG		A 205973	002	Dec 17, 2015	Jan	CAHN	
AB		8MG		A 205973	003	Dec 17, 2015	Jan	CAHN	
AB		16MG		A 205973	004	Dec 17, 2015	Jan	CAHN	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL		SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE							
	@ ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG		N 021105	001	Jun 26, 2001	Jan	CMS1	

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL		PHENOXYBENZAMINE HYDROCHLORIDE							
>D>	AB	ROXANE	10MG	A 201050	001	Jul 16, 2012	Nov	CAHN	
>A>	AB	WEST-WARD PHARMS INT	10MG	A 201050	001	Jul 16, 2012	Nov	CAHN	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL		PHENTERMINE HYDROCHLORIDE							
AA	AUROLIFE PHARMA LLC	15MG		A 204318	001	Nov 09, 2016	Oct	NEWA	
AA		30MG		A 204318	002	Nov 09, 2016	Oct	NEWA	
AA	SUN PHARM INDS	30MG		A 040525	001	Oct 23, 2003	Mar	CAHN	
	@	37.5MG		A 040527	001	Oct 23, 2003	Mar	CAHN	
TABLET; ORAL		LOMAIRA							
	+	AVANTHI INC	8MG	A 203495	001	Sep 12, 2016	Aug	NEWA	
TABLET; ORAL		PHENTERMINE HYDROCHLORIDE							
AA	INGENUS PHARMS NJ	37.5MG		A 091451	001	Sep 21, 2012	Jan	CAHN	
>A>	AA	POLYGEN PHARMS	37.5MG	A 206342	001	Nov 18, 2016	Nov	NEWA	
AA	SUN PHARM INDS	37.5MG		A 040526	001	Oct 23, 2003	Mar	CAHN	
TABLET, ORALLY DISINTEGRATING; ORAL		SUPRENZA							
	@	CITIUS PHARMS	15MG	N 202088	001	Jun 13, 2011	Jun	DISC	
	@		30MG	N 202088	002	Jun 13, 2011	Jun	DISC	
	@		37.5MG	N 202088	003	Mar 27, 2012	Jun	DISC	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL		PHENTERMINE RESIN COMPLEX							
	@	LANNETT HOLDINGS INC	EQ 15MG BASE	A 040872	001	Jul 28, 2011	Aug	DISC	
	@		EQ 30MG BASE	A 040872	002	Jul 28, 2011	Aug	DISC	

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION		PHENTOLAMINE MESYLATE							
AP	WEST-WARD PHARMS INT	5MG/VIAL		A 040235	001	Mar 11, 1998	Sep	CAHN	

PHENYL BUTAZONE

CAPSULE; ORAL		PHENYL BUTAZONE							
	@	SUN PHARM INDS	100MG	A 088994	001	Dec 04, 1985	Mar	CAHN	
TABLET; ORAL		PHENYL BUTAZONE							
	@	SUN PHARM INDS	100MG	A 088863	001	Dec 04, 1985	Mar	CAHN	

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

+ ACADIA PHARMS INC EQ 17MG BASE N207318 001 Apr 29, 2016 Apr NEWA

PINDOLOL

TABLET;ORAL

PINDOLOL

@ IDT AUSTRALIA LTD 5MG A073608 001 Mar 29, 1993 May CAHN  
 @ 10MG A073609 001 Mar 29, 1993 May CAHN  
 AB SUN PHARM INDS 5MG A074063 001 Jan 27, 1994 Mar CAHN  
 AB 10MG A074063 002 Jan 27, 1994 Mar CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB FLAMINGO PHARMS 10MG A207938 001 Sep 09, 2016 Aug NEWA  
 AB 20MG A207938 002 Sep 09, 2016 Aug NEWA  
 AB MYLAN IRELAND LTD 10MG A074116 001 Jun 15, 1993 Aug CAHN  
 AB 20MG A074118 001 Jun 15, 1993 Aug CAHN  
 AB MYLAN PHARMS INC 20MG A074118 001 Jun 15, 1993 Jan CAHN  
 @ SUN PHARM INDS 20MG A073536 001 Mar 12, 1993 Mar CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

+ ALLERGAN SALES LLC 0.5% N020529 001 Mar 13, 1997 Mar CAHN

SOLUTION;TOPICAL

CONDYLOX

AT + ALLERGAN SALES LLC 0.5% N019795 001 Dec 13, 1990 Mar CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

@ MEDA PHARMS

227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT

N018983 010 Jan 31, 1989 May DISC

COLYTE WITH FLAVOR PACKS

AA MEDA PHARMS

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. 84GM/BOT;22.72GM/BOT

N018983 012 Oct 08, 1998 Jul CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP AUROBINDO PHARMA LTD EQ 500,000 UNITS BASE/VIAL A206589 001 Apr 04, 2016 Mar NEWA  
 AP GLAND PHARMA LTD EQ 500,000 UNITS BASE/VIAL A207322 001 Apr 14, 2016 Apr NEWA  
 AP + WEST-WARD PHARMS INT EQ 500,000 UNITS BASE/VIAL A060716 001 Sep CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB GLENMARK PHARMS LTD 10MEQ A202868 001 Jan 19, 2016 Jan NEWA  
 AB KREMERS URBAN PHARMS 8MEQ A204210 001 Mar 28, 2016 Mar NEWA  
 AB 10MEQ A204210 002 Mar 28, 2016 Mar NEWA  
 AB NOVEL LABS INC 8MEQ A204828 001 Aug 16, 2016 Aug NEWA  
 AB 10MEQ A204828 002 Aug 16, 2016 Aug NEWA  
 AB TRIS PHARMA INC 8MEQ A201944 001 Mar 04, 2016 Feb NEWA  
 AB 10MEQ A201944 002 Mar 04, 2016 Feb NEWA

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

+ PHARMA RES SOFTWARE 20MEQ N208019 001 Aug 19, 2015 Jul CRLD

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1 GLENMARK PHARMS LTD 10MEQ A203562 001 Jul 26, 2016 Jul NEWA  
 AB1 20MEQ A203562 002 Jul 26, 2016 Jul NEWA  
 AB2 NOVEL LABS INC 8MEQ A206759 001 Aug 09, 2016 Jul NEWA  
 AB1 10MEQ A206347 001 Jan 21, 2016 Jan NEWA  
 AB2 10MEQ A206759 002 Aug 09, 2016 Jul NEWA  
 AB1 20MEQ A206347 002 Jan 21, 2016 Jan NEWA  
 AB2 SIGMAPHARM LABS LLC 8MEQ A207528 001 Aug 19, 2016 Aug NEWA  
 AB2 10MEQ A207528 002 Aug 19, 2016 Aug NEWA

PRAMIPEXOLE DIHYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr	NEWA
AB		0.75MG	A201963	002	Apr 21, 2016	Apr	NEWA
AB		1.5MG	A201963	003	Apr 21, 2016	Apr	NEWA
AB		2.25MG	A203615	001	Oct 14, 2016	Oct	NEWA
AB		3MG	A201963	004	Apr 21, 2016	Apr	NEWA
AB		4.5MG	A201963	005	Apr 21, 2016	Apr	NEWA
AB	MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun	NEWA
AB		0.75MG	A206156	002	Jun 24, 2016	Jun	NEWA
AB		1.5MG	A206156	003	Jun 24, 2016	Jun	NEWA
AB		2.25MG	A206156	004	Jun 24, 2016	Jun	NEWA
AB		3MG	A206156	005	Jun 24, 2016	Jun	NEWA
AB		4.5MG	A206156	007	Jun 24, 2016	Jun	NEWA
AB	SANDOZ INC	0.375MG	A202353	001	Dec 04, 2014	Jul	CDFR
AB		0.75MG	A202353	002	Dec 04, 2014	Jul	CDFR
AB		1.5MG	A202353	003	Dec 04, 2014	Jul	CDFR
AB		3MG	A202353	004	Dec 04, 2014	Jul	CDFR
AB		4.5MG	A202353	005	Dec 04, 2014	Jul	CDFR

>A> PRASTERONE

&gt;A&gt; INSERT;VAGINAL

&gt;A&gt; INTRAROSA

&gt;A&gt; + ENDOCEUTICS INC 6.5MG N208470 001 Nov 16, 2016 Nov NEWA

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>A> AB	ACCORD HLTHCARE	10MG	A207068	001	Nov 17, 2016	Nov	NEWA
>A> AB		20MG	A207068	002	Nov 17, 2016	Nov	NEWA
>A> AB		40MG	A207068	003	Nov 17, 2016	Nov	NEWA
>A> AB		80MG	A207068	004	Nov 17, 2016	Nov	NEWA
>D> AB	APOTEX	10MG	A076341	001	Oct 23, 2006	Nov	CAHN
>D> AB		20MG	A076341	002	Oct 23, 2006	Nov	CAHN
>D> AB		40MG	A076341	003	Oct 23, 2006	Nov	CAHN
>D> AB		80MG	A076341	004	Dec 28, 2007	Nov	CAHN
>A> AB	APOTEX INC	10MG	A076341	001	Oct 23, 2006	Nov	CAHN
>A> AB		20MG	A076341	002	Oct 23, 2006	Nov	CAHN
>A> AB		40MG	A076341	003	Oct 23, 2006	Nov	CAHN
>A> AB		80MG	A076341	004	Dec 28, 2007	Nov	CAHN
AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar	NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar	DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar	DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar	DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar	DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May	CAHN
	@	EQ 2MG BASE	A072577	001	May 16, 1989	May	CAHN
	@	EQ 5MG BASE	A072578	001	May 16, 1989	May	CAHN
AB	TEVA PHARMS	EQ 1MG BASE	A071745	002	Sep 12, 1988	Sep	CMS1
AB		EQ 2MG BASE	A071745	003	Sep 12, 1988	Sep	CMS1

PREDNISOLONE

TABLET;ORAL

PREDNISOLONE

@ AUROLIFE PHARMA LLC 5MG

A084773 001 Feb CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

OMNIPRED

>D> AB	ALCON	1%	N017469	001		Nov	CAHN
>A> AB	NOVARTIS PHARMS CORP	1%	N017469	001		Nov	CAHN

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL  
 PREDNISOLONE SODIUM PHOSPHATE

AA + WOCKHARDT EQ 15MG BASE/5ML A 076895 001 Oct 04, 2004 Mar CRLD

PREDNISONE

SOLUTION;ORAL  
 PREDNISONE

>D> + ROXANE 5MG/5ML A 088703 001 Nov 08, 1984 Nov CAHN  
 >A> + WEST-WARD PHARMS INT 5MG/5ML A 088703 001 Nov 08, 1984 Nov CAHN

PREDNISONE INTENSOL

>D> + ROXANE 5MG/ML A 088810 001 Feb 20, 1985 Nov CAHN  
 >A> + WEST-WARD PHARMS INT 5MG/ML A 088810 001 Feb 20, 1985 Nov CAHN

TABLET;ORAL

PREDNISONE

@ AUROLIFE PHARMA LLC 5MG A 084774 001 Mar CAHN  
 @ 10MG A 089983 001 Jan 12, 1989 Mar CAHN  
 @ 20MG A 085813 001 Mar CAHN  
 @ 50MG A 089984 001 Jan 12, 1989 Mar CAHN  
 AB DELCOR ASSET CORP 5MG A 080292 001 Mar CAHN  
 AB 10MG A 088832 001 Dec 04, 1985 Mar CAHN  
 AB 20MG A 083677 001 Mar CAHN  
 >D> AB + ROXANE 1MG A 087800 001 Apr 22, 1982 Nov CAHN  
 >D> AB + 2.5MG A 087801 001 Apr 22, 1982 Nov CAHN  
 >D> AB + 5MG A 080352 001 Nov CAHN  
 >D> AB + 10MG A 084122 001 Nov CAHN  
 >D> AB + 20MG A 087342 001 Nov CAHN  
 >D> AB + 50MG A 084283 001 Nov CAHN  
 AB SUN PHARM INDS 20MG A 089247 001 Dec 04, 1985 Mar CAHN  
 @ 50MG A 086596 001 Jun CAHN  
 >A> AB + WEST-WARD PHARMS INT 1MG A 087800 001 Apr 22, 1982 Nov CAHN  
 >A> AB + 2.5MG A 087801 001 Apr 22, 1982 Nov CAHN  
 >A> AB + 5MG A 080352 001 Nov CAHN  
 >A> AB + 10MG A 084122 001 Nov CAHN  
 >A> AB + 20MG A 087342 001 Nov CAHN  
 >A> AB + 50MG A 084283 001 Nov CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL  
 PRIMAQUINE PHOSPHATE

AB INGENUS PHARMS NJ EQ 15MG BASE A 206043 001 Jun 23, 2016 Jun NEWA

PRIMIDONE

TABLET;ORAL  
 PRIMIDONE

AB FRONTIDA BIOPHARM 50MG A 040626 001 Sep 29, 2005 Jul CAHN  
 AB 250MG A 040626 002 Sep 29, 2005 Jul CAHN  
 @ HIKMA INTL PHARMS 50MG A 040667 001 Jul 27, 2006 Jul CAHN  
 AB 250MG A 040667 002 Jul 27, 2006 Jul CAHN  
 @ IMPAX LABS 50MG A 040717 001 Feb 12, 2008 Mar DISC  
 @ 250MG A 040717 002 Feb 12, 2008 Mar DISC  
 AB SUN PHARM INDS 50MG A 040626 001 Sep 29, 2005 Mar CAHN  
 AB 250MG A 040626 002 Sep 29, 2005 Mar CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL  
 PROCAINAMIDE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 375MG A 089220 001 Jul 01, 1986 May CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION  
 PROCHLORPERAZINE EDISYLATE

@ AMPHASTAR PHARMS INC EQ 5MG BASE/ML A 040540 001 May 28, 2004 Aug DISC  
 AP EQ 5MG BASE/ML A 040540 001 May 28, 2004 Jun CAHN  
 AP + EMCURE PHARMS LTD EQ 5MG BASE/ML A 204147 001 Oct 15, 2013 Oct CTEC  
 + EQ 5MG BASE/ML A 204147 001 Oct 15, 2013 Sep CTEC  
 AP + EQ 5MG BASE/ML A 204147 001 Oct 15, 2013 Aug CRLD  
 AP EUROHLTH INTL SARL EQ 5MG BASE/ML A 040540 001 May 28, 2004 Apr CAHN  
 AP EQ 5MG BASE/ML A 089903 001 Aug 29, 1989 Oct CMFD  
 @ EQ 5MG BASE/ML A 089903 001 Aug 29, 1989 Aug DISC

PROGESTERONE

CAPSULE; ORAL		PROGESTERONE					
AB	BIONPHARMA INC	100MG	A200900 001	Aug 16, 2013	Jan	CAHN	
AB		200MG	A200900 002	Aug 16, 2013	Jan	CAHN	
PROMETRIUM							
AB	VIRTUS PHARMS	100MG	N019781 001	May 14, 1998	Jun	CAHN	
AB	+	200MG	N019781 002	Oct 15, 1999	Jun	CAHN	
	@	300MG	N019781 003	Oct 15, 1999	Jun	CAHN	
GEL; VAGINAL		CRINONE					
	+	ALLERGAN SALES LLC	4%	N020701 001	Jul 31, 1997	Apr	CAHN
	+		8%	N020701 002	Jul 31, 1997	Apr	CAHN
INJECTABLE; INJECTION		PROGESTERONE					
AO	+	ALLERGAN SALES LLC	50MG/ML	N017362 002		Apr	CAHN

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETHAZINE HYDROCHLORIDE					
AA	NOSTRUM LABS INC	6.25MG/5ML	A040891 001	Mar 13, 2009	Feb	CAHN	
TABLET; ORAL		PROMETHAZINE HYDROCHLORIDE					
	@	IMPAX LABS	12.5MG	A040724 001	Feb 12, 2008	Mar	DISC
	@		25MG	A040724 002	Feb 12, 2008	Mar	DISC
	@		50MG	A040791 001	May 20, 2008	Mar	DISC
>A>	AB	KVK TECH	50MG	A040712 003	Jul 31, 2006	Nov	CMS1
	@	SUN PHARM INDS	12.5MG	A084555 001		Mar	CAHN
	@		25MG	A084554 001		Mar	CAHN
	@		50MG	A084557 001		Jan	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		PROPAFENONE HYDROCHLORIDE					
AB	MYLAN PHARMS INC	225MG	A203803 001	Apr 29, 2016	Apr	NEWA	
AB		325MG	A203803 002	Apr 29, 2016	Apr	NEWA	
AB		425MG	A203803 003	Apr 29, 2016	Apr	NEWA	
TABLET; ORAL		PROPAFENONE HYDROCHLORIDE					
AB	ORION CORP ORION	150MG	A202445 001	May 11, 2016	Apr	NEWA	
AB		225MG	A202445 002	May 11, 2016	Apr	NEWA	
AB		300MG	A202445 003	May 11, 2016	Apr	NEWA	
AB	SUN PHARM INDS	150MG	A075998 001	Nov 29, 2001	Mar	CAHN	
AB		225MG	A075998 002	Nov 29, 2001	Mar	CAHN	
AB		300MG	A075998 003	Nov 29, 2001	Mar	CAHN	

PROPANTHELINE BROMIDE

TABLET; ORAL		PROPANTHELINE BROMIDE					
>D>	@	ROXANE	7.5MG	A080927 001		Nov	CAHN
>D>	+		15MG	A080927 002		Nov	CAHN
>A>	@	WEST-WARD PHARMS INT	7.5MG	A080927 001		Nov	CAHN
>A>	+		15MG	A080927 002		Nov	CAHN

PROPOFOL

INJECTABLE; INJECTION		PROPOFOL					
AB	SAGENT PHARMS	10MG/ML	A075102 001	Jan 04, 1999	Aug	CAHN	
	@	WEST-WARD PHARMS INT	10MG/ML	A074848 001	Apr 19, 2005	Sep	CAHN

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL		INDERAL LA					
AB	ANI PHARMS INC	60MG	N018553 004	Mar 18, 1987	Apr	CAHN	
AB		80MG	N018553 002	Apr 19, 1983	Apr	CAHN	
AB		120MG	N018553 003	Apr 19, 1983	Apr	CAHN	
AB	+	160MG	N018553 001	Apr 19, 1983	Apr	CAHN	
PROPRANOLOL HYDROCHLORIDE							
BX	UPSHER SMITH	60MG	A078311 001	Mar 06, 2009	Jun	CMFD	
	@		60MG	A078311 001	Mar 06, 2009	May	DISC
BX		60MG	A078311 001	Mar 06, 2009	Mar	CTEC	

<u>CAPSULE, EXTENDED RELEASE;ORAL</u>									
<u>PROPRANOLOL HYDROCHLORIDE</u>									
BX			80MG		A078311	002	Mar 06, 2009	Jun	CMFD
	@		80MG		A078311	002	Mar 06, 2009	May	DISC
BX			80MG		A078311	002	Mar 06, 2009	Mar	CTEC
BX			120MG		A078311	003	Mar 06, 2009	Jun	CMFD
	@		120MG		A078311	003	Mar 06, 2009	May	DISC
BX			120MG		A078311	003	Mar 06, 2009	Mar	CTEC
BX			160MG		A078311	004	Mar 06, 2009	Jun	CMFD
	@		160MG		A078311	004	Mar 06, 2009	May	DISC
BX			160MG		A078311	004	Mar 06, 2009	Mar	CTEC
<u>INJECTABLE;INJECTION</u>									
<u>PROPRANOLOL HYDROCHLORIDE</u>									
AP		AMPHASTAR PHARMS INC	1MG/ML		A075792	001	Aug 29, 2000	Jun	CAHN
AP		EUROHLTH INTL SARL	1MG/ML		A075792	001	Aug 29, 2000	Apr	CAHN
	@	SANDOZ	1MG/ML		A076400	001	Feb 26, 2003	Mar	DISC
<u>SOLUTION;ORAL</u>									
<u>PROPRANOLOL HYDROCHLORIDE</u>									
>D>	+	ROXANE	20MG/5ML		A070979	001	May 15, 1987	Nov	CAHN
>D>	+		40MG/5ML		A070690	001	May 15, 1987	Nov	CAHN
>A>	+	WEST-WARD PHARMS INT	20MG/5ML		A070979	001	May 15, 1987	Nov	CAHN
>A>	+		40MG/5ML		A070690	001	May 15, 1987	Nov	CAHN
<u>TABLET;ORAL</u>									
<u>PROPRANOLOL HYDROCHLORIDE</u>									
	@	FRONTIDA BIOPHARM	10MG		A070319	001	Oct 22, 1985	Jul	CAHN
	@		20MG		A070320	001	Oct 22, 1985	Jul	CAHN
	@		40MG		A070103	001	Oct 22, 1985	Jul	CAHN
	@		60MG		A070321	001	Sep 24, 1986	Jul	CAHN
	@		80MG		A070322	001	Aug 04, 1986	Jul	CAHN
AB		IMPAX LABS INC	10MG		A071972	001	Apr 06, 1988	Aug	CAHN
AB			20MG		A071973	001	Apr 06, 1988	Aug	CAHN
AB			40MG		A071974	001	Apr 06, 1988	Aug	CAHN
AB			60MG		A071975	001	Apr 06, 1988	Aug	CAHN
AB	+		80MG		A071976	001	Apr 06, 1988	Aug	CAHN
	@	SUN PHARM INDS	10MG		A070319	001	Oct 22, 1985	Mar	CAHN
	@		20MG		A070320	001	Oct 22, 1985	Mar	CAHN
	@		40MG		A070103	001	Oct 22, 1985	Mar	CAHN
	@		60MG		A070321	001	Sep 24, 1986	Jun	CAHN
	@		80MG		A070322	001	Aug 04, 1986	Mar	CAHN
<u>PROPYLTHIOURACIL</u>									
<u>TABLET;ORAL</u>									
<u>PROPYLTHIOURACIL</u>									
	@	HIKMA INTL PHARMS	50MG		A080154	001		Jul	CAHN
	@	SUN PHARM INDS	50MG		A083982	001		Mar	CAHN
<u>PROTRIPTYLINE HYDROCHLORIDE</u>									
<u>TABLET;ORAL</u>									
<u>PROTRIPTYLINE HYDROCHLORIDE</u>									
>D>	AB		5MG		A078913	001	Sep 16, 2008	Nov	CAHN
>D>	AB		10MG		A078913	002	Sep 16, 2008	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	5MG		A078913	001	Sep 16, 2008	Nov	CAHN
>A>	AB		10MG		A078913	002	Sep 16, 2008	Nov	CAHN
<u>PYRIDOSTIGMINE BROMIDE</u>									
<u>TABLET, EXTENDED RELEASE;ORAL</u>									
<u>PYRIDOSTIGMINE BROMIDE</u>									
AB		ALVOGEN MALTA	180MG		A204737	001	Jun 26, 2015	Jan	CAHN
<u>PYRIDOXINE HYDROCHLORIDE</u>									
<u>INJECTABLE;INJECTION</u>									
<u>PYRIDOXINE HYDROCHLORIDE</u>									
AP	+	FRESENIUS KABI USA	100MG/ML		A080618	001		Jul	CTEC
AP		MYLAN INSTITUTIONAL	100MG/ML		A204879	001	Jul 14, 2016	Jul	NEWA
<u>QUAZEPAM</u>									
<u>TABLET;ORAL</u>									
<u>DORAL</u>									
	@	CUTIS HEALTH LLC	7.5MG		N018708	003	Feb 26, 1987	Mar	CAHN
	+		15MG		N018708	001	Dec 27, 1985	Apr	CMFD
	@		15MG		N018708	001	Dec 27, 1985	Mar	CAHN

QUETIAPINE FUMARATE

## TABLET;ORAL

## QUETIAPINE FUMARATE

	@	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr	DISC
	@		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr	DISC
	@		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr	DISC
	@		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr	DISC
	@		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr	DISC
	@		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr	DISC
	@		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr	DISC
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May	NEWA
AB			EQ 50MG BASE	A203359	002	May 17, 2016	May	NEWA
AB			EQ 100MG BASE	A203359	003	May 17, 2016	May	NEWA
AB			EQ 200MG BASE	A203359	004	May 17, 2016	May	NEWA
AB			EQ 300MG BASE	A203359	005	May 17, 2016	May	NEWA
AB			EQ 400MG BASE	A203359	006	May 17, 2016	May	NEWA
>D>	AB	ROXANE	EQ 25MG BASE	A090120	001	Mar 27, 2012	Nov	CAHN
>D>	AB		EQ 50MG BASE	A090749	001	Mar 27, 2012	Nov	CAHN
>D>	AB		EQ 100MG BASE	A090749	002	Mar 27, 2012	Nov	CAHN
>D>	AB		EQ 200MG BASE	A090749	003	Mar 27, 2012	Nov	CAHN
>D>	AB		EQ 300MG BASE	A090749	004	Mar 27, 2012	Nov	CAHN
>D>	AB		EQ 400MG BASE	A090749	005	Mar 27, 2012	Nov	CAHN
AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb	NEWA
AB			EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb	NEWA
AB			EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb	NEWA
AB			EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb	NEWA
AB			EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb	NEWA
AB			EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb	NEWA
>A>	AB	WEST-WARD PHARMS INT	EQ 25MG BASE	A090120	001	Mar 27, 2012	Nov	CAHN
>A>	AB		EQ 50MG BASE	A090749	001	Mar 27, 2012	Nov	CAHN
>A>	AB		EQ 100MG BASE	A090749	002	Mar 27, 2012	Nov	CAHN
>A>	AB		EQ 200MG BASE	A090749	003	Mar 27, 2012	Nov	CAHN
>A>	AB		EQ 300MG BASE	A090749	004	Mar 27, 2012	Nov	CAHN
>A>	AB		EQ 400MG BASE	A090749	005	Mar 27, 2012	Nov	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	EQ 400MG BASE	A090681	004	Nov 01, 2016	Oct	NEWA
AB		SEROQUEL XR						
AB		ASTRAZENECA	EQ 400MG BASE	N022047	004	May 17, 2007	Oct	CFTG

QUINAPRIL HYDROCHLORIDE

## TABLET;ORAL

## QUINAPRIL HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan	DISC
	@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan	DISC
	@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan	DISC
	@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan	DISC
AB		PRINSTON INC	EQ 5MG BASE	A205823	001	Sep 15, 2016	Sep	NEWA
AB			EQ 10MG BASE	A205823	002	Sep 15, 2016	Sep	NEWA
AB			EQ 20MG BASE	A205823	003	Sep 15, 2016	Sep	NEWA
AB			EQ 40MG BASE	A205823	004	Sep 15, 2016	Sep	NEWA

QUINIDINE GLUCONATE

## TABLET, EXTENDED RELEASE;ORAL

## QUINIDINE GLUCONATE

BX	+	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar	CAHN
		SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar	CAHN

QUINIDINE SULFATE

## TABLET;ORAL

## QUINIDINE SULFATE

AB		SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun	CAHN
AB			200MG	A081030	001	Apr 14, 1989	Mar	CAHN
AB			300MG	A081031	001	Apr 14, 1989	Mar	CAHN

QUININE SULFATE

## CAPSULE;ORAL

## QUALAQUIN

AB	+	SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun	CAHN
----	---	----------------	-------	---------	-----	--------------	-----	------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL  
ACIPHEX SPRINKLE

	FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun	CAHN
+		10MG	N204736	002	Mar 26, 2013	Jun	CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL  
RALOXIFENE HYDROCHLORIDE

AB	AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar	NEWA
AB	GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar	NEWA
AB	SCIEGEN PHARMS INC	60MG	A206384	001	Oct 12, 2016	Oct	NEWA

RAMELTEON

TABLET;ORAL  
RAMELTEON

AB	DR REDDYS LABS INTL	8MG	A091693	001	Jul 26, 2013	Aug	CAHN
----	---------------------	-----	---------	-----	--------------	-----	------

RAMIPRIL

CAPSULE;ORAL  
RAMIPRIL

>D>	AB	ROXANE	1.25MG	A077900	001	Jun 18, 2008	Nov	CAHN
>D>	AB		2.5MG	A077900	002	Jun 18, 2008	Nov	CAHN
>D>	AB		5MG	A077900	003	Jun 18, 2008	Nov	CAHN
>D>	AB		10MG	A077900	004	Jun 18, 2008	Nov	CAHN
		@ SANDOZ	1.25MG	A077514	001	Jun 18, 2008	Aug	DISC
		@	2.5MG	A077514	002	Jun 18, 2008	Aug	DISC
		@	5MG	A077514	003	Jun 18, 2008	Aug	DISC
		@	10MG	A077514	004	Jun 18, 2008	Aug	DISC
>A>	AB	WEST-WARD PHARMS INT	1.25MG	A077900	001	Jun 18, 2008	Nov	CAHN
>A>	AB		2.5MG	A077900	002	Jun 18, 2008	Nov	CAHN
>A>	AB		5MG	A077900	003	Jun 18, 2008	Nov	CAHN
>A>	AB		10MG	A077900	004	Jun 18, 2008	Nov	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION  
RANITIDINE HYDROCHLORIDE

AP	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May	NEWA
AP	WEST-WARD PHARMS INT	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Sep	CAHN
AP		EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	Oct	CAHN
AP	ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May	CPOT
		ZANTAC					
AP	+ IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN
		ZANTAC IN PLASTIC CONTAINER					
		@ IGI LABS INC	N019593	002	Sep 27, 1991	Jan	CAHN
		@	N019593	001	Dec 17, 1986	Jan	CAHN

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar	CAHN
	@ WOCHKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr	DISC
	@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr	DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	STRIDES PHARMA	EQ 150MG BASE	A205512	001	Aug 22, 2016	Aug	NEWA
AB		EQ 300MG BASE	A205512	002	Aug 22, 2016	Aug	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB	ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb	NEWA
AB		EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb	NEWA
>D>	@ WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Nov	CMFD
>A>	AB	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	Nov	CMFD
>D>	@	EQ 1MG BASE	A201823	002	Jul 01, 2013	Nov	CMFD
>A>	AB	EQ 1MG BASE	A201823	002	Jul 01, 2013	Nov	CMFD



RESERPINE

TABLET; ORAL

RESERPINE

@	HIKMA INTL PHARMS	0.1MG	A 080975	001		Feb	CAHN
@		0.25MG	A 080975	002		Feb	CAHN
@		1MG	A 080975	003		Feb	CAHN

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	AQUA PHARMS LLC	1%	N 022055	001	Apr 12, 2007	Jan	CAHN
---	-----------------	----	----------	-----	--------------	-----	------

RIBAVIRIN

FOR SOLUTION; INHALATION

RIBAVIRIN

AN	NAVINTA LLC	6GM/VIAL	A 207366	001	Oct 06, 2016	Sep	NEWA
AN	+ VALEANT PHARM INTL	6GM/VIAL	N 018859	001	Dec 31, 1985	Sep	CFTG

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+	AVEDRO INC	0.146%	N 203324	001	Apr 15, 2016	Apr	NEWA
	PHOTREXA VISCOUS IN DEXTRAN 20%						
+	AVEDRO INC	0.146%	N 203324	002	Apr 15, 2016	Jun	CMS1
	PHOTREXA VISCOUS IN DEXTROSE 20%						
+	AVEDRO INC	0.146%	N 203324	002	Apr 15, 2016	Apr	NEWA

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP	HIKMA PHARMS	600MG/VIAL	A 205039	001	Mar 03, 2016	Feb	NEWA
AP	WATSON PHARMS INC	600MG/VIAL	A 206736	001	Jan 19, 2016	Jan	NEWA

RILUZOLE

TABLET; ORAL

RILUZOLE

AB	ALKEM LABS LTD	50MG	A 204048	001	Mar 30, 2016	Mar	NEWA
----	----------------	------	----------	-----	--------------	-----	------

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

@	ALCON	1%	N 020474	001	Dec 30, 1994	Jun	DISC
---	-------	----	----------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	APIL	5MG	N 020835	002	Apr 14, 2000	Jan	CAHN
AB		30MG	N 020835	001	Mar 27, 1998	Jan	CAHN
AB	+	35MG	N 020835	003	May 25, 2002	Jan	CAHN
	@	75MG	N 020835	004	Apr 16, 2007	Jan	CAHN
AB	+	150MG	N 020835	005	Apr 22, 2008	Jan	CAHN

RISEDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	150MG	A 206768	001	Oct 21, 2016	Oct	NEWA
>A>	AB MACLEODS PHARMS LTD	35MG	A 203533	003	Nov 29, 2016	Nov	NEWA

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+ APIL	35MG	N 022560	001	Oct 08, 2010	Jan	CAHN
----	--------	------	----------	-----	--------------	-----	------

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

>D>	AA AUROBINDO PHARMA	1MG/ML	A 078452	001	Sep 04, 2009	Nov	CAHN
>A>	AA LIFESTAR PHARMA	1MG/ML	A 078452	001	Sep 04, 2009	Nov	CAHN
>D>	AA ROXANE	1MG/ML	A 076904	001	Jul 29, 2009	Nov	CAHN
	@ SILARX PHARMS INC	1MG/ML	A 202386	001	Jan 12, 2015	Aug	DISC
>A>	AA WEST-WARD PHARMS INT	1MG/ML	A 076904	001	Jul 29, 2009	Nov	CAHN
	@ WOCKHARDT	1MG/ML	A 078744	001	Oct 08, 2009	Apr	DISC

RITONAVIR

TABLET;ORAL

RITONAVIR

>D>	AB	ROXANE	100MG	A202573	001	Jan 15, 2015	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	100MG	A202573	001	Jan 15, 2015	Nov	CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan	CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan	CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

AB	+ NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan	CRLD
AB	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar	NEWA
AB		EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar	NEWA
AB		EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar	NEWA
AB		EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar	NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb	NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb	NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan	CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

>D>	AB	ROXANE	EQ 0.25MG BASE	A077852	001	May 05, 2008	Nov	CAHN
>D>	AB		EQ 0.5MG BASE	A077852	002	May 05, 2008	Nov	CAHN
>D>	AB		EQ 1MG BASE	A077852	003	May 05, 2008	Nov	CAHN
>D>	AB		EQ 2MG BASE	A077852	004	May 05, 2008	Nov	CAHN
>D>	AB		EQ 3MG BASE	A077852	005	May 05, 2008	Nov	CAHN
>D>	AB		EQ 4MG BASE	A077852	006	May 05, 2008	Nov	CAHN
>D>	AB		EQ 5MG BASE	A077852	007	May 19, 2008	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	EQ 0.25MG BASE	A077852	001	May 05, 2008	Nov	CAHN
>A>	AB		EQ 0.5MG BASE	A077852	002	May 05, 2008	Nov	CAHN
>A>	AB		EQ 1MG BASE	A077852	003	May 05, 2008	Nov	CAHN
>A>	AB		EQ 2MG BASE	A077852	004	May 05, 2008	Nov	CAHN
>A>	AB		EQ 3MG BASE	A077852	005	May 05, 2008	Nov	CAHN
>A>	AB		EQ 4MG BASE	A077852	006	May 05, 2008	Nov	CAHN
>A>	AB		EQ 5MG BASE	A077852	007	May 19, 2008	Nov	CAHN

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar	NEWA
----	-----------	--------	---------	-----	--------------	-----	------

SOLUTION;INJECTION

NAROPIN

	@ FRESSENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May	DISC
		50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May	NEWA
AP		20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May	CMS1
AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar	CDFR
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar	NEWA
	@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr	DISC
		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr	NEWA
AP		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun	CFTG
		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May	CMS1
		100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar	CDFR
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar	NEWA
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar	CDFR
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar	NEWA
AP		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun	CFTG
		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar	NEWA
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar	NEWA
		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar	NEWA

SOLUTION; INJECTION  
NAROPIN

500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr	CMS1
500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar	NEWA
1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr	CMS1
1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar	NEWA

ROPIVACAINE HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun	NEWA
AP		100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun	NEWA
AP		100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun	NEWA
AP		150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun	NEWA
AP		150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun	NEWA
AP		200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun	NEWA
AP		200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun	NEWA
AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar	CDFR
AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar	NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar	CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar	CDFR

ROSUVASTATIN CALCIUM

TABLET; ORAL  
CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr	CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr	CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr	CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG
ROSUVASTATIN CALCIUM							
AB	ACCORD HLTHCARE INC	5MG	A206434	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A206434	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A206434	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A206434	004	Oct 31, 2016	Oct	NEWA
AB	APOTEX INC	5MG	A079145	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079145	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079145	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079145	004	Jul 19, 2016	Jul	NEWA
AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079170	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079170	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079170	004	Jul 19, 2016	Jul	NEWA
AB	BIOCON LTD	5MG	A207752	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207752	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A207752	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207752	004	Oct 31, 2016	Oct	NEWA
>A>	AB	CADILA PHARMS LTD	A207453	001	Nov 23, 2016	Nov	NEWA
>A>	AB		A207453	002	Nov 23, 2016	Nov	NEWA
>A>	AB		A207453	003	Nov 23, 2016	Nov	NEWA
>A>	AB		A207453	004	Nov 23, 2016	Nov	NEWA
AB	CHANGZHOU PHARM	5MG	A207408	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207408	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A207408	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207408	004	Oct 31, 2016	Oct	NEWA
AB	GLENMARK PHARMS	5MG	A079172	001	Jul 19, 2016	Sep	CAHN
AB		10MG	A079172	002	Jul 19, 2016	Sep	CAHN
AB		20MG	A079172	003	Jul 19, 2016	Sep	CAHN
AB		40MG	A079172	004	Jul 19, 2016	Sep	CAHN
AB	GLENMARK PHARMS LTD	5MG	A079172	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079172	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079172	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079172	004	Jul 19, 2016	Jul	NEWA
AB	HETERO LABS LTD V	5MG	A207616	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207616	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A207616	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207616	004	Oct 31, 2016	Oct	NEWA
AB	JUBILANT GENERICS	5MG	A207062	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A207062	002	Oct 31, 2016	Oct	NEWA

## TABLET;ORAL

## ROSUVASTATIN CALCIUM

AB		20MG	A207062	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A207062	004	Oct 31, 2016	Oct	NEWA
AB	MYLAN PHARMS INC	5MG	A079161	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079161	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079161	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079161	004	Jul 19, 2016	Jul	NEWA
AB	PAR PHARM INC	5MG	A079168	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079168	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079168	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079168	004	Jul 19, 2016	Jul	NEWA
AB	SANDOZ INC	5MG	A079171	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079171	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079171	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079171	004	Jul 19, 2016	Jul	NEWA
AB	SUN PHARMA GLOBAL	5MG	A079169	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079169	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079169	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079169	004	Jul 19, 2016	Jul	NEWA
AB	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul	NEWA
AB		10MG	A079166	002	Jul 19, 2016	Jul	NEWA
AB		20MG	A079166	003	Jul 19, 2016	Jul	NEWA
AB		40MG	A079166	004	Jul 19, 2016	Jul	NEWA
AB	TORRENT PHARMS LLC	5MG	A201619	001	Oct 31, 2016	Oct	NEWA
AB		10MG	A201619	002	Oct 31, 2016	Oct	NEWA
AB		20MG	A201619	003	Oct 31, 2016	Oct	NEWA
AB		40MG	A201619	004	Oct 31, 2016	Oct	NEWA
AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
AB		10MG	A079167	002	Apr 29, 2016	Apr	NEWA
AB		20MG	A079167	003	Apr 29, 2016	Apr	NEWA
AB		40MG	A079167	004	Apr 29, 2016	Apr	NEWA

RUBIDIUM CHLORIDE RB-82

## SOLUTION;INTRAVENOUS

## RUBY-FILL

## JUBILANT DRAXIMAGE

N/A

N202153 001 Sep 30, 2016 Sep NEWA

RUFINAMIDE

## TABLET;ORAL

## BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May	CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May	CFTG
AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May	NEWA
AB		400MG	A205075	002	May 16, 2016	May	NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May	NEWA
AB		400MG	A205095	002	May 16, 2016	May	NEWA
>D>	AB	ROXANE	A204988	001	May 16, 2016	Nov	CAHN
AB		200MG	A204988	001	May 16, 2016	May	NEWA
>D>	AB	400MG	A204988	002	May 16, 2016	Nov	CAHN
AB		400MG	A204988	002	May 16, 2016	May	NEWA
>A>	AB	WEST-WARD PHARMS INT	A204988	001	May 16, 2016	Nov	CAHN
>A>	AB	400MG	A204988	002	May 16, 2016	Nov	CAHN

SCOPOLAMINE

## FILM, EXTENDED RELEASE;TRANSDERMAL

## TRANSDERM SCOP

## GLAXOSMITHKLINE CON

1MG/72HR

N017874 001

May CAHN

SECOBARBITAL SODIUM

## CAPSULE;ORAL

## SECONAL SODIUM

## VALEANT PHARMS NORTH

50MG

A086101 001 Oct 03, 1983

Aug CAHN

## +

100MG

A086101 002 Oct 03, 1983

Aug CAHN

SERTRALINE HYDROCHLORIDE

## TABLET;ORAL

## SERTRALINE HYDROCHLORIDE

## @ FRONTIDA BIOPHARM

EQ 25MG BASE

A077818 001 Feb 06, 2007

Jul CAHN

## @

EQ 50MG BASE

A077818 002 Feb 06, 2007

Jul CAHN

## @

EQ 100MG BASE

A077818 003 Feb 06, 2007

Jul CAHN

## @ SUN PHARM INDS

EQ 25MG BASE

A077818 001 Feb 06, 2007

Mar CAHN

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	EQ 50MG BASE	A077818	002	Feb 06, 2007	Mar	CAHN
@	EQ 100MG BASE	A077818	003	Feb 06, 2007	Mar	CAHN

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB	@	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	DISC
		RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun	NEWA
	@	TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	DISC
			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	NEWA
	@		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	DISC
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	NEWA
	@		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	DISC
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr	CAHN
		8MG	N022206	002	Oct 08, 2008	Apr	CAHN

SIMVASTATIN

SUSPENSION;ORAL

SIMVASTATIN

	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr	NEWA
+		40MG/5ML	N206679	002	Apr 21, 2016	Apr	NEWA

TABLET;ORAL

SIMVASTATIN

	@	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb	DISC
	@		10MG	A076285	002	Dec 20, 2006	Feb	DISC
	@		20MG	A076285	003	Dec 20, 2006	Feb	DISC
	@		40MG	A076285	004	Dec 20, 2006	Feb	DISC
	@		80MG	A076285	005	Jun 23, 2006	Feb	DISC

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)

AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb	CFTG
		SODIUM PHENYLACETATE AND SODIUM BENZOATE						
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb	NEWA
AP		NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016	Jul	NEWA

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

	HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb	NEWA
--	-------------	-----------	---------	-----	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	HOSPIRA	450MG/100ML	N018090	001		Aug	CRLD
		SODIUM CHLORIDE 0.9%						
		B BRAUN	900MG/10ML	N019635	005	Aug 11, 2016	Aug	NEWA
		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May	NEWA
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER						
	+	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983	Aug	CRLD

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May	NEWA
AP		ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

JUBILANT DRAXIMAGE

0.009-0.1mCi

N021305 006 May 19, 2005 Mar CMS1

@

2-200mCi

N021305 004 Nov 18, 2004 Mar CMS1

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

NITROPRESS

>D> + HOSPIRA 25MG/ML A071961 001 Aug 01, 1988 Nov CTEC

>A> AP + 25MG/ML A071961 001 Aug 01, 1988 Nov CTEC

SODIUM NITROPRUSSIDE

>A> AP NAMIGEN LLC 25MG/ML A207426 001 Dec 08, 2016 Nov NEWA

SODIUM PHENYL BUTYRATE

POWDER;ORAL

BUPHENYL

AB + HORIZON PHARMA INC 3GM/TEASPOONFUL N020573 001 Apr 30, 1996 Mar CAHN

SODIUM PHENYL BUTYRATE

AB PAR PHARM 3GM/TEASPOONFUL A203918 001 Jun 15, 2016 Jun NEWA

TABLET;ORAL

BUPHENYL

AB + HORIZON PHARMA INC 500MG N020572 001 May 13, 1996 Mar CAHN

SODIUM PHENYL BUTYRATE

>D> AB AMPOLGEN 500MG A090910 001 Nov 18, 2011 Nov CAHN

>A> AB FERA PHARMS LLC 500MG A090910 001 Nov 18, 2011 Nov CAHN

AB PAR PHARM 500MG A204395 001 Apr 15, 2016 Apr NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA BELCHER PHARMS LLC 454GM/BOT A205727 001 Feb 23, 2016 Feb NEWA

AA INVATECH PHARMA 454GM/BOT A206815 001 Feb 18, 2016 Feb NEWA

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D> AA ROXANE 15GM/60ML A089049 001 Nov 17, 1986 Nov CAHN

>A> AA WEST-WARD PHARMS INT 15GM/60ML A089049 001 Nov 17, 1986 Nov CAHN

SOFOBUVIR; VELPATASVIR

TABLET;ORAL

EPCLUSA

+ GILEAD SCIENCES INC 400MG;100MG N208341 001 Jun 28, 2016 Jun NEWA

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

AB1 BEXIMCO PHARMS USA 80MG A207428 001 Oct 21, 2016 Oct NEWA

AB1 120MG A207428 002 Oct 21, 2016 Oct NEWA

AB1 160MG A207428 003 Oct 21, 2016 Oct NEWA

@ IMPAX PHARMS 80MG A075663 001 Nov 07, 2000 Mar DISC

@ 120MG A075663 002 Nov 07, 2000 Mar DISC

@ 160MG A075663 003 Nov 07, 2000 Mar DISC

@ 240MG A075663 004 Nov 07, 2000 Mar DISC

@ SUN PHARM INDS 80MG A075515 001 Oct 15, 2001 Mar CAHN

@ 80MG A076576 001 Apr 08, 2004 Mar CAHN

@ 120MG A075515 004 Oct 15, 2001 Mar CAHN

@ 120MG A076576 002 Apr 08, 2004 Mar CAHN

@ 160MG A075515 002 Oct 15, 2001 Mar CAHN

@ 160MG A076576 003 Apr 08, 2004 Mar CAHN

@ 240MG A075515 003 Oct 15, 2001 Mar CAHN

AB1 UPSHER-SMITH LABS 80MG A075366 001 May 01, 2000 Oct CAHN

AB1 120MG A075366 002 May 01, 2000 Oct CAHN

AB1 160MG A075366 003 May 01, 2000 Oct CAHN

AB1 240MG A075366 004 May 01, 2000 Oct CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB ACCORD HLTHCARE INC 25MG A203512 001 Sep 19, 2016 Sep NEWA

AB 50MG A203512 002 Sep 19, 2016 Sep NEWA

AB 100MG A203512 003 Sep 19, 2016 Sep NEWA

<u>TABLET; ORAL</u>							
SPIRONOLACTONE							
AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar	CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar	CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar	CAHN
<u>SUCRALFATE</u>							
TABLET; ORAL							
SUCRALFATE							
AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan	CAHN
<u>SUFENTANIL CITRATE</u>							
INJECTABLE; INJECTION							
SUFENTANIL CITRATE							
AP	WEST-WARD PHARMS INT	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Oct	CAHN
<u>SUGAMMADEX SODIUM</u>							
SOLUTION; INTRAVENOUS							
BRIDION							
	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan	CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan	CPOT
<u>SULCONAZOLE NITRATE</u>							
SOLUTION; TOPICAL							
EXELDERM							
+	SUN PHARM INDS LTD	1%	N018738	001	Aug 30, 1985	Oct	CAHN
<u>SULFAMETHOXAZOLE</u>							
TABLET; ORAL							
SULFAMETHOXAZOLE							
	@ AUROLIFE PHARMA LLC	500MG	A085844	001		Feb	CAHN
<u>SULFAMETHOXAZOLE; TRIMETHOPRIM</u>							
INJECTABLE; INJECTION							
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
	@ WEST-WARD PHARMS INT	80MG/ML; 16MG/ML	A070627	001	Dec 29, 1987	Oct	CAHN
	@	80MG/ML; 16MG/ML	A070628	001	Dec 29, 1987	Oct	CAHN
SUSPENSION; ORAL							
BACTRIM							
	@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	001		Jun	CAHN
	BACTRIM PEDIATRIC						
	@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	002		Jun	CAHN
TABLET; ORAL							
BACTRIM							
AB	SUN PHARM INDS	400MG; 80MG	N017377	001		Mar	CAHN
BACTRIM DS							
AB	+ SUN PHARM INDS	800MG; 160MG	N017377	002		Mar	CAHN
SULFAMETHOXAZOLE AND TRIMETHOPRIM							
AB	SUN PHARM INDS	800MG; 160MG	A071017	001	Aug 25, 1986	Mar	CAHN
<u>SULFASALAZINE</u>							
TABLET; ORAL							
SULFASALAZINE							
	@ SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987	Mar	CAHN
<u>SULFISOXAZOLE</u>							
TABLET; ORAL							
SULFISOXAZOLE							
	@ AUROLIFE PHARMA LLC	500MG	A085628	001		Feb	CAHN
<u>SULINDAC</u>							
TABLET; ORAL							
SULINDAC							
AB	SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991	Mar	CAHN
AB		200MG	A072051	001	Apr 17, 1991	Mar	CAHN

SUMATRIPTAN

		SPRAY;NASAL							
		IMITREX							
AB	+	GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb	CFTG	
AB	+		20MG/SPRAY	N020626	003	Aug 26, 1997	Feb	CFTG	
		SUMATRIPTAN							
AB		LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb	NEWA	
AB			20MG/SPRAY	A204841	002	Feb 19, 2016	Feb	NEWA	

SUMATRIPTAN SUCCINATE

		INJECTABLE;SUBCUTANEOUS							
		ALSUMA							
		@ MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Sep	DISC	
		POWDER;INHALATION							
		ONZETRA XSAIL							
	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan	NEWA	
		SOLUTION;SUBCUTANEOUS							
		ZEMBRACE SYMTOUCH							
		DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan	NEWA	

TACROLIMUS

		OINTMENT;TOPICAL							
		PROTOPIC							
AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun	CAHN	
AB	+		0.1%	N050777	002	Dec 08, 2000	Jun	CAHN	

TAMOXIFEN CITRATE

		SOLUTION;ORAL							
		SOLTAMOX							
		MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005	Jan	CAHN	
		TABLET;ORAL							
		TAMOXIFEN CITRATE							
		@ ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003	Jan	DISC	
		@	EQ 20MG BASE	A076179	002	Feb 20, 2003	Jan	DISC	
AB		MAYNE PHARMA	EQ 10MG BASE	A075797	001	Feb 20, 2003	Aug	CAHN	
AB	+		EQ 20MG BASE	A074858	001	Feb 20, 2003	Aug	CAHN	

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

		SOLUTION;INTRAVENOUS							
		ULTRA-TECHNEKOW FM							
	+	MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan	CAHN	
	@		0.25-3 CI/GENERATOR	N017243	002		Jan	CAHN	

TECHNETIUM TC-99M SUCCIMER KIT

		INJECTABLE;INJECTION							
		MPI DMSA KIDNEY REAGENT							
	@	GE HEALTHCARE	N/A	N017944	001	May 18, 1982	Aug	DISC	

TEGASEROD MALEATE

		TABLET;ORAL							
		ZELNORM							
	@	US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jan	CAHN	
	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Jan	CAHN	

TELITHROMYCIN

		TABLET;ORAL							
		KETEK							
	@	SANOVI AVENTIS US	300MG	N021144	002	Feb 09, 2005	Mar	DISC	
	@		400MG	N021144	001	Apr 01, 2004	Mar	DISC	

TELMISARTAN

		TABLET;ORAL							
		TELMISARTAN							
AB		HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Apr	NEWA	
AB			40MG	A205901	002	Apr 22, 2016	Apr	NEWA	
AB			80MG	A205901	003	Apr 22, 2016	Apr	NEWA	
AB		JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Aug	NEWA	
AB			40MG	A204164	002	Aug 22, 2016	Aug	NEWA	
AB			80MG	A204164	003	Aug 22, 2016	Aug	NEWA	



TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

AB	AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	May	NEWA
AB		15MG	A203482	002	May 23, 2016	May	NEWA
AB		22.5MG	A203482	003	May 23, 2016	May	NEWA
AB		30MG	A203482	004	May 23, 2016	May	NEWA
AB	SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009	Mar	CAHN
	@	15MG	A071174	001	Jul 10, 1986	Mar	CAHN
AB		22.5MG	A071175	002	Sep 14, 2009	Mar	CAHN
	@	30MG	A071175	001	Jul 10, 1986	Mar	CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB	AMERIGEN PHARMS LTD	5MG	A203490	001	Jul 13, 2016	Jul	NEWA	
AB		20MG	A203490	002	Jul 13, 2016	Jul	NEWA	
AB		100MG	A203490	003	Jul 13, 2016	Jul	NEWA	
AB		140MG	A203490	004	Jul 13, 2016	Jul	NEWA	
AB		180MG	A203490	005	Jul 13, 2016	Jul	NEWA	
AB		250MG	A203490	006	Jul 13, 2016	Jul	NEWA	
>A>	AB	CHEMI SPA	5MG	A204639	001	Nov 23, 2016	Nov	NEWA
>A>	AB		20MG	A204639	002	Nov 23, 2016	Nov	NEWA
>A>	AB		100MG	A204639	003	Nov 23, 2016	Nov	NEWA
>A>	AB		140MG	A204639	004	Nov 23, 2016	Nov	NEWA
>A>	AB		180MG	A204639	005	Nov 23, 2016	Nov	NEWA
>A>	AB		250MG	A204639	006	Nov 23, 2016	Nov	NEWA
AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA	
AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA	
AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA	
AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA	
AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA	
AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA	
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA	
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA	
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA	
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA	
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA	
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA	
AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun	NEWA	
AB		20MG	A205227	002	Jun 29, 2016	Jun	NEWA	
AB		100MG	A205227	003	Jun 29, 2016	Jun	NEWA	
AB		140MG	A205227	004	Jun 29, 2016	Jun	NEWA	
AB		180MG	A205227	005	Jun 29, 2016	Jun	NEWA	
AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA	

>A> TENOFOVIR ALAFENAMIDE FUMARATE

>A> TABLET;ORAL

>A> VEMLIDY

>A>	+	GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016	Nov	NEWA
-----	---	---------------------	--------------	---------	-----	--------------	-----	------

TERBUTALINE SULFATE

INJECTABLE;INJECTION

BRETHINE

@ PHARMACARE

TERBUTALINE SULFATE

AP	+	AMPHASTAR PHARMS INC	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
AP	+	EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN

TABLET;ORAL

BRETHINE

>D>	@	LEHIGH VALLEY	2.5MG	N017849	001		Nov	CAHN
>D>	@		5MG	N017849	002		Nov	CAHN
>A>	@	PHARMACARE LTD	2.5MG	N017849	001		Nov	CAHN
>A>	@		5MG	N017849	002		Nov	CAHN
		TERBUTALINE SULFATE						
	@	IMPAX LABS	2.5MG	A075877	001	Jun 26, 2001	Mar	DISC
	@		5MG	A075877	002	Jun 26, 2001	Mar	DISC
		LANNETT	2.5MG	A077152	001	Mar 25, 2005	Mar	CTEC
			5MG	A077152	002	Mar 25, 2005	Mar	CTEC

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL  
ANDRODERM

+	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN
@		2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN
+		4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN
@		5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN

GEL, METERED;NASAL  
NATESTO

	AYTU BIOSCIENCE INC	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	CAHN
--	---------------------	-------------------------	---------	-----	--------------	-----	------

PELLET;IMPLANTATION  
TESTOPEL

+	AUXILIUM PHARMS INC	75MG	A080911	001		Mar	CAHN
---	---------------------	------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;BUCCAL  
STRIANT

+	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

TETRABENAZINE

TABLET;ORAL  
TETRABENAZINE

AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL  
TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr	CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr	CMFD
	@ IDT AUSTRALIA LTD	250MG	A061471	001		Aug	CAHN
	@ SUN PHARM INDS	250MG	A060736	001		Mar	CAHN
	@	500MG	A060736	002		Mar	CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL  
THEO-24

	AUXILIUM PHARMS INC	200MG	A087943	001	Aug 22, 1983	Mar	CAHN
		300MG	A087944	001	Aug 22, 1983	Mar	CAHN
+		400MG	A081034	001	Feb 28, 1992	Mar	CAHN
	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Jul	CAHN
		300MG	A087944	001	Aug 22, 1983	Jul	CAHN

SOLUTION, ELIXIR;ORAL  
ELIXOPHYLLIN

+	NOSTRUM LABS INC	80MG/15ML	A085186	001		Jan	CAHN
---	------------------	-----------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL  
THEOCHRON

AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan	CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan	CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan	CAHN

THEOPHYLLINE

AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan	CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	Jan	CAHN
AB	RHODES PHARMS	400MG	A087571	001	Sep 01, 1982	Aug	CTNA

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL  
THIORIDAZINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar	CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar	CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar	CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar	CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar	CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar	CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar	CAHN

THIOTEPA

INJECTABLE;INJECTION  
THIOTEPA

+	WEST-WARD PHARMS INT	15MG/VIAL	A075547	001	Apr 02, 2001	Sep	CAHN
---	----------------------	-----------	---------	-----	--------------	-----	------

THIOTHIXENE

## CAPSULE;ORAL

## NAVANE

@	PFIZER	1MG	N016584	001		Aug	DISC
@		2MG	N016584	002		Aug	DISC
@		5MG	N016584	003		Aug	DISC
@		10MG	N016584	004		Aug	DISC

## THIOTHIXENE

## MYLAN

		1MG	A071093	002	Jun 23, 1987	Aug	CTEC
		2MG	A071093	003	Jun 23, 1987	Aug	CTEC
+		5MG	A071093	004	Jun 23, 1987	Aug	CRLD
		10MG	A071093	001	Jun 23, 1987	Aug	CTEC
@	SANDOZ	1MG	A071529	002	Jun 24, 1987	Sep	CMS1
@		2MG	A071529	003	Jun 24, 1987	Sep	CMS1
@		5MG	A071529	001	Jun 24, 1987	Mar	DISC
@		10MG	A071529	004	Jun 24, 1987	Sep	CMS1

TIMOLOL

## SOLUTION/DROPS;OPHTHALMIC

## BETIMOL

AT	+	OAK PHARMS INC	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Sep	CFTG
AT	+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Sep	CFTG

## TIMOLOL

AT		AKORN	EQ 0.25% BASE	A205309	001	Sep 30, 2016	Sep	NEWA
AT			EQ 0.5% BASE	A205309	002	Sep 30, 2016	Sep	NEWA

TINIDAZOLE

## TABLET;ORAL

## TINIDAZOLE

>D>	AB	ROXANE	250MG	A201172	001	Apr 30, 2012	Nov	CAHN
>D>	AB		500MG	A201172	002	Apr 30, 2012	Nov	CAHN
	BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr	CTEC
	BX		500MG	A202489	002	Oct 09, 2013	Apr	CTEC
>A>	AB	WEST-WARD PHARMS INT	250MG	A201172	001	Apr 30, 2012	Nov	CAHN
>A>	AB		500MG	A201172	002	Apr 30, 2012	Nov	CAHN

TIROFIBAN HYDROCHLORIDE

## SOLUTION;INJECTION

## AGGRASTAT

+	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016	Aug	NEWA
---	----------	---	---------	-----	--------------	-----	------

TOBRAMYCIN

## SOLUTION;INHALATION

## BETHKIS

+	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Sep	CRLD
---	----------------	-----------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

## INJECTABLE;INJECTION

## TOBRAMYCIN SULFATE

AP		CLARIS	EQ 40MG BASE/ML	A206965	001	Jul 01, 2016	Jun	NEWA
	@	WEST-WARD PHARMS INT	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991	Oct	CAHN
	@		EQ 10MG BASE/ML	A063128	001	Nov 27, 1991	Oct	CAHN
AP			EQ 40MG BASE/ML	A063117	001	Apr 26, 1991	Oct	CAHN
	@		EQ 40MG BASE/ML	A063118	001	Jul 29, 1991	Oct	CAHN
	@		EQ 40MG BASE/ML	A063127	001	Nov 27, 1991	Oct	CAHN

TOFACITINIB CITRATE

## TABLET, EXTENDED RELEASE;ORAL

## XELJANZ XR

+	PFIZER INC	EQ 11MG BASE	N208246	001	Feb 23, 2016	Feb	NEWA
---	------------	--------------	---------	-----	--------------	-----	------

TOLAZAMIDE

## TABLET;ORAL

## TOLAZAMIDE

@	SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
@		250MG	A071358	001	Jul 16, 1987	Mar	CAHN
@		500MG	A071359	001	Jul 16, 1987	Mar	CAHN

TOLMETIN SODIUM

	CAPSULE;ORAL							
	TOLMETIN SODIUM							
	@ SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar	CAHN	
	TABLET;ORAL							
	TOLMETIN SODIUM							
AB	SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar	CAHN	

TOLTERODINE TARTRATE

	CAPSULE, EXTENDED RELEASE;ORAL							
	TOLTERODINE TARTRATE							
>A>	AB	TEVA PHARMS USA	2MG	A079141	001	Nov 22, 2016	Nov	NEWA
>A>	AB		4MG	A079141	002	Nov 22, 2016	Nov	NEWA

TOPIRAMATE

	TABLET;ORAL							
	TOPIRAMATE							
	@ ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr	DISC	
AB		25MG	A078637	001	Feb 27, 2013	Jan	CAHN	
	@	50MG	A078637	002	Feb 27, 2013	Apr	DISC	
AB		50MG	A078637	002	Feb 27, 2013	Jan	CAHN	
	@	100MG	A078637	003	Feb 27, 2013	Apr	DISC	
AB		100MG	A078637	003	Feb 27, 2013	Jan	CAHN	
	@	200MG	A078637	004	Feb 27, 2013	Apr	DISC	
AB		200MG	A078637	004	Feb 27, 2013	Jan	CAHN	

TOPOTECAN HYDROCHLORIDE

	INJECTABLE;INJECTION							
	TOPOTECAN HYDROCHLORIDE							
>A>	AP	INGENUS PHARMS LLC	EQ 4MG BASE/VIAL	A206962	001	Nov 30, 2016	Nov	NEWA

TORSEMIDE

	INJECTABLE;INJECTION							
	TORSEMIDE							
	@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Oct	CAHN	
	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Oct	CAHN	
	TABLET;ORAL							
	TORSEMIDE							
>D>	AB	ROXANE	5MG	A076943	001	Mar 01, 2005	Nov	CAHN
>D>	AB		10MG	A076943	002	Mar 01, 2005	Nov	CAHN
>D>	AB		20MG	A076943	003	Mar 01, 2005	Nov	CAHN
>A>	AB	WEST-WARD PHARMS INT	5MG	A076943	001	Mar 01, 2005	Nov	CAHN
>A>	AB		10MG	A076943	002	Mar 01, 2005	Nov	CAHN
>A>	AB		20MG	A076943	003	Mar 01, 2005	Nov	CAHN

TRAMADOL HYDROCHLORIDE

	TABLET;ORAL							
	TRAMADOL HYDROCHLORIDE							
AB	ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar	CAHN	
AB	SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar	CAHN	
	TABLET, EXTENDED RELEASE;ORAL							
	TRAMADOL HYDROCHLORIDE							
AB1	+ LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Oct	CRLD	
	ULTRAM ER							
	@ VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Oct	DISC	
AB1	+	100MG	N021692	001	Sep 08, 2005	Mar	CAHN	
	@	200MG	N021692	002	Sep 08, 2005	Oct	DISC	
AB1		200MG	N021692	002	Sep 08, 2005	Mar	CAHN	
	@	300MG	N021692	003	Sep 08, 2005	Oct	DISC	
AB1		300MG	N021692	003	Sep 08, 2005	Mar	CAHN	

TRANEXAMIC ACID

	INJECTABLE;INJECTION							
	TRANEXAMIC ACID							
AP	AKORN	100MG/ML	A206634	001	Jun 09, 2016	May	NEWA	
AP	AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan	NEWA	
AP	NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb	NEWA	
	TABLET;ORAL							
	TRANEXAMIC ACID							
	@ AMERIGEN PHARMS LTD	650MG	A203256	001	Jul 25, 2016	Jul	DISC	
AB		650MG	A203256	001	Jul 25, 2016	Jul	NEWA	

TRAZODONE HYDROCHLORIDE

TABLET;ORAL		TRAZODONE HYDROCHLORIDE							
	@ AUROLIFE PHARMA LLC	50MG		A 072484	001	Apr 30, 1990	Feb	CAHN	
AB	SUN PHARM INDS	50MG		A 073137	002	Mar 24, 1993	Mar	CAHN	
AB		100MG		A 073137	001	Mar 24, 1993	Mar	CAHN	
AB		150MG		A 073137	003	Dec 22, 1995	Mar	CAHN	

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL		ORENITRAM							
	UNITED THERAP	EQ 5MG BASE		N 203496	005	Oct 07, 2016	Oct	NEWA	

TRETINOIN

CREAM;TOPICAL		TRETINOIN							
	+ ALLERGAN SALES LLC	0.0375%		A 090098	001	Mar 22, 2010	Jul	CAHN	
		0.075%		A 202209	001	Oct 11, 2012	Jul	CAHN	
AB	ELAN PHARMA INTL LTD	0.025%		A 075264	001	Dec 24, 1998	Feb	CAHN	
AB1		0.05%		A 075265	001	Dec 24, 1998	Feb	CAHN	
AB		0.1%		A 075213	001	Dec 24, 1998	Feb	CAHN	
AB	PERRIGO PHARMA INTL	0.025%		A 075264	001	Dec 24, 1998	Jul	CAHN	
AB1		0.05%		A 075265	001	Dec 24, 1998	Jul	CAHN	
AB		0.1%		A 075213	001	Dec 24, 1998	Jul	CAHN	
GEL;TOPICAL		TRETINOIN							
AB	ELAN PHARMA INTL LTD	0.01%		A 075589	001	Jun 11, 2002	Feb	CAHN	
AB		0.025%		A 075529	001	Feb 22, 2000	Feb	CAHN	
AB	PERRIGO PHARMA INTL	0.01%		A 075589	001	Jun 11, 2002	Jul	CAHN	
AB		0.025%		A 075529	001	Feb 22, 2000	Jul	CAHN	

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL		KENALOG							
>D>	@ DELCOR ASSET CORP	0.025%		N 011601	003		Nov	CMFD	
>D>	@	0.1%		N 011601	006		Nov	CMFD	
OTIC;TOPICAL		TRIAMCINOLONE ACETONIDE							
>A>	AT DELCOR ASSET CORP	0.025%		N 011601	003		Nov	CMFD	
>A>	AT	0.1%		N 011601	006		Nov	CMFD	
AT	GLENMARK PHARMS LTD	0.1%		A 207117	001	Aug 05, 2016	Jul	NEWA	
LOTION;TOPICAL		TRIAMCINOLONE ACETONIDE							
AT	TELIGENT PHARMA INC	0.025%		A 204608	001	Jul 07, 2016	Jun	NEWA	
AT		0.1%		A 204606	001	Jul 07, 2016	Jun	NEWA	
OINTMENT;TOPICAL		TRIAMCINOLONE ACETONIDE							
AT	GLENMARK PHARMS LTD	0.5%		A 206379	001	Jul 22, 2016	Jul	NEWA	
AT	TELIGENT PHARMA INC	0.1%		A 205373	001	May 13, 2016	May	NEWA	
SPRAY;TOPICAL		KENALOG							
AT	+ RANBAXY LABS LTD	0.147MG/GM		N 012104	001		Jul	CAHN	
OTIC;TOPICAL		TRIAMCINOLONE ACETONIDE							
>A>	AT AKORN	0.147MG/GM		A 207094	001	Dec 07, 2016	Nov	NEWA	
SPRAY, METERED;NASAL		TRIAMCINOLONE ACETONIDE							
	@ TEVA PHARMS	0.055MG/SPRAY		A 078104	001	Jul 30, 2009	Oct	DISC	

TRIAZOLAM

TABLET;ORAL		TRIAZOLAM							
>D>	AB ROXANE	0.125MG		A 074224	001	Jun 01, 1994	Nov	CAHN	
>D>	AB	0.25MG		A 074224	002	Jun 01, 1994	Nov	CAHN	
>A>	AB WEST-WARD PHARMS INT	0.125MG		A 074224	001	Jun 01, 1994	Nov	CAHN	
>A>	AB	0.25MG		A 074224	002	Jun 01, 1994	Nov	CAHN	

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL  
 TRIMETHOBENZAMIDE HYDROCHLORIDE  
 AB SUN PHARM INDS 300MG A076570 001 Aug 28, 2003 Mar CAHN

TRIMETHOPRIM

TABLET;ORAL  
 TRIMETHOPRIM  
 AB + MAYNE PHARMA 100MG N018679 001 Jul 30, 1982 Aug CAHN  
 @ SUN PHARM INDS 100MG A070494 001 Jan 22, 1986 Jun CAHN  
 @ 200MG A070495 001 Sep 24, 1986 Mar CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL  
 PRIMSOL  
 + AYTU BIOSCIENCE INC EQ 50MG BASE/5ML N074973 001 Jan 24, 2000 Jun CAHN  
 @ AYTU PHARMS EQ 25MG BASE/5ML N074374 001 Jun 23, 1995 Jun CMS2  
 @ EQ 25MG BASE/5ML N074374 001 Jun 23, 1995 Jan CAHN  
 + EQ 50MG BASE/5ML N074973 001 Jan 24, 2000 Jan CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL  
 TRIMIPRAMINE MALEATE  
 AB CROSSMEDIKA SA EQ 25MG BASE A208127 001 Apr 15, 2016 Apr NEWA  
 AB EQ 50MG BASE A208127 002 Apr 15, 2016 Apr NEWA  
 AB EQ 100MG BASE A208127 003 Apr 15, 2016 Apr NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR  
 TRELSTAR  
 + ALLERGAN SALES LLC EQ 3.75MG BASE/VIAL N020715 001 Jun 15, 2000 Apr CAHN  
 + EQ 11.25MG BASE/VIAL N021288 001 Jun 29, 2001 Apr CAHN  
 + EQ 22.5MG BASE/VIAL N022437 001 Mar 10, 2010 Apr CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
 TROSPIUM CHLORIDE  
 AB + ACTAVIS LABS FL INC 60MG A091289 001 Oct 12, 2012 Aug CRLD  
 @ SANDOZ INC 60MG A091635 001 Apr 29, 2015 Apr DISC  
 @ UPSHER-SMITH LABS 60MG A091635 001 Apr 29, 2015 Oct CAHN  
 TABLET;ORAL  
 TROSPIUM CHLORIDE  
 AB + GLENMARK GENERICS 20MG A091575 001 Aug 13, 2010 Aug CRLD  
 AB HERITAGE PHARMS INC 20MG A204945 001 Aug 30, 2016 Aug NEWA  
 AB INVAGEN PHARMS 20MG A091688 001 Aug 23, 2016 Aug NEWA

URSODIOL

CAPSULE;ORAL  
 ACTIGALL  
 @ ALLERGAN SALES LLC 150MG N019594 001 Dec 31, 1987 Mar CAHN  
 AB + 300MG N019594 002 Dec 31, 1987 Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL  
 VALACYCLOVIR HYDROCHLORIDE  
 >D> AB ROXANE EQ 500MG BASE A078656 001 May 24, 2010 Nov CAHN  
 >D> AB EQ 1GM BASE A078656 002 May 24, 2010 Nov CAHN  
 >A> AB WEST-WARD PHARMS INT EQ 500MG BASE A078656 001 May 24, 2010 Nov CAHN  
 >A> AB EQ 1GM BASE A078656 002 May 24, 2010 Nov CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL  
 VALCYTE  
 AB + HOFFMANN LA ROCHE 50MG/ML N022257 001 Aug 28, 2009 Jul CFTG  
 VALGANCICLOVIR HYDROCHLORIDE  
 AB ACTAVIS LABS FL INC 50MG/ML A205220 001 Jul 18, 2016 Jul NEWA  
 TABLET;ORAL  
 VALGANCICLOVIR HYDROCHLORIDE  
 AB AUROBINDO PHARMA LTD EQ 450MG BASE A204750 001 Mar 31, 2016 Mar NEWA  
 AB HETERO LABS LTD V EQ 450MG BASE A205166 001 Mar 18, 2016 Mar NEWA

VALPROATE SODIUMINJECTABLE; INJECTION  
VALPROATE SODIUM

AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A 076295	001	Nov 14, 2002	Jun	CAHN
AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A 076295	001	Nov 14, 2002	Apr	CAHN

VALPROIC ACID

CAPSULE; ORAL

AB	BIONPHARMA INC	250MG	A 073484	001	Jun 29, 1993	Jan	CAHN
----	----------------	-------	----------	-----	--------------	-----	------

SYRUP; ORAL

AA	NOSTRUM LABS INC	250MG/5ML	A 090517	001	May 28, 2010	Mar	CAHN
----	------------------	-----------	----------	-----	--------------	-----	------

VALSARTAN

TABLET; ORAL

AB	MACLEODS PHARMS LTD	40MG	A 202696	001	Sep 16, 2016	Sep	NEWA
AB		80MG	A 202696	002	Sep 16, 2016	Sep	NEWA
AB		160MG	A 202696	003	Sep 16, 2016	Sep	NEWA
AB		320MG	A 202696	004	Sep 16, 2016	Sep	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOLED

	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A 062682	001	Jul 22, 1986	Oct	CAHN
	@	EQ 1GM BASE/VIAL	A 062682	002	Mar 30, 1988	Oct	CAHN
	@	EQ 2GM BASE/VIAL	A 062682	003	May 11, 1988	Oct	CAHN
	@	EQ 5GM BASE/VIAL	A 062682	004	May 11, 1988	Oct	CAHN
	@	EQ 10GM BASE/VIAL	A 062682	005	May 11, 1988	Oct	CAHN

VANCOMYCIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A 065401	001	Jun 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A 065401	002	Jun 30, 2008	May	CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A 205780	001	Mar 31, 2016	Mar	NEWA
AP		EQ 1GM BASE/VIAL	A 205780	002	Mar 31, 2016	Mar	NEWA
AP		EQ 5GM BASE/VIAL	A 205779	001	Mar 29, 2016	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A 205779	002	Mar 29, 2016	Mar	NEWA
AP	CFT PHARMS LLC	EQ 5GM BASE/VIAL	A 204125	001	Dec 28, 2015	Jul	CAHN
AP		EQ 10GM BASE/VIAL	A 204125	002	Dec 28, 2015	Jul	CAHN
AP		EQ 500MG BASE/VIAL	A 204107	001	Dec 28, 2015	Jul	CAHN
AP		EQ 1GM BASE/VIAL	A 204107	002	Dec 28, 2015	Jul	CAHN
AP	FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A 062663	005	Aug 17, 2016	Aug	NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A 205694	001	Jan 21, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A 205694	002	Jan 21, 2016	Jan	NEWA
	@ WEST-WARD PHARMS INT	EQ 500MG BASE/VIAL	A 062879	001	Aug 02, 1988	Oct	CAHN
	@	EQ 1GM BASE/VIAL	A 062879	002	Aug 02, 1988	Oct	CAHN

VANDETANIB

TABLET; ORAL

CAPRELSA

	GENZYME CORP	100MG	N 022405	001	Apr 06, 2011	Jun	CAHN
+		300MG	N 022405	002	Apr 06, 2011	Jun	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	GLAND PHARMA LTD	10MG/VIAL	A 205390	001	May 26, 2016	May	NEWA
AP		20MG/VIAL	A 205390	002	May 26, 2016	May	NEWA
AP	SAGENT PHARMS	10MG/VIAL	A 078274	001	Dec 29, 2008	Jan	CAHN
AP		20MG/VIAL	A 078274	002	Dec 29, 2008	Jan	CAHN

VENETOCLAX

TABLET; ORAL

VENCLEXTA

	ABBVIE INC	10MG	N 208573	001	Apr 11, 2016	Apr	NEWA
		50MG	N 208573	002	Apr 11, 2016	Apr	NEWA
+		100MG	N 208573	003	Apr 11, 2016	Apr	NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS							
VERAPAMIL HYDROCHLORIDE							
AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr	CMFD
TABLET; ORAL							
CALAN							
	@ GD SEARLE LLC	40MG	N018817	003	Feb 23, 1988	Sep	DISC
VERAPAMIL HYDROCHLORIDE							
	@ SUN PHARM INDS	80MG	A071489	002	Jan 13, 1988	Jun	CAHN
	@	120MG	A071489	001	Jan 13, 1988	Jun	CAHN
TABLET, EXTENDED RELEASE; ORAL							
VERAPAMIL HYDROCHLORIDE							
AB	+ GLENMARK GENERICS	180MG	A090700	002	Aug 03, 2011	Aug	CRLD

VINBLASTINE SULFATE

INJECTABLE; INJECTION							
VINBLASTINE SULFATE							
+	WEST-WARD PHARMS INT	10MG/VIAL	A089395	001	Apr 09, 1987	Oct	CAHN

VORAPAXAR SULFATE

TABLET; ORAL							
ZONTIVITY							
+	ARALEZ PHARMS	EQ 2.08MG BASE	N204886	001	May 08, 2014	Sep	CAHN

VORICONAZOLE

FOR SUSPENSION; ORAL							
VORICONAZOLE							
AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar	NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May	NEWA
INJECTABLE; IV (INFUSION)							
VORICONAZOLE							
AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar	NEWA
TABLET; ORAL							
VORICONAZOLE							
AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May	NEWA
AB		200MG	A206181	002	May 24, 2016	May	NEWA
>A>	AB AKORN	50MG	A207049	001	Sep 07, 2016	Nov	CAHN
>A>	AB	200MG	A207049	002	Sep 07, 2016	Nov	CAHN
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May	NEWA
AB		200MG	A206762	002	May 24, 2016	May	NEWA
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan	NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan	NEWA
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May	NEWA
AB		200MG	A207371	002	May 24, 2016	May	NEWA
AB	PRINSTON INC	50MG	A206654	001	Aug 08, 2016	Jul	NEWA
AB		200MG	A206654	002	Aug 08, 2016	Jul	NEWA
>D>	AB VERSAPHARM INC	50MG	A207049	001	Sep 07, 2016	Nov	CAHN
AB		50MG	A207049	001	Sep 07, 2016	Aug	NEWA
>D>	AB	200MG	A207049	002	Sep 07, 2016	Nov	CAHN
AB		200MG	A207049	002	Sep 07, 2016	Aug	NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May	NEWA
AB		200MG	A206747	002	May 24, 2016	May	NEWA

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL							
TRINTELLIX							
	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun	CTNA
		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun	CTNA
		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun	CTNA
+		EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun	CTNA

XENON XE-133

GAS; INHALATION							
XENON XE 133							
	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb	CTEC
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb	CMFD
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb	CMFD



ZALEPLON

CAPSULE;ORAL

ZALEPLON

>D>	AB	ROXANE	5MG	A 077237	001	Jun 06, 2008	Nov	CAHN
>D>	AB		10MG	A 077237	002	Jun 06, 2008	Nov	CAHN
>D>	AB	UPSHER SMITH	5MG	A 078706	001	Jun 06, 2008	Nov	DISC
>A>		@	5MG	A 078706	001	Jun 06, 2008	Nov	DISC
>D>	AB		10MG	A 078706	002	Jun 06, 2008	Nov	DISC
>A>		@	10MG	A 078706	002	Jun 06, 2008	Nov	DISC
		@ UPSHER-SMITH LABS	5MG	A 078095	001	Jun 06, 2008	Oct	CAHN
		@	10MG	A 078095	002	Jun 06, 2008	Oct	CAHN
>A>	AB	WEST-WARD PHARMS INT	5MG	A 077237	001	Jun 06, 2008	Nov	CAHN
>A>	AB		10MG	A 077237	002	Jun 06, 2008	Nov	CAHN

ZIDOVUDINE

TABLET;ORAL

ZIDOVUDINE

>D>	AB	ROXANE	300MG	A 076844	001	Sep 19, 2005	Nov	CAHN
		@ SUNSHINE LAKE	300MG	A 202058	001	Oct 07, 2011	Aug	DISC
>A>	AB	WEST-WARD PHARMS INT	300MG	A 076844	001	Sep 19, 2005	Nov	CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

>D>	AB	APOTEX CORP	EQ 20MG BASE	A 077561	001	Mar 02, 2012	Nov	CAHN
>D>	AB		EQ 40MG BASE	A 077561	002	Mar 02, 2012	Nov	CAHN
>D>	AB		EQ 60MG BASE	A 077561	003	Mar 02, 2012	Nov	CAHN
>D>	AB		EQ 80MG BASE	A 077561	004	Mar 02, 2012	Nov	CAHN
>A>	AB	APOTEX INC	EQ 20MG BASE	A 077561	001	Mar 02, 2012	Nov	CAHN
>A>	AB		EQ 40MG BASE	A 077561	002	Mar 02, 2012	Nov	CAHN
>A>	AB		EQ 60MG BASE	A 077561	003	Mar 02, 2012	Nov	CAHN
>A>	AB		EQ 80MG BASE	A 077561	004	Mar 02, 2012	Nov	CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

>A>	AP	ACCORD HLTHCARE	EQ 4MG BASE/5ML	A 205279	001	Nov 28, 2016	Nov	NEWA
	AP	AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A 207751	001	Sep 26, 2016	Sep	NEWA
	AP	GLAND PHARMA LTD	EQ 5MG BASE/100ML	A 204217	001	Aug 18, 2016	Aug	NEWA

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB		AJANTA PHARMA LTD	2.5MG	A 204041	001	May 20, 2016	May	NEWA
AB			5MG	A 204041	002	May 20, 2016	May	NEWA
AB		AUROBINDO PHARMA LTD	2.5MG	A 207021	001	May 11, 2016	Apr	NEWA
AB			5MG	A 207021	002	May 11, 2016	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

>A>	AB	ALEMBIC PHARMS LTD	2.5MG	A 205074	001	Dec 01, 2016	Nov	NEWA
>A>	AB		5MG	A 205074	002	Dec 01, 2016	Nov	NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB		SANDOZ INC	5MG	A 077322	001	Apr 23, 2007	Aug	CAHN
AB			10MG	A 077322	002	Apr 23, 2007	Aug	CAHN
		@ SUN PHARM INDS	5MG	A 077288	001	Apr 23, 2007	Mar	CAHN
		@	10MG	A 077288	002	Apr 23, 2007	Mar	CAHN

TABLET;SUBLINGUAL

EDLUAR

AB		MEDA PHARMS	5MG	N 021997	001	Mar 13, 2009	Jul	CFTG
AB	+		10MG	N 021997	002	Mar 13, 2009	Jul	CFTG

ZOLPIDEM TARTRATE

>A>	AB	DR REDDYS LABS INC	1.75MG	A 204503	001	Nov 18, 2016	Nov	NEWA
>A>	AB		3.5MG	A 204503	002	Nov 18, 2016	Nov	NEWA
	AB	MYLAN PHARMS INC	5MG	A 202657	001	Aug 08, 2016	Jul	NEWA
	AB		10MG	A 202657	002	Aug 08, 2016	Jul	NEWA
	AB	PAR FORM	5MG	A 201509	001	Aug 01, 2016	Jul	NEWA
	AB		10MG	A 201509	002	Aug 01, 2016	Jul	NEWA

ZONISAMIDE

## CAPSULE;ORAL

## ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb	CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb	CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb	CAHN

## ZONISAMIDE

AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan	CAHN
	@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005	Mar	CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar	CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar	CAHN
	@ UPSHER-SMITH LABS	25MG	A077644	001	Dec 22, 2005	Oct	CAHN
	@	50MG	A077644	002	Dec 22, 2005	Oct	CAHN
	@	100MG	A077644	003	Dec 22, 2005	Oct	CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL  
ACETAMINOPHEN

AUROBINDO PHARMA LTD 650MG

A207229 001 Nov 09, 2016 Oct NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG;250MG;65MG

N020802 001 Jan 14, 1998 Feb CAHN

ADAPALENE

GEL;TOPICAL

DIFFERIN

+ GALDERMA LABS LP 0.1%

N020380 002 Jul 08, 2016 Aug NEWA

BUDESONIDE

SPRAY, METERED;NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY

A078949 002 Nov 20, 2015 Apr NEWA

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG

A077355 001 Feb 06, 2008 Aug CTNA

800MG;10MG;165MG

A204782 001 Aug 29, 2016 Aug NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX INC 10MG

A207235 001 Aug 12, 2016 Aug NEWA

BIONPHARMA INC 5MG

N022429 001 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG

N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 002 Jul 23, 2009 Jan CAHN

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML

A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG

A206793 001 Mar 08, 2016 Feb NEWA

10MG

A206793 002 Mar 08, 2016 Feb NEWA

CHLORHEXIDINE GLUCONATE

SPONGE;TOPICAL

CHLORHEXIDINE GLUCONATE

+ BECTON DICKINSON 4%

A072525 001 Oct 24, 1989 Jun CRLD

PHARMASEAL SCRUB CARE

@ CAREFUSION 4%

N019793 001 Dec 02, 1988 Jun DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ BECTON DICKINSON CO 2%;70% (3ML)

N020832 001 Jul 14, 2000 May CAHN

+ 2%;70% (10.5ML)

N020832 004 Aug 20, 2003 May CAHN

+ 2%;70% (26ML)

N020832 006 Nov 21, 2006 May CAHN

CHLORAPREP ONE-STEP FREPP

+ BECTON DICKINSON CO 2%;70% (1.5ML)

N020832 003 Apr 26, 2002 May CAHN

CHLORAPREP WITH TINT

+ BECTON DICKINSON CO 2%;70% (26ML)

N020832 002 May 03, 2005 May CAHN

+ 2%;70% (10.5ML)

N020832 005 Apr 03, 2006 May CAHN

+ 2%;70% (3ML)

N020832 007 Oct 10, 2006 May CAHN

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+ BECTON DICKINSON CO 2%;70% (0.67ML)

N021555 001 Oct 07, 2002 May CAHN

SWAB;TOPICAL

CHLORAPREP SINGLE SWABSTICK						
+	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005	May CAHN
CHLORAPREP TRIPLE SWABSTICK						
+	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	May CAHN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL						
CHLORPHENIRAMINE MALEATE						
@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL						
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE						
	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN

FAMOTIDINE

TABLET;ORAL						
FAMOTIDINE						
	AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016	Apr NEWA
		20MG	A206531	002	Apr 26, 2016	Apr NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL						
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY						
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016	Aug NEWA
FEXOFENADINE HYDROCHLORIDE ALLERGY						
	HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016	Aug NEWA
		180MG	A204097	003	Aug 19, 2016	Aug NEWA

FLUTICASONE FUROATE

SPRAY, METERED;NASAL						
FLONASE SENSIMIST ALLERGY RELIEF						
+	GLAXOSMITHKLINE	0.0275MG/SPRAY	N022051	002	Aug 02, 2016	Aug NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL						
FLUTICASONE PROPIONATE						
	APOTEX INC	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Jul CAHN
	APOTEX TECHNOLOGIES	0.05MG/SPRAY	A208150	001	Feb 29, 2016	Feb NEWA
>D>	ROXANE	0.05MG/SPRAY	A207957	001	May 26, 2016	Nov CAHN
		0.05MG/SPRAY	A207957	001	May 26, 2016	May NEWA
>A>	WEST-WARD PHARMS INT	0.05MG/SPRAY	A207957	001	May 26, 2016	Nov CAHN

IBUPROFEN

CAPSULE;ORAL						
IBUPROFEN						
	BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Sep CAHN
	PURACAP PHARM LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016	Jun NEWA
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016	Aug NEWA
MIDOL LIQUID GELS						
+	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002	Jan CAHN
TABLET;ORAL						
IBUPROFEN						
	GRANULES INDIA LTD	200MG	A202312	001	Oct 07, 2016	Sep NEWA
	STRIDES PHARMA	200MG	A079129	001	Mar 28, 2011	May CAHN
		200MG	A091355	001	Apr 04, 2011	May CAHN
@	SUN PHARM INDS	200MG	A070493	001	Dec 24, 1985	Mar CAHN
@		200MG	A070908	001	Sep 26, 1986	Mar CAHN
@		200MG	A071462	001	Oct 02, 1986	Mar CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

+	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Aug	CRLD
	ZADITOR						
@	ALCON PHARMA	EQ 0.025% BASE	N021066	002	Oct 19, 2006	Aug	DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

	MYLAN PHARMS INC	15MG	A203187	001	Jun 01, 2016	May	NEWA
	PREVACID 24 HR						
+	GLAXOSMITHKLINE CONS	15MG	N022327	001	May 18, 2009	Aug	CAHN
	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL						
	LANSOPRAZOLE						
	DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016	Jun	NEWA

LEVONORGESTREL

TABLET;ORAL

HER STYLE

	NOVAST LABS LTD	1.5MG	A207976	001	Mar 11, 2016	Feb	NEWA
	LEVONORGESTREL						
	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016	Mar	NEWA
	JAI PHARMA LTD	0.75MG	A202740	001	Sep 02, 2016	Aug	NEWA
	LOTUS PHARM CO LTD	0.75MG	A202684	001	Sep 02, 2016	Aug	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

	BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005	Jan	CAHN
+		2MG	N021855	002	Aug 04, 2005	Jan	CAHN

LORATADINE

CAPSULE;ORAL

LORATADINE

	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016	Sep	NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL						
	LORATADINE						
	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003	Oct	CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003	Oct	CAHN
		10MG;240MG	A075989	001	Mar 04, 2004	Oct	CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996	Mar	CMS1
---	------------------	----------	---------	-----	--------------	-----	------

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006	Mar	CAHN
---	----------------	---------------	---------	-----	--------------	-----	------

TABLET;ORAL

NAPROXEN SODIUM

	AUROBINDO PHARMA LTD	EQ 200MG BASE	A205497	001	Mar 18, 2016	Mar	NEWA
--	----------------------	---------------	---------	-----	--------------	-----	------

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

	DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999	Aug	CRLD
		14MG/24HR	N020076	005	Nov 12, 1999	Aug	CRLD
	NICODERM CQ						
	SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996	Aug	CRLD
		14MG/24HR	N020165	005	Aug 02, 1996	Aug	CRLD

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE  
EQ 4MG BASEA204794 001 May 10, 2016 Apr NEWA  
A204833 001 Feb 26, 2016 Feb NEWAOMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

ACTAVIS ELIZABETH 20MG;1.1GM  
AUROLIFE PHARMA LLC 20MG;1.1GM  
PAR PHARM 20MG;1.1GM  
PERRIGO R AND D 20MG;1.1GMA204137 001 Jul 15, 2016 Jul NEWA  
A204923 001 Nov 07, 2016 Oct NEWA  
A201946 001 Jul 15, 2016 Jul NEWA  
A201361 001 Jul 15, 2016 Jul NEWAOXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

NUVO PHARM INC 17GM/SCOOPFUL  
STRIDES PHARMA 17GM/SCOOPFUL  
17GM/PACKETA206105 001 Oct 28, 2016 Oct NEWA  
A203928 001 Aug 24, 2016 Aug NEWA  
A203928 002 Aug 24, 2016 Aug NEWAPOTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>A> APOTEX INC EQ 75MG BASE  
STRIDES PHARMA EQ 75MG BASE  
>D> TORPHARM EQ 75MG BASEA075167 001 May 04, 2000 Nov CAHN  
A201745 001 Feb 29, 2012 May CAHN  
A075167 001 May 04, 2000 Nov CAHNTRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

TEVA PHARMS 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Oct NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2016**

NO NOVEMBER 2016 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>



**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - ABACAVIR SULFATE AND LAMIVUDINE</u>						
A 079246 001					PC	Mar 28, 2017
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP			
	6028222*PED	Feb 05, 2018				
	6992218	Jun 06, 2021	DP			
	6992218*PED	Dec 06, 2021				
	9399012	Sep 11, 2031	U-1882			
	9399012*PED	Mar 11, 2032				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001 >A>	9468636	May 16, 2032	U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jul 24, 2018	DP U-1006			
	6514980	Jul 24, 2018	DP U-1484			
	7223387	Nov 13, 2022	DP U-1006			
	7223387	Nov 13, 2022	DP U-1484			
<u>ADAPALENE - DIFFERIN</u>						
N 020380 002					RTO	Jul 08, 2019
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	9463289	May 18, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
	9440922	Jun 09, 2030	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	>A> 9474752	Dec 11, 2027	U-1754			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	>A> 9474752	Dec 11, 2027	U-1754			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	6559183	Nov 12, 2019	DP U-804		NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>APREPITANT - EMEND</u>						
N 207865 001	>A> 6096742	Jul 01, 2018	DS DP U-1916			
	>A> 8258132	Sep 26, 2027	DP U-1916			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	9358207	Apr 12, 2020	DP			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	9452131	Mar 19, 2035	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	9452131	Mar 19, 2035	U-543			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	9452131	Mar 19, 2035	U-543			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200156 004					PC	Nov 28, 2016
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	5763476	Jun 09, 2020	DP U-1893			
	5763476*PED	Dec 09, 2020				
	7741358	Apr 06, 2026	DS DP U-1893			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
	9351984	Dec 19, 2021	DP			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	9364439	May 31, 2022	DP U-1902			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	6926907	Feb 28, 2023	DP U-1902		NC	Sep 14, 2019
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81		PED	Aug 20, 2018
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
	8163723*PED	Feb 29, 2024				
	9259428	Jun 13, 2023	U-644			
	9259428*PED	Dec 13, 2023				
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	9463289	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	9463289	May 18, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	>A> 9504704	Jun 03, 2029	DP U-124			
	>A> 9504704	Jun 03, 2029	DP U-134			
	>A> 9504704	Jun 03, 2029	DP U-818			
	>A> 9504704	Jun 03, 2029	DP U-916			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005					M-186	Sep 23, 2019
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006					M-186	Sep 23, 2019
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9421265	Jun 17, 2030	DP			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9474751	Apr 19, 2022	DP U-1524			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878		NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	6582727	Aug 22, 2020	DP		NP	Jun 17, 2019
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	DP U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353	004				I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	001	6723340	Oct 25, 2021	DP	I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493	NC	Aug 08, 2017
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	002	7943582	Feb 26, 2029	DS DP U-493	I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493	NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	003	6723340	Oct 25, 2021	DP	I-735	May 20, 2019
		7943582	Feb 26, 2029	DS DP U-493	NC	Aug 08, 2017
		7943788	Jul 14, 2027	DS DP	NCE	Mar 29, 2018
		8222219	Jul 30, 2024	U-493		
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879	004	7943582	Feb 26, 2029	DS DP U-493	I-735	May 20, 2019
		7943788	Jul 14, 2027	DS DP	NC	Aug 08, 2017
		8222219	Jul 30, 2024	U-493	NCE	Mar 29, 2018
		8513202	Dec 03, 2027	DS DP U-493		
		8785403	Jul 30, 2024	DP		
<u>CANGRELOR - KENGREAL</u>						
N 204958	001	9295687	Jul 10, 2035	DP		
<u>CARBAMAZEPINE - CARNEXTIV</u>						
N 206030	001	7635773	Mar 13, 2029	DP	>A> ODE	Oct 07, 2023
		8410077	Mar 13, 2029	DP		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	001	9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	002	9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	003	9463246	Dec 26, 2028	DP U-219		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312	004	9463246	Dec 26, 2028	DP U-219		
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	001	7417042	Jul 20, 2026	DS DP	I-722	Jan 21, 2019
		8129346	Apr 14, 2025	U-1260	I-723	Jan 21, 2019
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714	002	7232818	Apr 14, 2025	DS DP	I-712	Jul 24, 2018
		7417042	Jul 20, 2026	DS DP	I-722	Jan 21, 2019
		7491704	Apr 14, 2025	U-1260	I-723	Jan 21, 2019
		7737112	Dec 07, 2027	DP	NCE	Jul 20, 2017
		8129346	Apr 14, 2025	U-1260	ODE	Jul 20, 2019
		8207125	Apr 14, 2025	DS DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022	U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9457036	Jan 13, 2024	DP U-257			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	9399036	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	9415007	Jul 28, 2024	U-1896			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	9375410	Nov 14, 2023	U-1088			
	9399025	Nov 14, 2023	DP U-979			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	>A> 8629111	Aug 27, 2024	DP			
	>A> 8633162	Aug 27, 2024	U-1479			
	>A> 8642556	Aug 27, 2024	DP			
	>A> 8648048	Aug 27, 2024	U-1483			
	>A> 8685930	Aug 27, 2024	DP			
	>A> 9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	9421192	Aug 08, 2027	DS U-1724		D-161	Feb 05, 2019
	9421192	Aug 08, 2027	DS U-1725		D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAKLINZA - DACLATASVIR DIHYDROCHLORIDE</u>						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
<u>DALVANCE - DALBAVANCIN HYDROCHLORIDE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>ACZONE - DAPSONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>CUBICIN RF - DAPTOMYCIN</u>						
N 021572 003	9138456	Nov 23, 2030	DP			
<u>VIEKIRA PAK (COPACKAGED) - DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>VIEKIRA XR - DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR</u>						
N 208624 001	7148359	Jul 19, 2019	DP		NCE	Dec 19, 2019
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
<u>JADENU - DEFERASIROX</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>JADENU - DEFERASIROX</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>JADENU - DEFERASIROX</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFITELIO - DEFIBROTIDE SODIUM</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>FIRMAGON - DEGARELIX ACETATE</u>						
N 022201 001	9415085	Apr 27, 2032	U-1895			
<u>FIRMAGON - DEGARELIX ACETATE</u>						
N 022201 002	9415085	Apr 27, 2032	U-1895			
<u>OZURDEX - DEXAMETHASONE</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805		NPP	Jul 08, 2019
	9238029	Jan 17, 2026	DP		NPP	Jul 08, 2019
					NPP	Jul 08, 2019
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6328994	May 17, 2019	DP			
	6328994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	>A> 9320712	Jan 04, 2032	DP			
	>A> 9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	>A> 9320712	Jan 04, 2032	DP			
	>A> 9320712*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	>A> 9320712	Jan 04, 2032	DP			
	>A> 9320712*PED	Jul 04, 2032				
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002					PC	Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003					PC	Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385 9242986	Oct 05, 2027 Dec 08, 2029	DS DP DS DP		NCE	Aug 12, 2018
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385 9242986	Oct 05, 2027 Dec 08, 2029	DS DP DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8039009	Mar 24, 2029		U-1641		
	8039009*PED	Sep 24, 2029				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025		U-1641		
	8362085	Nov 22, 2025		U-1641		
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025		U-1641		
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 003	8039009	Mar 24, 2029		U-1641		
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029		U-1641		
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025		U-1641		
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025		U-1641		
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025		U-1641		
	8362085	Nov 22, 2025		U-1641		
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025		U-1641		
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	>A> 9486437	May 18, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	>A> 9486437	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM</u>						
A 203593 001					PC	Apr 09, 2017
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9457036	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELBASVIR; GRAZOPREXIVIR - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	9364489	Jul 07, 2028	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	9364489	Jul 07, 2028	U-1709			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 14, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003					M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004					M-174	Mar 18, 2019
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020		U-257		
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 21, 2025	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-257		
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	7125879	Apr 21, 2025	DS DP U-257			
	9457036	Jan 13, 2024	DP U-257			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	9457036	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-71			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-1892			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
					M-181	Jun 01, 2019
					>A> M-190	Oct 18, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
					M-181	Jun 01, 2019
					>A> M-190	Oct 18, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
					M-181	Jun 01, 2019
					>A> M-190	Oct 18, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	6310094	Jan 12, 2021	DP			
	6528540	Jan 12, 2021	DP			
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	6369085	May 25, 2018	DS DP U-1509			
	6369085	May 25, 2018	DS DP U-1875			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810	Nov 03, 2019	DP U-1874			
	6428810*PED	May 03, 2020				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031		U-1781		
	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029		U-1781		
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	9345695	May 31, 2022	DP			
	9393208	Sep 03, 2029		U-1781		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	8486907	Jun 28, 2025		U-1904	NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	>A> 9506058	Mar 14, 2034		U-1918		
	>A> 9506058	Mar 14, 2034		U-1919		
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	8486907	Jun 28, 2025		U-1904	NCE	Sep 19, 2021
	9018368	Jun 28, 2025	DS DP		ODE	Sep 19, 2023
	9416361	May 04, 2021	DS			
	>A> 9506058	Mar 14, 2034		U-1918		
	>A> 9506058	Mar 14, 2034		U-1919		
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	9364656	Sep 30, 2031	U-736			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9387191	Jul 21, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	9468639	Oct 16, 2022	U-1734			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	5808146	Nov 09, 2017	DS		NCE	May 27, 2021
	9387266	Nov 28, 2026	U-1879			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	6858596	Aug 03, 2021	DP U-1890			
	7101866	Aug 03, 2021	DS DP U-1890			
	7541350	Aug 03, 2021	DP U-1890			
	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
	9415009	May 28, 2030	U-1841			
	9463161	May 28, 2030	DP U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
	6774122	Jan 09, 2021	U-1826			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-596			
	7456160	Jan 09, 2021	U-1826			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8466139	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-1826			
	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001					NCE ODE	Jun 01, 2021 Jun 01, 2023
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	9402874	Aug 19, 2030	U-441			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP		NCE	Jul 01, 2016
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	6613355	Jun 28, 2021	DP		NDF	Aug 09, 2019
	6790458	May 11, 2021	DP			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 001					PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 002					PC	Apr 24, 2017
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE</u>						
A 078827 003					PC	Apr 24, 2017



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
>A>	9492390	Aug 24, 2027	U-1556			
>A>	9492391	Aug 24, 2027	U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027		U-1556		
	>A> 9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027		U-1556		
	>A> 9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027		U-1556		
	>A> 9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027		U-1556		
	>A> 9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027		U-1556		
	>A> 9492391	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	>A> 9492390	Aug 24, 2027		U-1556		
	>A> 9492391	Aug 24, 2027		U-1556		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165	May 06, 2019
					I-729	Mar 04, 2019
					I-736	May 06, 2019
					I-737	May 06, 2019
					ODE	Mar 04, 2023
					ODE	May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	>A> 9469643	Sep 02, 2033	DS			
	>A> 9492449	Mar 11, 2030		U-1914		
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	>A> 9469643	Sep 02, 2033	DS			
	>A> 9492449	Mar 11, 2030		U-1914		
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	6958335	Dec 19, 2021		U-791		
	6958335	Dec 19, 2021		U-1883		
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	6958335	Dec 19, 2021		U-791		
	6958335	Dec 19, 2021		U-1883		
	6958335*PED	Jun 19, 2022				
	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	>A> 6268343	Aug 22, 2022	DS DP		>A> NC	Nov 21, 2019
	>A> 6458924	Aug 22, 2017	DS DP		>A> NCE	Sep 25, 2020
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7235627	Aug 22, 2017	DS			
	>A> 7615532	May 25, 2025	DS DP			
	>A> 7686786	Aug 03, 2026	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8846618	Jun 27, 2022	DS DP			
	>A> 8920383	Jul 17, 2026	DP			
	>A> 8937042	May 05, 2029	DP			
	>A> 9108002	Jan 20, 2026	DP			
	>A> 9132239	Feb 01, 2032	DP			
	>A> 9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5866538	Jun 20, 2017	DP			
	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5866538	Jun 20, 2017	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5866538	Jun 20, 2017	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	9457154	Sep 27, 2027	DP			
>A>	9486588	Jan 02, 2022	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP U-1855			
	9408979	Mar 02, 2024	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001					>A> NC	Nov 21, 2019
					>A> NCE	Jul 27, 2021
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	9358352	Feb 15, 2031	DP U-1861			
	9393372	Jul 04, 2029	DP			
	9446133	Jun 12, 2029	DP U-1861			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
>A>	9492442	Jun 12, 2033	U-1848			
>A>	9492442	Jun 12, 2033	U-1899			
>A>	9492442	Jun 12, 2033	U-1917			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	8324242	Aug 05, 2027	U-1906			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8324242	Aug 05, 2027	U-1311		NCE	Jan 31, 2017
	8324242	Aug 05, 2027	U-1906			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8324242	Aug 05, 2027	U-1311		ODE	Sep 28, 2023
	8324242	Aug 05, 2027	U-1911			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8846718	Dec 04, 2028	U-1717			
	8846718	Dec 04, 2028	U-1908			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Aug 05, 2027	U-1911		NPP	Sep 28, 2019
	8410274	Dec 28, 2026	DP		ODE	Jul 02, 2022
	8507534	Sep 20, 2030	DS DP		ODE	Sep 28, 2023
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
	9399040	Jul 30, 2023	DP			
	9486406	Oct 23, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158	Feb 12, 2019
	9393256	Sep 14, 2032	U-1470		D-159	Feb 12, 2019
					D-160	Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028		DP U-1801		
	8357713	Nov 26, 2028		DP U-1802		
	8357713	Nov 26, 2028		DP U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 01, 2031		U-1806		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	9339489	Mar 14, 2034	DP U-1850			
	9463160	Feb 20, 2018	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 206263 001					PC	Feb 11, 2017
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	7252839	Nov 13, 2023	DP		NP	Sep 16, 2019
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7691411	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7691411	Mar 14, 2024	DP			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	9358338	Apr 27, 2035	U-1870			
	9370622	Sep 28, 2035	U-1870			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	7314938	Mar 10, 2025	DS DP		NCE	Jul 11, 2021
	7745460	Nov 05, 2024	DS DP	U-1880		
	7790743	Nov 05, 2024		U-1880		
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029		U-1880		
	8367701	Apr 15, 2029	DP	U-1880		
	8592450	May 17, 2026		U-1880		
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029		U-1900		
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Nov 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Oct 30, 2031		U-1515		
	8748573	Oct 30, 2031		U-1516		
	8802628	Nov 17, 2031	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
	>A> 9486526	Aug 05, 2029			U-1915	
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	6303661	Apr 24, 2017			U-802	
	6340475	Sep 19, 2016	DP		U-1852	
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-803	
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019			U-803	
	8119648	Aug 12, 2023			U-802	
	8178541	Aug 12, 2023	DP		U-1853	
	8673927	May 04, 2027			U-1503	
	8846695	Jun 04, 2030			U-1503	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1503	
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	6303661	Apr 24, 2017			U-802	
	6340475	Sep 19, 2016	DP		U-1852	
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6890898	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-803	
	7407955	May 02, 2025	DS DP			
	7459428	Feb 02, 2019			U-803	
	8119648	Aug 12, 2023			U-802	
	8178541	Aug 12, 2023	DP		U-1853	
	8673927	May 04, 2027			U-1503	
	8846695	Jun 04, 2030			U-1503	
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP		U-1503	
	9415016	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					M-188	Oct 14, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					M-188	Oct 14, 2019
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					M-188	Oct 14, 2019
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	9463183	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	8475414	Dec 28, 2030	DP U-1881		NCE	Jul 27, 2021
	8882721	Jun 28, 2031	DP			
	8915888	Jun 08, 2030	DP U-1881			
	9072836	Mar 15, 2032	DP			
	9084853	Oct 05, 2031	DP			
	9308329	Dec 28, 2030	DP U-1881			
	9408893	Aug 27, 2032	U-1894			
	RE45313	Jul 12, 2020	DS DP			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
	9169213	Dec 06, 2032	U-1884			
	9169213	Dec 06, 2032	U-1885			
	9169213	Dec 06, 2032	U-1886			
	9169213	Dec 06, 2032	U-1887			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	9370629	May 20, 2024	DP			
	9439907	Oct 26, 2021	DP			
	9440034	Oct 26, 2021	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MARAVIROC - SELZENTRY</u>						
N 208984 001	>A> 6586430	Dec 01, 2019	DS DP U-824			
	>A> 6667314	Aug 06, 2021	DS DP U-824			
	>A> 7368460	Nov 25, 2022	U-824			
	>A> 7576097	May 25, 2021	DS			
<u>MEBENDAZOLE - VERMOX</u>						
N 208398 001					NS	Oct 19, 2019
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	9382191	Mar 07, 2026	DP			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>MESALAMINE - CANASA</u>						
N 021252 001					M-187	Sep 02, 2019
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Jul 13, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9421333	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE444846	Aug 10, 2019	DP			
	RE444847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	6559158	Nov 03, 2017	U-1185		NP	Jul 19, 2019
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	7438930	Dec 16, 2019	DP	Y		
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532 RE44872	Mar 27, 2022 Nov 04, 2023	DS DP U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532 RE44872	Mar 27, 2022 Nov 04, 2023	DS DP U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP	>A> M-189		Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP	>A> M-189		Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP	>A> M-189		Oct 02, 2018
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP	>A> M-189		Oct 02, 2018
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001					M-185	Sep 27, 2019
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001					M-185	Sep 27, 2019
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599 002				>A> M-191		Nov 10, 2019
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7786133	Dec 19, 2027	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7786133	Dec 19, 2027	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108 9278182 9474869	Jan 22, 2027 Feb 01, 2026 Feb 28, 2031	DP DP DP U-1907			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9468747	Mar 16, 2035	DP U-1903			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 209862 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Jan 22, 2027	DP			
>A>	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
>A>	9511066	May 10, 2022	U-1921			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
>A>	9511066	May 10, 2022	U-1921			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556		NC	Jul 23, 2017
	9283216	May 10, 2022	DP U-1819			
	9283221	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
	9474750	Dec 22, 2018	DP U-1556			
>A>	9511066	May 10, 2022	U-1921			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 001	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 002	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 003	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 004	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 005	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 006	7815934	Dec 12, 2027	DP		NC	Aug 19, 2019
	8685443	Jul 03, 2025	U-1508			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP		NC	Jun 03, 2019
	7838552	Oct 04, 2027	U-185			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	9271975	Sep 09, 2031	U-528			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	9364564	Dec 26, 2027	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001 >A>	9061029	Apr 07, 2032	DP U-1374			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002 >A>	9061029	Apr 07, 2032	DP U-1374			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022	U-1854		ODE	May 27, 2023
	8377916	Feb 21, 2022	U-1854			
	9238673	Jun 17, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	7138390	Nov 16, 2022	DS DP		NCE	May 27, 2021
	8058267	Feb 21, 2022		U-1854	ODE	May 27, 2023
	8377916	Feb 21, 2022		U-1854		
	9238673	Jun 17, 2033	DP			
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 001					PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 002					PC	Apr 24, 2017
<u>OLMESARTAN MEDOXOMIL - OLMESARTAN MEDOXOMIL</u>						
A 078276 003					PC	Apr 24, 2017
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS	U-864		
	5900424	May 04, 2016	DS	U-1817		
	6428810	Nov 03, 2019		DP U-864		
	6428810	Nov 03, 2019		DP U-1817		
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS	U-864		
	5900424	May 04, 2016	DS	U-1817		
	6428810	Nov 03, 2019		DP U-864		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016		U-588		
	6489346	Jul 15, 2016		DP U-588	Y	
	6645988	Jul 15, 2016		DP	Y	
	6699885	Jul 15, 2016		U-588	Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016		U-588		
	RE45198	Jul 15, 2016		U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016		U-623		
	5840737	Jul 15, 2016		U-624		
	6489346	Jul 15, 2016		DP U-623	Y	
	6489346	Jul 15, 2016		DP U-624	Y	
	6645988	Jul 15, 2016		DP	Y	
	6699885	Jul 15, 2016		U-623	Y	
	6699885	Jul 15, 2016		U-624	Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016		U-623		
	7399772	Jul 15, 2016		U-624		
	RE45198	Jul 15, 2016		U-623		
	RE45198	Jul 15, 2016		U-624		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016		U-588		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEFRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2017	DS DP U-1569			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
<u>OXYBUTYNYN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	7399488	Mar 24, 2025	DP		NP	Apr 26, 2019
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	>A> 9492389	Aug 24, 2027	DP			
	>A> 9492391	Aug 24, 2027	U-1556			
	>A> 9492392	Aug 24, 2027	DP			
	>A> 9492393	Aug 24, 2027	U-1556			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001 >A>	9492443	May 26, 2024	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002 >A>	9492443	May 26, 2024	DS DP			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	6413499	Mar 20, 2020	U-1876		NC	Jun 29, 2019
	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	9393318	Aug 03, 2032	U-1290			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-543			
	9439906	Jan 26, 2031	U-1901			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457021	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 001					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					>A> ODE	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 002					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					>A> ODE	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 003					NPP	Oct 18, 2019
					NPP	Oct 18, 2019
					>A> ODE	Oct 18, 2023
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			
	9393237	Aug 04, 2026			U-904	
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	>A> 9492476	Oct 08, 2033			U-1766	
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	>A> 9492476	Oct 08, 2033			U-1766	
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	>A> 9492476	Oct 08, 2033			U-1766	
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP	U-106	NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Jun 18, 2019	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP	U-1843		
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026		U-1844		
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024		U-1845		
	8921393	Jan 15, 2024		U-1846		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	9296694	Mar 06, 2021	DS DP			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	>A> 9480652	May 12, 2032	DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					PC	Jan 01, 2017
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	>A> 8268806	Mar 19, 2031	DP		>A> NCE	Nov 16, 2021
	>A> 8629129	Aug 07, 2028	DP			
	>A> 8957054	Aug 07, 2028	U-1922			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		M-182	Jul 12, 2019
	5288726*PED	Oct 14, 2017			PED	Jan 12, 2020
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>QUETIAPINE FUMARATE - QUETIAPINE FUMARATE</u>						
A 090681 004					PC	Apr 30, 2017
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	9458107	Apr 08, 2031	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	8207191	Aug 30, 2024	U-805			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					NP	Apr 15, 2019
					ODE	Apr 15, 2023
					ODE	Jul 15, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
	9421195	Mar 10, 2030	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	7585860	Dec 11, 2020	DS			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-1303			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 001					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 002					PC	Oct 29, 2016



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 003					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - ROSUVASTATIN CALCIUM</u>						
A 079168 004					PC	Oct 29, 2016
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	9388134	Nov 08, 2026	U-1723			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	9433624	Nov 17, 2024	U-1589			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9433624	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001					>A> NPP	Nov 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP		>A> NPP	Oct 25, 2019
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP		>A> NPP	Oct 25, 2019
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Jun 28, 2021
	8334270	Mar 21, 2028	DS DP U-1470			
	8575135	Nov 16, 2032	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8889159	Mar 26, 2029	DP U-1470			
	8921341	Nov 16, 2032	DS DP U-1470			
	8940718	Nov 16, 2032	DS DP U-1470			
	9085573	Mar 21, 2028	DS DP U-1470			
	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	9457154	Sep 27, 2027	DP			
	>A> 9486588	Jan 02, 2022	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2017	DS U-1468			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	5686060	Nov 11, 2017	DS DP		I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8536130	Sep 22, 2028	U-1276			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	9439985	Sep 27, 2033	DS DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	>A> 7390791	May 07, 2022	DS DP		>A> NCE	Nov 05, 2020
	>A> 7803788	Feb 02, 2022	U-999		>A> NP	Nov 11, 2019
	>A> 8754065	Aug 15, 2032	DS DP U-999			
	>A> 9296769	Aug 15, 2032	DS DP U-999			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	7250419	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1860			
	7250419	Dec 02, 2019	DS DP U-1864			
	7250419	Dec 02, 2019	DS DP U-1865			
	7250419	Dec 02, 2019	DS DP U-1866			
	7250419	Dec 02, 2019	DS DP U-1867			
	7265124	Jul 09, 2021	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1860			
	7265124	Jul 09, 2021	DS DP U-1868			
	7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 002	5733919	Oct 23, 2016	DS			
	5965581	Oct 23, 2016	DP			
	5972967	Oct 23, 2016	DP			
	5978698	Oct 08, 2017	U-1897			
	6136794	Jan 29, 2019	U-1898			
	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003 >A>	6770660	May 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956041	Dec 08, 2020	DP		NCE	Nov 06, 2017
	6965027	Mar 25, 2023	DS			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156	Jan 28, 2019
	9393203	Apr 27, 2026	DP U-1877		D-157	Jan 28, 2019
	9422223	May 24, 2024	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	RE42353	Jun 27, 2022	DS DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-183	Aug 12, 2019
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-183	Aug 12, 2019
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035		U-1857		
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	9447089	Jun 06, 2032	DP		M-184	Aug 31, 2019
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030		U-1835	ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030		U-1835	ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030		U-1835	ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028		U-1825		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027		U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027		U-1668		
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.



## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)